Done? (Y),Company/Organization,Test Name,Select,*URL,Test Type (Lab or Kit),Country of Origin,US Regulatory Status,Category,Authorized Setting(s) per FDA,Technology,Analyte,Assay,Specimen Type,Transport Media,Gene,Antigen,Sample Prep,Detection,TAT,Analytical Sensitivity (LOD),LOD of FDA Reference Panel (NDU/mL),Cross- Reactivity,PPA/Sensitivity,PPA Sample Size,PPA Specimen Type,NPA/Specificity,NPA Sample Size,NPV @ 5% prevalence,PPV@ 5% prevalence,Manufacturer's Validation Notes,External Quality Control,Process (internal) Control,Positive Control,*Publications,*IFU,*Letter of Authorization (EUA),Creation Date,Modified Date,,,Needs Review
,,,,,,,,,,,,,,,,,,,,,*Don't fill this,,,,,,,,,,,,,,,,,,,,
,Ambry Genetics Laboratory,Ambry COVID-19 RT-PCR Test,,,Lab,USA,"EUA granted January 22, 2021",Laboratory,H,"Real-time RT-PCR, Home Collection, Saliva",RNA,,Sal,,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145409/download,https://www.fda.gov/media/145406/download,,,,,
,"United Biomedical, Inc.",UBI SARS-CoV-2 ELISA,,,Kit,USA,"EUA granted January 15, 2021",Laboratory,H,Serology ,IgG,ELISA,"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145277/download,https://www.fda.gov/media/145280/download,,,,,
,"Bio-Rad Laboratories, Inc.",Bio-Rad Reliance SARS-CoV-2 RT-PCR Assay Kit,,,Kit,USA,"EUA granted January 15, 2021",Laboratory,H,Molecular ,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, Ns swab, Ns wash, Ns aspirate",,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145265/download,https://www.fda.gov/media/145267/download,,,,,
,"SML GENETREE Co., Ltd.",Ezplex SARS-CoV-2 G Kit,,,Kit,Korea,"EUA granted January 13, 2021",Laboratory,H,Molecular ,RNA,"rRT-PCR, pooling","NP swab, OP swab, Spu",,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145134/download,https://www.fda.gov/media/145131/download,,,,,
,"Ortho Clinical Diagnostics, Inc.",VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Reagent Pack,,,Kit,USA,"EUA granted January 11, 2021",Laboratory,"H, M","Antigen Chemiluminescence Immunoassay, Instrument Read",Antigen,,"NP swab, Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145073/download,https://www.fda.gov/media/145069/download,,,,,
,Phadia AB,EliA SARS-CoV-2-Sp1 IgG Test,,,Kit,Sweden,"EUA granted January 11, 2021",Laboratory,"H, M","Serology IgG, Fluoroenzyme Immunoassay, Semi-quantitative",IgG,,"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145089/download,https://www.fda.gov/media/145082/download,,,,,
,"ADVAITE, Inc.",RapCov Rapid COVID-19 Test,,,Kit,USA,"EUA granted January 11, 2021","Laboratory, POC","H, M, W",Serology ,IgG,"Lateral Flow,  Fingerstick Whole Blood",,,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145080/download,https://www.fda.gov/media/145075/download,,,,,
,Siemens Healthcare Diagnostics Inc.,Dimension EXL SARS‑CoV‑2 IgG (CV2G),,,Kit,USA,"EUA granted January 08, 2021",Laboratory,"H, M",Serology ,IgG,Heterogeneous Immunoassay (CLIA),"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145015/download,https://www.fda.gov/media/145012/download,,,,,
,Siemens Healthcare Diagnostics Inc.,Dimension Vista SARS‑CoV‑2 IgG (COV2G),,,Kit,USA,"EUA granted January 08, 2021",Laboratory,"H, M",Serology,IgG,Heterogeneous Immunoassay (CLIA),"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/145020/download,https://www.fda.gov/media/145017/download,,,,,
,Quanterix Corporation,Simoa SARS-CoV-2 N Protein Antigen Test,,,Kit,USA,"EUA granted January 05, 2021",Laboratory,"H, M",Antigen Paramagnetic Microbead-based Immunoassay,Antigen,,NP swab,,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144929/download,https://www.fda.gov/media/144925/download,,,,,
,"Nirmidas Biotech, Inc.",MidaSpot COVID-19 Antibody Combo Detection Kit,,,Kit,USA,"EUA granted December 31, 2020","Laboratory, POC","H, M, W",Serology,"IgM, IgG","Lateral Flow, Fingerstick Whole Blood","Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144877/download,https://www.fda.gov/media/144874/download,,,,,
,Cepheid,Xpert Xpress SARS-CoV-2 DoD ,,,Kit,USA,"EUA granted December 23, 2020","Laboratory, POC","H, M, W",Molecular,RNA,"rRT-PCR, Pooling","NP swab, OP swab, MTNs swab, Ns swab, Ns wash, Ns aspirate",,,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144790/download,,,,,
,Quanterix Corporation,Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test ,,,Kit,USA,"EUA granted December 23, 2020",Laboratory,"H, M",Serology,IgG,ELISA,"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144764/download,https://www.fda.gov/media/144761/download,,,,,
,Quidel Corporation,Solana SARS-CoV-2 Assay ,,,Kit,USA,"EUA granted December 23, 2020",Laboratory,"H, M","Molecular Isothermal Reverse Transcriptase – Helicase-Dependent 
Amplification (RT-HDA)",RNA,,"NP swab, Ns swab",,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144759/download,https://www.fda.gov/media/144756/download,,,,,
,Siemens Healthcare Diagnostics Inc.,ADVIA Centaur IL6 assay ,,,Kit,USA,"EUA granted December 18, 2020",Laboratory,"H, M",One-step Direct Chemiluminescent Immunoassay,,,"Ser, Pla",,,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144672/download,https://www.fda.gov/media/144669/download,,,,,
,Quidel Corporation,QuickVue SARS Antigen Test ,,,Kit,Germany,"EUA granted December 18, 2020","Laboratory, POC","H, M, W","Antigen Lateral Flow, Visual Read",Antigen,,"ANs swab, Ns swab",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144668/download,https://www.fda.gov/media/144665/download,,,,,
,"Materials and Machines Corporation of America (DBA MatmaCorp, Inc.)",MatMaCorp COVID-19 2SF Test ,,,Kit,,"EUA granted December 17, 2020",Laboratory,H,Molecular ,RNA,"RT-PCR, isothermal amplification","NP swab, ANs swab, MTNs swab",,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144659/download,https://www.fda.gov/media/144656/download,,,,,
,"Hologic, Inc.",Aptima SARS-CoV-2/Flu assay ,,,Kit,USA,"EUA granted December 16, 2020",Laboratory,H,"Molecular Real-time TMA, chemiluminescent, Multi-analyte",RNA,,"NP swab, MTNs swab, Ns swab",,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144590/download,https://www.fda.gov/media/144587/download,,,,,
,"Abbott Diagnostics Scarborough, Inc.",BinaxNOW COVID-19 Ag Card Home Test ,,,,USA,"EUA granted December 16, 2020","Laboratory, POC","H, M, W","Antigen Lateral Flow, Visual Read, Prescription Home Testing",Antigen,,Ns swab,,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144574/download,https://www.fda.gov/media/144576/download,,,,,
,"ACON Laboratories, Inc.",ACON SARS-CoV-2 IgG/IgM Rapid Test ,,,Kit,USA,"EUA granted December 15, 2020",Laboratory,"H, M",Serology ,"IgM, IgG",Lateral Flow,"Ser, Pla, VWB",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144562/download,https://www.fda.gov/media/144559/download,,,,,
,"ResearchDx, Inc., DBA Pacific Diagnostics",PacificDx Covid-19 ,,,,,"EUA granted December 11, 2020",Laboratory,H,"Molecular TMA, chemiluminescent, Home Collection",RNA,,"NP swab, OP swab, MTNs swab, Ns swab",,,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144555/download,,,,,
,RCA Laboratory Services LLC dba GENETWORx,GENETWORx Covid-19 Nasal Swab Test ,,,,USA,"EUA granted December 15, 2020",Laboratory,H,"Molecular Real-time RT-PCR, Home Collection",RNA,,Ns swab,,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144554/download,https://www.fda.gov/media/144550/download,,,,,
,Ellume Limited,Ellume COVID-19 Home Test ,,,,Australia,"EUA granted December 16, 2020","Laboratory, POC, Home","Home, H, M, W","Antigen Lateral Flow, Fluorescence, Instrument Read, Over the Counter Home 
Testing",Antigen,,"MTNs swab, Ns swab",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144592/download,https://www.fda.gov/media/144457/download,,,,,
,Laboratory Corporation of America (LabCorp),Pixel by LabCorp COVID-19 Test Home Collection Kit ,,,Kit,,"EUA granted December 09, 2020",Laboratory,H,"Molecular Direct to Consumer (DTC), Real-time RT-PCR, Home Collection, 
Pooling, Screening",RNA,,"NP swab, OP swab, MTNs swab, Ns swab",,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/137154/download,https://www.fda.gov/media/144333/download,,,,,
,"Luminostics, Inc.",Clip COVID Rapid Antigen Test,,https://luminostics.com/,Kit,USA,"EUA granted December 07, 2020","Laboratory, POC","H, M, W",Antigen,Antigen,Lateral flow immunoluminescent assay,ANs swab,NA,NA,N,RNA extraction: Luminostics Extraction Tube,Luminostics Clip Analyzer,30 minutes after sample loading,0.88 x102 TCID50 per mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,96.88%,32,Clinical,100.00%,134,,,"PPA determined with 32 positive clinical Ns specimens collected from symptomatic individuals within 5 days of symptom onset at two undisclosed sites in the United States between late August and early October 2020 (positive determination made using patient-matched NP swabs collected concurrently with the Ns specimens transported in VTM and tested with an undisclosed EUA-authorized RT-PCR assay that includes a solid phase RNA extraction step at an undisclosed central laboratory; positive samples included 1 RT-PCR positive sample from an individual aged 6 to 21 years old and 31 RT-PCR positive samples from individuals aged 22 to 59 years old). 
NPA determined with 134 negative clinical Ns specimens collected from symptomatic individuals within 5 days of symptom onset at two undisclosed sites in the United States between late August and early October 2020 (negative determination made using patient-matched NP swabs collected concurrently with the Ns specimens transported in VTM and tested with an undisclosed EUA-authorized RT-PCR assay that includes a solid phase RNA extraction step at an undisclosed central laboratory; negative samples included 10 RT-PCR negative samples from individuals aged 6 to 21 years old, and 116 RT-PCR negative samples from individuals aged 22 to 59 years old, and 8 RT-PCR negative samples from individuals aged 60 years and older). 
Total and RT-PCR positive samples also stratified separately by days post symptom onset. Note that all Ns samples in study were tested with Clip COVID Rapid Antigen Test by 18 intended users with no laboratory training using only the package insert.",included,included,included,ND,https://www.fda.gov/media/144256/download,https://www.fda.gov/media/144253/download,,,,,
,"Quest Diagnostics Infectious Disease, Inc.",Quest Diagnostics RC COVID-19+Flu RT-PCR ,,,,USA,"EUA granted December 04, 2020",Laboratory,H,"Molecular Real-time RT-PCR, Multi-analyte, Home Collection",RNA,,,,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144179/download,https://www.fda.gov/media/144180/download,,,,,
,"Innovita (Tangshan) Biological Technology Co., Ltd.",Innovita 2019-nCoV Ab Test (Colloidal Gold) ,,,Kit,China,"EUA granted November 23, 2020",Laboratory,"H, M",Serology,"IgM, IgG",Lateral Flow,"Ser, Pla, VWB",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144071/download,https://www.fda.gov/media/144068/download,,,,,
,"Roche Diagnostics, Inc.",Elecsys Anti-SARS-CoV-2 S ,,,Kit,USA,"EUA granted November 25, 2020",Laboratory,"H, M","Serology Total Antibody, ECLIA, Semi-quantitative",,,"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144037/download,https://www.fda.gov/media/144034/download,,,,,
,Cepheid,Xpert Omni SARS-CoV-2 ,,,Kit,USA,"EUA granted November 27, 2020",Laboratory,"H, M",Molecular ,RNA,Real-time RT-PCR,"NP swab, OP swab, MTNs swab, Ns swab, Ns wash, Ns aspirate",,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144033/download,https://www.fda.gov/media/144029/download,,,,,
,"DxTerity Diagnostics, Inc.",DxTerity SARS-CoV-2 RT PCR CE Test,,https://dxterity.com/sars-cov-2-test-covid-19/,Lab,USA,"EUA granted August 28, 2020",Laboratory,H,"Molecular, Home Collection",RNA,"epRT-PCR, Capillary Electrophoresis",Sal,Spectrum Solutions LLC SDNA-1000 Saliva Collection Device,"N, E, ORF1ab",NA,"Extraction: GE Healthcare Sera-Mag SpeedBeads Carboxyl Magnetic Beads on the ABI MagMax 96 Magnetic Particle Processor
Amplification: ThermoFisher Scientific TaqPath 1-Step Multiplex Master Mix (No ROX) on the ABI VeritiDx PCR Thermal Cycler",ABI 3500xL Dx Genetic Analyzer (Data Collection Software Version 3.2),24 - 48 hours for result from lab,50 copies/mL,,No cross-reactivity predicted in silico,94.62%,93,Clinical and contrived,98.47%,588,,,"PPA determined with 
1) contrived specimens consisting of 30 negative saliva specimens collected with the Spectrum Solutions SDNA-1000 Saliva Collection Device (specimen provenance not disclosed; method of negative determination not disclosed) spiked with quantified SARS-CoV-2 genomic RNA (BEI Resources) and tested with all four Primer Mixes before combination of amplicons for analysis on the Genetic Analyzer (results from each primer mix are shown),
2) 37 positive clinical saliva specimens collected with the Spectrum Solutions SDNA-1000 Saliva Collection Device from symptomatic individuals (specimens collected at multiple undisclosed sites; positive determination made on sample-matched NP swabs collected within an hour of their respective saliva specimens and tested with the EUA authorized Roche cobas SARS-CoV-2 test at the Med Fusion Quest Laboratory (Lewisville, TX); 97.3% (36/37) positive agreement for this subgroup), and 
3) 26 positive clinical saliva specimens collected with the Spectrum Solutions SDNA-1000 Saliva Collection Device from asymptomatic individuals suspected of COVID-19 by their healthcare provider (specimens collected at multiple undisclosed sites; positive determination made on sample-matched NP swabs collected  within an hour of their respective saliva specimens and tested with the EUA authorized Roche cobas SARS-CoV-2 test at the Med Fusion Quest Laboratory (Lewisville, TX); 84.6% (22/26) positive agreement for this subgroup).
Note that a comparison was also made for low viral load in positive results from symptomatic (11/37) and asymptomatic (9/26) individuals.  

NPA determined with 
1) 30 individual negative saliva specimens collected with the Spectrum Solutions SDNA-1000 Saliva Collection Device (specimen provenance not disclosed; method of negative determination not disclosed) and tested with all four Primer Mixes before combination of amplicons for analysis on the Genetic Analyzer (results from each primer mix are shown),
2) 40 negative clinical saliva specimens collected with the Spectrum Solutions SDNA-1000 Saliva Collection Device from symptomatic individuals (specimens collected at multiple undisclosed sites; negative determination made on sample-matched NP swabs collected within an hour of their respective saliva specimens and tested with the EUA authorized Roche cobas SARS-CoV-2 test at the Med Fusion Quest Laboratory (Lewisville, TX); 90% (36/40) positive agreement for this subgroup), and 
3) 518 negative clinical saliva specimens collected with the Spectrum Solutions SDNA-1000 Saliva Collection Device from asymptomatic individuals suspected of COVID-19 by their healthcare provider (specimens collected at multiple undisclosed sites; negative determination made on sample-matched NP swabs collected within an hour of their respective saliva specimens and tested with the EUA authorized Roche cobas SARS-CoV-2 test at the Med Fusion Quest Laboratory (Lewisville, TX); 99% (513/518) negative agreement for this subgroup).

Also conducted studies on competitive intereference, carryover and cross-contamination, simulated shipping, sample volume tolerance, and human usability. ",included,included,included,ND,https://www.fda.gov/media/141669/download,https://www.fda.gov/media/141666/download,,,,,
,"Kantaro Biosciences, LLC","COVID-SeroKlir, Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit",,,Kit,USA,"EUA granted November 24, 2020",Laboratory,H,"Serology IgG, ELISA, Semi-quantitative",IgG,,"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/144010/download,https://www.fda.gov/media/144007/download,,,,,
,"Gravity Diagnostics, LLC",Gravity Diagnostics SARS-CoV-2 RT-PCR Assay,,,Lab,USA,"EUA granted November 23, 2020",Laboratory,H,"Molecular Real-time RT-PCR, Home Collection, Screening, Saliva",RNA,,"NP swab, OP swab, Ns swab",,,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/143932/download,,,,,
,"RapidRona, Inc.",RapidRona Self-Collection Kit,,,Lab,USA,"EUA granted November 23, 2020",,N/A,Home Collection Kit,RNA,,Ns swab,,NA,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/143929/download,https://www.fda.gov/media/143927/download,,,,,
,"Lucira Health, Inc.",Lucira COVID-19 All-In-One Test Kit ,,https://www.lucirahealth.com/,Kit,USA,"EUA granted November 18, 2020",POC,W,"Molecular, Prescription Home Testing",RNA,RT-LAMP,Ns swab,NA,N,NA,Lucira Health Sample Vial with Elution Buffer,Lucira Health Test Unit,~30 minutes after sample loading,2700 cp/swab (~900 cp/mL in 3 mL of VTM assuming 100% elution efficiency),,No cross-reactivity predicted in silico nor detected in wet lab testing,94.12%,51,Clinical,98.00%,50,,,"PPA determined with 51 clinical positive Ns specimens self-collected from symptomatic individuals suspected of COVID-19 and tested outside their residence (positive determination made on samples of an undisclosed specimen type collected concurrently with the Ns specimens and run in clinical laboratories with an undisclosed high sensitivity molecular FDA Authorized SARS-CoV-2 assay).  
NPA determined with 50 clinical negative Ns specimens self-collected from symptomatic individuals suspected of COVID-19 and tested outside their residence (negative determination made on samples of an undisclosed specimen type collected concurrently with the Ns specimens and run in clinical laboratories with an undisclosed high sensitivity molecular FDA Authorized SARS-CoV-2 assay).  
Also conducted studies on microbial interference, reproducibility of contrived samples with analyte concentrations near LoD, and a flex test of robustness of anticipated variability in test conditions/environments (sample mixing, contamination, battery removal, device movement, unlevel surfaces, and storage of packaged devices).",not included,included,not included,ND,https://www.fda.gov/media/143808/download,https://www.fda.gov/media/143810/download,,,,,
,GenScript USA Inc.,cPass SARS-CoV-2 Neutralization Antibody Detection Kit ,,,Kit,USA,"EUA granted November 06, 2020",Laboratory,H,Serology ,,ELISA,"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/143583/download,https://www.fda.gov/media/143584/download,,,,,
,"Quansys Biosciences, Inc.",Q-Plex SARS-CoV-2 Human IgG (4 Plex),,,Kit,USA,"EUA granted October 28, 2020",Laboratory,H,Serology ,IgG,,"Ser, Pla",,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/143452/download,https://www.fda.gov/media/143453/download,,,,,
,DNA Genotek Inc.,ORAcollect∙RNA OR-100 and ORAcollect∙RNA ORE-100 saliva collection devices ,,,,Canada,"EUA granted October 28, 2020",,N/A,Saliva Collection Device,NA,,Sal,,NA,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/143415/download,,,,,
,"Agena Bioscience, Inc.",MassARRAY SARS-CoV-2 Panel,,,Kit,USA,"EUA granted October 26, 2020",Laboratory,H,Molecular,RNA,"RT-PCR, MALDI-TOF  ","NP swab, OP swab, MTNs swab, Ns swab, NP aspirate, Ns aspirate, BAL",,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/143334/download,https://www.fda.gov/media/143331/download,,,,,
,"Celltrion USA, Inc.",Sampinute COVID-19 Antigen MIA,,,Kit,USA,"EUA granted October 23, 2020",Laboratory,"H, M",Antigen ,Antigen,Magnetic Force-assisted Electrochemical Sandwich Immunoassay (MESIA),NP swab,,NA,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/143270/download,https://www.fda.gov/media/143267/download,,,,,
,"binx health, Inc.",binx health At-Home Nasal Swab COVID-19 Sample Collection Kit ,,,Lab,USA,"EUA granted October 20, 2020",,N/A,Home Collection Kit,RNA,,Ns swab,,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,NA,,,,NA,NA,NA,,https://www.fda.gov/media/143186/download,https://www.fda.gov/media/143183/download,,,,,
,"Clinical Enterprise, Inc.",EmpowerDX At-Home COVID-19 PCR Test Kit,,,Lab,USA,"EUA granted October 15, 2020",,N/A,Home Collection Kit,RNA,,Ns swab,,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,NA,,,,NA,NA,NA,,https://www.fda.gov/media/143065/download,https://www.fda.gov/media/143063/download,,,,,
,DNA Genotek Inc.,OMNIgene·ORAL OM-505 and OME-505 (OMNIgene·ORAL) saliva collection devices ,,https://www.dnagenotek.com/US/products/collection-microbiome/omnigene-oral/OM-505.html,Collection,Canada,"EUA granted October 14, 2020",POC,N/A,Saliva Collection Kit,RNA,N/A,Sal,Kit stabilizing solution,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,NA,,,NA,NA,NA,NA,ND,https://www.fda.gov/media/143420/download,https://www.fda.gov/media/143418/download,,,,,
,LumiraDx UK Ltd.,LumiraDx SARS-CoV-2 RNA STAR Complete,,https://www.lumiradx.com/us-en/what-we-do/diagnostics/fast-lab-solutions/rna-star-test,Kit,UK,"EUA granted October 14, 2020",Laboratory,H,Molecular ,RNA,RT with qSTAR amplification,"OP swab, MTNs swab, Ns swab, NP swab","UTM, VTM, BD Universal Viral Transport, PBS, saline, Puritan UniTranz-RT Transport System",ORF1ab,NA,"LumiraDx SARS-CoV-2 RNA STAR extraction buffer, LumiraDx SARS-CoV-2 RNA STAR master mix ","Roche LightCycler 480 II (software version SW 1.5.1), ABI 7500 Fast Dx (software version 1.4.1), ABI QuantStudio 5 (software version 1.5.1), Agilent AriaMx (software version 1.71), Agilent Stratagene Mx3005P (software version 4.10)",20 min,7.5 copy/μL ,,No cross-reactivity predicted in silico,97.78%,45,Clinical,98.46%,65,,,"PPA determined with 45 clinical NP and Ns swabs confirmed positive with an undisclosed EUA-approved molecular test, randomized and tested in a blind study. 
NPA determined with 65 clinical NP and Ns swabs confirmed negative with an undisclosed EUA-approved molecular test, randomized and tested in a blind study. 
16 of the NP swabs were collected in VTM and 94 NP swabs were “dry swabs” expressed in Corning VTM. Samples were processed with the LumiraDx SARS-CoV-2 RNA STAR Complete test
using the Stratagene Mx3005P (software version 4.10). 
Additional experiments demonstrated comparable results when performed on the Roche LightCycler 480 II, Applied Biosystems 7500 Fast Dx, Applied Biosystems QuantStudio 5, Agilent AriaMx and Stratagene Mx3005P.",included,included,included,ND,https://www.fda.gov/media/143062/download,https://www.fda.gov/media/143059/download,,,,,
,Abbott Laboratories Inc.,AdviseDx SARS-CoV-2 IgM ,,https://www.corelaboratory.abbott/us/en/offerings/segments/infectious-disease/sars-cov-2,Kit,USA,"EUA granted October 09, 2020",Laboratory,"H, M",Serology,IgM,Chemiluminescent microparticle immunoassay (CMIA),"Pla, Ser","Dipotassium EDTA, tripotassium EDTA, lithium heparin, lithium heparin in separator tube, sodium heparin, serum separator tube",NA,S,Manual,"ARCHITECT i 1000SR system, ARCHITECT i 2000SR system, Alinity i System.",29 min,NA,,"No cross reactivity detected in wet lab testing of 142 different antibody types, 1 out of 5 samples with antibodies to Rheumatoid Factor had a positive result, out of a total 143 different cross-reactions tested",95% for both Architect and Alinity i,40 for both Architect and Alinity i,Clinical,99.6%  for both Architect and Alinity i,2965 for Architect and 2985 for Alinity i,,,"PPA  determined with 40 clinical frozen serum and plasma specimens collected from patients with COVID-19 symptoms, purchased from undisclosed medical institutions and  confirmed positive with an undisclosed EUA-approved molecular test. Specimens from immunocompromised subjects were not included in the analysis. Results were identical using the Architect and the Aliniti i systems. 
NPA determined with 2965 (Architect) and 2985 (Aliniti i) clinical frozen serum and plasma specimens collected from unique study subjects prior to September 2019 (pre-COVID-19 outbreak) and assumed to be negative. 
All specimens tested were assayed using one lot of the AdviseDx SARS-CoV-2 IgM Reagent Kit, one lot of the AdviseDx SARS-CoV-2 IgM Calibrator Kit, and one lot of the AdviseDx SARS-CoV-2 IgM Control Kit on one Alinity i instrument and on one Architect instrument. ",not included,not included,not included,https://jcm.asm.org/content/58/8/e00941-20,"https://www.fda.gov/media/142940/download 
https://www.fda.gov/media/142941/download",https://www.fda.gov/media/142937/download,,,,,
,"Access Bio, Inc.",CareStart COVID-19 Antigen test ,,https://accessbiodiagnostics.net/carestart-covid-19-antigen/,Kit,USA,"EUA granted October 08, 2020","Laboratory, POC","H, M, W",Antigen ,Antigen,Lateral Flow,NP swab,VTM,NA,N,Manual,Colorimetric with visual read,10 min,"8 x 100 TCID50/mL for direct NP swabs
6.4 x 1000 TCID50/mL for NP swabs in VTM",,"No cross-reactivity detected in wet lab testing, possible cross-reactivity predicted in silico for human coronavirus HKU1",87.70%,49,Clinical,100.00%,80,,,"PPA determined with 49 clinical samples consisting of 43 positive NP swabs collected from symptomatic patients in several undisclosed US locations and tested retrospectively, and 6 NP or nasal swabs tested in a multi-site prospective study in the US and confirmed positive using an undisclosed EUA-approved molecular assay. 
NPA determined with 80 clinical samples consisting of 63 negative NP swabs collected from patients in several undisclosed US locations and tested retrospectively, and 17 NP or nasal swabs tested in a multi-site prospective
study in the US, and confirmed negative using an undisclosed EUA-approved molecular assay.
Tests were performed blinded by minimally trained operators representative of the intended users. 
In addition, 20 contrived samples were tested, including 10 negatives (zero analyte in Ns swab VTM) and 10 positives (near the Limit of Detection at 2x LoD) prepared using the inactivated SARS-CoV-2 isolate USA-WA1/2020 spiked into Ns swab in VTM. There was 100% agreement between positive contrived samples and negative samples compared to expected results. ",included,included,included,ND,https://www.fda.gov/media/142919/download,https://www.fda.gov/media/142916/download,,,,,
,"Beckman Coulter, Inc.",Access SARS-CoV-2 IgM,,https://www.beckmancoulter.com/products/immunoassay/access-sars-cov-2-igm-antibody-test,Kit,USA,"EUA granted October 08, 2020",Laboratory,"H, M",Serology ,IgM,Heterogeneous Immunoassay (CLIA),"Pla, Ser","serum separator tube, lithium heparin, dipotassium EDTA, tripotassium EDTA, sodium citrate",NA,S1,Manual,"Fully automated Access Family of Immunoassay Analyzers Access 2, UniCel DxI 600, UniCel DxI 800, integrated chemistry/immunoassay platforms UniCel DxC 600i, UniCel DxC 680i, UniCel DxC 880i, UniCel DxC 660i, UniCel DxC 860i.",1h,NA,,Cross-reactivity detected in wet lab testing against Anti-Hepatitis C Virus (1/16 samples) and Rheumatoid Factor (RF) IgM (1/14 samples),96.70%,151,Clinical,99.90%,1400,,,"PPA determined with 151 clinical serum and plasma specimens from symptomatic subjects diagnosed with SARS-CoV-2 using undisclosed molecular tests from France and the United States.
NPA determined with 1,400 clinical specimens collected prior to December 2019 in France and the United States and presumed negative. This total includes 1,000 samples from blood donors in France and 200 samples each from routine clinical laboratory diagnostic samples in France and the United States.",not included,not included,not included,ND,https://www.fda.gov/media/142911/download,https://www.fda.gov/media/142908/download,,,,,
,"Genalyte, Inc.",Maverick SARS-CoV-2 Multi-Antigen Serology Panel v2 ,,https://www.genalytecovid19.com/,Kit,USA,"EUA granted October 08, 2020",Laboratory,"H, M",Serology ,IgM/IgG,Photonic ring immunoassay,"Pla, Ser, VWB",Dipotassium EDTA,NA,"N, S1, S2, S1-RDB",Manual,Maverick Diagnostic System,48h,NA,,No cross-reactivity detected in wet lab testing of only 5 non-corona viruses,96.10%,181,Clinical,97.70%,862,,,"PPA determined with 181 clinical serum and plasma samples collected prospectively or retrospectively and confirmed positive with an undisclosed molecular test.
NPA determined with 814 presumptively normal clinical samples collected prior to November 2019 (type of sample undisclosed) and 48 clinical samples collected from patients confirmed negative with an undisclosed molecular test.",included,included,included,,https://www.fda.gov/media/142915/download,https://www.fda.gov/media/142912/download,,,,,
,Spectrum Solutions LLC,SDNA-1000 Saliva Collection Device ,,https://spectrumsolution.com/COVID19-at-home/,Collection,USA,"EUA granted October 08, 2020",Home collection,N/A,Saliva Collection Kit,RNA,NA,Sal,"Spectrum stabilizing solution, included in kit",NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,NA,,,"Clinical validation of saliva samples showed 100% concordance using  3 different RNA extraction platforms (Perkin Elmer* Viral DNA/RNA 300 Kit H96,  ThermoFisher MagMax Viral/Pathogen II NA Extraction Kit, Qiagen DSP Virus/Pathogen Midi Kit) and 98% concordance using Roche Magna Pure LC Total Nucleic Acid Isolation Kit
100% negative sample concordance to previously analyzed matched clinical samples (undisclosed method of negativity determination) 
No significant degradation of viral RNA observed
No evidence of viral growth in the presence of SDNA-1000 lysis buffer detected (indicating virus inactivation in collected samples)",NA,NA,NA,,https://www.fda.gov/media/143055/download,https://www.fda.gov/media/142906/download,,,,,
Y,"GenMark Diagnostics, Inc.",ePlex Respiratory Pathogen Panel 2,,https://genmarkdx.com/panels/eplex-panels/respiratory-pathogen-panel/,Kit,USA,"EUA granted October 07, 2020",Laboratory,"H, M","Molecular, Multi-analyte",RNA,"RT, Nested multiplex PCR, Multi-analyte",NP swab,VTM,"SARS-CoV-2 (undisclosed target gene)  plus 15 other viruses and 2 bacteria: adenovirus, coronavirus (229E, HKU1, NL63, OC43), human metapneumovirus, human rhinovirus/enterovirus, influenza A, influenza A H1, influenza A H1-2009, influenza A H3, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, respiratory syncytial virus (RSV) A, respiratory syncytial virus (RSV) B, Chlamydia pneumoniae, and Mycoplasma pneumoniae.",NA,"Fully automated extraction, reverse transcription and amplification using GenMark ePlex instrument (software version not disclosed)",GenMark ePlex instrument (software version not disclosed),ND,0.25 copies/µL (1 x 10-2 TCID50/mL),,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,59,Clinical,100.00%,111,,,"PPA determined with 59 frozen clinical NP swab specimens collected in the US and confirmed positive using an undisclosed EUA-approved molecular test. Of note, the initial number of positive clinical samples was 60, with 1 sample not included in analysis because it did not have a valid ePlex RP2 Panel result. 
NPA determined with 111 frozen clinical NP swab specimens collected prior to 2017 in the US and presumed negative. The initial number of presumed negative clinical samples was 114, with 3 samples not included in analysis because they did not have a valid ePlex RP2 Panel result.",not included,included,not included,,https://www.fda.gov/media/142905/download,https://www.fda.gov/media/142902/download,,,,,
Y,"ZEUS Scientific, Inc.",ZEUS ELISA SARS-CoV-2 IgG Test System ,,https://www.zeusscientific.com/products/zeus-elisa-test-systems/zeus-elisa-sars-cov-2-igg-test-system,Kit,USA,"EUA granted October 06, 2020",Laboratory,"H, M",Serology,IgG,ELISA,"Ser, Pla","Dipotassium EDTA, lithium heparin, sodium citrate",NA,"S, N",Manual ,"Any plate reader for manual assay, AGILITY automated ELISA analyzer for automated assay (Dynex Technologies)",60-80min,NA,,"Cross-reactivity detected in wet lab testing: false-positive rate of 1.1% using specimens of patients with other respiratory illnesses, 4.3% using HIV-positive patients, 1.1% using specimens from healthy blood donors. ",93.30%,30,Clinical,100.00%,70,,,"PPa determined with 30  frozen positive serum and plasma clinical samples confirmed positive with a nucleic acid amplification test (NAAT) and in which both IgM and IgG antibodies  were confirmed to be present using several orthogonal methods prior to testing with the ZEUS ELISA SARS-CoV-2 IgG.
NPA determined with 70 frozen antibody-negative serum and plasma clinical samples collected prior to 2020 without regard to clinical status and assumed to be negative.  10 samples were collected from known HIV-positive patients to measure cross-reactivity with HIV antibodies but were not included in NPA. 
Clinical performance study was performed as an Independent Clinical Agreement Validation Study on July 2, 2020 at the Frederick National Laboratory for Cancer Research (FNLCR) sponsored by the National Cancer Institute (NCI).
Note: test is specific for human IgG and does not cross react with human IgM antibody",included,included,included,,https://www.fda.gov/media/142809/download,https://www.fda.gov/media/142806/download,,,,,
Y,"University of California, Los Angeles (UCLA)",UCLA SwabSeq COVID-19 Diagnostic Platform ,,https://compmed.ucla.edu/content/ucla-swabseq-covid-19-diagnostic-test,Lab,USA,"EUA granted October 06, 2020",Laboratory,H,Molecular ,RNA,NGS,"NP swab,OP swab, MTNs swab, ANs swab","VTM, Amies Transport Medium, Saline",S,NA,"Thermo Fisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on Thermo Fisher Kingfisher Instrument for extraction, TaqPath 1-Step RT-qPCR Master Mix on Veriti 384-Well Thermal Cycler for amplification. ","Illumina MiSeq sequencing system, Illumina NextSeq 500/550 sequencing system (both with UCLA Amplicon Quantification Software V1.0.)",ND,250 GCE/mL for both NextSeq and MiSeq systems,,No cross-reactivity predicted in silico ,100.00%,82,Clinical,100.00%,88,,,"PPa determined with 31 (MiSeq sequencer) and 51 (NextSeq sequencer) remnant positive NP swab clinical specimens collected in either VTM, Amies Transport Medium or Saline, and confirmed positive using an undisclosed EUA-authorized molecular assay at the UCLA Clinical Microbiology Laboratory. 
NPA determined with 35 (MiSeq sequencer) and 53 (NextSeq sequencer) negative NP swab clinical specimens and confirmed negative using an undisclosed EUA-authorized molecular assay at the UCLA Clinical  Microbiology Laboratory.",included,included,included,"https://www.medrxiv.org/content/10.1101/2020.08.04.20167874v1
https://www.biorxiv.org/content/10.1101/2020.08.15.252510v1",https://www.fda.gov/media/142805/download,https://www.fda.gov/media/142802/download,,,,,
,"SEASUN BIOMATERIALS, Inc.",AQ-TOP COVID-19 Rapid Detection Kit PLUS ,,,,,"EUA granted October 05, 2020",Laboratory,H,Molecular ,RNA,RT-LAMP,,,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/142800/download,https://www.fda.gov/media/142797/download,,,,,
,Quidel Corporation,Sofia 2 Flu + SARS Antigen FIA,,https://www.quidel.com/immunoassays/sofia-2-flu-sars-antigen-fia,Kit,USA,"EUA granted October 02, 2020","Laboratory, POC","H, M, W","Antigen Lateral Flow, Fluorescence, Instrument Read, Multi-Analyte",Antigen,,,,NA,,Manual,,15min,,,,,,,,,,,,,,,,https://www.fda.gov/media/142697/download,https://www.fda.gov/media/142697/download,,,,,
Y,Thermo Fisher Scientific,OmniPATH COVID-19 Total Antibody ELISA Test,,https://www.thermofisher.com/covid-19-antibody-testing/us/en/solutions/OmniPATH-COVID19-Total-Antibody-ELISA-Test.html,Kit,USA,"EUA granted October 02, 2020",Laboratory,"H, M",Serology ,IgA/IgM/IgG,ELISA,Ser,,NA,S,"Manual, Dynex AGILITY automated ELISA workstation","Any plate reader for manual assay, AGILITY automated ELISA analyzer for automated assay (Dynex Technologies)",ND,NA,,Cross-reactivity detected in wet lab testing of 240 specimens from 16 different disease categories: test detected 1 in 30 specimens positive for Chlamydophila pneumoniae IgG,96.70%,30,Clinical,97.50%,80,,,"PPa determined with 30  frozen positive serum clinical samples confirmed positive with a nucleic acid amplification test (NAAT) and in which both IgM and IgG antibodies  were confirmed to be present using several orthogonal methods prior to testing with the OmniPATH COVID-19 Total Antibody.
NPA determined with 80 frozen antibody-negative serum and anticoagulent citrate dextrose (ACD) plasma clinical samples collected prior to 2020 assumed to be negative. 70 negative samples were collected  without regard to clinical status and 10 samples were collected from known HIV-positive patients. 
Clinical performance study was performed as an Independent Clinical Agreement Validation Study on September 1, 2020 at the Frederick National Laboratory for Cancer Research (FNLCR) sponsored by the National Cancer Institute (NCI)",included,included,included,,https://www.fda.gov/media/142700/download,https://www.fda.gov/media/142697/download,,,,,
,"BioFire Diagnostics, LLC",BioFire Respiratory Panel 2.1-EZ (RP2.1-EZ),,https://www.biofiredx.com/products/the-filmarray-panels/filmarrayrp/,,USA,"EUA granted October 02, 2020","Laboratory, POC","H, M, W",Molecular ,RNA,"RT, Nested multiplex PCR, Multi-analyte",,,,NA,,,45min,,,,,,,,,,,,,,,,https://www.fda.gov/media/142696/download,https://www.fda.gov/media/142693/download,,,,,
,UMass Memorial Medical Center,UMass Molecular Virology Laboratory 2019-nCoV rRT-PCR Dx Panel,,https://www.umassmemorialhealthcare.org/umass-memorial-medical-center/patients-visitors/patient-resources/free-covid-19-testing,Lab,USA,"EUA granted October 01, 2020",Laboratory,H,Molecular ,RNA,rRT-PCR,,,,NA,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/142597/download,https://www.fda.gov/media/142689/download,,,,,
,"Beckman Coulter, Inc.",Access IL-6,,,,,"EUA granted October 01, 2020",Laboratory,"H, M","One-step immunoenzymatic (""sandwich"") assay, IL-6",,,,,,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/media/142600/download,https://www.fda.gov/media/142597/download,,,,,
,"Tempus Labs, Inc.",iC SARS-CoV2 Test,,https://www.tempus.com/pcr-testing/,Lab,USA,"EUA granted October 01, 2020",Laboratory,H,Molecular ,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, Ns swab","VTM, MAWI DNA Technologies iSWAB-Microbiome collection tube",", N, S, ORF1ab",NA,"Chemagic Viral DNA/RNA 300 H96 kit on the PerkinElmer Chemagic 360 instrument (software version 6.3.0.3) for automated extraction, TaqPath COVID-19 Combo Kit for reverse transcription and amplification",ABI QuantStudio 7 Flex 384 (software version 1.3).,24-48 hours,0.25 copies/µL (11 GCE/reaction),,No cross-reactivity predicted in silico ,100.00%,59,clinical,98.40%,61,,,"PPA determined with 59 clinical NP specimens collected from an undisclosed location in VTM and confirmed positive with Thermo Fisher Scientific TaqPath COVID-19 Combo kit (30 samples) or AvellinoCoV2 test (29 samples).
NPA determined with 61 clinical NP specimens  collected from an undisclosed location in VTM and confirmed negative with Thermo Fisher Scientific TaqPath COVID-19 Combo kit (31 samples) or AvellinoCoV2 test (30 samples).
Additional validation was performed using 38 negative clinical samples and 37 contrived samples prepared by spiking Twist Bioscience synthetic SARS-CoV-2 RNA Control 1 into leftover non-reactive clinical specimens ( NP swab, ANs swab) collected in Mawi or VTM at 2X LoD, resulting in 100% agreement with expected positive results and 100% agreement with expected negative results.
Samples were stable at room temperature (25°C) for 8 days in Mawi iSwab Microbiome medium.",included,included,included,,https://www.fda.gov/media/142596/download,https://www.fda.gov/media/142593/download,,,,,
,"Alimetrix, Inc.",Alimetrix SARS-CoV-2 RT-PCR Assay,,https://www.alimetrix.com/covid-19.html,Lab,USA,"EUA granted September 30, 2020",Laboratory,H,Molecular ,RNA,"RT-PCR, Microarray Hybridization","NP swab, OP swab, ANs swab, MTNs swab, NP wash, NP aspirate, Ns aspirate, BAL",Zymo Research DNA/RNA Shield media ,"N (N1, N2), Orf1ab",NA,"Qiagen QIAamp 96 Virus QIAcube HT (manual) on QiaVac manifold or Zymo Research Quick-DNA/RNA Viral MagBead Extraction Kit performed on the automated MagMAX Express 96 instrument (with software version 1.2) for extraction, amplification using Qiagen QuantiFast Multiplex RT-PCR +R kit on the Applied Biosystems GeneAmp 9700 Thermal Cycler ( AB software version 3.12), hybridization using Alimetrix Environmentally-controlled hybridization robot (Flair Automated Analysis Software version 3.0)",Sensovation Sensopot microarray scanner (software ArrayReader version 3.1.0.15245),24 hours,"0.25 copy/μL for automated RNA extraction using Zymo Research Quick-DNA/RNA Viral MagBead
1 copy/μL for manuel RNA extraction using Qiagen QIAamp 96 Virus QIAcube HT ",,No cross-reactivity predicted in silico nor detected in wet lab testing,98.70%,41,Clinical,95.50%,47,,,"PPA determined with 41 clinical specimens total, 36 of which were either leftover clinical NP swab specimens (BBL SARS-CoV-2 Validation Panel) purchased from BocaBiolistics Biobanx or leftover NP swab specimens obtained from an undisclosed outside laboratory. Positivity was confirmed using EUA authorized molecular tests in which 30 clinical specimens were tested with undisclosed comparator test 1 and 6 clinical specimens were tested with undisclosed comparator test 2.  In addition the first five positive clinical specimens determined by the Alimetrix SARS- CoV-2 RT-PCR Assay were sent to an undisclosed outside laboratory running an authorized molecular test for confirmatory positive determination.
NPA determined with 47 clinical specimens total, 36 of which were either leftover clinical NP  swab specimens (BBL SARS-CoV-2 Validation Panel) purchased from BocaBiolistics Biobanx or leftover NP swab specimens obtained from an undisclosed outside laboratory. Negativity was confirmed using EUA authorized molecular tests in which 30 clinical specimens were tested with undisclosed comparator test 1 and 12 clinical specimens were tested with undisclosed comparator test 2. In addition the first five negative clinical specimens determined by the Alimetrix SARS- CoV-2 RT-PCR Assay were sent to an undisclosed 
outside laboratory running an authorized molecular test for confirmatory negative determination.  
All specimens were tested twice using Zymo Quick-DNA/RNA Viral MagBead Extraction Method (automated) and Qiagen QIAamp 96 Virus QIAcube HT Kit (manual). ",included,included,included,ND,https://www.fda.gov/media/142592/download,https://www.fda.gov/media/142589/download,,,,,
,Aeon Global Health,Aeon Global Health SARS-CoV-2 Assay,,https://aeonglobalhealth.com/covid-19/,Lab,USA,"EUA granted September 30, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab, NP wash, NP aspirate, Ns aspirate, BAL",ND,"N, S, Orf1ab",NA,"Automated RNA extraction using Omega Bio-Tek Mag-Bind Viral DNA/RNA 96 kit on the MagMax Express-96 Magnetic Particle Processor, amplification using Thermo Fisher Scientific TaqPath COVID-19 Combo Kit and TaqPath 1-Step Multiplex Master Mix",AB QuantStudio 12K Flex Real-Time PCR System with QuantStudio 12K Software (v1.3) for primary analysis and AB Design and Analysis Software (DA2 v2.4.0) for secondary analysis,24 hours,0.25 copy/μL,,No cross-reactivity predicted in silico,100.00%,35,Clinical,97.14%,35,,,"PPA determined with 35 clinical NP specimens confirmed positive with 2 different undisclosed EUA-approved molecular tests.
NPA determined with 35 clinical NP specimens confirmed negative with 2 different undisclosed EUA-approved molecular tests.",included,included,included,,https://www.fda.gov/media/142535/download,https://www.fda.gov/media/142532/download,,,,,
,"DiaSorin, Inc.",DiaSorin LIAISON SARS-CoV-2 IgM Assay,,https://www.diasorin.com/en/immunodiagnostic-solutions/clinical-areas/infectious-diseases/covid-19,Kit,Italy,"EUA granted September 29, 2020",Laboratory,H,Serology,IgM,Heterogeneous Immunoassay (CLIA),"Ser, Pla","Dipotassium EDTA, sodium heparin, lithium heparin",NA,S,Manual,LIAISON® XL Analyzer,ND,NA,,"Crossreactivity in web lab testing indicated 1/10 positive for -Mycoplasma pneumoniae, 1/10 positive for HAMA, 1/10 positive for HSV 1/2",91.80%,122,Clinical,99.30%,2473,,,"PPA determined with 122 clinical samples from European patients (types of samples undisclosed) obtained between 8 to 30 days after diagnosis and confirmed positive with an undisclosed molecular test.
NPA determined with 2473 clinical samples collected before the COVID19 outbreak from a European laboratory routine (n=1072), a US laboratory routine (n=400) and European blood donors (n= 1001), presumed Sars-cov2 negative.                                                                            ",not included ,included,not included,,https://www.fda.gov/media/142552/download,https://www.fda.gov/media/142549/download,,,,,
,"NanoEntek America, Inc.",FREND COVID-19 total Ab ,,http://www.nanoentek.com/theme/nanont2_en/shop/02/product01_view.php?it_id=1585699547,Kit,South Korea,"EUA granted September 29, 2020",Laboratory,"H, M",Serology ,IgM/IgG,Lateral Flow Fluorescence immunoassay,Pla,Dipotassium EDTA,NA,N,Manual,FREND bench-top fluorescence reader,4 minutes,NA,,ND,96.70%,30,Clinical,98.80%,80,,,"PPA determined with 30 clinical serum samples confirmed positive with an undisclosed molecular test and in which the presence of IgM and IgG antibodies was confirmed using one or several undisclosed comparator methods. 
NPA determined with 80 serum or plasma clinical samples collected prior to 2020 and including 70 samples selected regardless of clinical status and 10 samples selected from HIV-positive patients, confirmed sars-cov2 negative using an undisclosed molecular test.                                                                            
Clinical performance was tested at the  NCI-sponsored Frederick National Laboratory for Cancer Research (USA).   ",not included ,included,not included,,https://www.fda.gov/media/142557/download,https://www.fda.gov/media/142554/download,,,,,
,"Nirmidas Biotech, Inc.",Nirmidas COVID-19 (SARS-CoV-2) IgM/IgG Antibody Detection Kit,,https://www.nirmidas.com/nirmidas-covid19-igmigg-antibody-detection-kit-eua-authorized,Kit,USA,"EUA granted September 29, 2020",Laboratory,"H, M",Serology ,IgM/IgG,Lateral Flow,"Ser, Pla","Dipotassium EDTA, Lithium heparin",NA,S,Manual,Colorimetric with visual read,15 minutes,NA,,ND,96.60%,58,Clinical,97.90%,97,,,"PPA determined with 58 clinical frozen serum samples confirmed positive with an undisclosed molecular test and in which the presence of IgM and IgG antibodies was confirmed using one or several undisclosed comparator methods. 
NPA determined with 97 clinical ACD-plasma samples collected prior to 2020 and including 87 samples selected regardless of clinical status and 10 samples selected from HIV-positive patients, confirmed sars-cov2 negative using an undisclosed molecular test.
Clinical performance was tested at the  NCI-sponsored Frederick National Laboratory for Cancer Research (USA). ",not included ,included,not included,https://www.nature.com/articles/s41551-020-00642-4,https://www.fda.gov/media/142561/download,https://www.fda.gov/media/142558/download,,,,,
,"CENTOGENE US, LLC",CentoSure SARS-CoV-2 RT-PCR Assay ,,https://www.centogene.com/covid-19/testing/about-the-sars-cov-2-test.html,Lab,USA,"EUA granted September 29, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,dry OP swab,None (sample should NOT be placed in transport medium),"N (N1, N2)",NA,Machery-Nagel NucleoMag VET kit with Thermo Fisher KingFisher Flex or Thermo Fisher MagMAX Viral with Thermo Fisher KingFisher Flex for RNA extraction ,LightCycler 480 II (Software Version 1.5.1.62 or higher),ND,"2 copy/μL NucleoMag Vet 
2 copy/μL MagMax Viral Kit",,No cross-reactivity predicted in silico,100.00%,25,Clinical,100.00%,100,,,"PPA determined with 25 clinical dry OP swabs confirmed positive with an undisclosed EUA-approved molecular test that measures different target genes (E- and RdRP-gene).
NPA determined with 100 clinical dry OP swabs  confirmed negative with an undisclosed EUA-approved molecular test that measures different target genes (E- and RdRP-gene). ",included,included,not included,,https://www.fda.gov/media/142539/download,https://www.fda.gov/media/142536/download,,,,,
N,Akron Children’s Hospital,Akron Children’s Hospital SARS-CoV-2 Assay,,https://www.akronchildrens.org/lab_tests/SARSCoV2COVID19RTPCRQualitative.html,Lab,USA,"EUA granted September 29, 2020",Laboratory,H,Molecular ,RNA,rRT-PCR,"NP swab, OP swab, ANs swabs, MTNs swabs, Ns aspirate, Ns wash, BAL","VTM, Remel M4 Medium, Phosphate Buffered Saline","E, S",NA,"Promega Maxwell 16 Viral Total Nucleic Acid Purification Kit on Promega Maxwell 16 MDx Instruments (firmware v1.4 or v1.6) or  Promega Maxwell RSC Viral Total Nucleic Acid Purification Kit  on Maxwell RSC 48 System (software v3.0.1) for nucleic acid extraction, Altona Diagnostics RealStar SARS-CoV-2 RT-PCR Kit (Kit 1.0 or Kit US) for PCR amplification",QIAGEN Rotor-Gene Q MDx Instrument and Rotor-Gene (Software V2.1.0.9),24-72 hours,"250 copies/mL with Promega Maxwell 16 Viral Total Nucleic Acid Purification Kit on  Maxwell 16 MDx instrument
1250 copies/mL with Promega Maxwell RSC Viral Total Nucleic Acid Purification Kit on Maxwell RSC 48 instrument",,No cross-reactivity predicted in silico nor detected in wet lab testing,96.70%,30,Clinical,96.70%,30,,,PPA determined with 30 clinical specimens confirmed positive with an Emergency Use Authorization (EUA) by FDA molecular test. NPA determined with 30 clinical specimens confirmed negative with an an Emergency Use Authorization (EUA) by FDA molecular test,included,included,included,ND,https://www.fda.gov/media/142543/download,https://www.fda.gov/media/142540/download,,,,,
,National Jewish Health,SARS-CoV-2 MassArray Test ,,https://www.nationaljewish.org/about/news/press-releases/2020/national-jewish-health-launches-additional-coronavirus-test,Lab,USA,"EUA granted September 29, 2020",Laboratory,H,Molecular,RNA,"RT-PCR, MALDI-TOF","NP swab, OP swab,  MTNs swab, Ns swab, Ns aspirate, NP aspirate, Ns wash, NP wash, BAL",ND,"ORF1ab, ORF1, N ",NA,"Thermo Fisher MagMAX Viral/Pathogen Nucleic Acid Isolation kit on the Thermo Fisher KingFisher Flex Purification System or Omega Bio-Tek Mag-Bind Viral DNA/RNA kit with Hamilton StarLet liquid handling system for RNA extraction,  TaqPath One-step Master Mix or One-step Multiplex Master Mix on the Thermo Fisher Veriti thermal cycler for PCR amplification",Agena Bioscience MassARRAY System (SpectroACQUIRE software v4.3.145 and v.5.0 and TyperAnalyzer software v.4.1.83 and v5.0.1). ,24-48 hours,"0.69 copies/µL with the KingFisher Flex Purification System and MagMAX Viral/Pathogen Nucleic Acid Isolation Kit
2.75 copies/µL with the Omega Viral DNA/RNA Kit on the Hamilton  StarLet Liquid Handling System ",,No cross-reactivity predicted in silico,100.00%,71,Clinical,99.65%,282,,,"PPA determined with 71 clinical NP swab specimens confirmed positive with an undisclosed EUA-approved molecular test, 39 of which were extracted using the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the KingFisher Flex Purification System, and 32 were extracted using the Omega Viral DNA/RNA kit on the Hamilton StarLet liquid handling system. 
NPA determined with 282 clinical NP swab specimens confirmed negative with an undisclosed EUA-approved molecular test, 208 of which were extracted using the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the KingFisher Flex Purification System, and 74 were extracted using the Omega Viral DNA/RNA kit on the Hamilton StarLet liquid handling system. ", included ,included,included,ND,https://www.fda.gov/media/142548/download,https://www.fda.gov/media/142545/download,,,,,
,"Genetrack Biolabs, Inc.",Genetrack SARS-CoV-2 Molecular Assay ,,http://www.genetrackus.com/,"Lab, collection",Canada,"EUA granted September 25, 2020",Laboratory,H,"Molecular, Home collection kit",RNA,rRT-PCR,ANs swab at home collection using Vo' COVID-19 Test Home Collection Kit,Genetrack Molecular Transport Buffer Solution,"N (N1, N2)",NA,"Thermo Fisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit for RNA extraction, Thermo Fisher TaqPath1-Step Multiplex Master Mix (No ROX) for reverse transcription",ABI QuantStudio 6 Pro Real-Time PCR System (software v2.4.1),ND,1 copy/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,,,"PPA determined with 30 clinical NP swab specimens confirmed positive with an undisclosed EUA-approved molecular test. 
NPA determined with 30 clinical NPswab specimens confirmed negative with an undisclosed EUA-approved molecular test. 
Home collection kit tested and found suitable for sample stability and human usability in simulated real-life conditions. ", included ,included,included,ND,https://www.fda.gov/media/142482/download,https://www.fda.gov/media/142479/download,,,,,
,Quotient Suisse SA,MosaiQ COVID-19 Antibody Magazine ,,https://www.quotientbd.com/covid-19,Kit,Switzerland,"EUA granted September 25, 2020",Laboratory,H,Serology ,IgM/IgG,Heterogenous solid phase photometric immunoassay,"Ser, Pla","dipotassium (K2) EDTA, tripotassium (K3) EDTA ",NA,S,Manual,MosaiQ 125 instrument,24 seconds,NA,,No cross-reactivity detected in wet lab testing,93.00%,86,Clinical,99.80%,408,,,"PPA determined with 86 clinical specimens (sample type not specified) confirmed positive with an undisclosed molecular test.
NPA determined with 408 clinical specimens  (sample type not specified) presumed negative.                                                                      
Clinical agreement studies were conducted at an unspecified site external to the manufacturer ",not included ,included,included,ND,https://www.fda.gov/media/142486/download,https://www.fda.gov/media/142483/download,,,,,
,Cepheid,Xpert Xpress SARS-CoV-2/Flu/RSV,,https://www.cepheid.com/coronavirus,Kit,USA,"EUA granted September 24, 2020","Laboratory, POC","H, M, W",Molecular,RNA,rRT-PCR,"NP swab, Ns swab, Ns wash, Ns aspirate",VTM,"Sars-CoV-2: N2, E
Influenza A: M, PB2, PA
Influenza B: M, NS
RSV: N",NA,"Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Cartridge on the Cepheid GeneXpert Dx System, Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Cartridge on the Cepheid GeneXpert Infinity-80 System, Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Cartridge on the Cepheid GeneXpert Infinity-48 System, Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Cartridge on the Cepeheid GeneXpert Xpress II System, Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Cartridge on the Cepeheid GeneXpert Xpress IV System","Cepheid GeneXpert Dx System (Software Version 4.7b or higher), Cepheid GeneXpert Infinity-80 System (Software Version 6.4b or higher), Cepheid GeneXpert Infinity-48 System (Software Version 6.4b or higher), Cepheid GeneXpert Xpress II System (Tablet Configuration, Software Version 5.0), Cepheid GeneXpert Xpress IV System (Tablet Configuration, Software Version 5.1), Cepheid GeneXpert Xpress IV System (Hub Configuration, Software Version 6.1)",~36 minutes (~25 minutes for SARS-CoV-2 alone),"SARS-CoV-2: 131 copies/mL
Influenza (A/California/7/2009): 0.004 TCID50/mL
Influenza (A/Victoria/361/2011): 0.087 TCID50/mL
Influenza (B/Mass/2/2012): 0.04 TCID50/mL
RSV (A2/Australia/61): 0.43 TCID50/mL
RSV (B/Wash/18537/62): 0.22 TCID50/mL",,"Cross-reactivity anticipated with Human and Bat SARS-coronaviruses from E gene.  No cross reacitiivity detected in wet lab testing for influenza A, Influenza B, or RSV (i.e. wet lab testing not conducted for SARS-CoV-2).",97.90%,47,Clinical,100.00%,193,,,"PPA determined with 47 blinded and randomized clinical positive NP specimens collected in VTM (sample provenance not disclosed; samples were archived and selected consecutively by date and previously known analyte result; positive determination made using the FDA-cleared Xpert Xpress Flu/RSV).  
NPA determined with 193 blinded and randomized clinical negative NP specimens collected in VTM (sample provenance not disclosed; samples were archived and selected consecutively by date and previously known analyte result; negative determination made using the FDA-cleared Xpert Xpress Flu/RSV).  
Also conducted a competitive inhibition study for all five viruses.",not included,included,not included,ND,"Labs: https://www.fda.gov/media/142437/download , Point of Care: https://www.fda.gov/media/142438/download",https://www.fda.gov/media/142434/download,,,,,
,"Clear Labs, Inc.",Clear Dx SARS-CoV-2 Test ,,https://www.clearlabs.com/covid-19/,Kit,USA,"EUA granted September 23, 2020",Laboratory,H,Molecular,RNA,NGS,"NP swab, OP swab, ANs swab, MTNs swab, NP wash, NP aspirate, Ns aspirate, BAL","VTM, UTM, Phosphate Buffer Saline (PBS), Saline",not disclosed,NA,"MagMAX Viral RNA Isolation Kit for RNA extraction, fully automated Clear Dx system including Hamilton STAR robotic workstation and Hamilton On-Deck Thermal Cyclers (software Venus v4)",NGS on Oxford Nanopore GridION Sequencer - MinKNOW 18.12.4,ND,2 copy/μL,,No cross-reactivity detected in wet lab testing,100.00%,50,Clinical,100.00%,32,,,"PPA determined with 50 clinical NP swab specimens confirmed positive with an undisclosed EUA-approved molecular test. 
NPA determined with 32 clinical NP swab specimens confirmed negative with an undisclosed EUA-approved molecular test. ",not included ,included,not included,,https://www.fda.gov/media/142418/download,https://www.fda.gov/media/142419/download,,,,,
,"Jiangsu Well Biotech Co., Ltd.",Orawell IgM/IgG Rapid Test,,ND,Kit,China,"EUA granted September 23, 2020",Laboratory,"H, M",Serology ,IgM/IgG,Lateral Flow,"Ser, Pla ",ACD (acid citrate dextrose) for plasma,NA,S,Manual,Colorimetric with visual read,10 minutes,NA,,No cross-reactivity detected in wet lab testing,100.00%,58,Clinical,94.80%,97,,,"PPA determined with 58 clinical frozen serum samples confirmed positive with an undisclosed molecular test and in which the presence of IgM and IgG antibodies was confirmed using one or several undisclosed comparator
 methods. 
NPA determined with 97 ACD-plasma samples collected prior to 2020 and including 87 samples selected regardless of clinical status and 10 samples selected from HIV-positive patients, , confirmed sars-cov2 negative using an undisclosed molecular test.                                                                                
Clinical performance was tested at the  NCI-sponsored Frederick National Laboratory for Cancer Research (USA). ",not included ,included,not included,,https://www.fda.gov/media/142422/download,https://www.fda.gov/media/142423/download,,,,,
,Quadrant Biosciences Inc.,Clarifi COVID-19 Test Kit,,https://www.quadrantbiosciences.com/covid-19-projects/,Kit,USA,"EUA granted September 22, 2020",Laboratory,H,Molecular ,RNA,rRT-PCR,Sal,ORAcollect•RNA (OR-100) saliva collection device,ORF1ab,NA,Quadrant Quick RNA Viral 96 Kit extraction kit (included),"Bio-Rad CFX96 Touch Real-Time PCR Detection System (BioRad CFX Maestro Software, version not disclosed), Bio-Rad CFX384 Touch Real-Time PCR Detection System (BioRad CFX Maestro Software, version not disclosed), AB QuantStudio 5 Real-Time PCR System (QuantStudio software, version not disclosed)",ND,1 copy/μL on all three authorized instruments,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,31,Clinical,100.00%,32,,,"PPA determined with 31 clinical saliva swabs collected from the same patients between 0 to 5 days after NP swab collection (collection site not disclosed) and confirmed positive with an undisclosed EUA-approved molecular test. 
NPA determined with 32 clinicalsaliva swabs collected from the same patients between 0 to 5 days after NP swab collection (collection site not disclosed) and confirmed negative with an undisclosed EUA-approved molecular test. ",included,included,included,,https://www.fda.gov/media/142379/download,https://www.fda.gov/media/142376/download,,,,,
,Vela Operations Singapore Pte. Ltd.,ViroKey SARS-CoV-2 RT-PCR Test v2.0 ,,https://www.veladx.com/product/qpcr-respiratory-viruses/virokey-sars-cov-2-rt-pcr-test-v2.html,Kit,Singapore,"EUA granted September 22, 2020",Laboratory,H,Molecular ,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, Ns aspirate, NP aspirate, Ns wash, BAL",ND,"N, ORF1a",NA,ViroKey™ SX Virus Total Nucleic Acid Kit on Sentosa® automated workflow using the liquid handler Sentosa® SX101 instrument. ,"Sentosa® SA201 Real-Time PCR system ( Sentosa® SA201 Reporter software, version not disclosed), AB 7500 Fast Dx Real-Time PCR System (ABI SDS Software 1.4.1)",ND,200 copies/mL with the Sentosa® SA201 Real-Time PCR system,,Cross-reactivity was observed with Mycoplasma pneumoniae and adenovirus 71 in wet lab testing,97.10%,34,Clinical,100.00%,34,,,"PPA determined with 34 clinical NP swabs collected from an undisclosed location and confirmed positive with an undisclosed EUA-approved molecular test. 
NPA determined with 34 clinical NP swabs collected from an undisclosed location and confirmed negative with an undisclosed EUA-approved molecular test. 
All samples were extracted with ViroKey™ SX Virus Total Nucleic Acid Kit on the Sentosa SX101 instrument and detected with the Sentosa® SA201.",included,included,included,,https://www.fda.gov/media/142383/download,https://www.fda.gov/media/142380/download,,,,,
,"KimForest Enterprise Co., Ltd.",KimForest SARS-CoV-2 Detection Kit v1 ,,https://www.kimforest.com/index.php?action=medicine&lang=3,Kit,Taiwan,"EUA granted September 21, 2020",Laboratory,H,Molecular ,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, NP wash, NP aspirate,  Ns aspirate, BAL",VTM,ORF1ab ,NA,QIAamp Viral RNA Mini Kit for RNA extraction (Qiagen),AB StepOne/StepOnePlus Real-Time PCR System (software v2.3),ND,200 copies/mL,,No cross-reactivity predicted in silico,100.00%,30,Clinical,100.00%,30,,,"PPA determined with 30 clinical samples (20 NP swabs, 10 OP swabs) collected from an undisclosed location and confirmed positive with an undisclosed EUA-approved molecular test.
NPA determined with 30 clinical samples (20 NP swabs, 9 OP swabs, 1 unknown swab specimen) collected from an undisclosed location and confirmed negative with an undisclosed EUA-approved molecular test.",included,included,included,,https://www.fda.gov/media/142363/download,https://www.fda.gov/media/142360/download,,,,,
,GK Pharmaceuticals Contract Manufacturing Operations,GK ACCU-RIGHT SARS-CoV-2 RT-PCR KIT,,https://www.gkcmo.com/sars-cov-2,Kit,USA,"EUA granted September 18, 2020",Laboratory,H,Molecular ,RNA,rRT-PCR,"NP swab, OP swab, MTNs swab, Ns swab",VTM,"N (N1, N2)",NA,QIAamp Viral RNA Mini Kit for RNA extraction (Qiagen),AB 7500 Dx Fast Real-Time PCR with Sequence Detection System (SDS) (software v1.4),3 hours,2 copies/uL,,No cross reactivity predicted in silico nor detected in wet lab testing,100.00%,45,Clinical,100.00%,45,,,"PPA determined with 45 clinical NP swab samples collected from an undisclosed CLIA lab in Puerto Rico and confirmed positive with an undisclosed EUA-approved test.
NPA determined with 45 clinical NP swab samples collected from an undisclosed CLIA lab in Puerto Rico and confirmed negative with an undisclosed EUA-approved test.",included,included,included,,https://www.fda.gov/media/142310/download,https://www.fda.gov/media/142307/download,,,,,
,"Visby Medical, Inc.",Visby Medical COVID-19 ,,https://www.visbymedical.com/covid-19-test,Kit,USA,"EUA granted September 16, 2020",Laboratory,"H, M",Molecular ,RNA,epRT-PCR,"NP swab, Ns swab, MTN swab collected by HSP, or self-collected  Ns swab, MTN swab ","UTM, UVT",N,NA,Automated,Visual read on Visby Medical COVID-19 test unit,30 minutes,1 copy/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100%%,30,,,"PPA determined with 30 clinical samples (undisclosed type of samples) collected from an undisclosed site and confirmed positive with an undisclosed test.
NPA determined with 30 clinical samples (undisclosed type of samples) collected from an undisclosed site and confirmed negative with an undisclosed test.",not included ,included,not included,,https://www.fda.gov/media/142228/download,https://www.fda.gov/media/142225/download,,,,,
,"Shenzhen New Industries Biomedical Engineering Co., Ltd.",MAGLUMI 2019-nCoV IgM/IgG,,https://www.snibe.com/zh_en/en_index.aspx,Kit,China,"EUA granted September 14, 2020",Laboratory,"H, M",Serology,IgM/IgG,Heterogeneous Immunoassay (CLIA),Ser,NA,NA,"S, N",Manual,MAGLUMIITM series fully-automated chemiluminescence immunoassay analyzer,ND,NA,,No cross-reactivity detected in wet lab testing,"100% for IgG, 77.5% for IgM",142,Clinical,"99.1% for IgG, 99.6% for IgM",226,,,"PPA determined with 142 clinical serum samples collected from an undisclosed clinical trial site and confirmed positive with an undisclosed PCR test.
NPA determined with 226 clinical serum samples collected from an undisclosed clinical trial site and confirmed negative using an undisclosed PCR test.",included,included,included,,https://www.fda.gov/media/142233/download,https://www.fda.gov/media/142230/download,,,,,
,"Roche Molecular Systems, Inc.","cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test for use on the cobas 
Liat System",,https://diagnostics.roche.com/us/en/products/params/cobas-sars-cov-2-influenza-a-b-nucleic-acid-test.html,Kit,USA,"EUA granted September 14, 2020","Laboratory, POC","H, M, W",Molecular,RNA,rRT-PCR,"NP swab, Ns swab","UTM (Copan Diagnostics), UVT (BD)","Sars-CoV-2: ORF1ab, N
Influenza A: M
Influenza B: NS",NA,Roche cobas Liat Lysis Buffer on the Roche cobas Liat Analyzer,Roche cobas Liat Analyzer,~20 minutes after sample loading,0.012 TCID50/mL (12 copies/mL),,No cross-reactivity predicted in silico nor detected in wet lab testing (only conducted wetlab testing against SARS-CoV-1 when evaluating cross-reactivity for SARS-CoV-2),100.00%,56,Clinical,100.00%,229,,,"PPA determined with 56 clinical positive NP specimens collected in UTM from patients with a suspected respiratory infection (sample provenance not disclosed; positive determination made using an FDA-cleared EUA, cobas SARS-CoV-2 test on cobas 6800/8800 Systems).  
NPA determined with 229 clinical negative NP and Ns specimens (number of each sample type not disclosed) collected in UTM from patients with a suspected respiratory infection (sample provenance not disclosed; negative determination made using an FDA-cleared EUA, cobas SARS-CoV-2 test on cobas 6800/8800 Systems).  Note that three of the negative samples initally generated an invalid result and were re-tested.
Also conducted a competitive inhibition study for all three viruses and a reproducibility study, a matrix equivalency study, and additional non-clinical and clinical studies for influenza A and B",included,included,included,ND,https://www.fda.gov/media/142193/download,https://www.fda.gov/media/142190/download,,,,,
,"BioCheck, Inc.",BioCheck SARS-CoV-2 IgM Antibody Test Kit,,https://acceleratediagnostics.com/products/biocheck-sars-cov-2-igm-and-igg-test-kits/?utm_source=biocheck&utm_medium=website&utm_campaign=biocheck_referral&utm_content=homelink,Kit,USA,"EUA granted September 09, 2020",Laboratory,"H, M",Serology,IgM,Heterogeneous Immunoassay (CLIA),Ser,NA,NA,S,Manual,MS-Fast Automated Chemiluminescent Immunoassay Analyzing System,30 minutes,NA,,No cross-reactivity detected in wet lab testing,95.50%,110,Clinical,97.20%,143,,,"PPA determined with 110 clinical serum samples collected from patients at two Chinese clinical trial centers (institutions not disclosed) and confirmed positive with an undisclosed PCR test. 
NPA determined with 43 pre-pandemic clinical serum samples collected from patients at two Chinese clinical trial centers and 100 pre-pandemic samples collected from patients in the United States (institutions not disclosed) and confirmed negative with an undisclosed PCR test.",included,included,included,,https://www.fda.gov/media/142002/download,https://www.fda.gov/media/141998/download,,,,,
,"BioCheck, Inc.",BioCheck SARS-CoV-2 IgG Antibody Test Kit,,https://acceleratediagnostics.com/products/biocheck-sars-cov-2-igm-and-igg-test-kits/?utm_source=biocheck&utm_medium=website&utm_campaign=biocheck_referral&utm_content=homelink,Kit,USA,"EUA granted September 09, 2020",Laboratory,"H, M",Serology,IgG,Heterogeneous Immunoassay (CLIA),Ser,NA,NA,S,Manual,MS-Fast Automated Chemiluminescent Immunoassay Analyzing System,30 minutes,NA,,No cross-reactivity detected in wet lab testing,99.10%,110,Clinical,100.00%,143,,,"PPA determined with 110 clinical serum samples collected from patients at two Chinese clinical trial centers (institutions not disclosed) and confirmed positive using a comparator PCR test (test identity not disclosed). 
NPA determined with 43 pre-pandemic clinical serum samples collected from patients at two Chinese clinical trial centers and 100 pre-pandemic samples collected from patients in the United States (institutions not disclosed) and confirmed negative for SARS-CoV-2 using a comparator PCR test (test identity not disclosed). ",included,included,included,,https://www.fda.gov/media/142006/download,https://www.fda.gov/media/142003/download,,,,,
,"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.",Wantai SARS-CoV-2 RT-PCR Kit,,http://www.ystwt.cn/covid-19/,Kit,China,"EUA granted September 09, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,OP swab,"VTM, UTM","ORF1ab, N",NA,"Wantai Nucleic Acid Extracting Reagent on the ThermoFisher KingFisher Flex 96, Wantai Nucleic Acid Extracting Reagent on the NEXOR 32, Wantai Nucleic Acid Extracting Reagent on the NEXOR 96, Qiagen QIAamp Viral RNA Mini Kit","Bio-Rad CFX-96 (Bio-Rad CFX Manager 3.1), ABI 7500 (Software version 2.3)",ND,50 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,36,Clinical,100.00%,40,,,"PPA determined with 36 clinical positive NP specimens (samples collected at the Third People’s Hospital of Shenzhen, China; extraction done with the Wantai Nucleic Acid Extracting Reagent and detection done on the ABI 7500; positive determination made using an undisclosed EUA authorized molecular comparator assay).  
NPA determined with 40 clinical negative NP specimens (samples collected at the Third People’s Hospital of Shenzhen, China; extraction done with the Wantai Nucleic Acid Extracting Reagent and detection done on the ABI 7500; negative determination made using an undisclosed EUA authorized molecular comparator assay).
*Note that an initial extraction of the samples resulted in 17 inconclusive results and the above validation numbers were from a secondary extraction of the same samples.",included,included,included,ND,https://www.fda.gov/media/141997/download,https://www.fda.gov/media/141994/download,,,,,
,"BillionToOne, Inc.",qSanger-COVID-19 Assay,,https://billiontoone.com/,Kit,USA,"EUA granted September 04, 2020",Laboratory,H,Molecular,RNA,"RT-PCR, Sanger Sequencing","Ns swab, MTNs swab, NP swab, OP swab",UTM,ND,NA,"Amplification: ABI Veriti Thermal Cycler
PCR Cleanup:  ThermoFisher ExoSAP-IT PCR Product Cleanup Reagent
Sequencing preparation: Fisher Scientific BigDye Terminator v3.1 Cycle Sequencing Kit","ABI 3730xl DNA Analyzer (Data Collection Software Version 5, Sequencing Analysis Software Version 7, optional BillionToOne qSanger-COVID-19 QC Software)",ND,3200 copies/mL (20 copies/rxn),,No cross-reactivity predicted in silico,90.00%,30,Clinical,100.00%,30,,,"PPA determined with 30 clinical positive NP specimens collected in BD UVT (samples collected during standard clinical visits at an undisclosed academic medical center; positive determination made using two undisclosed EUA authorized RT-PCR tests). 
NPA determined with 30 clinical negative NP specimens collected in BD UVT (samples collected during standard clinical visits at an undisclosed academic medical center; negative determination made using two undisclosed EUA authorized RT-PCR tests). 
",not included,included,included,ND,https://www.fda.gov/media/141935/download,https://www.fda.gov/media/141932/download,,,,,
Y,Verily Life Sciences,Verily COVID-19 RT-PCR Test,,https://verily.com/,Lab,USA,"EUA granted September 08, 2020",Laboratory,H,"Molecular, Pooling",RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab",ND,"ORF1ab, N, S",NA,"Sample pooling: Tecan Fluent GX Automated Liquid Handler (software version 2.6) 
RNA extraction: Thermofisher MagMAX Viral/Pathogen Nucleic Acid Isolation on the Thermofisher KingFisher Flex Magnetic Particle Processor","ABI 7500 Dx Fast Real-Time PCR (software version 1.4.1), ABI QuantStudio 5 Real-Time PCR Instrument (software version 1.5.1 )",ND,60 GCE/mL,,No cross-reactivity predicted in silico,98.87%,265,Pools of clinical specimens,100.00%,140,,,"PPA determined with: 
1) 35 individual clinical positive NP specimens with detection on the ABI 7500 Fast Dx (specimen provenance not disclosed; positive determination with the ThermoFisher TaqPath COVID-19 Combo Kit)
2) 35 individual clinical positive NP specimens with detection on the ABI Quantstudio 5 (specimen provenance not disclosed; positive determination with the ThermoFisher TaqPath COVID-19 Combo Kit; same specimens as those run on the ABI 7500 Fast Dx)
3) 40 positive sample pools each comprised of one individual positive NP specimen and seven negative NP specimens with detection on the ABI 7500 Fast Dx (specimen provenance not disclosed; positive and negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit; for negative sample pool creation, 49 individual negative specimens were used to create seven negative sample pools each containing seven unique negative samples, and the negative sample pools were then used to dilute up to six positive samples to create one of the 40 sample pools)
4) 9 positive sample pools each comprised of one individual positive NP specimen and seven negative NP specimens with detection on the ABI 7500 Fast Dx (specimen provenance not disclosed; positive and negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit;  for negative sample pool creation, 72 individual negative specimens were used to create nine unique negative sample pools with no sharing of negative specimens between sample pools)
5) 40 positive sample pools each comprised of one individual positive NP specimen and seven negative NP specimens with detection on the ABI QuantStudio 5 (specimen provenance not disclosed; positive and negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit; for negative sample pool creation, 49 individual negative specimens were used to create seven negative sample pools each containing seven unique samples, and the negative sample pools were then used to dilute up to six positive samples to create one of the 40 sample pools)
6) 9 positive sample pools each comprised of one individual positive NP specimen and seven negative NP specimens with detection on the ABI QuantStudio 5 (specimen provenance not disclosed; positive and negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit;  for negative sample pool creation, 72 individual negative specimens were used to create nine unique negative sample pools with no sharing of negative specimens between sample pools)
7) 40 positive sample pools each comprised of one individual positive NP specimen and eleven negative NP specimens with detection on the ABI 7500 Fast Dx (specimen provenance not disclosed; positive and negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit; for negative sample pool creation, 44 individual negative specimens were used to create four negative sample pools each containing eleven unique negative samples, and the negative sample pools were then each used to dilute ten positive samples to create one of the 40 sample pools)
8) 9 positive sample pools each comprised of one individual positive NP specimen and eleven negative NP specimens with detection on the ABI 7500 Fast Dx (specimen provenance not disclosed; positive and negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit;  for negative sample pool creation, 72 individual negative specimens were used to create negative sample pools in which 27 negative samples were used in up to three combination-unique negative sample pools)
9) 40 positive sample pools each comprised of one individual positive NP specimen and eleven negative NP specimens with detection on the ABI QuantStudio5 (specimen provenance not disclosed; positive and negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit; for negative sample pool creation, 44 individual negative specimens were used to create four negative sample pools each containing eleven unique negative samples, and the negative sample pools were then each used to dilute ten positive samples to create one of the 40 sample pools)
10) 9 positive sample pools each comprised of one individual positive NP specimen and eleven negative NP specimens with detection on the ABI QuantStudio5 (specimen provenance not disclosed; positive and negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit;  for negative sample pool creation, 72 individual negative specimens were used to create negative sample pools in which 27 negative samples were used in up to three combination-unique negative sample pools)


NPA determined with: 
1) 30 individual clinical negative NP specimens with detection on the ABI 7500 Fast Dx (specimen provenance not disclosed; negative determination with the ThermoFisher TaqPath COVID-19 Combo Kit)
2) 30 individual clinical negative NP specimens with detection on the ABI Quantstudio 5 (specimen provenance not disclosed; negative determination with the ThermoFisher TaqPath COVID-19 Combo Kit; same specimens as those run on the ABI 7500 Fast Dx)
3) 40 negative sample pools each comprised of twelve negative NP specimens with detection on the ABI 7500 Fast Dx (specimen provenance not disclosed; negative determination for individual samples conducted with ThermoFisher TaqPath COVID-19 Combo Kit; for negative sample pool creation, 65 individual negative specimens were used to create the 40 negative sample pools)


Sample position study was also conducted.

",Included,included,Included,ND,https://www.fda.gov/media/141951/download,https://www.fda.gov/media/141948/download,,,,,
,"Patients Choice Laboratories, LLC",PCL SARS-CoV-2 Real-Time RT-PCR Assay,,https://pclabsdx.com/covid-19-press-release-pcldx/,Lab,USA,"EUA granted August 28, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab",ND,"N, ORF1ab, S",ND,Omega BiotekMag-Bind Viral RNA Xpress Kit on the Hamilton Vantage Liquid Handling System,ABI QuantStudio 12K Flex Instrument (software version 1.4),ND,100 copies/uL,,No cross-reactivity predicted in silico,100.00%,40,Clinical,100.00%,35,,,"PPA determined with 
1) 11 clinical positive NP specimens collected from patients suspected of COVID-19 (exact sample provenance not disclosed, positive determination made using an undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at an undisclosed external laboratory),
2) 12 clinical positive NP specimens collected from patients suspected of COVID-19 (exact sample provenance not disclosed, positive determination made using a second undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at a second undisclosed external laboratory), and
3) 17 clinical positive NP specimens collected from patients suspected of COVID-19 (exact sample provenance not disclosed, positive determination made using a third undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at a third undisclosed external laboratory).
NPA determined with 
1) 19 clinical negative NP specimens collected from patients suspected of COVID-19 (exact sample provenance not disclosed, negative determination made using an undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at an undisclosed external laboratory),
2) 8 clinical negative NP specimens collected from patients suspected of COVID-19 (exact sample provenance not disclosed, negative determination made using a second undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at a second undisclosed external laboratory), and
3) 8 clinical negative NP specimens collected from patients suspected of COVID-19 (exact sample provenance not disclosed, negative determination made using a third undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at a third undisclosed external laboratory).",included,included,included,ND,https://www.fda.gov/media/141665/download,https://www.fda.gov/media/141665/download,,,,,
,"BayCare Laboratories, LLC",BayCare SARS-CoV-2 RT PCR Assay,,https://baycare.org/services/laboratories,Lab,USA,"EUA granted August 31, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Up to 2 pooled samples: NP swab,ND,"ORF1, E",NA,"Roche cobas 6800 System (software version 1.2, ASAP v10.1.0), Roche cobas 8800 System (software version 1.2, ASAP v10.1.0), Roche cobas 6800 System (software version 1.3, ASAP v11.1.0), Roche cobas 8800 System (software version 1.3, ASAP v11.1.0). ","Roche cobas 6800 System (software version 1.2, ASAP v10.1.0), Roche cobas 8800 System (software version 1.2, ASAP v10.1.0), Roche cobas 6800 System (software version 1.3, ASAP v11.1.0), Roche cobas 8800 System (software version 1.3, ASAP v11.1.0). ",ND,46 copies per mL for both targets with AccuPlex SARS-CoV-2; 0.009 TCID50/mL (ORF1ab) and 0.003 TCID50/mL (E gene) with live virus,,No cross-reactivity predicted in silico,88.00%,50,Pools of clinical specimens,100.00%,30,,,"PPA determined with 
1) 20 pools each comprised of one individual positive NP specimen and one individual negative NP specimen combined in equal volumes (NP specimens collected from a patient population with positivity rate of 0.16% based on 14,598 samples based on single sample testing from May 4th to June 30th) and 
2) 30 pools each comprised of one individual positive NP specimen with a viral amount close to the LoD of the Roche assay (Ct values >30) and one individual negative NP specimen combined in equal volumes.
Positive and negative determinations made with the Roche cobase SARS-CoV-2 test and results of pooled specimens compared to results compared against results from the corresponding positive NP specimens measured individually.
NPA determined with 30 negative pools (composition of negative pools not disclosed, NP specimens collected from a patient population with positivity rate of 0.16% based on 14,598 samples based on single sample testing from May 4th to June 30th)
In silico sensitivity study also conducted.

*Note that the assay under evalaution uses the Roche cobas SARS-CoV-2 assay",included,included,included,ND,https://www.fda.gov/media/141769/download,https://www.fda.gov/media/141766/download,,,,,
,"Mammoth Biosciences, Inc.",SARS-CoV-2 DETECTR Reagent Kit,,https://mammoth.bio/,Kit,USA,"EUA granted August 31, 2020",Laboratory,H,Molecular,RNA,DETECTR,"NP swab, OP swab, MTNs swab, ANs swab, NP wash, NP aspirate, Ns aspirate",UTM,N,NA,Qiagen EZ1 DSP Virus Kit on the Qiagen EZ1 Advanced Benchtop Automated Extraction Instrument,ABI 7500 Fast Dx Real-Time PCR Instrument (software version not disclosed),ND,20 copies/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,95.00%,40,Clinical,100.00%,62,,,"PPA determined with 40 blinded clinical positive NP specimens collected prospectively after January 2020 during routine testing of individuals presenting with COVID-19 symptoms and obtained from the UCSF CLIA certified high complexity clinical laboratory (positive determination made using an undisclosed comparator test).. 
NPA determined with 62 blinded clinical negative NP specimens collected prospectively after January 2020 during routine testing of individuals presenting with COVID-19 symptoms and obtained from the UCSF CLIA certified high complexity clinical laboratory (negative determination made using an undisclosed comparator test).",not included,included,not included,https://www.nature.com/articles/s41587-020-0513-4,https://www.fda.gov/media/141765/download,https://www.fda.gov/media/141762/download,,,,,
,MiraDx,MiraDx SARS-CoV-2 RT-PCR assay,,https://miradx.com/covid-19-testing/,Lab,USA,"EUA granted August 31, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab, NP wash, NP aspirate, Ns aspirate","NP swab: VTM, ITM, Liquid Amies, PBS, saline
OP swab: DNA Genotek ORAcollect RNA collection device","N (N1, N2)",NA,Omega Bio-Tek Mag-Bind Viral DNA/RNA Kit on the Hamilton Microlab STAR (software version 4.5.0.5217),ABI QuantStudio 6 Flex PCR Instrument (software version 1.3),24 - 48 hours for result from lab,4 copies/uL,,No cross-reactivity predicted in silico,96.90%,32,Clinical,100.00%,37,,,"PPA determined with 32 clinical positive NP and OP specimens (number of each sample type not disclosed, sample provenance not disclosed, positive determination made using two undisclosed FDA EUA tests). 
NPA determined with 37 clinical negative NP and OP specimens (number of each sample type not disclosed, sample provenance not disclosed, negative determination made using two undisclosed FDA EUA tests). ",included,included,included,ND,https://www.fda.gov/media/141760/download,https://www.fda.gov/media/141756/download,,,,,
,"T2 Biosystems, Inc.",T2SARS-CoV-2 Panel,,https://www.t2biosystems.com/products-technology/t2sars-cov-2-panel/,Kit,USA,"EUA granted August 31, 2020",Laboratory,H,Molecular,RNA,T2MR,"Ns swab, MTNs swab, NP swab, OP swab, BAL","VTM, Amies transport medium, saline",ND,NA,T2 Biosystems T2Dx Instrument,T2 Biosystems T2Dx Instrument,<2 hours for results,"2,000 GE/mL",,No cross-reactivity predicted in silico,95.00%,60,Clinical,100.00%,41,,,"PPA determined with 60 clinical positive NP specimens (sample provenance not disclosed, positive determination made using an undisclosed FDA EUA RT-PCR test). 
NPA determined with 41 clinical negative NP specimens (sample provenance not disclosed, negative determination made using an undisclosed FDA EUA RT-PCR test). ",not included,included,not included,https://pubmed.ncbi.nlm.nih.gov/25586686/,https://www.fda.gov/media/141755/download,https://www.fda.gov/media/141752/download,,,,,
,University of Arizona Genetics Core for Clinical Services,COVID-19 ELISA pan-Ig Antibody Test,,http://uagcclinical.arizona.edu/,Lab,USA,"EUA granted August 31, 2020",Laboratory,H,Serology,IgA/IgM/IgG,ELISA,Ser,NA,NA,"S1 (RBD), S2",Undisclosed liquid handling robot,Undisclosed microplate reader,ND,NA,,"3/320 serum samples collected between 2014 and 2019, prior to the onset of SARS-CoV-2 in the human population, and with a high prevalence of vaccination against and/or infection with expected cross-reactants tested indeterminate (indeterminate for RBD and positive for S2) for SARS-CoV-2 antibodies with assay under evaluation",97.50%,40,Clinical,99.06%,320,,,"PPA determined with 40 clinical serum specimens collected >14 days pso from patients that were confirmed positive for SARS-CoV-2 by PCR 14–67 days prior to serum collection (positive PCR determination using the FDA authorized assay for the Roche cobas 8800 Instrument performed on NP swabs at Banner University Medical Center at Banner University Medical Center).  
NPA determined with 320 serum specimens collected prior to the onset of SARS-CoV-2 (between 2014 and 2019) under an IRB from the general population, obtained through the UAHS Biorepository, and presumed to be negative. ",included,not included,included,ND,https://www.fda.gov/media/141777/download,https://www.fda.gov/media/141774/download,,,,,
,TBG Biotechnology Corp.,TBG SARS-CoV-2 IgG / IgM Rapid Test Kit,,http://www.tbgbio.com/en/product/product_detail/52,Kit,Taiwan,"EUA granted August 31, 2020",Laboratory,"H, M",Serology,IgM/IgG,Lateral Flow,"Ser, Pla",Acid Citrate Dextrose,NA,"S, N",Manual,Gold with visual read,15 minutes after sample loading,NA,,"1/5 samples positive for Anti-OC43 coronavirus-positive specimens, 1/5 samples positive for Anti-HKU1 coronavirus-positive specimens during wet lab testing",93.30%,30,Clinical,95.00%,80,,,"PPA determined with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR).  Positive assay results for PPA were those that were positive for IgG or IgM.
NPA determined with 80 frozen SARS-CoV-2 antibody-negative serum and plasma samples (number of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Negative assay results for NPA were those that were negative for both IgG and IgM. Testing was performed by one operator using one lot of the TBG SARS-CoV-2 IgG/IgM Rapid Test Kit. 
TBG also conducted a clinical agreement study with 580 serum specimens including 97 COVID-19 samples from positive patients whose respiratory sample was confirmed positive for SARS-CoV-2 using the EUA approved Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (positive agreement: 96.4% for 15-30 days pso, n=56; 97.6% for unknown days pso, n=41) and 483 negative serum samples collected from subjects in September 2019 (negative agreement: 99.8%, n = 483).",not included,included,not included,ND,https://www.fda.gov/media/141773/download,https://www.fda.gov/media/141770/download,,,,,
,"Color Genomics, Inc.",Color COVID-19 Test Unmonitored Collection Kit ,,https://www.color.com/covid,Collection,USA,"EUA granted August 31, 2020",Laboratory,H,Home Collection Kit,RNA,RT-LAMP,Ns swab,NA,NA,NA,NA,NA,NA,NA,,NA,100.00%,10,Contrived,100.00%,5,,,"Note: Home collection kit for use with the Color Genomics SARS-CoV-2 RT-LAMP Diagnostic Assay
PPA determined with 10 contrived positive specimens comprised of dry spun polyester swabs prepared with Zymo Research DNA/RNA Shield containing negative clinical anterior nares matrix and spiked with inactivated SARS-CoV-2 from ZeptoMetrix (isolate USAWA1/2020, Cat #0810587CFHI) (method of negative determination not disclosed). 
NPA determined with 5 dry spun polyester swabs prepared with Zymo Research DNA/RNA Shield containing negative clinical anterior nares matrix (method of negative determination not disclosed).",NA,NA,NA,ND,https://www.fda.gov/media/141797/download,https://www.fda.gov/media/141796/download,,,,,
,"OPTOLANE Technologies, Inc.",Kaira 2019-nCoV Detection Kit,,http://optolane.com/wp-content/uploads/2020/04/4-Kaira-2019-nCoV-Detection-kit-leaflet-0413-copy-Web-Version.pdf,Kit,South Korea,"EUA granted September 1, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP wash, NP aspirate, Ns aspirate, Spu, BAL","VTM, Amies transport medium, saline","RdRP, E",NA,Qiagen QIAsymphony DSP Virus/Pathogen Kit on the Qiagen QIAsymphony SP,"ABI QuantStudio 5 Real-Time PCR system (software version 1.5.1), ABI 7500 Real-Time PCR system (software version 2.3), Bio-Rad CFX96 Dx System (software version 3.1.1517.0823)",ND,"5,000 copies/mL (RdRP gene)
2,500 copies/mL (E gene)",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,,,"PPA determined with 
1) 15 single-blinded and randomized clinical positive OP specimens collected from patients who are suspected for COVID-19 (exact sample provenance not disclosed, positive determination made using an undisclosed FDA-authorized comparator real-time RT-PCR assay) and 
2) 15 single-blinded and randomized clinical positive sputum specimens collected from patients who are suspected for COVID-19 (exact sample provenance not disclosed, positive determination made using an undisclosed FDA-authorized comparator real-time RT-PCR assay). 
NPA determined with 
1) 16 single-blinded and randomized clinical negative OP specimens collected from patients who are suspected for COVID-19 (exact sample provenance not disclosed, negative determination made using an undisclosed FDA-authorized comparator real-time RT-PCR assay) and 
2) 14 single-blinded and randomized clinical negative sputum specimens collected from patients who are suspected for COVID-19 (exact sample provenance not disclosed, negative determination made using an undisclosed FDA-authorized comparator real-time RT-PCR assay). 
",included,included,included,ND,https://www.fda.gov/media/141795/download,https://www.fda.gov/media/141792/download,,,,,
,Detectachem Inc.,MobileDetect Bio BCC19 (MD-Bio BCC19) Test Kit ,,https://mobiledetectbio.com/,Kit,USA,"EUA granted September 1, 2020",Laboratory,H,Molecular,RNA,RT-LAMP,"NP swab, OP swab, MTNs swab, ANs swab",VTM,"N, E",NA,"MobileDetect Bio BCC19 Reagent 1, MobileDetect Bio BCC19 Reagent 2",Colorimetric with visual read or phone app,~30 minutes after sample preparation,75 copies/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,97.70%,44,Clinical,100.00%,63,,,"PPA determined with 44 randomized clinical positive NP specimens (sample provenance not disclosed, positive determination made using an undisclosed EUA authorized RT-PCR comparator assay). 
NPA determined with 63 randomized clinical negative NP specimens (sample provenance not disclosed, negative determination made using an undisclosed EUA authorized RT-PCR comparator assay).",included,not included,included,ND,https://www.fda.gov/media/141791/download,https://www.fda.gov/media/141788/download,,,,,
,Bioeksen R&D Technologies Ltd.,Bio-Speedy Direct RT-qPCR SARS-CoV-2 ,,https://bioeksen.com.tr/tr/covid-19-rt-qpcr-tespit-kiti/,Kit,Turkey,"EUA granted September 2, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, NP/OP swab, ANs swab, MTNs swab, Ns aspirate, NP aspirate, Ns wash, BAL",VTM,ORF1ab,NA,Bioeksen Viral Nucleic Acid Extraction Buffer (vNAT),"Roche LightCycler 96 Real-Time PCR System (software version undisclosed), Bio-Rad CFX96 Touch Real-Time PCR System (software version undisclosed), Qiagen Rotor-Gene 5 Plex Real-Time PCR System (software version 1.0) ",ND,"200 copies/mL for Nasopharyngeal Dacron Swab (NPDS) on the Bio-Rad CFX96 Touch
200 copies/mL for NPDS on the Roche LightCycler 96
200 copies/mL for NPDS on the Qiagen Rotor-Gene 5 Plex
200 copies/mL for Np aspirate (results not stratified by detection method)
281 copies/mL for BAL (results not stratified by detection method)
89 copies/mL for Nasopharyngeal Polyester Flocked Swab (NPFS) (results not stratified by detection method)
562 copies/mL for Oropharyngeal Dacron Swab (OPDS) (results not stratified by detection method)
562 copies/mL for Oropharyngeal Polyester Flocked Swab (OPFS) (results not stratified by detection method)




",,No cross-reactivity predicted in silico nor detected in wet lab testing,97.80%,357,Clinical,100.00%,94,,,"PPA determined with 357 clinical positive blinded NP swabs, OP swabs, NP aspirates, and BAL samples (number of each specimen type not disclosed, both dacron and polyester flocked swabs used) collected in either VTM (NP swabs, OP swabs, NP aspirates) or in dry collection tubes (BAL) from individuals suspected of COVID-19 or from individuals having COVID-19 (positive determination made with an undisclosed Real-Time RT-PCR kit authorized by the FDA). 
NPA determined with 94 clinical negative blinded NP swabs, OP swabs, NP aspirates, and BAL samples (number of each specimen type not disclosed, both dacron and polyester flocked swabs used) collected in either VTM (NP swabs, OP swabs, NP aspirates) or in dry collection tubes (BAL) from individuals suspected of COVID-19 or from individuals having COVID-19 (negative determination made with an undisclosed Real-Time RT-PCR kit authorized by the FDA). 
Bio-Rad CFX96 Touch used for detection.  Note that a total of 451 samples were collected from individuals suspected of COVID-19 (47%) or from individuals having COVID-19 (53%) who were either in the intensive care unit (ICU) (46%) or in non-ICU settings (54%).",included,included,included,ND,https://www.fda.gov/media/141823/download,https://www.fda.gov/media/141824/download,,,,,
,"Roche Molecular Systems, Inc.",cobas SARS-CoV-2 & Influenza A/B,,https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-influenza-a-b-test.html,Kit,USA,"EUA granted September 3, 2020",Laboratory,"H, M",Molecular,RNA,rRT-PCR,"NP swab, Ns swab","NP swab: Copan Universal Transport Medium System (UTM -RT), BD Universal Viral Transport System (UVT)
Ns swab: cobas PCR Media, saline","Sars-CoV-2: ORF1ab, E
Influenza A: M1, M2
Influenza B: NEP, NS1",NA,"Roche cobas 6800 System (software version not disclosed), Roche cobas 8800 System (software version not disclosed)","Roche cobas 6800 System (software version not disclosed), Roche cobas 8800 System (software version not disclosed)",<3.5 hours after sample loading,"0.058 TCID50/mL of single formulated USA-WA1/2020 heat-inactivated Cat No 0810587CFHI Lot 324045
0.12  TCID50/mL of USA-WA1/2020 heat-inactivated Cat No 0810587CFHI Lot 324045 co-formulated with Influenza A and Influenza B strains (unspecified)
0.0079 TCID50/mL of USA-WA1/2020 infectious culture Cat No NR-52281 Lot 70033175* co-formulated with Influenza A and Influenza B strains (unspecified) ",,No cross-reactivity predicted in silico nor detected in wet lab testing,96.40%,55,Clinical,98.00%,293,,,"PPA determined with 55 clinical positive archived NP swabs collected from patients with signs and symptoms of a respiratory infection in UTMRT or UVT (number of each media type not disclosed) at an undisclosed external site (positive determination made with the Roche cobas SARS-CoV-2 assay on the cobas Liat System). 
NPA determined with 293 clinical negative archived NP swabs collected from patients with signs and symptoms of a respiratory infection in UTMRT or UVT (number of each media type not disclosed) at an undisclosed external site (negative determination made with the Roche cobas SARS-CoV-2 assay on the cobas Liat System).
Roche instrument used for detection not disclosed.  Note that a total of 349 NP samples were collected, including 57 longitudinal samples from COVID-19 patients.  Samples were also evaluated for either Influenza A (60/60 positive agreement, 283/284 negative agreement) or Influenza B (37/37 positive agreement, 306/307 negative agreement) using the Influenza A/B & RSV on the cobas®Liat®System as a comparator.  ",not included,included,not included,ND,https://www.fda.gov/media/141887/download,https://www.fda.gov/media/141884/download,,,,,ALG
,"Sugentech, Inc.",SGTi-flex COVID-19 IgG ,,https://sugentech.com/products/products-view.php?ct=7&target=36,Kit,South Korea,"EUA granted September 3, 2020",Laboratory,"H, M",Serology,IgG,Lateral Flow,"Ser, Pla, VWB","sodium heparin, lithium heparin, sodium
citrate and tripotassium EDTA",NA,"N, S (RBD)",Manual,Gold with visual read,10 minutes after sample loading,NA,,No cross-reactivity detected in wet lab testing,96.70%,30,Clinical,100.00%,80,,,"PPA determined with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR).  
NPA determined with 80 frozen SARS-CoV-2 antibody-negative serum and anticoagulant citrate dextrose plasma samples (number of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Testing was performed by one operator using 1 lot of SGTi-flex COVID-19 IgG.
Sugentech also conducted a clinical agreement study with 419 specimens (specimen type and provenance not disclosed) with positive agreement of 95% (171/185 positive for IgG) and negative agreement of 99.15% (232/234 negative for IgG).  Results from positive samples in the latter study were further stratified into days post symptom onset.",not included,included,not included,ND,https://www.fda.gov/media/141891/download,https://www.fda.gov/media/141888/download,,,,,
,"Abbott Diagnostics Scarborough, Inc.",BinaxNOW COVID-19 Ag Card,,https://www.abbott.com/BinaxNOW-Test-NAVICA-App.html,Kit,USA,"EUA granted August 26, 2020","Laboratory, POC","H, M, W",Antigen,Antigen,Lateral Flow,Ns swab,not recommended,NA,N,Abbott Laboratories Extraction Reagent,visual read,15 minutes after sample loading,22.5 TCID50/Swab,,No cross-reactivity predicted in silico nor detected in wet lab testing,97.10%,35,Clinical,98.50%,67,,,"PPA determined with 35 clinical positive Ns specimens collected from symptomatic individuals presenting within 7 days of symptom onset with suspected COVID-19 at one of seven investigational sites throughout the U.S. (comparative positive determination conducted on a separate set of patient-matched Ns specimens collected concurrently into VTM and tested with an undisclosed FDA Emergency Use Authorized real-time Polymerase Chain Reaction (RT-PCR) assay at an undisclosed central laboratory). Positive results were also stratified by patient age, comparator method cycle threshold counts, and as cumulative test results each day post symptom onset up to 7 days.  
NPA determined with 67 clinical negative Ns specimens collected from symptomatic individuals presenting within 7 days of symptom onset with suspected COVID-19 at one of seven investigational sites throughout the U.S. (comparative negative determination conducted on a separate set of patient-matched Ns specimens collected concurrently into VTM and tested with an undisclosed FDA Emergency Use Authorized real-time Polymerase Chain Reaction (RT-PCR) assay at an undisclosed central laboratory).
Testing was performed by operators with no laboratory experience and who are representative of the intended users at CLIA waived testing sites. In this study testing was conducted by thirty-two (32) intended users. No training on the use of the test was provided to the operators.
",included,included,included,ND,https://www.fda.gov/media/141570/download,https://www.fda.gov/media/141567/download,,,,,
,Cuur Diagnostics,Cuur Diagnostics SARS-CoV-2 Molecular Assay,,https://cuurdiagnostics.com/,Lab,USA,"EUA granted August 26, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, MTNs swab, Ns swab",BD Universal Viral Transport Media,"N, S, ORF1ab",NA,ThermoFisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the ThermoFisher KingFisher Flex,ABI QuantStudio 12K Flex Real-Time PCR System (software version 1.4),Typically 24 -48 hours for result from lab,25 copies/uL,,No cross-reactivity predicted in silico,96.00%,50,Clinical,100.00%,50,,,"PPA determined with 
1) 20 clinical positive NP specimens collected from patients suspected of COVID-19 (positive determination made with an undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at an undisclosed laboratory). 
2) 30 clinical positive NP specimens collected from patients suspected of COVID-19 (positive determination made with a second undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at a second undisclosed laboratory).

NPA determined with 
1) 20 clinical negatve NP specimens collected from patients suspected of COVID-19 (negative determination made with an undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at an undisclosed laboratory). 
2) 30 clinical negative NP specimens collected from patients suspected of COVID-19 (negatve determination made with a second undisclosed FDA emergency use authorized SARS-CoV-2 molecular test at a second undisclosed laboratory).",included,included,included,ND,https://www.fda.gov/media/141627/download,https://www.fda.gov/media/141624/download,,,,,
,QDx Pathology Services,QDX SARS-CoV-2 Assay,,https://qdxpath.com/qdx-granted-fda-emergency-use-authorization/,Lab,USA,"EUA granted August 25, 2020",Laboratory,H,Home Collection,RNA,rRT-PCR,Ns swab,Buffered Saline Solution,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,NA,,,NA - Home collection kit,NA,NA,NA,ND,https://www.fda.gov/media/141545/download,https://www.fda.gov/media/141542/download,,,,,
,Fluidigm Corporation,Advanta Dx SARS-CoV-2 RT-PCR Assay,,https://www.fluidigm.com/singlearticles/covid-19-diagnostics,Kit,USA,"EUA granted August 25, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Sal,ND,"N(N1, N2)",NA,"ABI Veriti 96-Well Thermal Cycler for reverse transcription, Fluidigm Advanta Dx 192.24 IFC on the Fluidigm Juno system (software version 3.14.1) for sample processing, Fluidigm Advanta Dx 192.24 IFC on the Fluidigm IFC Controller RX (RX Controller) (software version 2.8) for sample processing",Fluidigm Biomark HD system with (software version 4.5.2),ND,6.25 GE/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,43,Clinical,100.00%,34,,,"PPA determined with 43 blinded clinical positive saliva specimens collected at an undisclosed clinical site (positive determination made with a matched NP sepcimen tested using an undisclosed FDA EUA SARS-Cov-2 Real-Time PCR tests authorized for use with NP swabs). 
NPA determined with 34 blinded clinical negative saliva specimens collected at an undisclosed clinical site (negative determination made with a matched NP sepcimen tested using an undisclosed FDA EUA SARS-Cov-2 Real-Time PCR tests authorized for use with NP swabs). ",not included,included,not included,ND,https://www.fda.gov/media/141541/download,https://www.fda.gov/media/141538/download,,,,,
,Biocan Diagnostics Inc.,Tell Me Fast Novel Coronavirus (COVID-19) IgG/IgM Antibody Test,,https://www.rapidtest.ca/products/tell-me-fast-novel-coronavirus-covid19-igg-igm-antibody-test-us-fda-eua/,Kit,Canada,"EUA granted August 25, 2020",Laboratory,"H, M",Serology,IgM/IgG,Lateral Flow,"Ser, Pla, VWB","Plasma: Lithium-Heparin, Sodium-Citrate, Acid Citrate Dextrose
VWB: Lithium-Heparin, Sodium-Citrate, Dipotassium-EDTA",NA,ND,manual,gold with visual read,10-15 minutes after sample addition,NA,,1/161 known negative samples (sample type not disclosed) collected in the United States prior to December 2019 with high rates of vaccination tested positive for IgG with assay under evaluation,93.30%,30,Clinical,96.20%,79,99.60%,55.40%,"PPA determined with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR). Positive assay results for PPA were those that were positive for IgG or IgM.  NPA determined with 80 frozen SARS-CoV-2 antibody-negative serum and plasma samples (number of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Negative assay results for NPA were those that were negative for both IgG and IgM. Biocan also conducted a clinical agreement study with 233 retrospective serum samples
all collected in the United States from hospital facilities or plasma centers with positive agreement of 100% (72/72 positive for IgM or IgG) and negative agreement of 99.4% (160/161 negative for both IgM and IgG).",not included,included,not included,ND,https://www.fda.gov/media/141550/download,https://www.fda.gov/media/141547/download,,,,,
,"Texas Department of State Health Services, Laboratory Services Section",Texas Department of State Health Services (DSHS) SARS-CoV-2 Assay,,https://dshs.texas.gov/lab/default.shtm,Lab,USA,"EUA granted August 21, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, Ns aspirate, Ns wash, BAL",ND,"N, ORF1ab",NA,"PerkinElmer Chemagic Viral DNA/RNA 300 Kit H96 on the PerkinElmer Chemagic 360 (software version 6.3.0.3) for extraction, PerkinElmer Janus G3 Automated Workstation (software version 5.5.48.0) for pipetting",ABI 7500 Fast Dx Real-Time PCR System (software version 1.4),ND,"20 copies/mL (VTM, Liquid Amies Medium, Saline)",,No cross-reactivity predicted in silico,100.00%,40,Clincal and contrived,100.00%,41,,,"PPA determined with 
1) contrived clinical specimens consisting of 12 individual negative NP swabs (specimen provenance and method of negative determination not disclosed) in VTM (n = 5), UTM (n = 3) or liquid Amies (n = 
 4) spiked with PerkinElmer nCoV Positive Control bacteriophage-packed RNA, 
2) contrived clinical specimens consisting of 11 individual negative OP swabs (specimen provenance and method of negative determination not disclosed) in VTM (n = 5) or UTM (n = 6) spiked with PerkinElmer nCoV Positive Control bacteriophage-packed RNA, 
3) a contrived clinical specimens consisting of 1 individual negative Ns swab (specimen provenance and method of negative determination not disclosed) in VTM spiked with PerkinElmer nCoV Positive Control bacteriophage-packed RNA, 
4) 7 positive clinical NP sepcimens in either VTM (n = 4) or UTM (n = 3) (sample provenance not disclosed, positive determination with Centers for Disease Control and Prevention (CDC) 2019-Novel Coronavirus (2019-nCoV) Diagnostic Panel), 
5) 3 positive clinical OP sepcimens in either VTM (n = 2) or UTM (n = 1) (sample provenance not disclosed, positive determination with CDC 2019-nCoV Diagnostic Panel), 
6) 1 positive clinical NP/OP sepcimen in VTM (sample provenance not disclosed, positive determination with CDC 2019-nCoV Diagnostic Panel), and 
7) 5 positive clinical NP specimens in either VTM (n = 2) or liquid Amies (n = 3) (sample provenance not disclosed, positive determination with CDC 2019-nCoV Diagnostic Panel).

NPA determined with 
1) 21 negative clinical NP specimens in either VTM (n = 8), UTM (n = 8) or liquid Amies (n = 5) (sample provenance not disclosed, positive determination with CDC 2019-nCoV Diagnostic Panel),
2) 13 negative clinical OP specimens in either VTM (n = 5) or UTM (n = 8) (sample provenance not disclosed, positive determination with CDC 2019-nCoV Diagnostic Panel),
3) 1 negative clinical NP/OP specimen in VTM (sample provenance not disclosed, positive determination with CDC 2019-nCoV Diagnostic Panel),
4) 1 negative clinical Ns specimen in VTM (sample provenance not disclosed, positive determination with CDC 2019-nCoV Diagnostic Panel), and
5) 5 negative clinical NP specimens in either VTM (n = 3) or liquid Amies (n = 2) (sample provenance not disclosed, positive determination with CDC 2019-nCoV Diagnostic Panel).",included,included,included,ND,https://www.fda.gov/media/141496/download,https://www.fda.gov/media/141493/download,,,,,
,"DxTerity Diagnostics, Inc.",DxTerity SARS-CoV-2 RT-PCR Test,,https://dxterity.com/sars-cov-2-test-covid-19/,Lab,USA,"EUA granted August 21, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Sal,Spectrum Solutions LLC SDNA-1000 Saliva Collection Device,"N, S, ORF1ab",NA,Sera-Mag SpeedBeads Carboxyl Magnetic Beads on the ABI MagMax 96 Magnetic Particle Processor (software version 4.0),ABI ViiA 7 Real-Time PCR System (QuantStudio 5 software version 1.3),24 -48 hours for result from lab,50 copies/mL,,No cross-reactivity predicted in silico,97.20%,36,Clinical,92.50%,40,,,"PPA determined with 36 clinical positive saliva specimens from synmptomatic individuals either purchased from The MT Group (Van Nuys, CA) with samples collected in California and Florida or obtained at undisclosed testing clinics throughout the greater Los Angeles area and Phoenix, Arizona (number of samples from each source not disclosed; positive determination made with a paired NP sepcimen collected concurrently and tested using an undisclosed EUA authorized comparator). 
NPA determined with 40 clinical negative saliva specimens from synmptomatic individuals either purchased from The MT Group (Van Nuys, CA) with samples collected in California and Florida or obtained at undisclosed testing clinics throughout the greater Los Angeles area and Phoenix, Arizona (number of samples from each source not disclosed; negative determination made with a paired NP sepcimen collected concurrently and tested using an undisclosed EUA authorized comparator).",included,included,included,ND,https://www.fda.gov/media/141491/download,https://www.fda.gov/media/141488/download,,,,,
,"Guardant Health, Inc.",Guardant-19,,https://investors.guardanthealth.com/news-releases/news-release-details/guardant-health-receives-fda-emergency-use-authorization-its,Lab,USA,"EUA granted August 21, 2020",Laboratory,H,Molecular,RNA,"RT-PCR, NGS","NP swab, OP swab, Ns swab, ANs swab, MTNs swab, NP aspirate, NP wash, Ns aspirate, Ns wash",ND,N (N1),NA,"Zymo Quick-DNA/RNA Viral MagBead Kit on the Hamilton Star (Venus Software version 4.5.0.5217) for extraction, Zymo Quick-DNA/RNA Viral MagBead Kit on the Hamilton Starlet Liquid Handling Systems (Venus Software version 4.5.0.5217) for extraction, ABI Veriti Thermal Cycler (Firmware version 2.0.4) and Agilent 4200 Tapestation System (Tapestation software version 3.2) for RT-PCR and library generation","Illumina NextSeq 500 Instrument (NextSeq software version 4.0.1) , Illumina NextSeq 550 Instrument (NextSeq software version 4.0.1)",ND,0.125 copies/uL,,No cross-reactivity predicted in silico,95.52%,67,Clinical,98.33%,60,,,"PPA determined with 1) 37 positive remnant NP and OP swab specimens (number of each specimen type not disclosed) collected by healthcare providers from patients seeking SARS-CoV-2 testing over March and April 2020 in an undisclosed county (exact specimens provenance not disclosed, positive determination using undisclosed EUA-approved comparator test at an undisclosed laboratory within the county) and 2) 30 positive remnant NP swab specimens collected by healthcare providers from patients seeking SARS-CoV-2 testing over March and April 2020 in either a second undisclosed county or on an undisclosed cruise ship (exact specimen provenance not disclosed, positive determination using undisclosed EUA-approved comparator test at an undisclosed laboratory in the second county). 
NPA determined with 1) 30 negative remnant NP and OP swab specimens (number of each specimen type not disclosed) collected by healthcare providers from patients seeking SARS-CoV-2 testing over March and April 2020 in an undisclosed county (exact specimens provenance not disclosed, negative determination using undisclosed EUA-approved comparator test at an undisclosed laboratory within the county) and 2) 30 negative remnant NP swab specimens collected by healthcare providers from patients seeking SARS-CoV-2 testing over March and April 2020 in either a second undisclosed county or on an undisclosed cruise ship (exact specimen provenance not disclosed, negative determination using undisclosed EUA-approved comparator test at an undisclosed laboratory in the second county). 
",included,included,included,ND,https://www.fda.gov/media/141487/download,https://www.fda.gov/media/141484/download,,,,,
,"Beckman Coulter, Inc.",Access SARS-CoV-2 IgG,,https://www.beckmancoulter.com/products/immunoassay/access-sars-cov-2-igg-antibody-test,Kit,USA,"EUA granted June 26, 2020",Laboratory,"H, M",Serology,IgG,Heterogeneous Immunoassay (CLIA),"Ser, Pla","lithium heparin, dipotassium EDTA, tripotassium EDTA, sodium citrate, serum separating tube",NA,S1 (RBD),"Beckman Coulter Access 2 (software version not disclosed), Beckman Coulter UniCel DxI 600 (software version not disclosed), Beckman Coulter UniCel DxI 800 (software version not disclosed),  Beckman Coulter UniCel DxC 600i (software version not disclosed), Beckman Coulter UniCel DxC 680i (software version not disclosed), Beckman Coulter UniCel DxC 880i (software version not disclosed), Beckman Coulter UniCel DxC 660i (software version not disclosed), Beckman Coulter UniCel DxC 860i (software version not disclosed)","Beckman Coulter Access 2 (software version not disclosed), Beckman Coulter UniCel DxI 600 (software version not disclosed), Beckman Coulter UniCel DxI 800 (software version not disclosed),  Beckman Coulter UniCel DxC 600i (software version not disclosed), Beckman Coulter UniCel DxC 680i (software version not disclosed), Beckman Coulter UniCel DxC 880i (software version not disclosed), Beckman Coulter UniCel DxC 660i (software version not disclosed), Beckman Coulter UniCel DxC 860i (software version not disclosed)",~25 min,NA,,No cross-reactivity detected in wet lab testing,96.80%,95,Clinical,99.60%,1400,99.80%,93.50%,"PPA determined with 95 serum and plasma samples  (number of each specimen type not disclosed) from symptomatic individuals diagnosed with  PCR-confirmed SARS-CoV-2 infection from France and the United States (specimens provenance not disclosed, positive determination using an undisclosed PCR test).  Sensitivity for all 192 specimens stratified by days post PCR positive: 75.8% (0-7d post PCR positive, n=33), 95.3% (8-14d post PCR positive , n=64), 96.8% (>15d post PCR positive, n=95). NPA determined with 1) 1,000 samples from blood donors in France collected prior to December 2019, and 2) 400 samples from routine clinical laboratory diagnostic samples (type of samples not disclosed) in France (n = 200) and the United States (n = 200) collected prior to December 2019.  A  longitudinal seroconversion study was also conducted",not included,not included,not included,ND,https://www.fda.gov/media/139627/download,https://www.fda.gov/media/139624/download,,,,,
,LumiraDx UK Ltd.,LumiraDx SARS-CoV-2 Ag Test,,https://www.lumiradx.com/us-en/what-we-do/diagnostics/test-technology/antigen-test,Kit,UK,"EUA granted August 18, 2020","Laboratory, POC","H, M, W",Antigen,Antigen,Fluorescence immunoassay,Ns swab,NA,NA,N,LumiraDx Extraction Buffer,LumiraDx Instrument,12 minutes after sample loading,32 TCID50/mL,,No cross-reactivity detected in wet lab testing,97.60%,83,Clinical,96.60%,174,,,"PPA determined with 83 clinical positive Ns specimens (comparative positive determination conducted on a separate set of patient-matched Ns specimens collected concurrently into UTM and tested with an undisclosed EUA PCR method).   Positive results were also stratified by patient age and days since symptom onset. No positive results were observed from patients without symptoms or beyond 12 days of symptom onset. 
NPA determined with 174 clinical negative Ns specimens (comparative negative determination conducted on a separate set of patient-matched Ns specimens collected concurrently into UTM and tested with an undisclosed EUA PCR method).
A total of 257 specimens were collected from sequentially enrolled subjects who presented with symptoms of COVID-19 (n = 159) or key workers (n = 98) at increased risk of infection from five sites across the United States and one site in the United Kingdom.  No positive results were observed from patients without symptoms or beyond 12 days of symptom onset.",included,not included,included,ND,https://www.fda.gov/media/141304/download,https://www.fda.gov/media/141301/download,,,,,
,"ZhuHai Sinochips Bioscience Co., Ltd.",COVID-19 Nucleic Acid RT-PCR Test Kit ,,http://www.sinochips.cn/index.php/home/News/detail/id/175.html,Kit,China,"EUA granted August 17, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab, NP wash, NP aspirate, Ns aspirate","VTM for swabs, no preservatives should be added to NP wash or NP aspirate","ORF1ab, N",NA,"Qiagen QIAamp® Viral RNA Mini Kit (manual extraction), Thermo Fisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the Thermo Fisher KingFisher™ Flex Magnetic Particle Processor (automated extraction)","ABI 7500 Real-Time PCR system (7500 Software v2.3) for manual extraction of RNA, ABI 7500 Fast Dx Real-Time PCR Instrument (SDS Software v1.4.1) for automated extraction of RNA",ND,"2 copies/uL using Qiagen QIAamp® Viral RNA Mini Kit and ABI 7500 Real-Time PCR system (manual)
2.5 copies/uL using Thermo Fisher MagMax Viral/Pathogen Nucleic Acid Isolation kit and ABI 7500 Fast Dx Real-Time PCR system (automated)                                                                                                                                                                                            ",,No cross-reactivity predicted in silico nor detected in wet lab testing,96.5 %,85,Clinical,100.00%,310,,,"PPA determined with clinical specimens consisting of 85 positive NP swabs (specimens provenance not disclosed, positive determination using an undisclosed FDA EUA-authorized test)
NPA determined with clinical specimens consisting of 310 negative NP swabs (specimens provenance not disclosed, negative determination using an undisclosed FDA EUA-authorized test)                                                                                          PPA and NPA dtermined using Thermo Fisher MagMax Viral/Pathogen Nucleic Acid Isolation kit and ABI 7500 Fast Dx Real-Time PCR system (automated)   ",included,included,included,ND,https://www.fda.gov/media/141246/download,https://www.fda.gov/media/141243/download,,,,,
,"BioCheck, Inc.",BioCheck SARS-CoV-2 IgG and IgM Combo Test ,,http://www.biocheckinc.com,Kit,USA,8/17/2020,"Laboratory, POC","H, M",Serology,IgM/IgG,CLIA(chemiluminescent immunoassay),Human Serum,NA,NA,NA,"Should only be performed on human serum samples. MS-Fast Automated Chemiluminescent Immunoassay Analyzing System. Avoid use of icteric, hyperlipemic, hemolyzed, or contaminated sera which may cause
erroneous results.",MS-Fast Automated Chemiluminescent Indirect antibodies based test. Detection and differentiation of IgG and IgM antibodies to SARS-CoV-2 in human serum.The product uses magnetic separation technology in two separate reactions to detect SARS-CoV- 2 lgG and lgM antibodies with magnetic particles as the solid phase of the reaction. ,30 min total,Cut off based analysis. RLU ≥18500 is positive IgM. RLU  ≥26000 is positive IgM.  If less it will be negative,,No cross-reactivity,99.10%,110,Clinical IgM PPA: 95.45% (105/110); [95% (89.80% - 98.04%)]IgG PPA: (99.09% 109/110); [95% CI (95.03%-99.84%)],14300.00%,97.20%,100%,65.1%%,"By comparing with the diagnostic results of a nucleic acid detection method, the positive percent agreement (PPA) and negative percent agreement (NPA) of the BioCheck SARS–CoV-2 IgM and IgG Antibody Combo Test Kit. IgM PPA: 95.45% (105/110); [95% (89.80% - 98.04%)](Please see the manual for the variation in the values based on the days post infection). IgG PPA: (99.09% 109/110); [95% CI (95.03%-99.84%)]",included,included,included,ND,https://www.fda.gov/media/141251/download,,,,,,
,"Diazyme Laboratories, Inc.",Diazyme DZ-Lite SARS-CoV-2 IgM CLIA Kit ,,https://www.diazyme.com/dz-lite-sars-cov-2,Kit,USA,8/17/2020,Laboratory,"H, M",Serology,IgM,CLIA,Human and Plasma,NA,NA,NA,"Samples should be collected from individuals within 15 days to 43 days post symptom onset. Human serum and plasma (potassium EDTA, disodium EDTA and lithium heparin) specimens.",Chemiluminescence,30-60min,"≥ 1.0> (Reactive) is Positive for SARS-CoV-2 IgM antibodies",,No cross-reactivity,100.00%,29,Clinical,97.40%,852,100.00%,67.10%,"Upon treatment with DTT, five SARS-CoV-2 patient samples (initially positive for both IgM and IgG) became negative for IgM when tested with the Diazyme DZ-Lite SARS- CoV-2 IgM CLIA assay and remained positive for IgG when tested with the Diazyme DZ- Lite SARS-CoV-2 IgG CLIA assay. This establishes the specificity of the Diazyme DZ- Lite SARS-CoV-2 IgM CLIA kit to the IgM class of antibodies. Samples should be collected from individuals within 15 days to 43 days post symptom onset. Samples collected less than 15 days post symptom onset should not be tested. Negative samples collected before 15 days post symptom onset should be reflexed to direct detection of the virus. Negative samples collected 15 days or more post-symptom onset should be reflexed to a test that detects and reports SARS-CoV-2 IgG.",,,included,ND,https://www.fda.gov/media/141255/download,,,,,,
,"Yale School of Public Health, Department of Epidemiology of Microbial Diseases",SalivaDirect,,https://news.yale.edu/2020/08/15/yales-rapid-covid-19-saliva-test-receives-fda-emergency-use-authorization,Lab,USA,"EUA granted August 15, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Sal,NA,N (N1),NA,Manual (no extraction),"Bio-Rad CFX96 Touch Real-Time PCR Detection System (software version not disclosed), ABI 7500 Fast Real-Time PCR System (software version not disclosed), ABI 7500 Fast Dx Real-Time PCR System (software version not disclosed)",ND,"6 copies/uL with ThermoFisher MagMAX Viral/Pathogen Proteinase K and New England Biolabs Luna Universal Probe One-Step RT-qPCR Kit using Bio-Rad CFX96 for detection
6 copies/uL with New England Biolabs Proteinase K, Molecular Biology Grade and New England Biolabs Luna Universal Probe One-Step RT-qPCR Kit using Bio-Rad CFX96 for detection
6 copies/uL with AmericanBio Proteinase K and New England Biolabs Luna Universal Probe One-Step RT-qPCR Kit using Bio-Rad CFX96 for detection
6 copies/uL with ThermoFisher MagMAX Viral/Pathogen Proteinase K and Bio-Rad Reliance One-Step Multiplex RT-qPCR Supermix using Bio-Rad CFX96 for detection
12 copies/uL with ThermoFisher MagMAX Viral/Pathogen Proteinase K and ThermoFisher TaqPath 1-Step RTqPCR Master Mix, GC using Bio-Rad CFX96 for detection
12 copies/uL with ThermoFisher MagMAX Viral/Pathogen Proteinase K and ThermoFisher TaqPath 1-Step RTqPCR Master Mix, GC using ABI 7500 Fast for detection
6 copies/uL with ThermoFisher MagMAX Viral/Pathogen Proteinase K and ThermoFisher TaqPath 1-Step RTqPCR Master Mix, GC using ABI 7500 Fast Dx for detection",,No cross-reactivity predicted in silico. 0/52 saliva specimens collected from adults during the 2018/2019 and 2019/2020 (pre-COVID19) autumn/winter influenza seasons tested positive with assay under evaluation,94.10%,34,Clinical,90.90%,33,,,"PPA determined with 34 clinical positive saliva specimens collected from inpatients and healthcare workers in the Yale-New Haven Hospital (comparative positive determination conducted on patient-matched paired NP specimens using the TaqPath COVID-19 combo kit). NPA determined with 33 clinical negative saliva specimens collected from inpatients and healthcare workers in the Yale-New Haven Hospital (comparative negative determination conducted on patient-matched paired NP specimens using the TaqPath COVID-19 combo kit). All saliva specimens were treated with ThermoFisher Scientific proteinase K,  and used theThermoFisher Scientific TaqPath RT-PCR kit and Bio-Rad CFX96 instrument for amplifiation and detection.   All NP specimens were extracted with the MagMax Viral/Pathogen Nucleic Acid Isolation Kit for extraction and with a multiplex RT-PCR diagnostic assay targeting 3 regions of the SARS-CoV-2 genome.  Note that all 67 NP specimens were also tested with modified version of the US CDC assay (2019-nCoV_N1, 2019-nCoV_N2, and RP primer-probe sets with the NEB Luna Universal Probe One-Step RT-qPCR kit on the Bio-Rad CFX96) as a second comparator, yielding 37 positive results and 30 negative results.  In comparison to results from the CDC test, the modified the assay under evaluation had 94.6% positive agreement (35/37) and 100% negative agreement (30/30). ",included,included,included,https://www.medrxiv.org/content/10.1101/2020.08.03.20167791v1,https://www.fda.gov/media/141192/download,https://www.fda.gov/media/141194/download,,,,,
,Pro-Lab Diagnostics,Pro-AmpRT SARS-CoV-2 Test,,http://www.pro-lab-direct.com/default.asp,Lab,USA,"EUA granted August 13, 2020",Laboratory,H,Molecular,RNA,Isothermal Amplification,"Ns swab, NP swab, OP swab",Pro-Lab Diagnostics SARS-CoV-2 transport media,ORF1ab,NA,Pro-Lab Diagnostics Pro-Mag RNA Extraction Kit,OptiGene Genie HT instrument (software version v4.00rc2),30 minutes after extraction,125 GEC/swab,,No cross-reactivity predicted in silico,96.60%,30,Clinical,100.00%,30,,,PPA determined with 30 de-identified clinical positive NP specimens in VTM (sample provenance not disclosed; positive determination with an undisclosed FDA EUA RT-PCR test). NPA determined with 30 de-identified clinical negative NP specimens (sample provenance not disclosed; negative determination with an undisclosed FDA EUA RT-PCR test).,not included,not included,not included,ND,https://www.fda.gov/media/141149/download,https://www.fda.gov/media/141146/download,,,,,
,LumiraDx UK Ltd.,LumiraDx SARS-CoV-2 RNA STAR,,https://www.lumiradx.com/us-en/what-we-do/diagnostics/fast-lab-solutions/rna-star-test,Kit,UK,"EUA granted August 11, 2020",Laboratory,H,Molecular,RNA,qSTAR ,"Ns swab, MTNs swab, NP swab, OP swab, BAL","VTM, DNA-RNA Shield",ORF1a,NA,"Qiagen DSP Virus/Pathogen Kit on the Qiagen QIAsymphony SP, ThermoFisher MagMax Viral/Pathogen Nucleic Acid Isolation Kit , Qiagen QIAamp Viral RNA Mini Kit","Roche LightCycler 480 II (software version SW 1.5.1), ABI 7500 Fast Dx (software version 1.4.1), ABI QuantStudio 5 (software version 1.5.1), Agilent AriaMx (software version 1.71), Agilent Stratagene Mx3005P (software version 4.10) ",12 minutes after extraction,500 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,97.06%,34,Clinical,96.77%,31,,,PPA determined with 34 blinded and randomized clinical positive NP specimens (sample provenance not disclosed; positive determination with an undisclosed FDA EUA RT-PCR test). NPA determined with 31 blinded and randomized clinical negative NP specimens (sample provenance not disclosed; negative determination with an undisclosed FDA EUA RT-PCR test).  All samples extracted with the MagMax Viral/Pathogen Nucleic Acid Isolation Kit and run on the ABI 7500 Fast Dx PCR Instrument.,included,included,included,ND,https://www.fda.gov/media/141057/download,https://www.fda.gov/media/141054/download,,,,,
,"Biomeme, Inc.",Biomeme SARS-CoV-2 Real-Time RT-PCR Test,,https://shop.biomeme.com/products/sars-cov-2,Kit,USA,"EUA granted August 11, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, Ns swab, OP swab, NP wash, NP aspirate, Ns aspirate","BDUniversal Viral Collection Kit, Biomeme DNA/RNAPreservation Buffer","ORF1ab, S",NA,Biomeme M1 Sample Prep Cartridge ,"Biomeme Franklin three9 Real-Time qPCR Thermocycler, Bio-Rad CFX96 (Maestro 1.1 software version 4.1.2433.1219), ABI QuantStudio 5 (software version 1.4.3)",< 1 hr,1.8 GE/µL ,,No cross-reactivity predicted in silico,97.47%,158,Clinical and contrived,98.85%,87,,,"PPA determined with 1) contrived clinical specimens consisting of 60 individual negative NP swabs (specimen provenance and method of negative determination not disclosed) in a matrix mixed with Biomeme Lysis Buffer (BLB) from the Biomeme M1 Sample Prep Cartridge for RNA 2.0 nucleic acid extraction kit and RPC spiked with genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WSA1/2020 (BEI NR-52285, Lot: 70033320, Mftg Date: 11FEB2020) and 2) 98 clinical positive NP specimens (sample provenance not disclosed; positive determination with an undisclosed FDA EUA RT-PCR assay). 

NPA determined with 1) clinical specimens consisting of 30 individual negative NP swabs (specimen provenance and method of negative determination not disclosed) and 2) 57 clinical negative NP specimens (sample provenance not disclosed; negative determination with an undisclosed FDA EUA RT-PCR assay).",not included,included,not included,ND,https://www.fda.gov/media/141052/download,https://www.fda.gov/media/141049/download,,,,,
,Solaris Diagnostics ,Solaris Multiplex SARS-CoV-2 Assay ,,https://solarisdx.com/coronavirus-2019/,Lab,USA,"EUA granted August 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, ANs swab, MTNs swab, OP swab, NP wash, NP aspirate, Ns aspirate, BAL",ND,"N (N1, N2)",NA,"ThermoFisher, MagMAX Viral/Pathogen Ultra Kit on the ThermoFisher Kingfisher Flex DNA Extraction System (software version V.1.2.2) for extraction, Tecan Evo 100 Liquid Handler with software version 2.8 for specimen pipetting",ABI QuantStudio 5 Real time PCR System (software version 1.5.1),ND,10 copies/µL,,No cross-reactivity predicted in silico,100.00%,60,Clinical and contrived,100.00%,60,,,"PPA determined with 1) randomized contrived clinical specimens consisting of 30 individual negative NP swabs (specimen provenance and method of negative determination not disclosed) spiked with SARS-CoV-2 isolate USA-WA1/2020 (NR52285 BEI Resources) and 2) 30 clinical positive NP specimens (sample provenance not disclosed; positive determination with TaqPath COVID-19 Combo kit). 
NPA determined with 1) randomized clinical specimens consisting of 30 individual negative NP swabs (specimen provenance and method of negative determination not disclosed) and 2) 30 clinical negative NP specimens (sample provenance not disclosed; negative determination with TaqPath COVID-19 Combo kit).",included,included,included,ND,https://www.fda.gov/media/141016/download,https://www.fda.gov/media/141013/download,,,,,
,Alpha Genomix Laboratories,Alpha Genomix TaqPath SARS-CoV-2 Combo Assay,,http://alphagenomix.com/,Lab,USA,"EUA granted August 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab",ND,"ORF1ab
 N
 S",NA,"Thermo Fisher MagNA Pure 96 DNA and Viral Nucleic Acid Small Volume Kit using Roche MagNA Pure 96 Instrument for automated nucleic acid extraction, Thermo Fisher TaqPath 1-Step Multiplex Master Mix for reverse transcription",ABI QuantStudio 12K Flex Real-Time PCR System (software version 2.4.0) for amplification and detection,ND,4 copies/uL,,No cross-reactivity predicted in silico,96.70%,30,Clinical,100.00%,35,,,"PPA determined with leftover clinical specimens consisting of 25 individual NP swab specimens  (specimens provenance not disclosed) that were previously tested with an undisclosed FDA EUA-authorized SARS-CoV-2 molecular test, five of which were retested and re-confirmed positive using the CDC EUA-authorized assay tested by an outside laboratory (identity of outside lab not disclosed). 
NPA determined with leftover clinical specimens consisting of 30 individual NP swab specimens (specimens provenance not disclosed) that were previously tested with an undisclosed FDA EUA-authorized SARS-CoV-2 molecular test, five of which were retested and re-confirmed negative using the CDC EUA-authorized assay tested by an outside laboratory (identity of outside lab not disclosed). ",included,included,included,ND,https://www.fda.gov/media/141021/download,https://www.fda.gov/media/141017/download,,,,,
,George Washington University Public Health Laboratory,GWU SARS-CoV-2 RT-PCR Test,,https://smhs.gwu.edu/covid-19-testing,Lab,USA,"EUA granted August 7, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MNTs swab, NP swab, OP swab, BAL",VTM,"N (N1, N2)",NA,"Life Technologies Ambion MagMAX-96 Viral RNA Isolation Kit on the Hamilton Microlab STAR liquid-handling system (Hamilton VENUS software, version not disclosed) for extraction, QuantaBio qScript XLT for amplification",Roche LightCycler 480 (Software version 1.5),7 days,12.5 copies/uL,,No cross-reactivity predicted in silico ,95.00%,40,Clinical,100.00%,42,,,"PPA determined with 40 blinded clinical NP specimens (specimens provenance undisclosed) previously confirmed positive using an undisclosed FDA-authorized comparator test
NPA determined with 42 blinded clinical NP specimens (specimens provenance undisclosed) previously confirmed negative using an undisclosed FDA-authorized comparator test ",included,included,included,ND,https://www.fda.gov/media/140980/download,https://www.fda.gov/media/140977/download,,,,,
Y,Helix OpCo LLC (dba Helix),Helix COVID-19 NGS Test ,,https://www.helix.com/pages/covid19-efforts,Lab,USA,"EUA granted August 6, 2020",Laboratory,H,Molecular,RNA,NGS,"NP swab, OP swab, MTNs swab, ANs swab",iSwab Microbiome collection media,S,NA,"ThermoFisher MagMax Viral/Pathogen II Nucleic Acid Isolation kit for extraction,  Hamilton Microlab STAR liquid handler (software version 4.5.0.7797) or STP Labtech Mosquito HV (software version 1.0.0.0) for additional sample prep, Bio-Rad C-1000 Touch Thermocycler for reverse transcription","Illumina NovaSeq 6000 with Illumina SP Flow Cell (Illumina NovaSeq software version 1.6, Illumina Real Time Analysis Software (RTA3 version 3.4.4), Illumina bcl2fastq version 2.20, and Helix COVID-19 NGS Test Bioinformatics Pipeline (AmpFinder) version 0.1.0.)",ND,125 GCE/mL,,No cross-reactivity predicted in silico,100.00%,30,Clinical,100.00%,30,,,PPA determined with 30 clinical positive NP specimens in Mawi iSwab Collection Media (sample provenance not disclosed; positive determination with an undisclosed EUA authorized test). NPA determined with 30 clinical negative NP specimens in Mawi iSwab Collection Media (sample provenance not disclosed; negative determination with an undisclosed EUA authorized test).  All samples extracted using MagMax Viral/Pathogen II (MVP II) Nucleic Acid Isolation kit and semi-automated workflow using the Hamilton Microlab STAR.,included,included,included,ND,https://www.fda.gov/media/140917/download,https://www.fda.gov/media/140914/download,,,,,
Y,bioMérieux SA,VIDAS SARS-CoV-2 IgG ,,https://www.biomerieux-diagnostics.com/vidas-sars-cov-2,Kit,France,"EUA granted August 6, 2020",Laboratory,"H, M",Serology,IgG,Heterogeneous immunoassay (ELFA),"Ser, Pla",lithium heparin,NA,S (RBD),"BioMerieux VIDAS, BioMerieux MINI VIDAS, BioMerieux VIDAS 3","BioMerieux VIDAS, BioMerieux MINI VIDAS, BioMerieux VIDAS 3",~27 minutes after sample loading,NA,,1/5 samples positive for RF-positive specimens and 1/5 samples positive for HIV-positive specimens during wet lab testing,100.00%,29,Clinical,99.90%,989,100.00%,98.10%,"PPA determined by comparison to 29 >14d post symptom onset specimens (specimen type not disclosed); Sensitivity for all 67 specimens collected from SARS-CoV-2 PCR patients (PCR positive determination method not disclosed) and stratified by days post PCR positive for which the information was available: 36.8% (0-7d pso, n=19), 84.2% (8-14d pso, n=19), 100.00% (>14d pso, n=29).  Also stratified these and another 53 samples by days post PCR positive, and conducted serial measurements from some individuals. NPA determined with 308 samples collected from negative individuals before September 2019 (sample type not disclosed ;method of negative determination not disclosed).  All testing done on the BioMerieux VIDAS instrument.  Also conducted a longitudinal seroconversion study.",included,included,included,ND,https://www.fda.gov/media/140937/download,https://www.fda.gov/media/140934/download,,,,,
Y,bioMérieux SA,VIDAS SARS-CoV-2 IgM,,https://www.biomerieux-diagnostics.com/vidas-sars-cov-2,Kit,France,"EUA granted August 6, 2020",Laboratory,"H, M",Serology,IgM,Heterogeneous immunoassay (ELFA),"Ser, Pla",lithium heparin,NA,S (RBD),"BioMerieux VIDAS, BioMerieux MINI VIDAS, BioMerieux VIDAS 3","BioMerieux VIDAS, BioMerieux MINI VIDAS, BioMerieux VIDAS 3",~27 minutes after sample loading,NA,,"1/5 samples positive for ANA-positive specimens, 2/5 samples positive for RF-positive specimens, 1/3 samples positive for Plasmodium falciparum-positive specimens, 1/5 samples positive for Trypanosoma cruzi-positive specimens, and 1/6 samples positive for Coronavirus NL63-positive specimens during wet lab testing",100.00%,23,Clinical,99.40%,308,100.00%,89.00%,"PPA determined by comparison to 23 15-30d post symptom onset specimens (specimen type not disclosed); Sensitivity for all 112 specimens collected from SARS-CoV-2 PCR patients (PCR positive determination method not disclosed) and stratified by days post PCR positive: 36.8% (0-7d pso, n=19), 82.4% (8-14d pso, n=17), 100.00% (15-30d pso, n=23).  Also stratified these samples by days post PCR positive, and conducted serial measurements from some individuals. NPA determined with 308 samples collected from negative individuals before September 2019 (sample type not disclosed ;method of negative determination not disclosed).  All testing done on the BioMerieux VIDAS instrument.  Also conducted a longitudinal seroconversion study.",included,included,included,ND,https://www.fda.gov/media/140933/download,https://www.fda.gov/media/140930/download,,,,,
Y,Vela Operations Singapore Pte Ltd,ViroKey SARS-CoV-2 RT-PCR Test,,https://www.veladx.com/product/qpcr-respiratory-viruses/virokey-sars-cov-2-rt-pcr-test.html,Kit,Singapore,"EUA granted August 5, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab, NP wash, NP aspirate, Ns aspirate ","VTM, Amies transport medium, saline","ORF1a, RdRp",NA,Sentosa® SX Virus Total Nucleic Acid Kit (4x24) v2.0,"ABI 7500 Fast Dx Real-Time PCR System (software version 1.4.1), Sentosa® SA201 Real-Time PCR Instrument (software version 1.0.1)",ND,560 GE/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,97.20%,36,Clinical,95.10%,82,,,"PPA determined with 36 clinical positive NP specimens (sample provenance not disclosed; positive determination with an undisclosed EUA authorized test). NPA determined with 82 clinical negative NP specimens (sample provenance not disclosed; negative determination with an undisclosed EUA authorized test).  All samples used ABI 7500 Fast Dx for detection,",included,included,included,ND,https://www.fda.gov/media/140922/download,https://www.fda.gov/media/140919/download,,,,,
Y,"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.",WANTAI SARS-CoV-2 Ab ELISA,,http://www.ystwt.cn/covid-19/,Kit,China,"EUA granted August 5, 2020",Laboratory,H,Serology,IgM/IgG,ELISA,"Ser, Pla",Acid Citrate Dextrose,NA,S (RBD),Manual (with unspecified automated microplate washer),Microplate reader (manufacturer not specified),ND,NA,,No cross-reactivity detected in wet lab testing,96.70%,30,Clinical,97.50%,80,99.80%,67.10%,PPA determined with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR). Positive assay results for PPA were those that were positive for IgG or IgM.  NPA determined with 80 frozen SARS-CoV-2 antibody-negative serum and plasma samples (distribution of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Negative assay results for NPA were those that were negative for both IgG and IgM.  Testing was performed by one operator using one lot of the WANTAI SARS-CoV-2 Ab ELISA.,not included,included,not included,https://www.medrxiv.org/content/10.1101/2020.04.09.20056325v1.full.pdf,https://www.fda.gov/media/140929/download,https://www.fda.gov/media/140926/download,,,,,
Y,Wren Laboratories LLC,Wren Laboratories COVID-19 PCR Test,,https://www.wrenlaboratories.com/covid-19/covid-19-testing,Lab,USA,"EUA granted August 3, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Np swab, OP swab, ANs swab, MTNs swab, NP wash, Ns aspirate, BAL",ND,"N(N1, N3)",NA,"Qiagen QIAamp Viral RNA Mini Kit forextraction, ThermoFisher High Capacity cDNA Reverse Transcription Kit on the Eppendorf Nexus Gradient Mastercycler (software version 3.6.9.0) for reverse trascription.",ABI QuantStudio 7-Flex Real-Time PCR Instrument (software v1.3),ND,15 copies/μL,,No cross-reactivity predicted in silico,100.00%,60,Clinical,95.00%,60,,,"PPA determined with clinical nasopharyngeal positive (n=60) swab specimens that were previously tested with an undisclosed FDA EUA authorized SARS-CoV-2 molecular test (sample provenance not disclosed). NPA determined with clinical nasopharyngeal negative (n=60)  swab specimens that were previously tested with an undisclosed FDA EUA authorized SARS-CoV-2 molecular test (sample provenance not disclosed). FALSE positive samples were further tested using second FDA EUA authorized SARS-CoV-2 molecular test that targets N1, N2, and RNase P. It was determined that 2/3 discordant specimens were also positive with second comparator assay. The first 5 positive and 5 negative samples determined by the Wren Laboratories COVID-19 PCR Test were sent to an outside laboratory and tested with the first undisclosed comparator (with 100% positive and negative agreement).",Included,Included,Included,ND,https://www.fda.gov/media/140776/download,https://www.fda.gov/media/140773/download,,,,,
Y,Ethos Laboratories,Ethos Laboratories SARS-CoV-2 MALDI-TOF Assay,,https://www.ethos-labs.com/,Lab,USA,"EUA granted August 3, 2020",Laboratory,H,"Molecular, Home Collection",RNA,"RT-PCR, MALDI-TOF","Ns swab, MTNs swab, NP swab, OP swab, BAL",VTM (Hardy Diagnostics) in the Ethos Laboratories U-Collect At Home Collections Kit,"N, ORF1, ORF1ab",NA,"Omega Bio-tek MagBind Viral DNA/RNA kit on the ThermoFisher KingFisher Flex Purification System (software version 4.0) for extraction, ABI Veriti 96 Thermal Cycler with Thermal Cycler Fleet Control (software version 1.7.1) with the Agena SARS-CoV-2 Panel Set (RUO) kit for amplification
",Agena Bioscience MassARRAY System (software version 5.0),,1 TCID50/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,98.10%,53,Clinical,96.30%,54,,,PPA determined with 53 clinical positive NP (sample provenance not disclosed; positive determination with the CDC 2019-Novel Coronavirus (2019- nCoV) Real-Time RT-PCR Diagnostic Panel). NPA determined with 54 clinical negative NP (sample provenance not disclosed; negative determination with the CDC 2019-Novel Coronavirus (2019- nCoV) Real-Time RT-PCR Diagnostic Panel).  Also conducted simulated shipping stability studies with simulated summer and winter shipping conditions and a human usability study.,included,included,included,ND,https://www.fda.gov/media/140780/download,https://www.fda.gov/media/140777/download,,,,,
Y,Cleveland Clinic Robert J. Tomsich Pathology and Laboratory Medicine Institute,Cleveland Clinic SARS-CoV-2 Assay,,https://clevelandcliniclabs.com/2020/05/01/coronavirus-2019-covid-19-testing/#covid19-collection,Lab,USA,"EUA granted August 3, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Ns swab, BAL, Tr aspirate, Spu",ND,"E, RdRP",NA,Roche MagNA Pure 96 DNA and Viral NA Small Volume Kit on the Roche MagNA Pure 96 (software version 3.0),"Roche LightCycler 480, cobas z 480 instruments (software version 1.2.1.62 SP3)",ND,10 copies/μl,,No cross-reactivity predicted in silico nor detected in wet lab testing,98.44%,64,Clinical,100.00%,69,,,"PPA determined with 1) 30 blinded positive clinical NP specimens (sample source not disclosed; positive determination with the CDC EUA assay) and 2) positive clinical sputum (n= 10), BAL (n = 11), and Tr aspirate (n = 11) specimens (sample source not disclosed; positive determination with the CDC EUA assay). Note that one sputum specimen and two tracheal aspirates were presumed positive as RdRP was not detected but they were positive for E gene. NPA determined with 1) 30 blinded negative clinical NP specimens (sample source not disclosed; negative determination with the CDC EUA assay) and 2) negative clinical sputum (n= 10), BAL (n = 11), and Tr aspirate (n = 18) specimens (sample source not disclosed; negative determination with the CDC EUA assay)",included,included,included,ND,https://www.fda.gov/media/140788/download,https://www.fda.gov/media/140785/download,,,,,
,Poplar Healthcare,Poplar SARS-CoV-2 TMA Pooling assay,,https://www.micropathid.info/micropathid-tests/covid-19-test/,Lab,USA,"EUA granted August 3, 2020",Laboratory,H,"Molecular, Sample Pooling",RNA,"TMA, DKA","Up to 7 pooled specimens: NP swab, Ns swab, OP swab",ND,ORF1ab,NA,Hologic Panther System; additional sample pooling either manually or with Tecan Evo liquid handling system,Hologic Panther System,ND,0.01 TCID50/mL,,No cross-reactivity predicted in silico,100.00%,37,Pools of clinical specimens,100.00%,32,,,"Positive validation with 1) 23 pools comprised of one positive Ns specimen and six negative Ns samples (compared against results from corresponding positive Ns specimens measured alone) and 2) 14 pools comprised of one positive Ns specimen and six negative Ns samples (positive Ns specimens determined to be low positive results with Cobas SARSCoV-2 Assay,  and then tested Individually and in 7-Sample Pools). Negative validation with 32 (25?) pools comprised of seven negative Ns specimens.

Note that this uses the Hologic Aptima SARS-CoV-2 assay",included,included,included,ND,https://www.fda.gov/media/140792/download,https://www.fda.gov/media/140789/download,,,,,
,"ISPM Labs, LLC dba Capstone Healthcare",Genus SARS-CoV-2 Assay,,https://npiprofile.com/npi/1497175905,Lab,USA,"EUA granted August 3, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab",ND,"N (N1, N2)",NA,"Thermofisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (manual), Thermofisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the ThermoFisher KingFisher Flex platform, Omega
Biotek Mag-Bind DNA/RNA kit (manual), Omega Biotek Mag-Bind DNA/RNA kit on the ThermoFisher KingFisher Flex platform",ABI QuantStudio12K Flex Real Time PCR instrument (software version 1.3) ,ND,"40 copies/uL
",,No cross-reactivity predicted in silico,100.00%,49,Clinical,100.00%,34,,,PPA determined with 1) 43 clinical positive NP and OP specimens (sample provenance and number of each sample type not disclosed; positive determination with the EUA authorized CDC assay) and 2) 6 positive NP/OP specimens (specimens previously tested at Capstone Healthcare; each sample consisted of an NP and an OP swab in molecular transport media; positive determination with IPSUM Diagnostic’s EUA authorized test). NPA determined with 1) 28 clinical negative NP and OP specimens (sample provenance and number of each sample type not disclosed; negative determination with the EUA authorized CDC assay) and 2) 6 negative NP/OP specimens (specimens previously tested at Capstone Healthcare; each sample consisted of an NP and an OP swab in molecular transport media; negative determination with IPSUM Diagnostic’s EUA authorized test).,included,included,included,ND,https://www.fda.gov/media/140818/download,https://www.fda.gov/media/140815/download,,,,,
,Siemens Healthcare Diagnostics Inc.,Atellica IM SARS-CoV-2 IgG (COV2G),,https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/cov2g-assay,Kit,USA,"EUA granted July 31, 2020",Laboratory,"H, M",Serology,IgG,Heterogeneous immunoassay,"Ser, Pla",potassium EDTA and lithium heparin,NA,S1 (RBD),Atellica IM Analyzer,Atellica IM Analyzer,ND,0.50 Index,,No cross-reactivity detected in wet lab testing,100.00%,42,Clinical,99.95%,1841,100.00%,99.00%,"PPA determined by comparison to 42 >13d post PCR positive specimens (specimen type not disclosed); Sensitivity for all 197 specimens collected from 94 unique donor subjects with a clinical diagnosis of COVID-19
based on a positive SARS-CoV-2 PCR method and stratified by days post PCR positive: 56.04% (0-6d post PCR positive, n=91), 92.19% (7-13d post PCR positive, n=64), 100.00% (>13d post PCR positive, n=42). NPA determined using pre-COVID outbreak (before November 2019) samples from apparently healthy individuals (n = 1744, 1/1734 reactive) and apparently healthy pregnant women (n = 97, 0/97 reactive).  All testing done on the Atellica IM Analyzer.",not included,not included,included,ND,https://www.fda.gov/media/140699/download,https://www.fda.gov/media/140700/download,,,,,
,Siemens Healthcare Diagnostics Inc.,ADVIA Centaur SARS-CoV-2 IgG (COV2G),,https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/cov2g-assay,Kit,USA,"EUA granted July 31, 2020",Laboratory,"H, M",Serology,IgG,Heterogeneous immunoassay,"Ser, Pla",potassium EDTA and lithium heparin,NA,S1 (RBD),"ADVIA Centaur XP System, ADVIA Centaur XPT System","ADVIA Centaur XP System, ADVIA Centaur XPT System",ND,0.50 Index,,No cross-reactivity detected in wet lab testing,100.00%,42,Clinical,99.89%,1831,100.00%,98.00%,"PPA determined by comparison to 42 >13d post PCR positive specimens (specimen type not disclosed); Sensitivity for all 189 specimens collected from 89 unique donor subjects with a clinical diagnosis of COVID-19
based on a positive SARS-CoV-2 PCR method and stratified by days post PCR positive: 53.49% (0-6d post PCR positive, n=86), 93.44% (7-13d post PCR positive, n=61), 100.00% (>13d post PCR positive, n=42). NPA determined using pre-COVID outbreak (before November 2019) samples from apparently healthy individuals (n = 1734, 2/1734 reactive) and apparently healthy pregnant women (n = 97, 0/97 reactive).  All testing done on the ADVIA Centaur XP system.",not included,not included,included,ND,https://www.fda.gov/media/140704/download,https://www.fda.gov/media/140703/download,,,,,
,"Xiamen Zeesan Biotech Co., Ltd.",SARS-CoV-2 Test Kit (Real-time PCR),,http://www.zeesandx.com/products/1083.html,Kit,China,"EUA granted July 31, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, NP washes, NP aspirate, Ns aspirate, BAL","VTM, UTM","N, ORF1ab",NA,"Xiamen Zeesan Biotech Co., Ltd. Virus RNA Extraction Kit (Cat. No.: 602101)",ABI QuantStudio 3 real-time PCR thermal cycler (software version 1.4.3) ,ND,200 copies/mL ,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,,,"Positive validation with 19 NP swabs, 11 OP swabs; negative validation with 15 NP swabs, 15 OP swabs",included,included,included,ND,https://www.fda.gov/media/140717/download,https://www.fda.gov/media/140718/download,,,,,
,University of California San Diego Health,UCSD RC SARS-CoV-2 Assay,,https://health.ucsd.edu/coronavirus/Pages/testing.aspx,Lab,USA,"EUA granted July 31, 2020",Laboratory,H,"Molecular, Pooling",RNA,rRT-PCR,"Up to 5 pooled specimens: NP swab, MTNs swab, ANs swab, OP swab",ND,"ORF1ab, E",NA,Roche cobas 6800 and 8800,Roche cobas 6800 and 8800 Systems (software version 1.2 (ASAP v10.1.0) and version 1.3 (ASAP v11.1.0)).,ND,46 copies per mL for both targets with AccuPlex SARS-CoV-2; 0.009 TCID50/mL (ORF1ab) and 0.003 TCID50/mL (E gene) with live virus,,No cross-reactivity predicted in silico nor detected in wet lab testing,97.72%,44,Pools of clinical specimens,98.33%,60,,,"Positive validation with pools comprised of one positive specimen and nine negative samples, negative validation with pools comprised of ten negative specimens, also conducted an in silico analysis to predict how many individual positive specimens would yield negative results if pooled based on Ct values

Note that this uses the cobas SARS-CoV-2 asssay (EUA200009)",not included,not included,not included,ND,https://www.fda.gov/media/140712/download,https://www.fda.gov/media/140714/download,,,,,
,"Clinical Reference Laboratory, Inc.",CRL Rapid Response,,https://www.crlcorp.com/covid-19-testing/,Lab,USA,"EUA granted July 30, 2020",Laboratory,H,"Molecular, Home Collection",RNA,rRT-PCR,Sal,DNA Genotek OMNIgene ORAL OM-505 collection device,RdRP,NA,Zymo Quick RNA/DNA Viral MagBead Kit on the Tecan Fluent 780/480 DreamPrep ,BioRad CFX-96 TOUCH Thermal Cycler instrument (software version 3.1),ND,250 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,32,Clinical,100.00%,27,,,"Clinical validation with NP swabs (Note; also used nasal swabs, but did not include these in their numbers, even though the agreement was poor)",included,included,included,ND,https://www.fda.gov/media/140661/download,https://www.fda.gov/media/140664/download,,,,,AG
,Sandia National Laboratories,SNL-NM 2019 nCoV Real-Time RT-PCR Diagnostic Assay,,https://www.sandia.gov/working_with_sandia/technology_partnerships/opportunities.html,Lab,USA,"EUA granted July 27, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, ANs swab, MTNs swab, OP swab, Ns wash, Ns aspirate, BAL",ND,"N (N1, N2)",NA,Zymo Research Quick-RNA Viral Kit,"ABI 7500 (software version 2.3), ABI Quant Studio 5 (software version 1.5.1), Bio-Rad CFX Connect (software version 3.1), Bio-Rad CFX 96 Real PCR (software version 4.1.2433.1219)",ND,6.25 copies/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,98.00%,100,Clinical and contrived,100.00%,83,,,"Contrived study with NP swabs, clinical study with NP swabs, and detection method comparison with contrived samples",included,included,included,ND,https://www.fda.gov/media/140547/download,https://www.fda.gov/media/140544/download,,,,,AG
,Eli Lilly and Company,Lilly SARS-CoV-2 Assay,,https://www.lilly.com/news/stories/coronavirus-covid19-global-response,Lab,USA,"EUA granted July 27, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, Ns aspirate, Ns wash, BAL",ND,"N (N1, N2)",NA,"QIAGEN QIAamp 96 Virus QIAcube HT Kit on the QIAGEN QIAcube HT (software v1.1.0.39),  QIAGEN QIAamp 96 Virus QIAcube HT Kit on the Hamilton MicroLab STARlet (software v4.5)","ABI QuantStudio 7 Flex Real-Time PCR System (software version 1.3), ABI QuantStudio Dx Real-Time PCR System (software version 1.0.3), ABI QuantStudio 12K Flex RealTime PCR System (software version 1.3)",ND,10^3 copies viral RNA/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,44,Clinical and contrived,97.14%,35,,,"Contrived study with undisclosed samples, clinical study with NP swabs (some were also re-used for a bridging study)",included,included,included,ND,https://www.fda.gov/media/140543/download,https://www.fda.gov/media/140540/download,,,,,AG
,"Jiangsu CoWin Biotech Co., Ltd.",Novel Coronavirus (SARS-CoV-2) Fast Nucleic Acid Detection Kit (PCR-Fluorescence Probing),,https://www.cwbiosciences.com/goods/index?id=77,Kit,China,"EUA granted July 24, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,OP swab,CoWin SARSCoV-2 Collection Fluid,"N, ORF1ab",NA,Manual (no extraction required),"ABI 7500 RealTime PCR (software v2 series, specific version not disclosed)",ND,300 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,40,Clinical,100.00%,56,,,Clinical validation with OP swabs,included,included,included,ND,https://www.fda.gov/media/140425/download,https://www.fda.gov/media/140426/download,,,,,
,"Xiamen Biotime Biotechnology Co., Ltd.",BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test,,http://www.biotime.cn/En_Pr_d_gci_80_id_69.html,Kit,China,"EUA granted July 24, 2020",Laboratory,"H, M",Serology,IgM/IgG,Lateral Flow,"Ser, Pla, VWB",potassium EDTA,NA,ND,Manual,Gold with visual read,10 minutes after sample loading,NA,,No cross-reactivity detected in wet lab testing,100.00%,30,Clinical,96.20%,80,100%,58.10%,PPA determined with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR). Positive assay results for PPA were those that were positive for IgG or IgM.  NPA determined with 80 frozen SARS-CoV-2 antibody-negative serum and plasma samples (distribution of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Negative assay results for NPA were those that were negative for both IgG and IgM.  Testing was performed by one operator using one lot of the BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test.,not included,included,not included,ND,https://www.fda.gov/media/140443/download,https://www.fda.gov/media/140440/download,,,,,
,"Access Bio, Inc.",CareStart COVID-19 IgM/IgG,,http://www.accessbio.net/eng/about/about01.asp,Kit,USA,"EUA granted July 24, 2020",Laboratory,"H, M",Serology,IgM/IgG,Lateral Flow,"Ser, Pla, VWB","sodium citrate, sodium heparin,
or dipotassium EDTA",NA,"N protein, S1 (RBD) protein",Manual,Gold with visual read,10 minutes after sample loading,NA,,No cross-reactivity detected in wet lab testing,98.40%,64,Clinical,98.90%,182,99.90%,82.50%,PPA determined with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR). Positive assay results for PPA were those that were positive for IgG or IgM.  NPA determined with 80 frozen SARS-CoV-2 antibody-negative serum and plasma samples (distribution of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Negative assay results for NPA were those that were negative for both IgG and IgM.  Testing was performed by one operator using one lot of the CareStart COVID-19 lgM/lgG.,not included,included,not included,ND,https://www.fda.gov/media/140447/download,https://www.fda.gov/media/140444/download,,,,,
,Helix OpCo LLC (dba Helix),Helix COVID-19 Test,,https://www.helix.com/pages/covid19-efforts,Lab,USA,"EUA granted July 23, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, MTNs swab, ANs swab","VTM, iSwab Microbiome collection media (ISWABMD-1200, Mawi DNA Technologies)","N, ORF1ab, S",NA,"MagMax Viral/Pathogen II Nucleic Acid Isolation Kit on the Hamilton Microlab STAR liquid handler (software version 4.5.0.7797), additional sample preparation with the STP Labtech Mosquito HV (software version 1.0.0.0)",ABI QuantStudio 7 Flex Quantitative Real Time PCR Instrument (software version 2.4),ND,1000 GCE/mL,,No cross-reactivity predicted in silico,98.33%,60,Clinical,100.00%,60,,,"""A clinical study was performed to evaluate the performance of the Helix COVID-19
Test using sixty remnant positive upper respiratory clinical samples, and sixty negative
upper respiratory clinical samples in two collection media types (Mawi and either VTM or UTM (it's unclear)).""",included,included,included,ND,https://www.fda.gov/media/140420/download,https://www.fda.gov/media/140422/download,,,,,
,"DiaCarta, Inc.",QuantiVirus SARS-CoV-2 Multiplex Test Kit,,https://diacarta.com/products/covid19/multiplex,Kit,USA,"EUA granted July 21, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, NP swab, OP swab, Spu","UTM, VTM",ORF1ab,NA,"Thermo Fisher PureLink viral RNA/DNA Mini Kit (manual), MGI MGIEasy Magnetic Beads Virus DBA/RNA Extraction Kit on the MGI SP-960 High-throughput Automated Sample Preparation System","ABI QuantStudio 5 Real-Time PCR Instrument (software version 1.4), ABI 7500 Fast DX (software version 1.4), Bio-Rad CXF 384 Real-Time PCR Instrument (software version 3.1)",ND,"100 copies/mL on the  ABI QuantStudio 5
50 copies/mL on the ABI 7500 Fast Dx 
100 copies/mL on the Bio-Rad CFX 384",,No cross-reactivity predicted in silico nor detected in wet lab testing,99.17%,241,Clinical and contrived,100.00%,142,,,"Contrived studies with sputum of all three machines, Clinical validation with NP swabs on ABI QuantStudio 5",included,included,included,ND,https://www.fda.gov/media/140354/download,https://www.fda.gov/media/140355/download,,,,,
,"Access Genetics, LLC",OraRisk COVID-19 RT-PCR,,https://www.oraldna.com/test/covid-19/,Lab,USA,"EUA granted July 17, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, Ns swab","UTM (NP swab, Ns swab), saline (Ns swab)",RdRP,NA,Chemagic Viral DNA/RNA 300 Kit H96 on the  PerkinElmer Chemagic MSM I Automated Specimen Processing System,Roche LightCycler 480 II qPCR System (Software version 1.5.1.62),ND,15 copies/µL,,No cross-reactivity predicted in silico,100.00%,37,Clinical,97.37%,38,,,Clinical validation with nasal and NP swabs,included,included,included,ND,https://www.fda.gov/media/140293/download,https://www.fda.gov/media/140290/download,,,,,
,"Megna Health, Inc.",Rapid COVID-19 IgM/IgG Combo Test Kit ,,https://www.megnahealth.com/products/megna-antibody-test-kit/,Kit,USA,"EUA granted July 17, 2020",Laboratory,"H, M",Serology,IgM/IgG,Lateral Flow,"Ser, Pla",acid citrate dextrose,NA,N protein,Manual,Gold with visual read,15 minutes after sample loading,NA,,No cross-reactivity detected in wet lab testing,100.00%,30,Clinical,95.00%,80,100.00%,51.30%,PPA determined with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR). Positive assay results for PPA were those that were positive for IgG or IgM.  NPA determined with 80 frozen SARS-CoV-2 antibody-negative serum and plasma samples (distribution of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Negative assay results for NPA were those that were negative for both IgG and IgM.  Testing was performed by one operator using one lot of the  Rapid COVID-19 IgM/IgG Combo Test Kit.,not included,included,not included,ND,https://www.fda.gov/media/140297/download,https://www.fda.gov/media/140294/download,,,,,
,Boston Heart Diagnostics,Boston Heart COVID-19 RT-PCR Test,,https://bostonheartdiagnostics.com/,Lab,USA,"EUA granted July 16, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, NP swab, MTNs swab, OP swab, NP aspirate, BAL",ND,"N, S, ORF1ab",NA,ThermoFisher MagMax Viral/Pathogen Nucleic Acid Isolation Kit; ABI KingFisher Flex 96 Deep-Well Magnetic Particle Processor; ,ABI QuantStudio 12K Flex Real-Time PCR System (software version 1.4).,NA,250 copies/mL,,No cross reactivity predicted in silico,96.70%,30,Clinical,,96.70%,,,PPA determined with 30 clinical positive NP specimens (sample provenance not disclosed; positive determination with the EUA authorized Viracor Eurofins assay). NPA determined with 30 clinical negative NP specimens (sample provenance not disclosed; negative determination with the EUA authorized Viracor Eurofins assay),included,included,included,ND,https://www.fda.gov/media/140259/download,https://www.fda.gov/media/140261/download,,,,,
,Luminex Corporation,xMAP SARS-CoV-2 Multi-Antigen IgG Assay,,https://www.luminexcorp.com/xmap-sars-cov-2-antibody-testing/,Lab,USA,"EUA granted July 16, 2020",Laboratory,H,Serology,IgG,Heterogeneous immunoassay (FMIA),"Ser, Pla",dipotassium EDTA,NA,"S(RBD, S1), N",Manual,"Luminex 200 (software version 4.3), Luminex MAGPIX® (all configurations, software version 4.3), Luminex FLEXMAP 3D (with MFI divider enabled, software version 4.3",ND,NA,,"0/308 serum specimens collected in the US prior to December 2019 tested positive for IgG with assay under evaluation.  1/132 plasma  specimens collected in the US prior to December 2019 tested positive for IgG with assay under evaluation.""",96.30%,82,Clinical,99.30%,603,99.80%,88.50%,"PPA determined with human serum and plasma. Clinical Agreement of xMAP® SARS-CoV-2 Multi-Antigen IgG Assay on the MAGPIX® NxTAG®-enabled System: Serum >14 PPA was 96.2%, NPA was 100.0%. Plasma >14 was 96.6% and NPA was 99.2%. Clinical Agreement of xMAP® SARS-CoV-2 Multi-Antigen IgG Assay on the MAGPIX® System: Serum >14 PPA was 98.1% and Serum >14 NPA 100.0%. Plasma >14 PPA was 96.6% and NPA was 99.2%.",not included,included,not included,,https://www.fda.gov/media/140256/download,https://www.fda.gov/media/140257/download,,,,,
,"Quest Diagnostics Infectious Disease, Inc.",Quest Diagnostics HA SARS-CoV-2 Assay,,https://www.questdiagnostics.com/home/Covid-19/HCP/NAAT/,Lab,USA,"EUA granted July 15, 2020",Laboratory,H,Home Collection,RNA,NA,Nasal swab,"VCM, 0.9% saline, PBS",NA,NA,NA,NA,NA,NA,,NA,NA,NA,,,,,,,NA,NA,NA,ND,https://www.fda.gov/media/140239/download,https://www.fda.gov/media/140236/download,,,,,
,"Quest Diagnostics Infectious Disease, Inc.",Quest Diagnostics RC SARS-CoV-2 Assay,,https://www.questdiagnostics.com/home/Covid-19/HCP/NAAT/,Lab,USA,"EUA granted July 15, 2020",Laboratory,H,Home Collection,RNA,NA,Nasal swab,"VCM, 0.9% saline, PBS",NA,NA,NA,NA,NA,NA,,NA,NA,NA,,,,,,,NA,NA,NA,ND,https://www.fda.gov/media/140234/download,https://www.fda.gov/media/140231/download,,,,,
,"Quest Diagnostics Infectious Disease, Inc.",Quest Diagnostics PF SARS-CoV-2 Assay,,https://www.questdiagnostics.com/home/Covid-19/HCP/NAAT/,Lab,USA,"EUA granted July 15, 2020",Laboratory,H,Home Collection,RNA,NA,Nasal swab,"VCM, 0.9% saline, PBS",NA,NA,NA,NA,NA,NA,,NA,NA,NA,,,,,,,NA,NA,NA,ND,https://www.fda.gov/media/140229/download,https://www.fda.gov/media/140226/download,,,,,
,"Compass Laboratory Services, LLC",Compass Laboratory Services SARS-CoV2 Assay,,http://www.compasslabservices.com/molecular-diagnostics,Lab,USA,"EUA granted July 13, 2020",Laboratory,H,"Molecular, Home Collection",RNA,rRT-PCR,"NP swab, OP swab, MTNs swab, ANs swab, NP wash, NP aspirate, Ns aspirate","Everlywell COVID-19 test home collection kit, otherwise not disclosed",ORF1ab,NA,Thermo Fisher Scientific MagMax Viral Pathogen Kit automated on the MagMax Express 96 instrument (software not disclosed),Thermo Fisher Scientific QuantStudio 12K Flex (software v1.3) or QuantStudio 7 Flex Quantitative Real Time (Software v1.3),ND,5 copies/μL ,,No cross-reactivity predicted in silico nor detected in wet lab testing,98.40%,62,Clinical and contrived,98.40%,64,,,"PPA determined with 1) contrived clinical specimens consisting of 38 negative NP swabs (specimen provenance and method of negative determination not disclosed) spiked with SARS-CoV-2 RNA isolated
from a patient specimen (specimen provenance not disclosed and method of positive determination not disclosed ), and 2) 24 clinical specimens consisting of positive NP swabs (positive determination based on FDA-authorized CDC 2019-Novel Coronavirus real time RT-PCR Diagnostic Panel). 
NPA determined with clinical specimens consisting of 39 NP swabs (from persons without symptoms and without documented exposure to the virus, specimen provenance not disclosed) and 25 negative NP swabs (negative determination based on FDA-authorized CDC 2019-Novel Coronavirus real time RT-PCR Diagnostic Panel). ",included,included,included,ND,https://www.fda.gov/media/140078/download,https://www.fda.gov/media/140074/download,,,,,
,Trax Management Services Inc.,PhoenixDx SARS-CoV-2 Multiplex,,https://shop.procomcure.com/produkt/phoenixdx-2019-ncov-rna-detection-kit/,Kit,Austria,"EUA granted  July 13, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab, BAL",ND,"ORF1ab, N",NA,"RTA Labs RTA Viral Nucleic Acid Isolation Kit, Qiagen QIAamp MinElute Virus Spin Kit, Roche High Pure Viral RNA Kit, Thermo Fisher Scientific MagMax kit, Procomcure Biotech SphaeraMag DNA/RNA Isolation Kit","Thermo Fisher Scientific QS1 (software version not disclosed), Qiagen Rotor-Gene Q (software version not disclosed), ABI 7500 Fast Real time PCR Dx (software version not disclosed), DNA Technologie DTPrime5 (software version not disclosed), Analytik Jena qTower3G (software version not disclosed), BioRad CFX-96 IVD marked instrument (software version not disclosed)",ND,"50 copies/μL with all extraction kits using ABI 7500 Fast Instrument (ABI 7500 Software v2.3)
50 copies/μL with Procom Biotech SphaeraMag DNA/RNA Isolation kit using any of the detection systems Thermo Fisher QS1, Qiagen Rotor-Gene Q, ABI 7500 Fast Real time PCR Dx, DNA Technologie DTPrime5, Analytik Jena qTower3G ",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,42,Clinical,100.00%,42,,,"PPA determined with clinical specimens of 8 OP swabs and 34 NP swab from patients with signs and symptoms of an upper respiratory infection obtained from three government laboratories, confirmed to be positive using an undisclosed EUA authorized SARS-CoV-2 kit, and tested in a blinded manner. NPA determined with clinical specimens of 4 OP swabs and 38 NP swab from patients obtained from three government laboratories, confirmed to be negative using an undisclosed EUA authorized SARS-CoV-2 kit, and tested in a blinded manner. Samples extracted with the Procomcure Biotech SphaeraMag DNA/RNA Isolation Kit and tested using ABI 7500 Fast Real time PCR Dx (software version not disclosed). ",included,included,included,ND,https://www.fda.gov/media/140073/download,https://www.fda.gov/media/140070/download,,,,,
,"KogeneBiotech Co., Ltd.",PowerChek 2019-nCoV Real-time PCR Kit,,https://products.kanto.co.jp/uploads/pj46_m_pdf/509/pdf1.pdf,Kit,S. Korea,"EUA granted July 13, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"ANs swab, MTNs swab, NP swab, OP swab, NP wash and NP aspirate, Ns aspirate, BAL, Spu",VTM,"RdRP, E",NA,Qiagen QIAamp DSP Viral RNA Mini Kit,"ABI 7500,ABI 7500 Fast, Bio-Rad CFX96 Real-time PCR Detection System ",ND,"4 copies/μL for ABI7500 Real Time PCR instrument
4 copies/μL ABI7500 Fast Real Time PCR instrument
4 copies/μL for CFX96 Real-time PCR Detection System 
",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,,,"PPA determined with : 1) 60 blinded and randomized contrived specimens spiked with viral genomic RNA of SARS-CoV-2 (BetaCoV/Korea/KCDC03/2020 Human coronavirus, NCCP43326) into individual negative clinical NP (n = 30) and Spu (n = 30) specimens (source of specimens and method of negative determination not disclosed) and 2) 30 randomized and blinded clinical NP (n =15) and sputum (n = 15) specimens previously tested from April to June 2020 and confirmed to be positive with an undisclosed FDA-authorized assay.",included,included,included,,https://www.fda.gov/media/140069/download,https://www.fda.gov/media/140066/download,,,,,
,Salofa Oy,Sienna-Clarity COVIBLOCK COVID-19 IgG/IgM Rapid Test Cassette,,https://www.salofa.com/en/covid-19-rapid-diagnostic-test-available,Kit,Finland,"EUA granted July 13, 2020",Laboratory,"H, M",Serology ,IgM/IgG,Lateral Flow,"VWB, Ser, Pla","dipotassium EDTA, sodium citrate, sodium heparin",NA,S (RBD region),Manual,Gold with visual read,10 minutes after sample loading,NA,,"Some cross reactivity for RF-positive specimens (number of samples not disclosed), some cross reactivity for MERS-CoV-positive specimens (number of samples not disclosed) during wet lab testing",93.30%,30,Clinical,98.80%,80,,,"PPA determined for study #1 with 57 samples IgG positive at 0-7 days (Days between collection of PCR comparator and collection of plasma/serum sample). IgG PPA was 83.82%. PPA determined 2 samples IgG positive at 8-14 days. IgG PPA was 100%. PPA determined 61 IgM positive at 0-7 days. IgM PPA was 89.71%. PPA determined 2 samples IgM positive at 8-14 days. IgM PPA was 100%. IgG NPA tested 10 samples and resulted in 100%.
In study #2, PPA determined with 60 samples IgG positive at ≥15 days at 100%. PPA determined 61 IgM positive at 0-7 days. IgM PPA was 89.71%. PPA determined 2 samples IgM positive at ≥15 days at 93.33%. IgG NPA tested 50 samples and resulted in 100%.
The specificity of the SiennaTM-Clarity COVIBLOCKTM COVID-19 IgG/IgM Rapid Test Cassette was evaluated using a total of 220 plasma/ serum samples collected from individuals, before the COVID19 outbreak. In the first study, 80 presumed negative plasma samples (K2 EDTA) collected within the US, before October 2019 were tested; 30 presumed negative plasma samples (K2 EDTA) collected within Cote d-Ivoire, in 2016 were tested; 58 presumed negative plasma samples (K2 EDTA) collected within Uganda, in 1995 were tested. Testing were performed at the Washington University School of Medicine. In the second study, 52 presumed negative serum sample collected within France, between October and November 2019, were tested.
",not included,included,not included,ND,https://www.fda.gov/media/140082/download,https://www.fda.gov/media/140079/download,,,,,s
,"Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.",WANTAI SARS-CoV-2 Ab Rapid Test,,http://www.ystwt.cn/covid-19/,Kit,China,"EUA granted July 10, 2020",Laboratory,"H, M",Serology,IgA/IgM/IgG,Lateral Flow,"WVB, Ser, Pla","dipotassium EDTA, lithium heparin, and sodium citrate",NA,S (RBD region),Manual,Gold with visual read,~15 minutes after sample loading,NA,,No cross-reactivity detected in wet lab testing,100.00%,30,Clinical,98.80%,80,,,Clinical validation and independent validation,not included,included,not included,ND,https://www.fda.gov/media/140030/download,https://www.fda.gov/media/140035/download,,,,,s
,Boston Medical Center,BMC-CReM COVID-19 Test,,https://www.bmc.org/here-for-you/screen-covid-19,Lab,USA,"EUA granted July 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, NP wash, NP aspirate, Ns aspirate, BAL",ND,"N (N1, N2)",NA,Qiagen RNeasy Mini Kit,"Two step singleplex: Eppendorf Mastercycler Nexus X2 (software version 3.5.1) for cDNA synthesis and ABI QuantStudio 6 Flex Real-Time PCR System (software version 1.3) for PCR amplification
One step singleplex: ABI QuantStudio 6 Flex Real-Time PCR System (software version 1.3)",ND,"10 gene copies/µL for two step singleplex with cDNA synthesis on the Eppendorf Mastercycler Nexus X2 and PCR amplification on the ABI QuantStudio 6 Flex Real-Time PCR System
1 gene copy/µL for one step singleplex on the ABI QuantStudio 6 Flex Real-Time PCR System",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,70,Clinical,100.00%,70,,,"Clinical evlaution of 30 +/- samples and 5 +/- samples with two step, then 30 +/- samples and 5 +/- samples with one step",included,included,included,ND,https://www.fda.gov/media/140007/download,https://www.fda.gov/media/140007/download,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,7/12/2020 update,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y,"UCSF Health Clinical Laboratories, UCSF Clinical Labs at China Basin",SARS-CoV-2 RNA DETECTR Assay,,https://clinlab.ucsf.edu/covid-19,Lab,USA,"EUA granted July 09, 2020",Laboratory,H,Molecular,RNA,DETECTR,"NP swab, OP swab, MTNs swab, ANs swab, Ns wash, Ns aspirate",UTM ,N,NA,Qiagen EZ1 DSP Virus Kit (Catalog #955134) on the Qiagen EZ1 Advanced benchtop automated extraction instrument,ABI 7500 Fast Dx Real-Time PCR System (Software Version 1.4.1.),ND,20 copies/uL or 100 copies/rxn,,No cross-reactivity predicted in silico nor detected in wet lab testing,95.00%,40,Clinical,100.00%,62,,,PPA determined with 40 individual clinical NP specimens (source not disclosed) confirmed to be positive with an undisclosed comparator assay.  PPA determined with 62 individual clinical NP specimens (source not disclosed) confirmed to be positive with an undisclosed comparator assay. Positive and negative agreement were based on the comparator result.,included,included,included,https://www.nature.com/articles/s41587-020-0513-4,https://www.fda.gov/media/139937/download,https://www.fda.gov/media/139934/download,,,,,
Y,"BioSewoom, Inc.",Real-Q 2019-nCoV Detection Kit,,http://www.biosewoom.com/main#__79346__item0,Kit,S. Korea,"EUA granted July 09, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, Ns aspirate, MTNs swab, Ns swab, OP swab, Spu, Tr aspirate, BAL",UTM ,"RdRP, E",NA,"Qiagen QIAamp MinElute Virus Spin Kit, Roche DNA and Viral RNA Small Volume Kit on the Roche MagNA Pure 96","ABI 7500 Real-Time PCR Instrument System (software version 2.3), ABI 7500 fast Real-Time PCR Instrument System (software version 2.3), ABI QuantStudio 5 Real-Time PCR Instrument System (software version 1.4), Bio-Rad CFX96 real-time PCR detection system (software version 1.6), Bio-Rad CFX96 DX real-time PCR detection system (software version 1.6)",ND,"6.25 copies/uL for sputum with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with ABI 7500 Real-Time PCR Instrument System;  
 6.25 copies/uL for sputum with extraction using Roche DNA and Viral RNA Small Volume Kit on the Roche MagNA Pure 96 and detection with ABI 7500 Real-Time PCR Instrument System;  
 6.25 copies/uL for sputum with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with ABI 7500 fast Real-Time PCR Instrument System;
 6.25 copies/uL for sputum with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with ABI QuantStudio 5 Real-Time PCR Instrument System; 
 6.25 copies/uL for sputum with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with Bio-Rad CFX96 real-time PCR detection system; 
 6.25 copies/uL for sputum with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with Bio-Rad CFX96 DX real-time PCR detection system;      
 6.25 copies/uL for NP swab with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with ABI 7500 Real-Time PCR Instrument System;
 3.125 copies/uL for NP swab with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with ABI 7500 fast Real-Time PCR Instrument System;
 6.25 copies/uL for NP swab with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with ABI QuantStudio 5 Real-Time PCR Instrument System; 
 3.125 copies/uL for NP swab with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with Bio-Rad CFX96 real-time PCR detection system; 
 6.25 copies/uL for NP swab with manual extraction using QIAGEN QIAamp MinElute Virus Spin Kit and detection with Bio-Rad CFX96 DX real-time PCR detection system
",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,77,Clinical and contrived,100.00%,56,,,"PPA determined : 1) 30 contrived specimens spiked with SARS-CoV-2 genomic RNA (National Culture Collection for Pathogen (NCCP) in Republic of Korea, NCCP No. 43326) into individual negative clinical sputum specimens (source of specimens and method of negative determination not disclosed) extracted using the QIAamp MinElute Virus Spin Kit and tested with assay under evaluation on the ABI 7500 Fast Real-Time PCR Instrument, 2) 21 archived clinical sputum specimens from patients with suspected and symptomatic COVID-19 infection collected with the Viral Collection, Preservation and Transport Medium Kit, confirmed to be positive with an undisclosed FDA-authorized assay, extracted with the Qiagen QIAamp MinElute Virus Spin Kit and tested with assay under evaluation on the CFX96 real-time PCR detection system and 3) 26 archived clinical NP and OP specimens (number of each sample type not disclosed) from patients with suspected and symptomatic COVID-19 infection collected with the Viral Collection, Preservation and Transport Medium Kit, confirmed to be positive with an undisclosed FDA-authorized assay, extracted with the Qiagen QIAamp MinElute Virus Spin Kit and tested with assay under evaluation on the CFX96 real-time PCR detection system. 

NPA determined with: 1) 30 negative clinical sputum specimens (source of specimens and method of negative determination not disclosed) extracted using the QIAamp MinElute Virus Spin Kit and tested with assay under evaluation on the ABI 7500 Fast Real-Time PCR Instrument, 2) 9 archived clinical sputum specimens from patients with suspected and symptomatic COVID-19 infection collected with the Viral Collection, Preservation and Transport Medium Kit, confirmed to be negative with an undisclosed FDA-authorized assay, extracted with the Qiagen QIAamp MinElute Virus Spin Kit and tested with assay under evaluation on the CFX96 real-time PCR detection system and 3) 17 archived clinical NP and OP specimens (number of each sample type not disclosed) from patients with suspected and symptomatic COVID-19 infection collected with the Viral Collection, Preservation and Transport Medium Kit, confirmed to be negative with an undisclosed FDA-authorized assay, extracted with the Qiagen QIAamp MinElute Virus Spin Kit and tested with assay under evaluation on the CFX96 real-time PCR detection system. 
",included,included,included,ND,https://www.fda.gov/media/139941/download,https://www.fda.gov/media/139938/download,,,,,
Y,"Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT and Harvard",CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay,,https://covid-19-test-info.broadinstitute.org/,Lab,USA,"EUA granted July 08, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Ns swab, MTNs swab, NP aspirate, Ns aspirate, Ns wash, BAL","VTM, saline","N (N1, N2) for Assay Version 1; N (N2) for Assay Version 2",NA,ThermoFisher MagMAX Viral RNA Isolation Kit on the Agilent Bravo Liquid Handling Platform (running VWorks (Build 11.4.0.1233)) (additional sample prep on the Hamilton STARlet and the Formulatrix Tempest),For Assay Version 1: Applied Biosystems Viia7 thermocycler (QuantStudio Software V1.3) or Applied Biosystems QuantStudio 7 Flex (QuantStudio software v1.3); for Assay Version 2: Applied Biosystems QuantStudio 7 Flex (QuantStudio software v1.3),24 hours from receipt of samples,"4 copies/uL for Assay Version 1 (N (N1, N2) gene, measured on NP samples, Applied Biosystems Viia7 thermocycler, QuantStudio software version 1.3);                                                                                                                                                                                                                                                            1.6 copies/uL for Assay Version 2 (N (N2) gene, measured on synthetic RNA from Twist Biosciences Cat no. MN908947.3, Applied Biosystems QuantStudio 7 thermocycler - QuantStudio software version 1.3)",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,63,Clinical,100.00%,68,,,"PPA determined with 1) 13 OP swabs, 10 NP swabs, 10 OP/NP swabs (number of each of the latter specimen types not disclosed), all clinical specimens collected from individual patients, confirmed positive with the CDC EUA authorized SARS-CoV-2 test by Massachusetts State Public Health Laboratory (MSPHL), and tested with Assay Version 1; and 2) 30 residual NP specimens collected from individual patients in VTM, confirmed positive by Assay Version 1 and tested with Assay Version 2.

NPA determined with 1) 40 clinical NP specimens collected from individual patients, confirmed negative with the CDC EUA authorized SARS-CoV-2 test by Massachusetts State Public Health Laboratory (MSPHL), and tested with Assay Version 1, and 2) 28 residual NP specimens collected from individual patients in VTM, confirmed negative by Assay Version 1 and tested with Assay Version 2.

Assay Version 1 uses N1, N2, and human RP primers and probes, manual initial sample handling, a 96 well format for extraction, and either the ABI Viia7 thermocycler or the QuantStudio 7 Flex thermocycler for  detection.  ABI Viia7 thermocycler was used for detection in validation experiments. Assay Version 2 uses N2 and human RP primers and probes, the Hamilton STARlet for initial sample handling, a 384 well format for extraction, and the QuantStudio 7 Flex thermocycler for detection.",included,included,included,ND,https://www.fda.gov/media/139858/download,https://www.fda.gov/media/139860/download,,,,,
Y,"Diazyme Laboratories, Inc.",Diazyme DZ-Lite SARS-CoV-2 IgG CLIA Kit,,https://www.diazyme.com/images/covid19/60900-Diazyme-Dz-Lite-SARS-CoV-2-IgG-CLIA-Kit-RevB.pdf,Kit,USA,"EUA granted July 08, 2020",Laboratory,"H, M",Serology,IgG,Heterogeneous Immunoassay,"Serum, Plasma","Potassium EDTA, disodium EDTA and lithium heparin",NA,S protein,Manual,Diazyme DZ-Lite 3000 Plus Chemiluminescence Analyzer (software version not disclosed),ND,NA,,No cross-reactivity detected in wet lab testing,100.00%,29,Clinical,97.40%,852,100.00%,67.10%,"PPA determined with 29 serum and plasma specimens (number of each specimen type not disclosed) collected from individuals with PCR-confirmed SARS-CoV-2 infections (method of positive determination not disclosed). (Sensitivity for all 77 samples taken from 51 individuals stratified by windows post symptom onset: 0-7d pso, 43.48%, n=23; 8-14d pso, 91.67%, n=24; >14d pso, 100.00%, n=29). NPA determined with 852 non-novel coronavirus infected specimens (specimen type not disclosed) collected before December 2019.",included,Included,Included,ND,https://www.fda.gov/media/139865/download,https://www.fda.gov/media/139866/download,,,,,
,"Enzo Life Sciences, Inc.",AMPIPROBE SARS-CoV-2 Test System,,https://www.enzolifesciences.com/ENZ-GEN215/ampiprobe-sars-cov-2-assay-kit/,Kit,USA,"EUA granted July 7, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NS swab, NTNs swab, NP swab, OP swab, NP wash, NP aspirate, Ns aspirate",VTM,"N (N1, N2)",NA,Enzo Life Sciences AMPIXTRACT SARS-CoV-2 Extraction kit on the Hamilton Microlab Star liquid handler as part of the Enzo Life Sciences GENEFLEX Platform v1.0,ABI QuantStudio 5 instrument (software version 1.5.1) as part of the Enzo Life Sciences GENEFLEX Platform v1.0,ND,280 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,96.20%,53,Clinical,98.00%,147,,,Clinical evaluation,included,included,included,ND,https://www.fda.gov/media/139828/download,https://www.fda.gov/media/139829/download,,,,,
,"Access Bio, Inc.",CareStart COVID-19 MDx RT-PCR,,http://www.accessbio.net/eng/main/main.asp,Kit,USA,"EUA granted July 7, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Ns swab, NP wash, NP aspirate, Ns aspirate, BAL","Universal Transport (UTM-RT®, Copan Diagnostics, Inc), Universal Viral Transfer (UVT, BD™ Diagnostics) or equivalent","N, RdRP",NA,Qiagen QIAamp Viral RNA Mini Kit,"ABI 7500/7500 Fast Real-Time PCR instrument (software version 1.4 21 CFR Part 11 Module), CFX96 TouchTM Real-Time PCR Detection System (software version 3.1)",ND,10 copies/rxn,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,92,Clinical,100.00%,92,,,"Clinical evaluation with 46 positive and 46 negative, each run on both machines",included,included,included,ND,https://www.fda.gov/media/139832/download,https://www.fda.gov/media/139833/download,,,,,
,Gene By Gene,Gene By Gene SARS-CoV-2 Detection Test,,https://genebygene.com/coronavirus-covid-19/,Lab,USA,"EUA granted July 7, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, NP swab",RNAlater Stabilization Solution,"N (N1, N2)",NA,"Qiagen miRNeasy Serum/Plasma Advanced Kit on the Qiagen QIAcube HT/QIAxtractorExtraction workcell (additional sample prep with Tecan Evo 8span Liquid Handler, Beckman NX 8span Liquid Handler or Beckman FX 96head Liquid Handler)",Bio-Rad CFX384 Touch Real-Time PCR Detection System (software version 4.1.2433.1219),ND,6.25 copies/µL ,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,69,Clinical and contrived,100.00%,67,,,"Contrived study, clinical study, media equivalency study, sample stability study",included,included,included,ND,https://www.fda.gov/media/139836/download,https://www.fda.gov/media/139838/download,,,,,
,Laboratorio Clinico Toledo,Laboratorio Clinico Toledo SARS-CoV-2 Assay ,,https://laboratoriotoledo.com/,Lab,USA,"EUA granted July 6, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab, BAL",ND,"N, E",NA,Roche MagNA Pure 96 DNA and Viral NA Small volume kit on the Roche Magna Pure 96 system (Software version 3.1.1),Roche Light Cycler 480 (software version LCS480 1.5.16.2 SP@-UDF v 2.0),~5 hours after sample collection,"21,000 cp/mL (N gene)
203 cp/mL (E gene)",,No cross-reactivity detected in wet lab testing,98.00%,50,Clinical and contrived,100.00%,31,,,"Contrived study, clinical study",included,included,included,ND,https://www.fda.gov/media/139788/download,https://www.fda.gov/media/139785/download,,,,,
,"Assure Tech. (Hangzhou Co., Ltd)",Assure COVID-19 IgG/IgM Rapid Test Device,,http://www.assuretech.com.cn/product_show_5.html,Kit,China,"EUA granted July 6, 2020",Laboratory,"H, M",Serology,IgM/IgG,Lateral Flow,"VWB, Ser, Pla",sodium EDTA,NA,"N, S1",Manual,Gold with visual read,~15 minutes after sample loading,NA,,No cross-reactivity detected in wet lab testing,100.00%,30,Clinical,98.80%,80,100.00%,81.40%,"Independent clinical evaluation, clinical evaluation",included,included,included,ND,https://www.fda.gov/media/139792/download,https://www.fda.gov/media/139789/download,,,,,
,Centers for Disease Control and Prevention (CDC),Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay,,https://www.cdc.gov/coronavirus/2019-ncov/lab/multiplex.html,Kit,USA,"EUA granted July 2, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Ns swab, Spu, LRT aspirates, BAL, NP wash, NP aspirate, Ns aspirate","VTM, Amies transport medium, sterile saline","N (Cov2), M1 (Influenza A), NS2 (Influenza B)",NA,"Qiagen QIAmp DSP Viral RNA Mini Kit, Qiagen Viral RNA Mini Kit,  Qiagen EZ1 DSP Virus Kit on the Qiagen EZ1 Advanced XL, Qiagen EZ1 Virus Mini Kit v2.0 on the Qiagen EZ1 Advanced XL, Roche DNA and Viral NA Small Volume
Kit on the Roche MagNA Pure 96, Qiagen QIAmp DSP Viral RNA Mini Kit on the Qiagen QIAcube,  Qiagen Viral RNA Mini Kit on the Qiagen QIAcube ",ABI 7500 Fast Dx Real-Time (Software Version 1.4.1),ND,"1.01E-02 ID50/rxn extracted with the QIAGEN EZ1 DSP Virus Kit on the QIAGEN EZ1 Advanced XL and using TaqPathTM Multiplex Master Mix (No ROX) 
5.06E-02 ID50/rxn extracted with the QIAGEN EZ1 DSP Virus Kit on the QIAGEN EZ1 Advanced XL and using  Quantabio UltraPlexTM 1-Step ToughMix® (4X)",,No cross-reactivity detected in wet lab testing,100.00%,33,Clinical,100.00%,71,,,Clinical evaluation,included,included,included,ND,https://www.fda.gov/media/139743/download,https://www.fda.gov/media/139744/download,,,,,
Y,"Becton, Dickinson and Company (BD)",BD Veritor System for Rapid Detection of SARS-CoV-2,,https://www.bd.com/en-us/offerings/capabilities/microbiology-solutions/point-of-care-testing/bd-veritor-sars-cov-2,Kit,USA,"EUA granted July 2, 2020","Laboratory, POC","H, M, W",Antigen,Antigen,Chromatographic digital immunoassay,Ns swab,NA,NA,N,BD Extraction Reagent,BD Veritor Plus Analyzer,~15 minutes,1.4 x 10^2 TCID50/mL,,In silico analysis predicts potential reaction with human coronavirus HKU1. No cross-reactivity detected in wet lab testing,83.87%,31,Clinical,100.00%,195,,,PPA determined with 31 blinded direct Ns swab specimens prospectively collected within a prespecified date range with the dual nares method by qualified personnel in 21 geographically diverse areas across the United States from individual symptomatic patients (within 5 days of onset) who were suspected of COVID-19 and confirmed to be positive compared to results of an NP or OP swab (number of each sample type not disclosed) stored in viral transport media and tested with an undisclosed EUA RT-PCR test for detection of SARS-CoV-2.  NPA determined with 195 blinded direct Ns swab specimens prospectively collected within a prespecified date range with the dual nares method by qualified personnel in 21 geographically diverse areas across the United States from individual symptomatic patients (within 5 days of onset) who were suspected of COVID-19 and confirmed to be negative compared to results of an NP or OP swab (number of each sample type not disclosed) stored in viral transport media and tested with an undisclosed EUA RT-PCR test for detection of SARS-CoV-2.,included,included,included,ND,https://www.fda.gov/media/139755/download,https://www.fda.gov/media/139752/download,,,,,
Y,"CENTOGENE US, LLC",CentoFast-SARS-CoV-2 RT-PCR Assay,,https://www.centogene.com/covid-19/testing/about-the-sars-cov-2-test.html,Lab,USA,"EUA granted July 1, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,OP Swab,Dry swab,"E, RdRP",NA,Macherey-Nagel NucleoMag VET Kit on the ThermoFisher KingFisher Flex,Roche LightCycler 480 II (Software Version 1.5.1.62 or higher),ND,5 copies/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,,,PPA determined with 30 clinical blinded and randomized dry OP specimens (source not disclosed) confirmed to be positive with an undisclosed EUA RT-PCR test.  NPA determined with 30 clinical blinded and randomized dry OP specimens (source not disclosed) confirmed to be negative with an undisclosed EUA RT-PCR test.,included,included,included,ND,https://www.fda.gov/media/139725/download,https://www.fda.gov/media/139722/download,,,,,
Y,The Kroger Co.,Kroger Health COVID-19 Test Home Collection Kit,,https://www.krogerhealth.com/,Collection,USA,"EUA granted June 30, 2020",Laboratory,NA,Home Collection Kit,RNA,NA,Nasal swab,Saline,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,NA,0.00%,,NA - collection kit,NA,NA,NA,ND,https://www.fda.gov/media/139683/download,https://www.fda.gov/media/139681/download,,,,,
Y,"TNS Co., Ltd (Bio TNS)",COVID-19 RT-PCR Peptide Nucleic Acid (PNA) kit,,https://biotns.co.kr/index#COVID19,Kit,S. Korea,"EUA granted June 30, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swabs, ANs swab, MTNs swab, BAL, NP wash, NP aspirate, Ns aspirate","VTM, saline","RdRP, N",NA,Qiagen RNeasy Mini Kit,"Bio-Rad CFX-96 real-time PCR detection system with C1000 Thermal cycler (with CFX Manager v. 3.0 or v. 3.1 software or CFX Maestro software), ABI 7500/7500 Fast (software version 2.3)",ND,"3.715 copies/uL (N gene), 2.524 copies/uL (RdRP gene)",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,33,Clinical,100.00%,32,,,PPA determined with 33 archived clinical NP specimens from symptomatic patients suspected of COVID-19 infection and confirmed to be positive with the EUA authorized Seegene Allplex 2019-nCoV Assay.  NPA determined with 32 archived clinical NP specimens from symptomatic patients suspected of COVID-19 infection and confirmed to be negative with the EUA authorized Seegene Allplex 2019-nCoV Assay.,included,included,included,ND,https://www.fda.gov/media/139680/download,https://www.fda.gov/media/139677/download,,,,,
Y,"Psomagen, Inc.",Psoma COVID-19 RT Test,,https://psomagen.com/covid-test/,Lab,USA,"EUA granted June 30, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab, BAL",ND,"N (N1, N2)",NA,Takara Bio NucleoSpin RNA Virus Kit ,Roche Light cycler 480 instrument ( with software Version l.5.),ND,1 cp/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,85,Clinical and contrived,100.00%,85,,,"PPA determined with 1) 30 contrived specimens spiked with SARS-CoV-2 RNA Isolate (BEI Resources, Cat # 52285) into negative clinical NP specimens (source of specimens and method of negative determination not disclosed) and 2) 55 clinical NP specimens (source not disclosed) confirmed to be positive with either the FDA EUA RT-PCR the TaqPath COVID-19 Method (EUA200010) or the LabCorp COVID-19 RT_PCR Test (EUA200011) (number of samples run with each comparator not disclosed). NPA determined with 1) 30 negative clinical NP specimens (source of specimens and method of negative determination not disclosed) and 2) 55 clinical NP specimens (source not disclosed) confirmed to be negative with either the FDA EUA RT-PCR the TaqPath COVID-19 Method (EUA200010) or the LabCorp COVID-19 RT_PCR Test (EUA200011) (number of samples run with each comparator not disclosed).",included,included,included,ND,https://www.fda.gov/media/139676/download,https://www.fda.gov/media/139673/download,,,,,
Y,"InBios International, Inc.",SCoV-2 Detect IgM ELISA,,https://inbios.com/scov-2-detect-igm-elisa-kit/,Kit,USA,"EUA granted June 30, 2020",Laboratory,H,Serology,IgM,ELISA,Serum,NA,NA,ND,Manual (with unspecified automated plate washer),Microplate reader (manufacturer not specified),~1 hour and 50 minutes after sample preparation,NA,,2/180 samples positive for normal human serum specimens (collected in the US prior to the COVID-19 outbreak) during wet lab testing,96.70%,30,Clinical,98.80%,80,99.80%,80.90%,"PPA determined from 120 serum specimens collected from 85 individuals who tested positive by SCoV-2 PCR assay (method not disclosed). Sensitivity for samples were further stratified into specific windows post symptom onset with PCR positive at any time (0-7d pso, 66.67%, n=9; 8-14d pso, 92.11%, n=38; >14d pso, 94.12%, n=51; unknown, 100.00%, n=22). NPA determined using 95 normal human serum specimens (source and method of negative determination not disclosed).  As part of cross-reactivity studies, also reported results from testing 180 normal human serum samples collected in the US prior to the COVID-19 outbreak (2/180 reactive).  Also conducted reproducibility tests on positive and negative serum samples assayed by three trained operators on three different days in triplicate (n = 27 total runs per sample), showing 100% positive or negative agreement between runs for each positive and negative sample, respectively.",not included,included,included,ND,https://www.fda.gov/media/139730/download,https://www.fda.gov/media/139726/download,,,,,
Y,LifeHope Labs,LifeHope 2019-nCoV Real-Time RT-PCR Diagnostic Panel,,https://www.lifehopetestkit.com/,Lab,USA,"EUA granted June 29, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Ns swab, MTNs swab, NP swab, OP swab, BAL",ND,"N (N1, N2)",NA,Indical IndiMag Extraction Kit ,ABI QuantStudio 5 (software version 1.5.1),ND,2.5 GE/µL ,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,,,PPA determined with 30 clinical NP specimens (source not disclosed) confirmed to be positive with the CDC 2019-Novel Coronavirus (2019-nCoV) Real_Time RT-PCR Diagnostic Panel.  NPA determined with 30 clinical NP specimens (source not disclosed) confirmed to be negative with the CDC 2019-nCoV Real_Time RT-PCR Diagnostic Panel.,included,included,included,ND,https://www.fda.gov/media/139623/download,https://www.fda.gov/media/139620/download,,,,,
Y,"Acupath Laboratories, Inc.",Acupath COVID-19 Real-Time (RT-PCR) Assay,,https://www.acupath.com/covid-19-testing/,Lab,USA,"EUA granted June 29, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, NP aspirate, BAL",ND,"Orf1ab, N, S",NA,ThermoFisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit using the ThermoFisher KingFisher Flex Purification System,ABI QuantStudio 12K Flex Real-Time PCR (with QuantStudio software version 1.4.),ND,25 copies/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,,,PPA determined with 30 clinical NP specimens (source not disclosed) confirmed to be positive with the EUA-authorized Cepheid Xpert Xpress SARS-CoV-2 assay.  NPA determined with 30 clinical NP specimens (source not disclosed) confirmed to be negative with the EUA-authorized Cepheid Xpert Xpress SARS-CoV-2 assay.,included,included,included,ND,https://www.fda.gov/media/139672/download,https://www.fda.gov/media/139669/download,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Y,"Inform Diagnostics, Inc.",Inform Diagnostics SARS-CoV-2 RT-PCR Assay,,https://www.informdx.com/Our-Services/Hematopathology/COVID-19-Testing.aspx,Lab,USA,"EUA granted June 26, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, ANs swab, MTNs swab, NP wash, NP aspirate, Ns aspirate, BAL",ND,"N (N1, N2)",NA,ViralXpress DNA/RNA Extraction Reagent (Qiagen QIAgility for additional sample prep),"ABI 7500 Fast Dx Real-Time PCR Instrument (software version 1.4), ABI QuantStudio (software version 1.0.3)",ND,20 copies/uL,,No cross-reactivity predicted in silico,97.03%,131,Clinical and contrived,100.00%,127,,,"PPA determined with 1) 33 clinical NP and OP specimens (source and number of each specimen type not disclosed) confirmed positive with an unmodified CDC EUA Authorized Assay and tested with assay under evaluation using two different detection methods: the ABI7500 Fast System (n = 33) and the ABI QuantStudio (n = 33) 2) 5 specimens (source and type not disclosed) confirmed positive with the CDC EUA assay by the Arizona Health Department (detection method for assay under evaluation not disclosed), and 3) 30 blinded and randomized contrived specimens spiked with synthetic viral RNA provided from Twist Bioscience (catalog number not disclosed) into negative clinical NP specimens (source of specimens not disclosed) determined negative with the unmodified CDC EUA Authorized Assay and tested with assay under evaluation using two different detection methods: the ABI7500 Fast System (n = 30) and the ABI QuantStudio (n = 30). Note that it is not disclosed whether the 5 specimens evaluated by the Arizona Health Department were from a specimen set mutually exlusive from those used in other validation experiments.  NPA determined with 1) 31 clinical NP and OP specimens (source and number of each specimen type not disclosed) confirmed negative with an unmodified CDC EUA Authorized Assay and tested with assay under evaluation using two different detection methods: the ABI7500 Fast System (n = 31) and the ABI QuantStudio (n = 31) 2) 5 specimens (source and type not disclosed) confirmed negative with the CDC EUA assay by the Arizona Health Department (detection method for assay under evaluation not disclosed), and 3) 30 blinded and randomized negative clinical NP specimens (source of specimens and method of negative determination not disclosed) and tested with assay under evaluation using two different detection methods: the ABI7500 Fast System (n = 30) and the ABI QuantStudio (n = 30). Note that it is not disclosed whether the 5 specimens evaluated by the Arizona Health Department were from a specimen set mutually exlusive from those used in other validation experiments.  An additional sample was excluded due to an indeterminate result with both detection methods based on the reporting strategy for the original CDC EUA authorization.",included,included,included,ND,https://www.fda.gov/media/139572/download,https://www.fda.gov/media/139569/download,,,,,
Y,"PlexBio Co., Ltd",IntelliPlex SARS-CoV-2 Detection Kit,,https://www.plexbio.com/intelliplex%E2%84%A2-sars-cov-2-detection-kit,Kit,Taiwan,"EUA granted June 25, 2020",Laboratory,H,Molecular,RNA,rRT-PCR/πCode,"NP swab, OP swab, ANs swab, MTNs swab, NP wash, NP aspirate, Ns aspirate, BAL","VTM, saline","RdRP, E, N",NA,QIAamp Viral RNA Mini Kit (as well as the Thermo Fisher MiniAmp Thermal cycler for amplication and the PlexBio IntelliPlex 1000 πCode Processor for hybridization),PlexBio 100 Fluorescent Analyzer (with DeXipher MD software),~4.5 hours (including sample prep),140 copies/mL,,"In silico analysis showed homologies >80% to Human coronavirus OC43 and Human coronavirus HKUI for RdRP probe, forward primer, and reverse primer. No cross reactivity detected in wet testing.",100.00%,35,Clinical and contrived,100.00%,30,,,"PPA determined with 30 blinded and randomized contrived specimens spiked with SARS-CoV-2 Reference Material (SeraCare; AccuPlex™ SARS-CoV-2 Reference Material Kit, Cat. No. 0505-0126) into individual, unique negative clinical NP specimens (source of specimens and method of negative determination not disclosed) and with 5 clinical NP specimens confirmed to be positive with the EUA authorized Hologic Panther Fusion SARS-CoV-2 Assay. NPA determined with 30 blinded and randomized negative clinical NP specimens (source of specimens and method of negative determination not disclosed).",included,included,included,ND,https://www.fda.gov/media/139527/download,https://www.fda.gov/media/139528/download,,,,,
Y,PreciGenome LLC,FastPlex Triplex SARS-CoV-2 detection kit (RT-Digital PCR),,https://www.precigenome.com/coronavirus-covid19-pcr-assay,Kit,USA,"EUA granted June 25, 2020",Laboratory,H,Molecular,RNA,RT-dPCR,OP swab,"VTM, UTM","Orf1ab, N",NA,QIAamp Viral RNA Mini Kit,DropX-2000 Digital PCR System (with GeneCount Software V1.61.0508),ND,571.4 copies/mL (8 copies/rxn),,No cross-reactivity predicted in silico nor detected in wet lab testing,96.30%,108,Clinical,96.67%,60,,,PPA determined with 108 randomized and blinded clinical OP specimens collected by qualified personnel (source not disclosed) and confirmed to be positive with an undisclosed EUA authorized RT-PCR test for use with upper respiratory specimens run using the ABI 7500 per comparator instructions.  NPA determined with 60 randomized and blinded clinical OP specimens collected by qualified personnel (source not disclosed) and confirmed to be negative with an undisclosed EUA authorized RT-PCR test for use with upper respiratory specimens run using the ABI 7500 per comparator instructions.  Two additional samples were excluded due to an invalid test result.,included,included,included,ND,https://www.fda.gov/media/139523/download,https://www.fda.gov/media/139524/download,,,,,
Y,"Diagnostic Solutions Laboratory, LLC",DSL COVID-19 Assay,,https://www.diagnosticsolutionslab.com/tests/covid-19-sars-cov-2,Lab,USA,"EUA granted June 25, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Ns swab, MTN swab, BAL","Dry swab, VTM","N (N1, N3), S",NA,Omega BioTek MagBind Viral DNA/RNA 96 Kit on the ThermoFisher Scientific KingFisher Flex Purification System,ABI QuantStudio 5 Real-Time PCR System (QuantStudio Analysis software version 1.5.1),ND,10 copies/swab,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,29,Clinical,97.00%,33,,,"PPA determined with 29 dry clinical NP specimens (source not disclosed) confirmed to be positive with an undisclosed FDA EUA authorized SARS-CoV-2 PCR test with three targets (ORF1ab, S and N).  NPA determined with 33 dry clinical NP specimens (source not disclosed) confirmed to be negative with an undisclosed FDA EUA authorized SARS-CoV-2 PCR test with three targets (ORF1ab, S and N).  Two additional samples were run and considerend inconclusive by the comparator assay. Note that for both PPA and NPA, the same extraction products from the clinical specimens were tested with both the comparator assay and the assay under evaluation.  ",included,included,included,ND,https://www.fda.gov/media/139516/download,https://www.fda.gov/media/139513/download,,,,,
Y,"University of Texas MD Anderson Cancer Center, Molecular Diagnostics Laboratory",MD Anderson High-throughput SARS-CoV-2 RT-PCR Assay,,https://www.mdanderson.org/patients-family/becoming-our-patient/planning-for-care/coronavirus-protections.html,Lab,USA,"EUA granted June 24, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Ns swab, MTN swab",ND,"N (N1, N2)",NA,"Promega Maxwell HT Viral TNA Kit (manual),  Promega Maxwell HT Viral TNA Kit on the Hamilton Robotics MicroLab Star, Promega Maxwell HT Viral TNA Kit on the Hamilton Robotics MicroLab Starlet (additional sample prep with the Hamilton Robotics MicroLab Star), undisclosed extraction kit on the Promega Maxwell RSC 48","ABI QuantStudio 7 Flex Fast Sequence Detection System (software version 1.3), ABI 7500 Fast Real-Time PCR Instrument (software version 1.5.1), ABI QuantStudio Dx Real-Time PCR Instrument with 96-well fast block (software version 1.0.3)",ND,"1.67 copies/uL with manual extraction using Promega Maxwell HT Viral TNA Kit and detection with ABI QuantStudio 7 Flex Fast Sequence Detection System;  
5 copies/uL with extraction using Promega Maxwell HT Viral TNA Kit on the Hamilton Robotics MicroLab Starlet and detection with ABI QuantStudio 7 Flex Fast Sequence Detection System;
5 copies/uL with extraction using Promega Maxwell HT Viral TNA Kit on the Hamilton Robotics MicroLab Star and detection with ABI QuantStudio 7 Flex Fast Sequence Detection System;
5 copies/uL with extraction using Promega Maxwell HT Viral TNA Kit on the Hamilton Robotics MicroLab Starlet and detection with ABI 7500 Fast Real-Time PCR Instrument;
5 copies/uL with extraction using Promega Maxwell HT Viral TNA Kit on the Hamilton Robotics MicroLab Starlet and detection with ABI QuantStudio Dx Real-Time PCR Instrument with 96-well fast block;",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,31,Clinical,100.00%,28,,,"PPA determined with 26 individual clinical NP specimens collected at MD Anderson and confirmed to be positive with an undisclosed FDA Emergency Use Authorized (EUA) assay by MD Anderson, and with 5 clinical NP specimens collected at MD Anderson and confirmed to be positive with undisclosed FDA Emergency Use Authorized (EUA) assay by the Houston Health Department Laboratory.  NPA determined with 22 individual clinical NP specimens collected at MD Anderson and confirmed to be neegative with an undisclosed FDA Emergency Use Authorized (EUA) assay by MD Anderson, and with 6 clinical NP specimens collected at MD Anderson and confirmed to be negative with undisclosed FDA Emergency Use Authorized (EUA) assay by the Houston Health Department Laboratory.  All specimens for the assay under evaluation were processed with manual extraction using the Promega Maxwell HT Viral TNA Kit and detection with the ABI QuantStudio 7 Flex Fast Sequence Detection System",included,included,included,ND,https://www.fda.gov/media/139512/download,https://www.fda.gov/media/139509/download,,,,,
Y,"Gencurix, Inc.",GenePro SARS-CoV-2 Test,,http://www.gencurix.com/eng/sub_2_6.php,Kit,South Korea,"EUA granted June 23, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, AN swab, MTN swab, NP wash, NP aspirate, Ns aspirate, BAL",UTM or equivalent,"Orf1ab, E",NA,"Qiagen QIAamp Viral RNA Mini Kit (manual), Qiagen QIAamp DSP Viral RNA Mini Kit (manual),
Qiagen QIAamp Viral RNA Mini Kit on the Qiagen QIAcubeConnnect, 
Qiagen QIAamp DSP Viral RNA Mini Kit on the Qiagen QIAcubeConnect,
Thermo Fisher Scientific MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the Thermo Fisher Scientific KingFisher Flex System ","ABI QuantStudio Dx Real-Time PCR Instrument (software version 1.0.3), Bio-Rad CFX9 Dx System (software version 3.1)",ND,"5550 GE/mL (777 GE/140 uL, 71 GE/rxn) for Orf1ab gene and 6000 GE/mL (840 GE/140 µL, 77 GE/rxn) for E gene with manual extraction using QIAamp Viral RNA Mini Kit and detection with ABI QuantStudioDx;  
6000 GE/mL (840 GE/140 µL, 77 GE/rxn) for both targets with manual extraction using QIAamp Viral RNA Mini Kit and detection with Bio-Rad CFX9 Dx System;
6000 GE/mL (840 GE/140 µL, 77 GE/rxn) for both targets with extraction using MagMAX Viral/Pathogen RNA Isolate Kit on the Thermo Fisher Scientific KingFisher Flex System and detection with ABI QuantStudioDx ",,No cross-reactivity predicted in silico,100.00%,100,Contrived,100.00%,90,,,"PPA determined with contrived specimens spiked with heat inactivated SARS-CoV-2 provided from BEI Resources (Cat. No. NR-52286, lot number 70033548) into unique negative clinical NP specimens (source of specimens and method of negative determination not disclosed) and tested with assay under evaluation with three combinations of extraction and detection methods: manual extraction with Qiagen QIAamp Viral RNA Mini Kit (QIAamp) and detection with ABI QuantStudio Dx (QSDx) (n = 30), manual extraction with QIAamp and detection with Bio-Rad CFX9 Dx System (n = 30), and extraction with MagMAX Viral/Pathogen Nucleic Acids Isolation Kit on the KingFisher Flex System and detection with QSDx (n=40). Note that it is not disclosed whether the specimens evaluated for each method combination were from mutually exlusive specimen sets.  NPA determined with unique negative clinical NP specimens (source of specimens and method of negative determination not disclosed) and tested with assay under evaluation with three combinations of extraction and detection methods: manual extraction with Qiagen QIAamp Viral RNA Mini Kit (QIAamp) and detection with ABI QuantStudio Dx (QSDx) (n = 30), manual extraction with QIAamp and detection with Bio-Rad CFX9 Dx System (n = 30), and extraction with MagMAX Viral/Pathogen Nucleic Acids Isolation Kit on the KingFisher Flex System and detection with QSDx (n=30). Note that it is not disclosed whether the specimens evaluated for each method combination were from mutually exlusive specimen sets",not included,included,included,ND,https://www.fda.gov/media/139442/download,https://www.fda.gov/media/139443/download,,,,,
Y,University of Alabama at Birmingham Fungal Reference Lab,FRL SARS CoV-2 Test,,https://npidb.org/organizations/laboratories/clinical-medical-laboratory_291u00000x/1891980934.aspx,Lab,USA,"EUA granted June 23, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Ns swab, AN swab, MTN swab, NP wash, NP aspirate, Ns aspirate, BAL",ND,N (N1),NA,Omega Scientific E.Z.N.A. Viral RNA Kit,ABI QuantStudio 5 Real-Time PCR System (Software version V1.4.3),ND,125 copies/mL,,No cross-reactivity predicted in silico,100.00%,35,Clinical,100.00%,35,,,"PPA determined with 30 clinical NP specimens (source not disclosed) confirmed to be positive with an undisclosed EUA sanctioned SARS-CoV-2 real-time RT-PCR assay, and 5 NP specimens (source not disclosed) confirmed to be positive with an undisclosed EUA sanctioned SARS-CoV-2 real-time RT-PCR assay by an undisclosed high complexity CLIA laboratory. Note that it is not disclosed whether the latter 5 specimens were from a specimen set that was mutually exlusive from the others reported.  NPA determined with 30 clinical NP specimens (source not disclosed) confirmed to be negative with an undisclosed EUA sanctioned SARS-CoV-2 real-time RT-PCR assay, and 5 NP specimens (source not disclosed) confirmed to be negative with an undisclosed EUA sanctioned SARS-CoV-2 real-time RT-PCR assay by an undisclosed high complexity CLIA laboratory. Note that it is not disclosed whether the latter 5 specimens were from a specimen set that was mutually exlusive from the others reported.",included,included,included,ND,https://www.fda.gov/media/139437/download,https://www.fda.gov/media/139439/download,,,,,
Y,HealthQuest Esoterics,HealthQuest Esoterics TaqPath SARS-CoV-2 Assay,,https://www.hqesoterics.com/covid-19,Lab,USA,"EUA granted June 23, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, AN swab, MTN swab, NP wash, NP aspirate, Ns aspirate, BAL","ClearPrep Specimen Transport Medium, UTM, VTM, Saline, PBS","Orf1ab, N, S",NA,Perkin Elmer Chemagic Viral DNA/RNA 300 Kit H96 on the Chemagic 360 extraction instrument software version 6.3.0.3. (with additional sample prep on the Janus G3 workstation (software 5.5.48)),QuantStudio 12K Flex Real-Time PCR System software version 1.3.,ND,20 copies/mL,,No cross-reactivity predicted in silico,100.00%,115,Clinical and contrived,100.00%,73,,,"PPA determined with 75 blinded and randomized contrived specimens spiked with SARS-CoV-2 targeted RNA fragments (ThermoFisher; TaqPath COVID-19 Positive Control) into negative clinical NP specimens (source of specimens and method of negative determination not disclosed), 35 clinical NP specimens (source not disclosed) confirmed to be positive with the CDC 2019-CoV Real-Time RT-PCR Diagnostic Panel by the Orange County Health Department, and 5 clinical NP specimens (source not disclosed) confirmed to be positive with the CDC 2019-CoV Real-Time RT-PCR Diagnostic Panel by Vitae Laboratories. Note that it is not disclosed whether the latter 5 specimens were from a specimen set that was mutually exlusive from the others reported.  NPA determined with 34 blinded and randomized negative clinical NP specimens (source of specimens and method of negative determination not disclosed), 34 clinical NP specimens (source not disclosed) confirmed to be negative with the CDC 2019-CoV Real-Time RT-PCR Diagnostic Panel by the Orange County Health Department, and 5 clinical NP specimens (source not disclosed) confirmed to be negative with the CDC 2019-CoV Real-Time RT-PCR Diagnostic Panel by Vitae Laboratories. Note that it is not disclosed whether the latter 5 specimens were from a specimen set that was mutually exlusive from the others reported.",included,included,included,ND,https://www.fda.gov/media/139434/download,https://www.fda.gov/media/139449/download,,,,,
Y,"Babson Diagnostics, Inc.",Babson Diagnostics aC19G1,,https://babsondx.com/science/covid-19-testing,Lab,USA,"EUA granted June 23, 2020",Laboratory,H,Serology,IgG,Heterogeneous immunoassay,"Serum, Plasma",NA,NA,S1,"Siemens Atellica Sample Handler, Siemens Atellica Direct Load",Siemens Atellica IM Analyzer,ND,NA,,No cross-reactivity detected in wet lab testing,100.00%,29,Clinical,100.00%,100,100.00%,100.00%,"PPA determined with 29 clinical serum and plasma samples (number of each sample type not disclosed) collected from symptomatic individuals tested >14 days post symptom onset (pso) and confirmed positive for SARS-CoV-2 by an FDA-authorized PCR assay based on NP and OP swabs. (Sensitivity for other windows: 66.67% 8-14d pso with n=3 and 100.00% asymptomatic individuals with n=2).  A total of 34 samples were tested, including 20 sputum (n = 18 from COVID-19 symptomatic individuals, n = 2 from asymptomatic individuals) and 14 plasma EDTA specimens from individuals who had COVID-19 symptoms with one or more documented positive FDA-authorized PCR results.  While stratification by post sytmpom onset and sample type was not disclosed, additional stratification was provided for days post PCR positive and sample type.  Stratification of sensitivity for sputum samples post PCR positive: 75.00% 8-14d post PCR positive with n=4 and 100.00% >14d post PCR positive with n=16.  Stratification of sensitivity for plasma EDTA samples post PCR positive: 100.00% 8-14d post PCR positive with n=6 and 100.00% >14d post PCR positive with n=8.  FDA-authorized methods used to determine SARS-CoV-2 positve status included the Roche cobas SARS-CoV-2,  the Quest SARS-CoV-2 rRT-PCR, the Qiagen QIAstat-Dx Respiratory SARS-CoV-2 Panel, the Abbott M2000 RealTime SARS-CoV-2 assay, and the Luminex NxTAG CoV (number of individuals tested with each method not disclosed). Tests for assay under evaluation were run at a single site (Babson Diagnostics laboratory, Austin, TX) by two operators trained on laboratory procedures for the instrument and the test method.  NPA determined with clinical serum and plasma samples (number of each sample type not disclosed) collected from individuals between September 25, 2019 and October 7, 2019. ",included,not included,included,ND,https://www.fda.gov/media/139446/download,https://www.fda.gov/media/139450/download,,,,,
Y,"Hangzhou Laihe Biotech Co., Ltd.",LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold),,http://www.lyherbio.com/default.aspx?pageid=2&pageType=detail&id=27,Kit,China,"EUA granted June 19, 2020",Laboratory,"H, M",Serology,IgM/IgG ,Lateral Flow,"Serum, Plasma",NA,NA,S1,Manual,Gold with visual read,10 minutes after sample loading,NA,,No cross-reactivity detected in wet lab testing,100.00%,30,Clinical,98.80%,80,100.00%,81.40%,"PPA determined with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR). Positive assay results for PPA were those that were positive for IgG or IgM.  NPA determined with 80 frozen SARS-CoV-2 antibody-negative serum and plasma samples (distribution of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Negative assay results for NPA were those that were negative for both IgG and IgM.  Testing was performed by one operator using one lot of the COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma).   

A validation test for positive agreement with PCR positive results was also conducted with 178 clinical samples (sample type not disclosed) collected at four medical centers in Hubei Province, China (number from each site not disclosed) from patients either in quarantine (n=90) or who had recovered from COVID-19 (n= 88) who had all been confirmed positive at any time with PCR assay for SARS-CoV-2 (method not disclosed). (Sensitivity for either IgM or IgG positive result for 178 samples stratified by windows of time post PCR positive: 100.00% positive agreement for 0-6d post PCR positive with n=23, 85.71% positive agreement for 7-14d post PCR positive with n=21, and 99.25% positive agreement for >14d post PCR positive with n =134).  An additional validation test for negative agreement was conducted with clinical samples (sample type not disclosed) collected from individuals with coronavirus infections not caused by SARS-CoV-2 (n =239) or collected prior to August 2019 from individuals with other respiratory tract infections (n = 110), some of which were tested negative at a local hospital (number of samples and method not disclosed). (Specificity for IgM-/IgG-: 99.43%, n = 349).",not included,included,not included,ND,https://www.fda.gov/media/139410/download,https://www.fda.gov/media/139407/download,,,,,***
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,6/21/2020 update,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"3B Blackbio Biotech India Ltd., a subsidiary of Kilpest India Ltd.",TRUPCR SARS-CoV-2 Kit,,https://3bblackbio.com/covid-19-corona-virus-real-time-qpcr-kit-sars-cov-2-trupcr.html,Kit,India,"EUA granted June 18, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Anterior nasal swab, Mid-turbinate nasal swab,
NP aspirate/wash, Nasal aspirate, BAL","VTM (TRUPCR® Viral Transport Medium or other), UTM","RdRP, N",NA,TRUPCR® Viral RNA Extraction Kit (3B213V/3B214V),"ABI QuantStudio 3 (software version 1.4.3), Qiagen Rotor-Gene Q 5Plex HRM Platform (software version 2.3.1)",ND,10 copies/µL,,No cross-reactivity detected in wet lab testing,96.77%,31.00,Clinical,96.67%,30.00,,,"PPA determined with 31 blinded and randomized clinical NP and OP specimens (source and number of each not disclosed) confirmed to be positive with the FDA authorized RealStar SARS-CoV-2 RT-PCR Kit and tested with assay under evaluation by an unbiased operator. NPA determined with 30 blinded and randomized clinical NP and OP specimens (source and number of each not disclosed) confirmed to be negative with the FDA authorized RealStar SARS-CoV-2 RT-PCR Kit and tested with assay under evaluation by an unbiased operator. Note that while it is indicated that 25 OP and 36 NP clinical specimens were used during validation, it is not disclosed how many of each were confirmed positive or negative.",not included,included,included,ND,https://www.fda.gov/media/139296/download,https://www.fda.gov/media/139293/download,,,,,
,"Jiangsu Bioperfectus Technologies Co., Ltd.",COVID-19 Coronavirus Real Time PCR Kit,,http://en.s-sbio.com/product/420.html,Kit,China,"EUA granted June 18, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Anterior nasal swab, Mid-turbinate nasal swab, Nasal aspirate,
Nasal wash, BAL",ND,"ORF1ab , N",NA,"Bioperfectus Nucleic Acid Isolation Kit (manual or on the Bioperfectus SSNP 2000A extraction system, 32 channel v1.0), QiagenQIAamp Viral RNA Mini Kit","ABI 7500 (software versions V2.3 and V2.4), QuantStudio 5 (Software versions V1.4.3 and V1.5.1), Roche LightCycler 480 (Software
version V1.5.1.62)",ND,3.5×10^2 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,570.00,Clinical and contrived,96.54%,780.00,,,"PPA determined with contrived NP (n = 30), sputum (n = 30), and throat swab (n = 30) specimens (source of specimens not disclosed) spiked with pseudo-virus (source and type of psuedovirus not disclosed), clinical NP (n = 20), sputum (n = 20), and throat swab (n = 20) specimens determined to be positive by an undisclosed NMPA authorized assay, and clinical NP (n = 185), sputum (n = 82), and throat swab (n = 153) specimens (source of specimens not disclosed) confirmed to be positive with an undisclosed NMPA-certified molecular diagnostic assay. NPA determined with clinical NP (n = 100), sputum (n = 30), and throat swab (n = 100) specimens determined to be negative by an undisclosed NMPA authorized assay, and clinical NP (n = 141, 127/141 negative agreement), sputum (n = 129, 120/129 negative agreement), and throat swab (n = 280, 276/280 negative agreement) specimens (source of specimens not disclosed) confirmed to be negative with an undisclosed NMPA-certified molecular diagnostic assay.  Also reported positive (94.9%, n = 433) and negative (98.7%, 464/470) agreement of 903 samples (sample type and source not disclosed) compared to clinical diagnosis of COVID-19 (symptoms consistent with COVID-19 and a positive test result with an NMPA-certified molecular assay).  For the lattermost group, it is not disclosed whether these samples derive from a mutually exlusive sample set from other validation tests reported.",not included,included,included,ND,https://www.fda.gov/media/139279/download,https://www.fda.gov/media/139284/download,,,,,
,Biohit Healthcare (Hefei) Co. Ltd.,Biohit SARS-CoV-2 IgM/IgG Antibody Test Kit,,https://www.biohithealthcare.com/en/,Kit,China,"EUA granted June 18, 2020",Laboratory,"H, M",Serology,IgM/IgG,Lateral Flow,"Serum, Plasma, Venous whole blood",NA,NA,N protein,Manual,Gold with visual read,15-20 minutes,NA,,No cross-reactivity detected in wet lab testing,96.70%,30.00,Clinical,95.00%,80.00,99.80%,50.40%,"PPA determined with 132 clinical serum samples collected from hospitalized individuals tested >14 days post symptom onset (pso) and confirmed positive at any time with PCR assay for SARS-CoV-2 (method not disclosed) (Sensitivity for 197 serum samples collected from 40 individuals stratified by windows of time post symptom onset: 33.33% 0-7d pso with n=12, 83.02% 8-14d pso with n=53, and 97.73% >14d pso with n =132), and with 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed) tested at the Frederick National Laboratory for Cancer Research (FNLCR). Positive assay results for PPA were those that were positive for IgG or IgM. NPA determined with clinical samples (sample type not disclosed) collected at an undisclosed hospital during COVID-19 pandemic from individuals with other (non SARS-CoV-2-mediated) respiratory tract infections (n = 78) and healthy individuals lacking respiratory symptoms by physical examination (n =108) all confirmed negative with RT-PCR assay for SARS-CoV-2 (method not disclosed), with clinical serum samples collected in the clinical laboratory of an undisclosed hospital from February to March 2020 from patients with other respiratory tract infections (n = 203), from pregnant patients (n = 416), and from healthy people undergoing physical examination (n = 28) all confirmed SARS-CoV-2 negative by PCR (method not disclosed), with 144 clinical serum samples collected in the clinical laboratory of an undisclosed hospital from pre-COVID (May 2019 to October 2019) inpatients in non-respiratory departments, and with 80 frozen SARS-CoV-2 antibody-negative serum and plasma samples (distribution of each sample type not disclosed) collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Negative assay results for NPA were those either those that were negative for both IgG and IgM or, if that information was unavailable, the result between IgG and IgM with a lower number of agreements with comparator. ",not included,included,not included,ND,https://www.fda.gov/media/139283/download,https://www.fda.gov/media/139280/download,,,,,***
,Omnipathology Solutions Medical Corporation,Omni COVID-19 Assay by RT-PCR,,https://www.omnipathology.com/,Lab,USA,"EUA granted June 17, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"NP swab, OP swab, Anterior nasal swab, Mid-turbinate nasal swab, NP wash/aspirate, Nasal aspirate, BAL","UTM, VTM, Saline",N,NA,BD MAX ExK TNA-2 or 3 Kit on the BD MAX System (software version 4.70),BD MAX System (software version 4.70),ND,1.23 copies/µL,,No cross-reactivity predicted in silico,97.30%,37.00,Clinical and contrived,100.00%,35.00,,,"PPA determined with 30 contrived specimens spiked with SARS-CoV-2 RNA material (AccuPlex SARS-CoV-2 Verification Panel, cat. # 505-0129) into individual negative clinical NP specimens in VTM (source of specimens and method of negative determination not disclosed) and 7 clinical NP specimens (source not disclosed) confirmed to be positive with an undisclosed authorized SARS-CoV-2 real-time RT-PCR assay by an undisclosed high complexity CLIA laboratory. NPA determined with 30 individual negative clinical NP specimens in VTM (source of specimens and method of negative determination not disclosed) and 5 clinical NP specimens (source not disclosed) confirmed to be negative with an undisclosed authorized SARS-CoV-2 real-time RT-PCR assay by an undisclosed high complexity CLIA laboratory.  Samples for contrived study (i.e. 30 positive and 30 negative) were processed over the course of three separate runs spanning two separate days. Note that it is not disclosed whether the 60 specimens used for the contrived study and the 12 specimens tested with the SARS-CoV-2 real-time RT-PCR comparator assay were from mutually exlusive specimen sets.",not included,included,included,ND,https://www.fda.gov/media/139292/download,https://www.fda.gov/media/139289/download,,,,,
,The Ohio State University Wexner Medical Center,OSUWMC COVID-19 RT-PCR test,,https://wexnermedical.osu.edu/features/coronavirus/patient-care/covid-19-testing,Lab,USA,"EUA granted June 17, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, OP swab, NP swab",ND,N,NA,bioMérieux EasyMAG Extraction System,ABI 7500 Fast RealTime PCR instrument (software version 1.5.1),ND,0.25 cp/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,62,Clinical and contrived,100.00%,61.00,,,"PPA determined with 30 randomized and blinded contrived specimens spiked with Exact Diagnostics SARS-CoV-2 (catalog number not disclosed) into individual negative clinical NP specimens (source of specimens and method of negative determination not disclosed), 1 clinical NP specimen determined to be positive by the Ohio State Public health lab (method of positive determination not disclosed), 26 clinical NP specimens confirmed to be positive with the Simplexa COVID19 Direct Assay (source of specimens not disclosed), and 5 clinical NP specimens tested to be positive with the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostics Panel by the Ohio Department of Health (source of specimens not disclosed). NPA determined with 30 randomized and blinded individual negative clinical NP specimens (source of specimens and method of negative determination not disclosed), 25 clinical NP specimens confirmed to be negative with the Simplexa COVID19 Direct Assay (source of specimens not disclosed), and 6 clinical NP specimens confirmed to be negative with the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostics Panel by the Ohio Department of Health (source of specimens not disclosed).  Note that it is not disclosed whether the 51 clinical specimens tested with the Simplexa COVID19 Direct Assay and the 11 specimens tested with the CDC 2019-nCoV Real-Time RT-PCR Diagnostics Panel were from mutually exlusive specimen sets.",not included,included,included,ND,https://www.fda.gov/media/139288/download,https://www.fda.gov/media/139285/download,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"Warrior Diagnostics, Inc.",Warrior Diagnostics SARS-CoV-2 Assay,,https://warrior-dx.com/covid-19/,Lab,USA,"EUA granted June 9, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal swab,ND,N (N1 and N2 regions),NA,Invitrogen PureLink Viral RNA/DNA Mini Kit,Agilent AriaMX running Aria (software V1.5),ND,"150,000 copies/mL",,No cross-reactivity predicted in silico,100.00%,93,Clinical,98.90%,87,100.00%,82.07%,,PPA determined with 31 clinical NP specimens (sample source not disclosed) confirmed positive with the LabCorp COVID-19 RT-PCR test. NPA determined with 29 clinical NP specimens (sample source not disclosed) confirmed negative with the LabCorp COVID-19 RT-PCR test. Each sample for PPA and NPA was run in triplicate with combined results shown.,not included,included,included,ND,https://www.fda.gov/media/138790/download,https://www.fda.gov/media/138791/download,6/18/2020 9:44,6/19/2020 17:11,,
,Cormeum Laboratory Services,Cormeum SARS-CoV-2 Assay,,https://npidb.org/organizations/laboratories/clinical-medical-laboratory_291u00000x/1285287821.aspx,Lab,USA,"EUA granted June 12, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal swab,ND,"Orf1ab, N, S",NA,MagMax Viral/Pathogen Isolation Kit (A42352) on the MagMax Express 96 Fast,ABI Quantstudio 12K Flex Real-Time PCR with QuantStudio 12K Flex Software (V.1.1.2),ND,2 copies/uL,,No cross-reactivity predicted in silico,97.00%,67,Clinical and contrived,100.00%,167,99.84%,100.00%,,"PPA determined with 37 randomized and blinded clinical NP specimens confirmed positive with the EUA ThermoFisher (TF) assay at an undisclosed CLIA and CAP accredited laboratory, and with 30 randomized and blinded contrived clinical specimens created with known positive patient clinical specimens (source and method of positive determination not disclosed) spiked into leftover individual clinical specimens (source and method of negative determination not disclosed). NPA determined with 137 randomized and blinded clinical NP specimens confirmed negative with the EUA ThermoFisher (TF) assay at an undisclosed CLIA and CAP accredited laboratory, and with 30 randomized and blinded negative clinical specimens (source and method of negative determination not disclosed).",not included,included,included,ND,https://www.fda.gov/media/138934/download,https://www.fda.gov/media/138933/download,6/18/2020 9:44,6/18/2020 9:44,,
,ChromaCode Inc.,HDPCR SARS-CoV-2 Assay,,https://chromacode.com/products/hdpcr-sars-cov-2-assay/#/sars-cov-2,Kit,USA,"EUA granted June 9, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab Oropharyngeal swab, Anterior nasal swab, Midturbinate nasal swab, Nasal aspirate, Nasal wash, Bronchoalveolar lavage (BAL)","UTM, VCM, or equivalent",N (N1 and N2 regions),NA,"Roche MagNA Pure 24 Total Nucleic Acid Isolation Kit on the Roche MagNA Pure 24 Nucleic Acid Extraction System, 
 Applied Biosystem MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the Thermo Scientific KingFisher Flex Extraction System","ABI QuantStudio 7 Flex (Software Version 1.3), 
 ABI 7500 Fast (Software Version 2.3), 
 ABI QuantStudio 12K Flex (Software Version 1.3)",ND,"1000 copies/mL (20 copies/rxn) on the ABI 7500 Fast (software version 1.3) and the ABI Quant Studio 7 (software version 2.3)
 250 copies/mL (5 copies/rxn) on the ABI Quant Studio 12K system (software version 1.3)",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,90,Contrived,97.80%,90,100.00%,70.33%,,"PPA determined with contrived samples of Armored RNA Quant® SARS-CoV-2 Control obtained (Asuragen, cat #52030) spiked into negative clinical NP specimens (sample source and negative determination method not disclosed) and assayed with one of three methods: extraction with the Roche MagNA Pure 24 Pathogen 200 2.0 Protocol with the Total Nucleic Acid Isolation Kit for qRT-PCR and measurement on the ABI QuantStudio 7 (n =30, 100% positive agreement), extraction with the Roche MagNA Pure 24 Pathogen 200 2.0 Protocol with the Total Nucleic Acid Isolation Kit for qRT-PCR and measurement on the ABI 7500 Fast (n =30, 100% positive agreement), or extraction with the KingFisher MVP_Flex Protocol was with the Fisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit for qRT-PCR on the ABI QuantStudio 12K Flex (n =30, 100% positive agreement). Validation notes do not specify uniqueness of original samples processed with each method. NPA determined with negative clinical NP specimens (sample source and negative determination method not disclosed) and assayed with one of three methods: extraction with the Roche MagNA Pure 24 Pathogen 200 2.0 Protocol with the Total Nucleic Acid Isolation Kit for qRT-PCR and measurement on the ABI QuantStudio 7 (n =30, 96.7% negative agreement), extraction with the Roche MagNA Pure 24 Pathogen 200 2.0 Protocol with the Total Nucleic Acid Isolation Kit for qRT-PCR and measurement on the ABI 7500 Fast (n =30, 96.7% negative agreement), or extraction with the KingFisher MVP_Flex Protocol was with the Fisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit for qRT-PCR on the ABI QuantStudio 12K Flex (n =30, 100% negative agreement). Validation notes do not specify uniqueness of original samples processed with each method.",not included,included,included,ND,https://www.fda.gov/media/138786/download,https://www.fda.gov/media/138787/download,6/18/2020 9:43,6/19/2020 16:52,,
,Cue Health Inc.,Cue COVID-19 Test,,https://www.cuehealth.com/covid-19,Kit,USA,"EUA granted June 10, 2020","Laboratory, POC","H, M, W",Molecular,RNA,Isothermal Amplification (proprietary),Nasal swab,ND,N,NA,Manual,Cue Health Monitoring System with the Cue Cartridge Reader and Cue Health App,25 minutes from Sample Wand insertion,20 genomic copies/sample wand or 1.3 genomic copies/uL,,"One undisclosed microbial organism showed ≥80% sequence homology to more than one of the three Cue COVID-19 Test primers during in silico analysis. 1/9 positive for Staphylococcus epidermidis-positive specimens, 2/9 positive for Adenovirus Type 1-positive specimens, 1/10 positive for Rhinovirus type 1A-positive specimens during wet lab testing.",98.80%,81,Clinical and contrived,95.60%,68,99.93%,54.10%,,"PPA determined with 6 clinical specimens collected from individuals with signs and/or symptoms of COVID-19 at two emergency departments (ED) located in an epicenter for the COVID-19 outbreak in the US (number from each site not disclosed) tested by untrained operators at the point of care and confirmed positive with an undisclosed standard of care EUA SARS-CoV-2 Test, with 45 frozen NP swab samples in VTM from individuals suspected of SARS-CoV-2 infection and confirmed positive with an undisclosed standard of care EUA SARS-CoV-2 Test, and with 30 blinded and randomized contrived clinical specimens with genomic RNA from SARS-Related Coronavirus 2, Isolate USAWA1/2020 spiked into negative nasal samples collected from consented healthy volunteers (method of negative determination not disclosed). NPA determined with 38 clinical specimens collected from individuals with signs and/or symptoms of COVID-19 at two emergency departments (ED) located in an epicenter for the COVID-19 outbreak in the US (number from each site not disclosed) tested by untrained operators at the point of care and confirmed negative with an undisclosed standard of care EUA SARS-CoV-2 Test, and with 30 blinded and randomized negative nasal samples collected from consented healthy volunteers (method of negative determination not disclosed)",not included,included,not included,ND,https://www.fda.gov/media/138826/download,https://www.fda.gov/media/138823/download,6/18/2020 9:43,6/20/2020 7:47,,
,Euroimmun US Inc.,EURORealTime SARS-CoV-2,,https://www.euroimmun.com/products/indications/infektions-serologie/weitere-parameter/sars-coronavirus.html,Kit,USA,"EUA granted June 8, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, Mid-turbinate swab, Nasopharyngeal swab, Oropharyngeal swabs, Bronchioalveolar lavage (BAL)",ND,"ORF1ab, N",NA,"Qiagen QIAmp Viral RNA Mini Kit (manual), Chemagen CMG-2015 Prepito Viral DNA/RNA200 Kit (automated system not disclosed)","ABI 7500 Fast Real-Time PCR Instrument (software version not disclosed),
 Roche LightCycler® 480 II (software version not disclosed),
 Bio-Rad CFX 96 Touch (software version not disclosed)",ND,150 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,96.00%,50,clinical,100.00%,30,99.79%,100.00%,,"PPA determined with 50 clinical OP specimens (source not disclosed) confirmed positive with an undisclosed SARS-CoV-2 molecular comparator test. NPA determined with 30 clinical OP specimens (source not disclosed) confirmed negative with an undisclosed SARS-CoV-2 molecular comparator test. Note that samples in validation were extracted with either QIAamp Viral RNA Mini Kit (n =55, distribution of positive and negative specimens not disclosed) or the CMG-2015 Prepito Viral DNA/RNA200 Kit (n = 25, distribution of positive and negative not disclosed), and run on the LightCylcer480 II.",included,included,included,ND,https://www.fda.gov/media/138761/download,https://www.fda.gov/media/138758/download,6/18/2020 9:43,6/19/2020 16:52,,
,"Illumina, Inc.",Illumina COVIDSeq Test,,https://www.illumina.com/products/by-type/ivd-products/covidseq.html,Kit,USA,"EUA granted June 9, 2020",Laboratory,H,Molecular,RNA,NGS,"Nasopharyngeal swab, Oropharyngeal swab, Anterior nasal swab, Mid-turbinate nasal swab, Nasopharyngeal wash/aspirate, Nasal aspirate, Bronchoalveolar lavage (BAL)",ND,ND,NA,Qiagen QIAamp Viral RNA Mini Kit,"Illumina NovaSeq 6000 Sequencing System using the NovaSeq Xp S4 flow cell
 workflow and Illumina DRAGEN COVIDSeq Test Pipeline",ND,1000 copies/mL,,No cross-reactivity predicted in silico,98.20%,54,Clinical,97.40%,39,99.90%,66.86%,,PPA determined with 54 clinical NP specimens (source not disclosed) confirmed positive with an undisclosed SARS-CoV-2 molecular comparator test authorized for use under FDA EUA. NPA determined with 39 clinical NP specimens (source not disclosed) confirmed negative with an undisclosed SARS-CoV-2 molecular comparator test authorized for use under FDA EUA.,included,included,included,ND,https://www.fda.gov/media/138776/download,https://www.fda.gov/media/138778/download,6/18/2020 9:43,6/18/2020 9:43,,
,"InBios International, Inc.",SCoV-2 Detect IgG ELISA,,https://inbios.com/scov-2-detect-igg-elisa-kit-2/,Kit,USA,"EUA granted June 10, 2020",Laboratory,H,Serology,IgG,,Serum,NA,NA,ND,Manual,Microplate reader (manufacturer not specified),~1 hour and 50 minutes after sample preparation,NA,,3/18 samples positive for RF-positive specimens during wet lab testing,97.80%,45,Clinical,99.00%,95,99.88%,83.10%,,"PPA determined from 45 serum specimens collected from 39 individuals who tested positive by SCoV-2 PCR assay (method not disclosed). Sensitivity for samples were further stratified into specific windows post symptom onset with PCR positive at any time (0-7d pso, NA, n=0; 8-14d pso, 100.00%, n=1; >14d pso, 95.45%, n=22; unknown, 100.00%, n=22), into days since first symptom (14-21d, 87.50%, n=8; 22-30d, 100.00%, n=5; 31-64d, 100.00%, n=9; unknown, 100.00%, n=12), or into days after PCR confirmation or diagnosis (0-7d, 100.00%, n=5; 8-14d, 100.00%, n=3; 15-21d, 100.00%, n=1; unknown, 100.00%, n=2). NPA determined using 95 normal human serum specimens (source and method of determination not disclosed).",not included,included,included,ND,https://www.fda.gov/media/138810/download,https://www.fda.gov/media/138807/download,6/18/2020 9:43,6/18/2020 9:43,,
,Siemens Healthcare Diagnostics Inc.,Dimension Vista SARS-CoV-2 Total antibody assay (COV2T),,https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/cov2t-assay,Kit,USA,"EUA granted June 8, 2020",Laboratory,"H, M",Serology,IgG/IgM,Homogeneous Immunoassay,"Serum, Plasma",NA,NA,S1 RBD,Manual,Siemens Dimension Vista System (software version not disclosed),16 minutes after sample preparation,NA,,No cross-reactivity detected in wet lab testing,100.00%,79,Clinical,99.80%,1529,100.00%,96.34%,,"PPA determined by comparison to >13d post PCR positive specimens; Sensitivity for earlier windows: 66.67% (0-6d post PCR positive, n=96), 97.37% (7-13d post PCR positive, n=38). Samples used for PPA were also reported post symptom onset, with sensitivities of 64.20% (0-6d pso, n=81), 91.30% (7-13d pso, n=46), and 100.00% (>13d pso, n=79). NPA determined using pre-COVID (mid-December 2019) outbreak samples from apparently healthy individuals (n = 1462, 3/1462 reactive) and apparently healthy pregnant women (n = 67, 0/67 reactive).",not included,included,included,ND,https://www.fda.gov/media/138753/download,https://www.fda.gov/media/138750/download,6/18/2020 9:43,6/20/2020 7:47,,
,Siemens Healthcare Diagnostics Inc.,Dimension EXL SARS-CoV-2 Total antibody assay (CV2T),,https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/cov2t-assay,Kit,USA,"EUA granted June 8, 2020",Laboratory,"H, M",Serology,IgG/IgM,Homogeneous Immunoassay,"Serum, Plasma",NA,NA,S1 RBD,Manual,"Siemens Dimension EXL with LOCI module (software version not disclosed), Siemens Dimension EXL 200 (software version not disclosed)",16 minutes after sample preparation,NA,,No cross-reactivity detected in wet lab testing,100.00%,79,Clinical,99.90%,1529,100.00%,97.59%,,"PPA determined by comparison to >13d post PCR positive specimens; Sensitivity for earlier windows: 68.75% (0-6d post PCR positive, n=96), 97.37% (7-13d post PCR positive, n=38). Samples used for PPA were also reported post symptom onset, with sensitivities of 66.67% (0-6d pso, n=81), 91.30% (7-13d pso, n=46), and 100.00% (>13d pso, n=79). Samples measured on the Siemens Dimension EXL system. NPA determined using pre-COVID (mid-December 2019) outbreak samples from apparently healthy individuals (n = 1462, 2/1462 reactive) and apparently healthy pregnant women (n = 67, 0/67 reactive).",not included,included,included,ND,https://www.fda.gov/media/138757/download,https://www.fda.gov/media/138754/download,6/18/2020 9:43,6/20/2020 7:47,,
,TBG Biotechnology Corp.,ExProbe SARS-CoV-2 Testing Kit,,http://www.tbgbio.com/en/product/product_detail/51,Kit,China,"EUA granted June 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, Oropharyngeal swab, Anterior nasal swab, Mid-turbinate nasal swab, Nasopharyngeal aspirate/wash, Nasal aspirate, Bronchoalveolar lavage (BALs)",UTM,"RdRP, N, E",NA,Qiagen Viral RNA MiniKit (Cat. No. 52904),ABI7500 Real Time PCR instrument (software version 2.3),ND,10 copies/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,35,Clinical and contrived,99.60%,230,100.00%,92.45%,,"PPA determined with 5 clinical OP specimens (source not disclosed) confirmed positive with the Novel Coronavirus (2091-nCoV) Nucleic Acid Diagnostic Kit (Sansure BioTech Inc. China), and with 30 blinded and randomized contrived clinical specimens with SARS-CoV-2 synthetic RNA (Twist Bioscience Cat # MN9089478.3, USA) spiked into individual, unique negative OP samples (source of specimens and method of negative determination not disclosed). NPA determined with 200 clinical OP specimens (source not disclosed) confirmed negative with the Novel Coronavirus (2091-nCoV) Nucleic Acid Diagnostic Kit (Sansure BioTech Inc. China), and with 30 blinded and randomized contrived clinical specimens with water spiked into negative OP samples (source of specimens and method of negative determination not disclosed).",not included,included,included,ND,https://www.fda.gov/media/138822/download,https://www.fda.gov/media/138819/download,6/18/2020 9:43,6/19/2020 16:52,,
,"Tide Laboratories, LLC",DTPM COVID-19 RT-PCR Test,,https://www.dtpm.com/coronavirus-assay/,Lab,USA,"EUA granted June 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, Oropharyngeal swab, Nasal swab, Mid-turbinate swab",ND,N,NA,Qiagen RNeasy Kit,ThermoFisher QuantStudio 5 instrument (software version 1.5.1.),ND,22 copies/uL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,53,Clinical and contrived,100.00%,48,100.00%,100.00%,,PPA determined with 23 clinical NP specimens (source not disclosed) confirmed positive with an undisclosed FDA EUA assay and with 30 blinded and randomized contrived clinical specimens with whole viral SARS-CoV-2 RNA (USA—WA1/2020) spiked into negative NP samples (source of specimens and method of negative determination not disclosed). NPA determined with 18 clinical NP specimens (source not disclosed) confirmed negative with an undisclosed FDA EUA assay and with 30 blinded and randomized negative NP samples (source of specimens and method of negative determination not disclosed),not included,included,included,ND,https://www.fda.gov/media/138818/download,https://www.fda.gov/media/138815/download,6/18/2020 9:43,6/18/2020 9:43,,
,RTA Laboratories Biological Products Pharmaceutical and Machinery Industry,Diagnovital SARS-CoV-2 Real-Time PCR Kit,,http://a1lifesciences.com.tr/Products/Detail/38,Kit,USA,"EUA granted June 12, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Anterior nasal swab, Mid-turbinate nasal swab, Nasopharyngeal swab, Oropharyngeal swab, Nasopharyngeal wash/aspirate, Nasal aspirate, Bronchoalveolar lavage (BAL)","Copan Universal Transport Medium System (UTM-RT), BD Universal Viral Transport System (UVT)","RdRP, E",NA,RTA Viral RNA Isolation Kit,"BioRad CFX-96 IVD with CFX Manager Software (version 3.0), ABI QuantStudio 5 Dx with QuantStudio 5 Dx TD Software (version 1.0)",ND,38 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,90,Clinical and contrived,100.00%,130,100.00%,100.00%,,"PPA determined with 30 clinical NP specimens (source not disclosed) confirmed positive with the PhoenixDx 2019-nCoV EUA (Trax Management Services Inc.), and with blinded contrived clinical specimens with RNA extracted from a clinical NP specimen positive for SARS-CoV-2 (extracted using the RTA Viral RNA Isolation Kit and quantitated by the BioRad QX200 Droplet Digital PCR System) spiked into negative NP (n = 30) and BAL (n = 30) samples (collected from patients with signs and symptoms of an upper respiratory infection with Copan Universal Transport Medium System and confirmed negative with the Roche Cobas SARS-CoV-2 Test). NPA determined with 30 clinical NP specimens (source not disclosed) confirmed negative with the PhoenixDx 2019-nCoV EUA (Trax Management Services Inc.), and with blinded OP (n = 30), nasal (n = 10), NP (n = 30), and BAL (n = 30) samples collected from patients with signs and symptoms of an upper respiratory infection with Copan Universal Transport Medium System and confirmed negative with the Roche Cobas SARS-CoV-2 Test. Note that contrived positive samples were made from aliquots of the negative NP and BAL clinical samples.",not included,included,included,ND,https://www.fda.gov/media/138928/download,https://www.fda.gov/media/138929/download,6/18/2020 9:43,6/18/2020 9:43,,
,Kaiser Permanente Mid-Atlantic States,KPMAS COVID-19 Test,,https://about.kaiserpermanente.org/community-health/communities-we-serve/mid-atlantic-community,Lab,USA,"EUA granted June 13, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasal swab,Saline,NA,NA,NA,Roche Cobas 6800 instrument,NA,NA,,NA,,,NA,,,0.00%,0.00%,,NA - collection kit,NA,NA,NA,ND,https://www.fda.gov/media/139067/download,https://www.fda.gov/media/139066/download,6/11/2020 12:18,6/19/2020 17:12,,
,Emory Medical Laboratories,SARS-CoV-2 RBD IgG test,,https://www.emoryhealthcare.org/centers-programs/medical-laboratory/index.html,Lab,USA,"EUA granted June 15, 2020",Laboratory,H,Serology,IgG,ELISA,Serum,NA,NA,RBD region of S protein,"Manual, BioTek 50TS12 MicroPlate Washer 12 well",BioTek 800TS Absorbance Reader,ND,NA,,No cross-reactivity detected in wet lab testing,100.00%,30,Clinical,96.40%,638,100.00%,59.32%,,"PPA determined by comparison to 30 >14d post PCR positive serum samples. Sensitivity for earlier windows: 73.01% (0-7d post PCR positive, n=163), 100.00% (8-14d post PCR positive, n=38). Serum specimens collected either at Emory University Hospital (n=132, stratification of days post PCR positive not disclosed) or Emory University Hospital-Midtown (n =99, stratification of days post PCR positive not disclosed) from individuals with prior or coincident positive nasopharyngeal RT-PCR results confirmed by one of three SARS-CoV-2 RT-PCR tests used on NP specimens (the Roche SARS-CoV-2 EUA, the Cepheid Xpert Xpress SARS-CoV-2 EUA, or the Emory-modified CDC EUA). All testing was performed by a group of eight medical technologists in the Clinical Immunology Laboratory of EML. NPA determined using serum specimens archived prior to December 2019 (n = 388, 9/388 reactive) and serum specimens collected by EML during a sero surveillance study of health care workers in the Emory Healthcare system with negative RT-PCR results (method of negative determination not disclosed) (n = 250, 9/250 reactive, 5/250 indeterminate).",not included,not included,included,ND,https://www.fda.gov/media/139053/download,https://www.fda.gov/media/139050/download,6/11/2020 12:15,6/19/2020 16:34,,
,"Applied BioCode, Inc.",BioCode SARS-CoV-2 Assay,,http://www.apbiocode.com/sars-cov-2.htm,Kit,USA,"EUA granted June 15, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, Oropharyngeal swab, Nasal swab, Bronchoalveolar lavage (BAL)",ND,N,NA,"Roche DNA and Viral Small Volume Kit on the Roche MagNA Pure 96, bioMerieux NucliSENS easyMAG",BioCode® MDx-3000 with MDx software (version not disclosed),~5 hrs,1.72 x10-2 TCID50/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,"PPA determined with randomized contrived clinical specimens with quantitated inactivated virus (Zeptometrix, catalog #: 0810587CFHI USA-WA1/2020 NCBI ACC #: MN985325) spiked into unique negative NP (n = 30) and BAL (n = 30) samples (source and method of negative determination not disclosed). NPA determined with randomized unique negative NP (n = 30) and BAL (n = 30) samples (source and method of negative determination not disclosed)",not included,included,not included,ND,https://www.fda.gov/media/139049/download,https://www.fda.gov/media/139046/download,6/11/2020 11:54,6/19/2020 17:05,,
,"Genetron Health (Beijing) Co., Ltd.",Genetron SARS-CoV-2 RNA Test,,http://en.genetronhealth.com/Coronavirus.html,Kit,China,"EUA granted June 5, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Oropharyngeal swab, nasopharyngeal swab, anterior nasal swab, mid-turbinate nasal swab",UTM or VTM,"ORF1ab, N",NA,"QIAamp Viral RNA Mini Kit (Qiagen, Item No. 52904)",ABI 7500 Real-Time PCR System (7500 software version 2.3),ND,1000 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,50,Clinical,97.10%,35,100.00%,64.79%,,"PPA determined with 50 clinical OP specimens (specimen source not disclosed) determined to be positive with the EUA authorized SARS-CoV-2 Fluorescent PCR Kit from Maccura Biotechnology Co., Ltd.. NPA determined with 35 clinical OP specimens (specimen source not disclosed) determined to be negative with the EUA authorized SARS-CoV-2 Fluorescent PCR Kit from Maccura Biotechnology Co., Ltd.",not included,included,included,ND,https://www.fda.gov/media/138685/download,https://www.fda.gov/media/138682/download,6/9/2020 10:22,6/19/2020 16:52,,
,"Gravity Diagnostics, LLC",Gravity Diagnostics COVID-19 Assay,,https://www.gravitydiagnostics.com/,Lab,USA,"EUA granted June 1, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, nasopharyngeal swab, oropharyngeal swab, Bronchoalveolar Lavage",ND,N (N1 and N2 regions),NA,Magmax Pathogen Kit RNA/DNA on the King Fisher Flex with 96 Deep Well Head instrument (software version not disclosed),"ABI QuantStudio7 Flex instrument (software version 1.3), ABI QuantStudio12 Flex instrument (software version 1.2.2)",ND,2.4 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,96.80%,31,Clinical,100.00%,65,99.83%,100.00%,,"PPA determined with 31 clinical NP specimens (source of specimens not disclosed) in Liquid Amies media tested to be positive with a modified** CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostics Panel on a combination of the Applied Biosystems QuantStudio7 Flex and Applied Biosystems QuantStudio12 Flex instruments. NPA determined with 65 clinical NP specimens (source of specimens not disclosed) in Liquid Amies media tested to be positive with a modified** CDC 2019-nCoV Real-Time RT-PCR Diagnostics Panel on a combination of the Applied Biosystems QuantStudio7 Flex and Applied Biosystems QuantStudio12 Flex instruments. Also conducted a comparative analytic sensitivity between assay under evaluation and modified** CDC 2019-nCoV Real-Time RT-PCR Diagnostics Panel using viral genomic RNA (BGI) spiked in triplicate into liquid Amies Media extracted using the Magmax Pathogen Kit RNA/DNA on the KingFisher extraction system and run in parallel on the Applied Biosystems QuantStudio12 Flex instrument. 
 
 **A modified CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostics Panel was separately validated with the Magmax Pathogen Kit RNA/DNA and the Applied Biosystems QuantStudio7 Flex and Applied Biosystems QuantStudio12 Flex instruments, for use as the comparator for the assay under evaluation. Validation of the modified CDC 2019-nCoV Real-Time RT-PCR Diagnostics Panel included determination of analytical sensitivity with dilutions of Genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020 (BEI Resources Cat#: NR-52285, Lot#: 70033320) spiked into clinical NP matrix in liquid Amies media in quintuplicate. Validation also included evaluation of 60 individual clinical NP specimens in Liquid Amies Media, presumed negative for SARS-CoV-2 as described: ""Sixty nasopharyngeal swab clinical samples were tested using the modified CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostics Panel on the QuantStudio 12K Flex. All specimens tested negative for SARS-CoV-2 RNA. Viral genomic RNA, at a concentration of 5X LoD (12 cp/µL) and 2X LoD (4.8 cp/µL), was spiked into 10 and 20, respectively, of the confirmed-negative NP swab specimens and then tested using the modified CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostics Panel on the QuantStudio 12K Flex. The remining 30 negative clinical sample and the 30 contrived samples were tested on the QS12 and QS7 using the modified CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostics Panel."" Samples tested on the QuantStudio 12K Flex had 30/30 positive agreement and 60/60 negative agreement (it appears that initial baseline measurement for all 60 samples is included here), while samples tested on the QuantStudio 7 Flex had 30/30 positive agreement and 30/30 negative agreement. Clinical evaluation also included analysis of 5 positive and 5 negative patient samples (determination method of positive or negative status not disclosed) that were sent to the Kentucky Public Health Lab (KYPHL) and tested on the CDC assay under an EUA.",not included,included,included,ND,https://www.fda.gov/media/138530/download,https://www.fda.gov/media/138532/download,6/9/2020 9:56,6/11/2020 11:54,,
,"Hangzhou Biotest Biotech Co., Ltd.",RightSign COVID-19 IgG/IgM Rapid Test Cassette,,http://en.biotests.com.cn/product/278188250,Kit,China,"EUA granted June 4, 2020",Laboratory,H,Serology,IgG/IgM,Lateral Flow,"Venuous Whole Blood, Serum, Plasma",NA,NA,S (RBD region),Manual,Gold with visual read,~10 minutes after sample loading,NA,,2/33 samples positive for RF-positive specimens during wet lab testing,100.00%,30,Clinical and contrived,100.00%,80,100.00%,100.00%,,"PPA determined with 158 clinical serum samples collected at two sites from symptomatic individuals tested 14 days post symptom onset (pso) and confirmed positive at any time with RT-PCR assay for SARS-CoV-2 (method not disclosed), 45 samples (specimen type not disclosed) from individuals residing at a third site for Diagnosis and Treatment of Infectious Disease patients confirmed positive at any time with RT-PCR assay for SARS-CoV-2 (method not disclosed), and 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed). (Sensitivity for earlier windows of clinical samples pooled from all three sites: 39.02% 0-7d pso with n=41 and 82.73% 8-14d pso with n=110). Positive assay results for PPA were those that were positive for IgG or IgM. NPA determined with 200 clinical serum samples collected at two sites from symptomatic individuals confirmed negative with RT-PCR assay for SARS-CoV-2 (method not disclosed), 10 clinical plasma samples collected at a third site from symptomatic individuals confirmed negative with RT-PCR assay for SARS-CoV-2 (method not disclosed), and 80 frozen SARS-CoV-2 antibody-negative serum samples collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Testing was performed by one operator using one lot of the RightSign COVID-19 IgG/IgM Rapid Test Cassette. Negative assay results for NPA were those either those that were negative for both IgG and IgM or, if that information was unavailable, the
  result between IgG and IgM with a lower number of agreements with comparator. Contrived positive and negative samples tested on 2020-04-21 at the Frederick National Laboratory for Cancer Research (FNLCR) sponsored by the National Cancer Institute (NCI).",not included,included,not included,ND,https://www.fda.gov/media/138660/download,https://www.fda.gov/media/138657/download,6/9/2020 9:55,6/11/2020 12:14,,
,Phosphorus Diagnostics LLC,Phosphorus COVID-19 RT-qPCR Test,,https://www.phosphorus.com/covid-19-rt-qpcr-test,Lab,USA,"EUA granted June 4, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Saliva,"Oragene
 Dx OGD-510",N (N1 and N2 regions),NA,"MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (ThermoFisher Scientific), Promega Maxwell HT Viral TNA Kit (Promega), and the Maxwell RSC TNA Viral Kit performed on the Maxwell RSC 48 System (software version not disclosed)",Bio-Rad CFX384 Touch Real-Time PCR Detection System with Bio-Rad CFX Manager software version 3.1.,ND,5 copies/µL,,No cross-reactivity detected in wet lab testing,100.00%,71,Clinical and contrived,100.00%,87,100.00%,100.00%,,"PPA determined with 34 clinical NP specimens transported with the BD Universal Viral Transport Standard Kit from individuals presenting with signs and symptoms of COVID-19 at two
 different sites and confirmed positive with an EUA authorized assay at Rutgers Clinical Genomics Laboratory (method not disclosed), and with 37 blinded and randomized contrived clinical specimens with Twist Bioscience synthetic SARSCoV-2 RNA (catalog number not disclosed) spiked into leftover unique and individual NP specimens (source and method of negative determination not disclosed). NPA determined with 57 clinical NP specimens transported with the BD Universal Viral Transport Standard Kit from individuals presenting with signs and symptoms of COVID-19 at two different sites and confirmed negative with an EUA authorized assay at Rutgers Clinical Genomics Laboratory (method not disclosed), and with 30 blinded and randomized clinical NP specimens (source and method of negative determination not disclosed). Each sample for both PPA and NPA was extracted three times using either the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (ThermoFisher Scientific), the Promega Maxwell HT Viral TNA Kit (Promega), and the Maxwell RSC TNA Viral Kit performed on the Maxwell RSC 48 System (software version not disclosed), with 100% agreement between extraction methods for each NP sample. 91 saliva specimens (n=34 positive, n=57 negative) were also self-collected with the Oragene Dx (OGD-510) within 15 minutes of their patient-matched clinical NP specimens, run with the same three extraction methods, and assayed in comparison to the NP specimens to validate use of saliva specimens, with agreement above 96.5% between patient-matched NP and saliva specimens for all cases. Additionally, a saliva shipping validation study applied a simulated summer thermocycling protocol to contrived clinical saliva samples (n=20 positive samples, n=10 negative samples) and compared assay results after three extraction methods to results of the samples prior to simulated summer shipping conditions.",not included,included,included,ND,https://www.fda.gov/media/138654/download,https://www.fda.gov/media/138652/download,6/9/2020 9:55,6/11/2020 11:54,,
,Vibrant America Clinical Labs,Vibrant COVID-19 Ab Assay,,https://www.vibrant-america.com/covid-19/,Lab,USA,"EUA granted June 4, 2020",Laboratory,H,Serology,IgG/IgM,Heterogeneous Immunoassay,"Human serum, Dry Blood Spot (DBS) from fingerstick blood specimen",NA,NA,"S (S1, RBD, S2 regions) N (full length)","Dried Blood Spot samples: Hamilton easyPunch STAR then manual preparation 
 All samples: Vibrant COVID-19 Ab Assay Method (V1.0.0.1) on the Hamilton MicroLab STAR liquid handling system (software version not disclosed)",Quansys Q-View Imager Pro (software version not disclosed) with addtional Vibrant COVID-19 Ab assay software (Vibrant COVID-19 Ab Reporter V1.0.0.1),ND,NA,,No cross-reactivity detected in wet lab testing,98.10%,53,Clinical,98.60%,501,99.93%,78.77%,,"PPA determined by comparison to 79 >13d post PCR positive serum specimens (26/26; method of PCR measurement not disclosed) and specimens used in a serum comparison where days post-PCR positive were not disclosed (52/53); Sensitivity for earlier windows: 85.71% (0-6d post PCR positive, n=7), 100.00% (7-13d post PCR positive, n=20). Positive assay results for PPA were those that were positive for IgG or IgM.
 NPA determined using either PCR negative NP specimens (method of PCR measurement not disclosed) or pre-SARS-CoV-2 outbreak samples (number of PCR-negative or pre-SARS-Cov-2 samples not disclosed, n=501 in total).",not included,not included,included,ND,https://www.fda.gov/media/138629/download,https://www.fda.gov/media/138626/download,6/9/2020 9:55,6/20/2020 7:47,,
,CSI Laboratories,CSI SARS-CoV-2 RT PCR Test,,https://www.csilaboratories.com/,Lab,USA,"EUA granted June 2, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, nasopharyngeal swab, oropharyngeal swab, Bronchoalveolar Lavage (BAL)",ND,N (N1 and N2 regions),NA,Omega Bio-Tek Mag-Bind Viral DNA/RNA 96 Kit on the 5073 EPMotion liquid handler (software version not disclosed),ABI Quantstudio 7 instrument (software version 1.3),ND,6.25 copies/µL,,No cross-reactivity predicted in silico,100.00%,77,Contrived and clinical,100.00%,66,100.00%,100.00%,,"PPA determined with 48 randomized and blinded contrived specimens spiked with whole viral SARS-CoV-2 (Isolate USA—WA1/2020 from BEI) into pooled negative clinical NP specimens (source of specimens and method of negative determination not disclosed), 25 blinded leftover frozen clinical NP specimens from an undisclosed hospital tested to be positive with the Cepheid Xpert Xpress SARS-CoV-2 test, and 4 blinded clinical NP specimens tested to be positive with the Quest Diagnostics SARS-CoV-2 rRT-PCR assay (EUA200015) (source of specimens not disclosed). NPA determined with 30 randomized and blinded negative clinical NP specimens (source of specimens and method of negative determination not disclosed), 30 blinded leftover frozen clinical NP specimens from an undisclosed hospital tested to be negative with the Cepheid Xpert Xpress SARS-CoV-2 test, and 6 blinded clinical NP specimens tested to be negative with the Quest Diagnostics SARS-CoV-2 rRT-PCR assay (EUA200015) (source of specimens not disclosed).",not included,included,included,ND,https://www.fda.gov/media/138528/download,https://www.fda.gov/media/138529/download,6/9/2020 9:55,6/11/2020 11:54,,
,Aspirus Reference Laboratory,Aspirus SARS-CoV-2 rRT Assay,,https://www.aspirus.org/coronavirus-covid19,Lab,USA,"EUA granted June 1, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, mid-turbinate swab, nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage",VTM,N,NA,BD MAX TNA-3 kit on the BD MAX (software version 4.72 A),BD MAX (software version 4.72 A),ND,.5 copies/µL,,No cross-reactivity predicted in silico,100.00%,40,Contrived and clinical,100.00%,60,100.00%,100.00%,,"PPA determined with 10 contrived specimens spiked with SARS-CoV-2 positive control (SeraCare’s AccuPlex SARS-CoV-2 Reference Material, #0505-0126) into negative clinical NP specimens (source of specimens and method of negative determination not disclosed) and 30 clinical NP specimens from the Wisconsin State Laboratory of Hygiene (WSLH) tested to be positive with the BD BioGX SARS-CoV-2 EUA Assay (EUA200020). NPA determined with 30 clinical NP specimens determined to be negative for SARS-CoV-2 (source of specimens and method of negative determination not disclosed) and 30 clinical NP specimens from the Wisconsin State Laboratory of Hygiene (WSLH) tested to be negative with the BD BioGX SARS-CoV-2 EUA Assay (EUA200020).",not included,included,included,ND,https://www.fda.gov/media/138526/download,https://www.fda.gov/media/138527/download,6/9/2020 9:54,6/11/2020 11:50,,
,Nebraska Medicine Clinical Laboratory,NEcov19 RT-PCR Assay,,https://www.nebraskamed.com/featured?treatment=18691,Lab,USA,"EUA granted June 4, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Human nasopharyngeal swab, oropharyngeal (throat) swab, anterior nasal swab, mid-turbinate swab, nasal wash, nasal aspirate and bronchoalveolar lavage (BAL)",VTM,E,NA,"Roche MagNA Pure Total Nucleic Acid Kit with External Lysis Buffer (Roche Applied Science, Indianapolis, IN), Catalog #03038505001 on the Roche MagNA Pure Compact instrument (software version not disclosed), MagMAX Viral/Pathogen II (MVP II) Nucleic Acid Isolation kit on the ThermoFisher KingFisher Flex platform (software version not disclosed), QiaAmp DSP Viral RNA Mini Kit",ABI QuantStudio Dx with QuantStudio Test Development (Software version 1.0.3),ND,"1000 copies/mL (or 8 copies/µL, assuming 100% extraction efficiency)",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,44,Clinical,100.00%,58,100.00%,100.00%,,"PPA determined with 11 clinical NP swab specimens tested positive with the ""CDC EUA assay"", 3 clinical sputum samples from confirmed COVID-19 cases (method of COVID determination not disclosed), and 30 residual NP swab
 specimens (source not disclosed) in VTM tested positive with the RMS cobas EUA test and extracted with the KingFisher extraction method. NPA determined with 58 clinical NP swab specimens either tested negative with the ""comparator CDC assay"" or an expected negative result stratified by risk group. Note that positive samples other than the 30 residual NP swab specimens and all negative samples were taken from one of three groups of individuals (patients under investigation for COVID-19, heath care workers under monitoring, and patients with respiratory symptoms tested by the FDA-cleared FilmArray respiratory pathogen panel prior to the SARS-CoV-2 circulation in the U.S.) without disclosure of which result came from which group. Of these samples, EUA CDC comparator assay results were available only for samples taken from patients under investigation, while samples from health care workers and individuals tested with the FilmArray were compared against an expected negative result.",not included,included,included,ND,https://www.fda.gov/media/138625/download,https://www.fda.gov/media/138624/download,6/9/2020 9:54,6/11/2020 11:55,,
,"Applied DNA Sciences, Inc.",Linea COVID-19 Assay Kit,,https://adnas.com/dxcovid/,Kit,USA,"EUA granted May 13, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, oropharyngeal swab, nasopharyngeal wash/aspirate, nasal aspirate, nasal and mid-turbinate nasal swab",ND,S,NA,"Life Technologies TRIzol (RNA Extraction), Qiagen QIAamp® Viral RNA Mini Kit",ABI QuantStudioTM Dx Real-Time PCR system with software v1.0.3,ND,1.25 copies/µL,,No cross-reactivity predicted in silico,98.40%,63,Clinical,92.50%,67,99.91%,40.98%,,"PPA determined with 63 clinical OP and NP swab specimens tested positive with the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel by the University Hospital Pathology Laboratory and extracted with QIAamp RNA extraction kit (29/30) positive agreement) or Trizol Extraction (n = 33, 33/33 positive agreement). NPA determined with 67 clinical OP and NP swab specimens (number of each not disclosed) tested negative with the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel by the University Hospital Pathology Laboratory.",not included,included,included,ND,https://www.fda.gov/media/138059/download,https://www.fda.gov/media/138060/download,5/31/2020 15:26,5/31/2020 23:42,,
,Avera Institute for Human Genetics,Avera Institute for Human Genetics SARS-CoV-2 Assay,,https://www.avera.org/locations/profile/avera-institute-for-human-genetics-sioux-falls/,Lab,USA,"EUA granted May 22, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, nasal, and oropharyngeal swab",ND,N (N1 and N2 regions),NA,QIAGEN RNeasy mini kit,ABI Quant Studio 7 Flex equipped with Quant Studio software v1.1; Applied Biosystems Viia 7 equipped with the Quant Studio software v1.1,ND,1.6 copies/µL,,No cross-reactivity predicted in silico,100.00%,30,clinical,100.00%,30,100.00%,100.00%,,PPA determined NP swab specimens tested positive by the Cepheid Xpert Xpress SARS-CoV-2 Test. NPA determined with NP swab specimens tested negative by the Cepheid Xpert Xpress SARS-CoV-2 Test (source not disclosed).,not included,included,included,ND,https://www.fda.gov/media/138332/download,https://www.fda.gov/media/138331/download,5/31/2020 15:26,5/31/2020 23:46,,
,"BioCore Co., Ltd.",BioCore 2019-nCoV Real Time PCR Kit,,http://www.bio-core.com/biocore/en/information/news_detail.do?BRD_ID=1587110353227,Kit,South Korea,"EUA granted May 21, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, mid-turbinate swab, oropharyngeal swab, nasopharyngeal swab, sputum, bronchioalveolar lavage (BAL), tracheal aspirate",VTM,"ORF1ab (RdRP region)
  N",NA,Qiagen QIAamp DSP Viral RNA Mini Kit,"Bio-Rad CFX96 Dx System, Applied Biosystems 7500, SLAN-96P",ND,500 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,40,Clinical,100.00%,80,100.00%,100.00%,,"PPA determined using clinical sputum (n = 20) and OP and NP swab specimens (n = 20 in total, number of each not disclosed) specimens tested positive with a comparator device authorised by an FDA EUA comparator method; NPA determined with sputum (n = 40) and OP and NP swab specimens (n = 40 in total, number of each not disclosed) tested negative with a comparator device authorised by an FDA EUA comparator method.",not included,included,included,ND,https://www.fda.gov/media/138290/download,https://www.fda.gov/media/138292/download,5/31/2020 15:26,5/31/2020 23:34,,
,"Cedars-Sinai Medical Center, Department of Pathology and Laboratory Medicine",SARS-CoV-2-Assay,,https://www.cedars-sinai.org/covid-19-your-health/antibody-testing.html,Lab,USA,"EUA granted May 13, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal swab,ND,ORF1ab (NSP-3 region),NA,"Qiagen QIAmp Viral Mini QIAcube kit on the Qiagen QIA Connect, QIAsymphony DSP Virus/Pathogen Midi kit on the QIAsymphony extraction","ABI QuantStudio 6 Flex instrument with version 1.3, ABI 7500 Fast Real Time PCR system with version 1.4",ND,10 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,100.00%,100.00%,,"PPA determined with 4 NP clinical specimens tested positive by the Los Angeles County Department of Public Health with the CDC 2019-nCoV Realtime PCR Test, 21 NP clinical specimens tested positive by an undisclosed outside reference laboratory with the Quest SARS-CoV-2 rRT-PCR, and 5 NP clinical specimens tested positive by a second undisclosed outside clinical laboratory with the Panther Fusion SARS-CoV-2. NPA determined with 4 NP clinical specimens tested negative by the Los Angeles County Department of Public Health with the CDC 2019-nCoV Realtime PCR Test and 26 NP clinical specimens tested negative by an undisclosed outside reference laboratory with the Quest SARS-CoV-2 rRT-PCR.",not included,included,included,ND,https://www.fda.gov/media/138065/download,https://www.fda.gov/media/138064/download,5/31/2020 15:26,5/31/2020 23:50,,
,"Color Genomics, Inc.",Color SARS CoV-2 Diagnostic Assay,,https://www.color.com/wp-content/uploads/2020/05/Color-Diagnostic-Testing-short-Updated-052020.pdf,Lab,USA,"EUA granted May 18, 2020",Laboratory,H,Molecular,RNA,RT-LAMP,"Nasopharyngeal swabs, oropharyngeal swabs, anterior nares swabs, mid-turbinate nasal swabs, nasopharyngeal wash/aspirate, bronchoalveolar lavage or nasal aspirates",ND,"ORF1ab
 E
 N",NA,Extraction with Viral DNA/RNA 200 Kit H96 on the Perkin Elmer Chemagic 360 extraction instrument platform and Chemagic software v6.3.0.3. LAMP prep with Hamilton STAR/STARlet automated liquid handler with Venus 4 software,Biotek Synergy NEO2 multi-mode microplate reader with Gen5 software v3.9,70 minutes reaction time (after RNA extraction and reaction peparation steps),0.75 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,87,Clinical and Contrived,100.00%,548,100.00%,100.00%,,"PPA determined with 46 randomized and blinded contrived specimens spiked with SARS-CoV-2 genomic RNA (ATCC VR-1986D) into individual negative clinical anterior nares matrix (source and method not disclosed) in DNA/RNA Shield media, 7 NP specimens tested positive by Clinical Research Sequencing Platform with the CDC 2019-nCoV Realtime PCR Test, and 34 NP clinical specimens tested positive by the CZI (Chan Zuckerberg Initiative) BioHub (University of California San Francisco) with the CDC 2019-nCoV Realtime PCR Test. NPA determined with 46 randomized and blinded negative specimens (source and method not disclosed) and 502 NP clinical specimens tested negative by Clinical Research Sequencing Platform with the CDC 2019-nCoV Realtime PCR Test.",not included,included,included,ND,https://www.fda.gov/media/138249/download,https://www.fda.gov/media/138248/download,5/31/2020 15:26,6/11/2020 11:58,,
,Columbia University Laboratory of Personalized Genomic Medicine,Triplex CII-CoV-1 rRT-PCR Test,,https://research.columbia.edu/covid/diagnostics,Lab,USA,"EUA granted May 12, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, nasal, and mid-turbinate nasal swab samples",UTM,N (N1 and N2 regions),NA,"bioMerieux NucliSENS easyMAG extraction kit on the bioMérieux easyMAG
 automated extraction platform",ABI 7500 Fast Dx Real-Time PCR Instrument (ABI Fast) with software version 2.3.,ND,0.28 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,97.90%,67,clinical and contrived,100.00%,53,99.89%,100.00%,,"PPA determined with 30 contrived OP specimens spiked with T7 RNA in vitro transcript for SARS-COV-2 N1 and N2 targets (source not disclosed) collected in VTM and 17 NP clinical specimens tested positive by the Columbia University Pathology & Cell Biology laboratory with the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel. Also demonstrated positive measurement of viral genomic RNA with 20 contrived OP specimens (source and method unknown) spiked with full length SARS-CoV-2 viral genomic RNA, sourced from infected Vero E6 cells (2019-nCoV/USA-WA1/2020; accession MN985325 grown in Vero E6 Cat# ATCC CRL-158) in VTM. NPA determined with 30 individual presumed negative clinical OP specimens (source and method not disclosed) collected in VTM and 23 NP clinical specimens tested negative by the Columbia University Pathology & Cell Biology laboratory with the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel.",included,included,included,ND,https://www.fda.gov/media/137983/download,https://www.fda.gov/media/137982/download,5/31/2020 15:26,5/31/2020 23:54,,
,dba SpectronRx,Hymon SARS-CoV-2 Test Kit,,https://spectronrx.com/,Kit,USA,"EUA granted May 22, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, mid-turbinate swab, nasopharyngeal swab, and oropharyngeal swab, bronchoalveolar lavage",UTM or equivalent,"E
  N",NA,Hymon SARS-CoV-2 Test Kit,ABI 7500 Real-Time PCR System with software v2.3,ND,1.2 copies/µL,,No cross-reactivity predicted in silico,100.00%,31,Clinical,100.00%,45,100.00%,100.00%,,PPA determined with 31 clinical OP and NP swab specimens (number and source of each not disclosed) tested positive with the Sansure Biotech Novel Coronavirus (2019-NCOV) Nucleic Acid Diagnostic Kit. NPA determined with 45 clinical OP and NP swab specimens (number and source of each not disclosed) tested negative with the Sansure Biotech Novel Coronavirus (2019-NCOV) Nucleic Acid Diagnostic Kit.,not included,included,included,ND,https://www.fda.gov/media/138345/download,https://www.fda.gov/media/138343/download,5/31/2020 15:26,5/31/2020 23:08,,
,Exact Sciences Laboratories,Exact Sciences SARS-CoV-2 (N gene detection) Test,,https://www.exactlabs.com/lab-client-services/covid-19-fact-sheets,Lab,USA,"EUA granted May 22, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, or nasal swabs",UTM,N (N1 and N2 regions),NA,Exact Sciences extraction procedure on the Hamilton STARlet liquid handler,ABI 7500 Fast Dx (software version not disclosed),ND,2.6 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,95.00%,40,Clinical,100.00%,38,99.74%,100.00%,,PPA determined with clinical OP and NP swab specimens (number of each not disclosed) tested positive with either the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel by the Wisconsin State Laboratory of Hygiene (17/17) or the Exact Sciences Laboratories SARS-CoV-2 Test (21/23). NPA determined with clinical OP and NP swab specimens (number of each not disclosed) tested negative with either the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel by the Wisconsin State Laboratory of Hygiene (32/32) or the Exact Sciences Laboratories SARS-CoV-2 Test (6/6).,not included,included,included,ND,https://www.fda.gov/media/138328/download,https://www.fda.gov/media/138327/download,5/31/2020 15:26,5/31/2020 23:44,,
,Express Gene LLC (dba Molecular Diagnostics Laboratory),Express Gene 2019-nCoV RT-PCR Diagnostic Panel,,https://expressgene.us/covid-19,Lab,USA,"EUA granted May 22, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swabs, nasopharyngeal wash/aspirate or nasal aspirates as well as BAL specimens",ND,"ORF1ab
 N
 S",NA,ABI MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the KingFisher Flex automated DNA extraction instrument with software version 1.01,ABI QuantStudio 12K Flex with design and analysis software 2.2.3,ND,800 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,clinical,100.00%,30,100.00%,100.00%,,PPA determined with NP swab specimens tested positive with the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel by CapStone Healthcare. NPA determined with NP swab specimens tested negative with the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel by CapStone Healthcare.,not included,included,included,ND,https://www.fda.gov/media/138330/download,https://www.fda.gov/media/138329/download,5/31/2020 15:26,5/31/2020 23:45,,
,"One Health Laboratories, LLC",SARS-CoV-2 Real-Time RT-PCR-Test,,http://onehealthlaboratory.com/,Lab,USA,"EUA granted May 13, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, mid-turbinate, nasopharyngeal, and oropharyngeal swab specimens, and nasopharyngeal wash/aspirate or nasal aspirate",ND,"ORF1ab
 S",NA,Biomeme M1 Sample Prep Cartridge for RNA 2.0,"Biomeme Franklin three9 Real-Time PCR Thermocycler equipped with Franklin
 Firmware version v6.3.1 and Franklin Software version v1.4.5.",ND,1.8 copies/µl,,No cross-reactivity predicted in silico,98.90%,90,Clinical and Contrived,100.00%,60,99.94%,100.00%,,"PPA determined with 60 contrived specimens spiked with genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WSA1/2020 (BEI NR522285) into individual negative clinical NP specimens (source and method not disclosed) in Biomeme Lysis Buffer (BLB) and 30 clinical specimens tested to be positive (sample type/source and testing method not disclosed). NPA determined with 30 negative specimens (source and method not disclosed) and 30 clinical specimens tested to be negative (sample type/source and testing method not disclosed).",not included,included,included,ND,https://www.fda.gov/media/138063/download,https://www.fda.gov/media/138062/download,5/31/2020 15:26,5/31/2020 23:49,,
,"P23 Labs, LLC.",P23 Labs TaqPath SARS-CoV-2 Assay,,https://p23labs.com/,Lab,USA,"EUA granted May 21, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Anterior nasal swa, mid-turbinate nasal swab, oropharyngeal (throat) swab, nasopharyngeal
  swab, nasopharyngeal wash/aspirate, nasal aspirate specimen, and bronchoalveolar lavage, saliva (including home collection)","UTM, liquid Amies (MTM), OMNIgene®·ORAL OM-505 device (for saliva)","ORF1ab
  S
  N",NA,ABI MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit on the automated KingFisher Duo Primer Purification System (software v4.0),ABI QuantStudio 5 Real-Time PCR System with software v1.3,ND,10 copies/µL,,No cross-reactivity predicted in silico,100.00%,96,Contrived,100.00%,96,100.00%,100.00%,,"PPA determined with 60 contrived samples of SARS-CoV-2 genomic RNA (SeraCare, AccuPlexTM SARS-CoV-2, cat # 0505-0126) spiked into individual negative clinical NP (n=30) and saliva (n=30) specimens (sample source and negative determination method not disclosed). NPA determined with 80 negative clinical NP specimens (sample source and negative determination method not disclosed). First 5 positive and 5 negative NP specimens as determined by assay under evaluation were also tested by the Arkansas State Health Department using the previously authorized CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel with 100% (5/5) positive and negative agreement. Also conducted comparative parallel study of 42 saliva and NP specimens collected from individuals 7-21 days after a previously detected SARS-CoV-2 positive test and demonstrated both 100% positive (n=31) and 100% negative (n=11) agreement between saliva and NP and collected from each individual.",not included,included,included,ND,https://www.fda.gov/media/138297/download,https://www.fda.gov/media/138295/download,5/31/2020 15:26,5/31/2020 23:39,,
,"PrivaPath Diagnostics, Inc.",LetsGetChecked Coronavirus (COVID-19) Test,,https://www.letsgetchecked.com/us/en/home-coronavirus-test/,Lab,USA,"EUA granted May 28, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Self-collected nasal swab,VTM,ND,NA,Hologic Panther Fusion SARS-CoV-2,Hologic Panther Fusion SARS-CoV-2,ND,0.01 TCID50/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,69,Contrived,100.00%,109,100.00%,100.00%,,PPA determined with 69 contrived NP specimens spiked with inactivated cultured SARS-CoV-2 virus (USA-WA1/2020). NPA determined with 109 NP specimens (method not disclosed).,not included,not included,not included,ND,https://www.fda.gov/media/138406/download,https://www.fda.gov/media/138405/download,5/31/2020 15:26,5/31/2020 23:11,,
,"Seasun Biomaterials, Inc.",AQ-TOP COVID-19 Rapid Detection Kit,,http://www.seasunbio.com/english/etc.html,Kit,USA,"EUA granted May 21, 2020",Laboratory,H,Molecular,RNA,RT-LAMP,"Oropharyngeal swab, nasopharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, nasopharyngeal wash/aspirate, nasal aspirate, bronchoalveolar lavage (BAL), sputum",ND,ORF1ab,NA,QIAamp DSP virus kit,"BioRad CFX 96 real-time PCR detection system with software CFX manager V3.1,
  Applied Biosystems real-time PCR system 7500 with Software 2.0.6",ND,7 copies/uL,,No cross-reactivity predicted in silico,100.00%,95,Clinical and contrived,100.00%,100,100.00%,100.00%,,PPA determined with 60 randomized and blinded contrived specimens spiked with SARS-CoV-2 viral genomic RNA (NCCP No. 43326) into individual negative clinical NP (n = 30) or sputum (n = 30) specimens (source not disclosed) and 35 clinical NP (n = 20) and sputum (n=15) specimens tested to be positive with the U-TOP COVID-19 Detection Kit (source not disclosed). NPA determined with 60 randomized and blinded individual negative clinical NP (n = 30) or sputum (n = 30) specimens (source not disclosed) and 40 clinical NP (n = 20) and sputum (n=15) specimens tested to be negative with the U-TOPTM COVID-19 Detection Kit (source not disclosed). Specimens for positive contrived samples were determined to be negative with the U-TOP™ COVID-19 Detection Kit prior to spiking with genomic RNA.,not included,included,included,ND,https://www.fda.gov/media/138307/download,https://www.fda.gov/media/138300/download,5/31/2020 15:26,6/11/2020 11:59,,
,Siemens Healthcare Diagnostics Inc.,ADVIA Centaur SARS-CoV-2 Total (COV2T),,https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/cov2t-assay,Kit,USA,"EUA granted May 29, 2020",Laboratory,"H, M",Serology,"IgG, IgM",Homogeneous Immunoassay,"Serum, plasma",NA,NA,ND,"ADVIA Centaur XP System, ADVIA Centaur XPT System","ADVIA Centaur XP System, ADVIA Centaur XPT System",ND,NA,,No cross-reactivity detected in wet lab testing,100.00%,47,Clinical,99.80%,1589,100.00%,96.52%,,"Sensitivity determined by comparison to >13d post PCR positive specimens; Sensitivity for earlier windows: 61.05% (0-6d post PCR positive, n=95), 97.50% (7-13d post PCR positive, n=120). Samples were collected from 67 unique individuals over time. NPA determined using pre-COVID (before November 2019) outbreak samples from apparently healthy individuals (n = 1489, 3/1489 reactive) and apparently healthy pregnant women (n = 100, 0/100 reactive). All testing conducted with ADVIA Centaur XP system.",not included,not included,included,ND,https://www.fda.gov/media/138446/download,https://www.fda.gov/media/138443/download,5/31/2020 15:26,6/20/2020 7:47,,
,Siemens Healthcare Diagnostics Inc.,Atellica IM SARS-CoV-2 Total (COV2T),,https://www.siemens-healthineers.com/en-us/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/cov2t-assay,Kit,USA,"EUA granted May 29, 2020",Laboratory,"H, M",Serology,"IgG, IgM",Homogeneous Immunoassay,"Serum, plasma",NA,NA,ND,Atellica IM Analyzer,Atellica IM Analyzer,ND,NA,,No cross-reactivity detected in wet lab testing,100.00%,42,Clinical,99.80%,1091,100.00%,96.69%,,"Sensitivity determined by comparison to >13d post PCR positive specimens; Sensitivity for earlier windows: 60.67% (0-6d post PCR positive, n=89), 97.48% (7-13d post PCR positive, n=119). Samples were collected from 66 unique individuals over time. NPA determined using pre-COVID (before November 2019) outbreak samples from apparently healthy individuals (n = 993, 2/993 reactive) and apparently healthy pregnant women (n = 98, 0/98 reactive).",not included,not included,included,ND,https://www.fda.gov/media/138442/download,https://www.fda.gov/media/138439/download,5/31/2020 15:26,6/20/2020 7:47,,
,"SolGent Co., Ltd.",DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit,,http://www.solgent.com/english/sub03020102/view/id/45,Kit,South Korea,"EUA granted May 21, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, oropharyngeal (throat) swab, anterior nasal swab, mid-turbinate nasal swab, nasal aspirate, nasal wash, bronchoalveolar lavage (BAL) fluid, sputum",ND,"ORF1ab
  N",NA,"Qiagen QIAamp Viral RNA Mini Kit, Roche MagNA Pure 96 DNA and Viral NA Small Volume Kit with External Lysis Buffer on the MagNA Pure 96 nucleic acid extraction system with software V3.1","ABI 7500 Real-Time PCR Instrument System with software V2.0.6, ABI 7500 Fast Real-Time PCR Instrument System with software V2.0.6, Bio-Rad CFX96™ Real-time PCR Detection System with software V3.1",ND,200 copies/mL,,No cross-reactivity detected in wet lab testing,100.00%,60,Clinical and contrived,100.00%,60,100.00%,100.00%,,PPA determined with 30 contrived samples of SARS-CoV-2 packaged viral RNA (source not disclosed) spiked into negative clinical NP specimens (source not disclosed) and 30 clinical sputum specimens tested to be positive with an alternate real-time PCR method with FDA EUA approval (source and method not disclosed). NPA determined with 30 negative clinical NP specimens (source not disclosed) and 30 clinical sputum specimens tested to be negative with an alternate real-time PCR method with FDA EUA approval (source and method not disclosed).,not included,not included,included,ND,https://www.fda.gov/media/138303/download,https://www.fda.gov/media/138306/download,5/31/2020 15:26,5/31/2020 23:08,,
,Healgen Scientific LLC,COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma),,https://www.healgen.com/if-respiratory-covid-19,Kit,USA,"EUA granted May 29, 2020",Laboratory,"H, M",Serology,"IgG, IgM",Lateral Flow,"Venous whole blood, plasma from anticoagulated blood, serum",ND,NA,S (S1 region),None,Gold with visual read,Less than 10 mins,NA,,No cross-reactivity detected in wet lab testing,100.00%,30,Clinical,97.50%,80,100.00%,67.80%,,"PPA determined with 90 clinical plasma samples collected from January to mid-March 2020 at two sites in China from individual patients exhibiting COVID symptoms and confirmed positive with RT-PCR assays for SARS-CoV-2 (method not disclosed), and 30 frozen SARS-CoV-2 antibody-positive serum samples confirmed positive with a nucleic acid amplification test (NAAT) and confirmed to contain both IgM and IgG antibodies with at least one orthogonal method (methods not disclosed). Positive assay results for PPA were those that were positive for IgG or IgM. NPA determined with 101 clinical plasma (K2EDTA) samples collected from January to mid-March 2020 at two sites in China from individual patients exhibiting COVID symptoms and confirmed negative with RT-PCR assays for SARS-CoV-2 (method not disclosed), and 80 frozen SARS-CoV-2 antibody-negative serum samples collected prior to 2020 including a subset selected from banked serum from HIV+ patients (n=10). Testing was performed by one operator using one lot of the COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma). Negative assay results for PPA were those that were negative for both IgG and IgM. *Note that respiratory samples collected from sites in China were both OP swabs (site #1, n = 65) and sputum (site #2, n = 126), but association of positive and negative plasma samples to corresponding respiratory specimen types was not disclosed. Also, the time from RT-PCR result to collection of plasma specimens ranged from 15- 45 days (Site #1) and 0-38 days (Site #2) and the time from collection of specimens (plasma) from each individual to testing ranged from 12-23 days (Site #1) and 3-29 days (Site #2).",not included,included,not included,ND,https://www.fda.gov/media/138438/download,https://www.fda.gov/media/138435/download,5/28/2020 12:09,6/20/2020 7:47,,
,Abbott Molecular Inc.,Alinity m SARS-CoV-2 assay,,https://www.molecular.abbott/us/en/products/infectious-disease/alinity-m-sars-cov-2-assay,Kit,USA,"EUA granted May 11, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swabs, nasopharyngeal (NP) and oropharyngeal (OP) swabs, bronchoalveolar lavage fluid (BAL)",Specimen Transport Buffer,"ORF1ab (RdRp region)
 N",NA,Abbott Alinity m,Abbott Alinity m,ND,100 copies/mL,,No cross-reactivity predicted in silico,100.00%,40,Contrived,100.00%,31,100.00%,100.00%,,PPA determined with contrived NP specimens spiked with SARS-CoV-2 RNA sequences. NPA determined with negative NP specimens,not included,included,included,ND,https://www.fda.gov/media/137979/download,https://www.fda.gov/media/137980/download,5/21/2020 0:47,5/21/2020 1:19,,
,1drop Inc.,1copy COVID-19 qPCR Multi Kit,,http://www.1drop.co.kr/sp.php?p=63,Kit,South Korea,"EUA granted May 11, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, anterior nasal swab, midturbinate nasal swab and oropharyngeal swab as well as nasopharyngeal wash/aspirate and
 nasal aspirate",Puritan UniTranz-RT,ORF1ab (RdRP region) E,NA,Qiagen QIAamp Viral RNA Mini Kit RNA mini kit,"Roche Light Cycler 480 with Software version 1.5, Qiagen Rotor-Gene Q 5plex HRM with Software version 2.3.4, ABI Quantstudio5 with Software version 1.4.3, ABI 7500 Real-Time PCR Instrument system with Software version 2.0.6, Bio-Rad CFX96™ Real-Time PCR Detection system with CFX Maestro version 1.1",ND,200 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,PPA determined with contrived NP (n=30) and OP (n=30) specimens spiked with SeraCare AccuPlex™ RNA reference material. NPA determined with negative NP/OP specimens,not included,included,included,ND,https://www.fda.gov/media/137935/download,https://www.fda.gov/media/137934/download,5/21/2020 0:45,5/21/2020 1:06,,
,Quidel Corporation,Lyra Direct SARS-CoV-2 Assay,,https://www.quidel.com/molecular-diagnostics/lyra-direct-sars-cov-2-assay,Kit,USA,"EUA granted May 18, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal, or oropharyngeal swabs",None - should not be used,ORF1ab,NA,Manual buffer addition and heating,"ABI 7500 Fast Dx, ABI 7500 Standard, Roche LightCycler 480, Roche
 Cobas Z480, Bio-Rad CFX96 Touch, Thermofisher QuantStudio 7 Pro, Qiagen Rotor-Gene Q",ND,6.8 x 10^4 copies/mL (QuantStudio) 3.40E+04 copies/mL (other platforms),,No cross-reactivity predicted in silico nor detected in wet lab testing,97.80%,45,Contrived,100.00%,38,99.88%,100.00%,,PPA determined with contrived NP (29/30) and OP (15/15) specimens spiked with virus; NPA determined with 38 NP (30) and OP (8) negative specimens,included,included,included,ND,https://www.fda.gov/media/138178/download,https://www.fda.gov/media/138179/download,5/19/2020 16:55,5/21/2020 1:03,,
,"Everlywell, Inc.",Everlywell COVID-19 Test Home Collection Kit,,https://www.everlywell.com/products/covid-19-test/,Collection,USA,"EUA granted May 15, 2020",Laboratory,NA,Home Collection Kit,RNA,NA,Nasal swab,Saline,NA,NA,NA,NA,NA,NA,,NA,,,NA,,,0.00%,0.00%,,NA - collection kit,NA,NA,NA,ND,https://www.fda.gov/media/138146/download,https://www.fda.gov/media/138144/download,5/18/2020 18:13,6/20/2020 7:48,,
,GeneMatrix,NeoPlex COVID-19 Detection Kit,,http://genematrix.net/2018/subpage.php?p=m1_2_neoplexCOVID19,Kit,South Korea,"EUA granted May 15th, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, midturbinate, and nasal swabs and sputum, tracheal aspirates, and
 bronchoalveolar lavage",UTM,"ORF1ab (RdRp region)
 N",NA,Qiagen QIAamp DSP Viral RNA Mini Kit,ABI 7500 Fast Dx Real-Time PCR Instrument with SDS software version 1.4,ND,50 copies/rxn,,No cross-reactivity predicted in silico,100.00%,120,Contrived,100.00%,120,100.00%,100.00%,,"PPA determined with contrived NP (n=40), OP (n=40), Sputum (n=40) specimens spiked with viral RNA extracted from positive patients. NPA determined with clinical NP (n=40), OP (n=40), Sputum (n=40) specimens confirmed negative for SARS-CoV-2 by a sequencing panel established by the Ministry of Health of Japan",not included,included,included,ND,https://www.fda.gov/media/138100/download,https://www.fda.gov/media/138101/download,5/18/2020 0:18,5/21/2020 0:47,,
,Assurance,ASSURANCE SARS-COV-2 PANEL,,https://assurancescientificlabs.com/coronavirus/,Lab,USA,"EUA granted May 15th, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal (including Everlywell home collection), nasopharyngeal or oropharyngeal swabs","Saline, Amies",E,NA,Zymo Quick-RNA Viral Kit RNA Extraction Kit with Abnova Precipitor32 or Indical Indimag 48,BioRad CFX96 or CFX384,ND,37 copies/rxn,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,77,Clinical and Contrived,100.00%,78,100.00%,100.00%,,"PPA determined with contrived (n=72) combined NP, OP, nasal specimens spiked with viral genomic RNA and clinical (n=5) specimens. NPA determined with negative NP, OP, nasal specimens",included,included,included,ND,https://www.fda.gov/media/138154/download,https://www.fda.gov/media/138151/download,5/17/2020 23:42,6/20/2020 7:50,,
,Fulgent Therapeutics LLC,Fulgent COVID-19 by RT-PCR Test,,https://www.fulgentgenetics.com/covid19,Lab,USA,"EUA granted May 15, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal, and oropharyngeal
 swabs and self collected nasal swabs",Saline,N,NA,Qiagen QIAamp Viral RNA Mini Kit or Zymo QuickRNA Viral Kit RNA Extraction Kits,QuantStudio 6 or QuantStudio 7 realtime PCR systems,1 - 2 days (from receiving sample),5 copies/µL,,No cross-reactivity predicted in silico,100.00%,30,Clinical,100.00%,64,100.00%,100.00%,,"PPA determined with 30 clinical NP, OP and mid-turbinate swab specimens that tested positive with an EUA molecular test. NPA determined with 64 negative NP, OP and mid-turbinate swab specimens",ND,included,included,ND,https://www.fda.gov/media/138150/download,https://www.fda.gov/media/138147/download,5/17/2020 21:05,5/21/2020 1:22,,
,"Hologic, Inc",Aptima SARS-CoV-2 assay,,https://www.hologic.com/coronavirus-test,Kit,USA,"EUA granted May 14, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal (NP), nasal, mid-turbinate and oropharyngeal (OP) swab specimens",VTM/UTM,ORF1ab,NA,Hologic Panther or Panther Fusion Systems,Hologic Panther or Panther Fusion Systems,2.4 hours,0.01 TCID50/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,50,Clinical,98.20%,54,100.00%,74.52%,,PPA/NPA determined using remnant clinical NP specimens vs Panther Fusion system as reference method.,not included,included,included,ND,https://www.fda.gov/media/138096/download,https://www.fda.gov/media/138097/download,5/17/2020 20:34,5/25/2020 8:42,,
,Rutgers Clinical Genomics Laboratory-Rutgers University copy,ThermoFisher - Applied Biosystems TaqPath COVID-19 Combo Kit,,https://www.rutgers.edu/news/rutgers-launches-genetic-testing-service-new-coronavirus,Lab,USA,"EUA granted Apr 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Oropharyngeal swab, nasopharyngeal swab, anterior nasal swab, mid-turbinate nasal swab and saliva","VTM; Spectrum Solutions LLC SDNA-1000
 Saliva Collection Device (saliva only)","ORF1ab
 N
 S",NA,Qiagen QIAamp® DSP Viral RNA Mini Kit,ABI 7500 Fast Dx Real-Time PCR Instrument,under 3 hours,200 copies/mL,,No cross-reactivity predicted in silico,100.00%,60,Clinical and Contrived,100.00%,60,100.00%,100.00%,,PPA determined with 30 contrived clinical NP specimens spiked with SARS-CoV-2 in vitro transcripts (Exact Diagnostics); another 30 prospective clinical saliva specimens were compared to NP (n=26) and OP (n=4) samples. NPA determined with 30 contrived NP specimens spiked with human gDNA (Exact Diagnostics) and 30 prospective clinical saliva specimens compared to NP (n=27) and OP (n=3).,included,included,included,ND,https://www.fda.gov/media/136875/download,https://www.fda.gov/media/136876/download,5/13/2020 17:00,5/14/2020 18:38,,
,"Biocollections Worldwide, Inc.",Biocollections Worldwide SARS-Co-V-2 Assay,,http://www.biocollections.com/,Lab,USA,"EUA granted on May 07, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab,
 nasopharyngeal swab, oropharyngeal swab, nasopharyngeal wash/aspirate or nasal
 aspirate, bronchoalveolar lavage",VTM,N,NA,Abbott m2000 system m2000sp (software version 8.1.8.0),Abbott m2000 system m2000rt (software version 8.1.8.0),ND,1 copy/μL,,No cross-reactivity predicted in silico,100.00%,35,Clinical,100.00%,35,100.00%,100.00%,,PPA determined with clinical NP (n=32) and OP (n=3) specimens (source not disclosed) each assessed for agreement with a positive result from an FDA-authorized EUA test. NPA determined with clinical NP (n=25) and OP (n=10) specimens (source not disclosed) each assessed for agreement with a negative result from an FDA-authorized EUA test. Tests conducted in blinded fashion.,not included,included,included,ND,https://www.fda.gov/media/137897/download,https://www.fda.gov/media/137896/download,5/12/2020 21:49,5/25/2020 9:05,,
,BioMérieux SA,SARS-COV-2 R-GENE,,https://www.biomerieux-diagnostics.com/sars-cov-2-r-gene,Kit,France,"EUA granted on May 06, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, oropharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, nasal aspirate, nasal wash and bronchoalveolar lavage",UTM,"ORF1ab (RdRp region)
 N",NA,"bioMérieux EMAG® (with software version 1.1),
 bioMérieux NucliSENS easyMAG (with software version 2.1),
 QIAgen QIASymphony SP (with software version 4.1),
 Roche MagNA Pure 96 (with software version 3.1)","ABI 7500 Fast(1) (with software version 2.3),
 ABI 7500 Fast Dx(1) (with software version 1.4.), ABI QuantStudio 5 Dx(1) (with software version 1.0), Roche LightCycler 480 (System II) (with software version 1.5), Bio-Rad CFX96 (with software Maestro 1.1), Qiagen Rotor‑Gene Q (with software 2.3)",ND,0.43 TCID 50/mL (380 genomic copies/mL),,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,50,Contrived,100.00%,76,100.00%,100.00%,,"PPA determined with 50 contrived clinical NP specimens in UTM spiked with inactivated SARS‑CoV‑2 (source not disclosed). NPA determined with 76 contrived clinical NP specimens (source not disclosed). All samples were extracted with the EMAG® instrument, following the B31 extraction method protocol
 then amplified on the Applied Biosystems 7500 Fast Dx",not included,included,included,ND,https://www.fda.gov/media/137742/download,https://www.fda.gov/media/137743/download,5/12/2020 21:49,5/25/2020 8:44,,
,Fast Track Diagnostics Luxembourg S.á.r.l. (a Siemens Healthineers Company),FTD SARS-CoV-2,,http://www.fast-trackdiagnostics.com/human-line/products/ftd-sars-cov-2/,Kit,Luxembourg,"EUA granted on May 05, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, nasopharyngeal swab, oropharyngeal swab, nasopharyngeal wash/aspirate or nasal aspirate), Bronchoalveolar lavage (BAL)",VTM,"ORF1ab
 N",NA,bioMérieux NucliSENS® easyMAG® (software version not specified),Applied Biosystems® 7500 Real-Time PCR System (software version not specified),ND,0.0023 TCID50/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,44,Clinical,100.00%,30,100.00%,100.00%,,PPA determined with 44 clinical NP specimens (source not disclosed) each assessed for agreement with a positive result from FDA-authorized RT-PCR test. NPA determined with 36 clinical NP specimens (source not disclosed) each assessed for agreement with a negative result from FDA-authorized RT-PCR test. *Note that 1 negative sample was excluded due to protocol deviation and 5 negative samples did not pass criteria for a valid run (internal control failure).,not included,included,included,ND,https://www.fda.gov/media/137690/download,https://www.fda.gov/media/137687/download,5/12/2020 21:49,5/21/2020 0:54,,
,"OPTI Medical Systems, Inc.",OPTI SARS-CoV-2 RT PCR Test,,https://www.optimedical.com/products-services/C19-test.html,Kit,USA,"EUA granted on May 06, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, nasopharyngeal swab, oropharyngeal swab, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate",VTM,N (N1 and N2 regions),NA,IDEXX RealPCR DNA/RNA Magnetic Bead Kit on the ABI/ThermoFisher KingFisher™ Flex; Machery-Nagel NucleoMag VET Magnetic Extraction Kit on the ABI/ThermoFisher KingFisher™ Duo Prime,"Applied Biosystems® 7500 FAST
 PCR instrument (software v2.0.6), Applied Biosystems® QuantStudio 5 (software v1.5.1), Agilent Mx3005P (MxPro qPCR software v4.10), Bio Molecular Systems Mic qPCR (micPCR software v2.8.10), Roche LightCycler® 480 (with LightCycler 480 SW software v1.5.1)",ND,"0.7 copies/μL (sputum), 0.9 copies/μL (NP swabs)",,No cross-reactivity predicted in silico,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,"PPA determined with contrived clinical NP (n=30) and sputum (n=30) specimens collected and stored prior to 2020, confirmed negative and then spiked with SARS-CoV-2 RNA (Twist Bioscience part# MT007544.1). NPA determined with clinical NP (n=30) and sputum (n=30) specimens collected and stored prior to 2020.",not included,included,included,ND,https://www.fda.gov/media/137739/download,https://www.fda.gov/media/137737/download,5/12/2020 21:49,5/25/2020 8:48,,
,Sansure BioTech Inc.,Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing),,http://eng.sansure.com.cn/index.php?g=portal&m=article&a=index&id=81,Kit,China,"EUA granted on May 04, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, oropharyngeal (throat) swab, anterior nasal swab, midturbinate swab, nasal wash, nasal aspirate",Sample Storage Reagent (Use Qiagen QIAamp Viral RNA Mini Kit for samples in VTM/UTM),ORF1ab N,NA,"One step centrifugation and lysis, then sample directly added to master mix using QIAamp Viral RNA Mini Kit",ABI 7500 Real-Time PCR System (software v1.5),ND,200 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,94.30%,53,Clinical,99.00%,193,99.70%,82.68%,,"PPA determined with 53 clinical OP specimens in Sample Storage Reagent (source not disclosed) each assessed for agreement with a positive result from Real-Time Fluorescent RT-PCR kit for Detecting SARS-2019-nCoV from BGI Genomics. NPA determined with 193 clinical OP specimens (source not disclosed) each assessed for agreement with a negative result from from Real-Time Fluorescent RT-PCR kit for Detecting SARS-2019-nCoV from BGI Genomics. In both positive and negative cases, tests run with assay being evaluated used the Sample Release Reagent RNA extraction while BGI Genomics comparator assay extraction method was the Qiagen QIAamp Viral RNA Mini Kit.",not included,included,included,ND,https://www.fda.gov/media/137651/download,https://www.fda.gov/media/137652/download,5/12/2020 21:49,5/20/2020 23:56,,
,"Sherlock BioSciences, Inc.",Sherlock CRISPR SARS-CoV-2 Kit,,https://sherlock.bio/sherlock-biosciences-receives-fda-emergency-use-authorization-for-crispr-sars-cov-2-rapid-diagnostic/,Kit,USA,"EUA granted on May 06, 2020",Laboratory,H,Molecular,RNA,RT-LAMP,"Nasal swab, nasopharyngeal swab,
 oropharyngeal swab, nasopharyngeal wash/aspirate or nasal aspirate and bronchoalveolar lavage","VTM, UTM, M4RT","ORF1ab
 N",NA,ThermoFisher PureLink Viral RNA/DNA Mini Kit,Biotek Plate Reader running Gen5 3.08 software,~1 hr,6.75 copies/μL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,"PPA determined with 30 contrived clinical NP specimens collected and stored during 2018-2019 flu season, confirmed negative and then spiked with SARS-CoV-2 viral genomic RNA (source not disclosed). NPA determined with 30 contrived clinical NP specimens collected and stored during 2018-2019 flu season and confirmed negative.",not included,included,included,ND,https://www.fda.gov/media/137746/download,https://www.fda.gov/media/137747/download,5/12/2020 21:49,6/11/2020 11:59,,
,UTMG Pathology Laboratory,UTHSC/UCH SARS-CoV-2-RT-PCR Assay,,https://www.utmedicalcenter.org/covid-19-information/,Lab,USA,"EUA granted on May 03, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal swab",VTM,N (N1 and N2 regions),NA,Promega Maxwell RSC (software version not specified); Tecan Genesis LH platform,AriaMx Real Time PCR system and Aria software (version not specified),ND,100 PFUs,,No cross-reactivity detected in wet lab testing,96.70%,30,Contrived,100.00%,30,99.83%,100.00%,,PPA determined with 30 contrived clinical nasal specimens spiked with SARS-Related Coronavirus 2 Isolate USA- WAl/2020 (Catalog # NR-52281) viral cell supernatant. NPA determined with 30 NP nasal specimens (source and method not disclosed). Also confirmed 4/5 positive samples and 5 negative samples from above evaluation with Roche cobas SARSCoV-2. A separate analysis not included for PPA or NPA involved 10 positive and 10 negative blinded remnant swabs in VTM tested comparatively against the Roche cobas SARS-CoV-2.,not included,included,included,ND,https://www.fda.gov/media/137656/download,https://www.fda.gov/media/137654/download,5/12/2020 21:49,5/25/2020 8:51,,
,Zymo Research Corporation,Quick SARS-CoV-2rRT-PCR Kit,,https://www.zymoresearch.com/products/quick-sars-cov-2-rrt-pcr-kit,Kit,USA,"EUA granted on May 07, 2020; amended on May 18, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swab, nasopharyngeal swag, mid-turbinate nasal swab, oropharyngeal swab, sputum, tracheal aspirates, and bronchoalveolar lavage",ND,N,NA,Zymo Quick-DNA/RNA Viral MagBead extraction kit either manually or on the automated ABI/ThermoFisher KingFisher™ Flex Purification System,Bio-Rad CFX96 Touch Real-Time PCR Detection System using the Bio-Rad CFX Maestro™ 1.1 Version 4.1.2433.1219 software,ND,83 GEC/ml (5 GEC/rxn),,"≥80% homology in silico found for Streptococus pneumoniae, Mycoplasma pneumoniae, Legionella longbeachae,
 and Neisseria meningitidis. Follow up wet lab testing with 1 x 10^6
 cells/sample specimens of these as well Pseudomonas aeruginosa and Candida albicans found 0/3 samples tested positive in all cases.",100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,"PPA determined with 30 contrived clinical sputum specimens collected with DNA/RNA
 Shield™ Saliva Collection Kit and spiked with whole genome SARS-CoV-2 RNA (source not disclosed). NPA determined with clinical sputum (n=21) and OP (n=9) specimens collected from patients experiencing one or more symptoms of respiratory infection under supervision of a healthcare provider, using the DNA/RNA Shield™ Saliva Collection Kit and the DNA/RNA Shield™ Swab Collection Kit, respectively.",not included,included,included,ND,https://www.fda.gov/media/137780/download,https://www.fda.gov/media/137781/download,5/12/2020 21:49,6/1/2020 0:06,,
,Rutgers Clinical Genomics Laboratory at RUCDR Infinite Biologics - Rutgers University,Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2-Assay,,https://www.rutgers.edu/news/fda-approves-first-home-saliva-collection-test-coronaviruest,Lab,USA,"EUA granted on May 07, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Oropharyngeal (throat) swab, nasopharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, and bronchoalveolar lavage (BAL) fluid, saliva","VTM; Spectrum Solutions
 LLC SDNA-1000 Saliva Collection Device (saliva only, including home collection)","ORF1ab
 N
 S",NA,"Chemagic Viral DNA/RNA 300 Kit H96 on the PerkinElmer Chemagic 360
 automated specimen processing system","Applied Biosystems QuantStudio 5 Real-Time PCR System equipped with
 software v1.3",ND,200 copies/mL,,No cross-reactivity predicted in silico,100.00%,65,Clinical and Contrived,100.00%,65,100.00%,100.00%,,"PPA determined with 30 contrived clinical NP specimens spiked with SARS-CoV-2 in vitro transcripts or human DNA (Exact Diagnostics); another 30 prospective clinical saliva specimens were compared to NP (n=26) and OP (n=4) samples. 5 clinical NP samples were run comparatively with both this test and CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic for agreement. Simulated saliva shipping study used residual clinical saliva samples that had already tested positive with Rutgers TaqPath SARS-CoV-2 Assay Panel that were re-tested after simulated summer (n=30), winter (n=30), and control (n=30) temperature cycles. NPA determined with 30 contrived clinical NP specimens spiked with in vitro transcripts or human DNA (Exact Diagnostics) and 30 prospective clinical saliva specimens compared to NP (n=27) and OP (n=3). 5 clinical NP samples were run comparatively with both this test and CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic for agreement. Simulated saliva shipping study used residual clinical saliva samples that had already tested negative with Rutgers TaqPath SARS-CoV-2 Assay Panel that were re-tested after simulated summer (n=10), winter (n=10), and control (n=10) temperature cycles.",not included,included,included,ND,https://www.fda.gov/media/137782/download,https://www.fda.gov/media/137773/download,5/11/2020 23:38,5/21/2020 0:55,,
,Gnomegen LLC,Gnomegen COVID-19-RT-qPCR Detection Kit,,https://gnomegendx.com/,Kit,USA,"EUA granted on May 08, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal and nasal swab,VTM,N (N1 and N2 regions),NA,Qiagen QIAamp DSP virus kit,"7500 Fast
 Dx Real-Time PCR Instrument (SDS version 1.4)",ND,10 copies/rxn (20µL),,No cross-reactivity predicted in silico,100.00%,60,Clinical and Contrived,100.00%,30,100.00%,100.00%,,"PPA determined with upper respiratory specimens (n=30) positive with another EUA test, and contrived upper respiratory specimens (n=30) spiked with purified whole viral RNA (COV20851-2). NPA determined with 30 negative upper respiratory specimens.",not included,included,included,ND,https://www.fda.gov/media/137895/download,https://www.fda.gov/media/137892/download,5/11/2020 23:37,5/21/2020 0:54,,
,Quidel Corporation,Sofia 2 SARS Antigen FIA,,https://ir.quidel.com/news/news-release-details/2020/Quidel-Receives-Emergency-Authorization-for-Rapid-Antigen-COVID-19-Diagnostic-Assay/default.aspx,Kit,USA,"EUA granted on May 08, 2020","Laboratory, POC","H, M, W",Antigen,Antigen,Lateral Flow,Nasopharyngeal and nasal swab,UTM,NA,N (SARS-CoV and SARS-CoV-2),Manual,Sofia 2,15 min,113 TCID50/mL (swab) 850 TCID50/mL (UTM),,No cross-reactivity detected in wet lab testing,79.70%,64,Clinical,100.00%,127,98.94%,100.00%,,PPA determined with frozen NP in UTM (47/59) and fresh NS (4/5) and NPA determined with NP (n=84) and NS (n=43) compared to EUA PCR-tested clinical specimens,not included,included,not included,ND,https://www.fda.gov/media/137885/download,https://www.fda.gov/media/137886/download,5/11/2020 22:04,5/29/2020 23:28,,
,Southwest Regional PCR Laboratory LLC. dba MicroGen DX,COVID-19 Key,,https://microgendx.com/covid19/,Lab,USA,"EUA granted Apr 23, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swabs, nasopharyngeal awash/aspirate or nasal aspirates as well as sputum specimens",ND,"N (N1, N2 and N3 regions)",NA,"Zymo Viral RNA Mag
 Bead Kit performed on the Thermo Fisher Scientific King Fisher Flex II extraction platform",Roche Lightcycler 480II with Lightcycler 480 software version 1.5.1 sp3.,ND,"200 copies/mL (sputum), 500 copies/mL (NP)",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,PPA determined by contrived sputum (n=30) and NP (n=30) specimens spiked with SARS-CoV-2 positive patient RNA.,included,included,included,ND,https://www.fda.gov/media/137370/download,https://www.fda.gov/media/137369/download,5/5/2020 1:13,5/11/2020 23:30,,
,AIT Laboratories,SARS-CoV-2 Assay,,http://healthtrackrx.com/news-media/ait-laboratories-a-healthtrackrx-company-launches-testing-to-detect-novel-coronavirus-covid-19,Lab,USA,"EUA granted Apr 24, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper respiratory specimens such as nasal, midturbinate, nasopharyngeal, and oropharyngeal swab and lower respiratory specimens such as sputum and BAL.",ND,"ORF1ab
 N
 S",NA,Omega Biotek MagBind Universal Pathogen Kit,ThermoFisher Scientific TaqPath COVID-19 Combo Kit run on ABI QuantStudio 12K Flex,ND,1 copy/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,55,Clinical,100.00%,55,100.00%,100.00%,,"PPA determined with clinical sputum (n=34), nasal (n=13) and OP (n=8) specimens compared to the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.",included,included,included,ND,https://www.fda.gov/media/137374/download,https://www.fda.gov/media/137373/download,5/5/2020 1:13,5/5/2020 1:26,,
,EUROIMMUN US Inc.,Anti-SARS-CoV-2 Elisa (IgG),,https://www.coronavirus-diagnostics.com/,Kit,USA,"EUA granted May 4th, 2020",Laboratory,H,Serology,IgG,ELISA,Serum or plasma,NA,NA,S,Manual,Microplate reader (manufacturer not specified),ND,NA,,"1/15 positive for Mycoplasma antibody-positive specimens, 1/3 positive for RSV antibody-positive specimens, 2/12 positive for Streptococcus pneumoniae antibody-positive specimens, 2/58 positive for bacterial pneumonia antibody-positive specimens, 1/15 positive for Chlamydophila pneumoniae antibody-positive specimens.",90.00%,30,Clinical,100.00%,80,99.50%,100.00%,,"Sensitivity determined by comparison to PCR positive specimens: >10 days post-symptom onset (28/42), >11 days post-PCR confirmation (30/37), independent validation study (27/30).
 Sensitivity for earlier windows: 13.9% (<11d pso), 21.7% (<5d ppc), 69.4% (<10d ppc).
 Specificity was determined with specimens collected pre-COVID (1415/1445) and during COVID from healthy donors (303/311).",not included,included,included,ND,https://www.fda.gov/media/137609/download,https://www.fda.gov/media/137606/download,5/4/2020 16:06,5/20/2020 22:56,,
,Nationwide Children’s Hospital,SARS-CoV-2 Assay,,https://www.nationwidechildrens.org/family-resources-education/health-wellness-and-safety-resources/covid-19,Lab,USA,"EUA granted Apr 27, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper and lower respiratory specimens
 including nasopharyngeal swabs, nasal swabs, mid-turbinate nasal swabs, oropharyngeal swabs,
 nasopharyngeal wash/aspirates, nasal aspirates, bronchoalveolar lavage, lower respiratory
 tract aspirates, and sputum",ND,N (N1 and N2 regions),NA,bioMérieux NucliSENS EasyMAG automated nucleic acid extraction system,ABI QuantStudio 7 Flex Real-Time PCR Instrument with QuantStudio Real-Time PCR software v.1.3,ND,"12.5 copies/rxn (NP), 125 copies/rxn (sputum)",,No cross-reactivity predicted in silico,100.00%,60,Contrived,100.00%,30,100.00%,100.00%,,"PPA determined with contrived NP (n=30) and sputum (n=30) specimens spiked with genomic RNA from SARS-Related Coronavirus 2 Isolate USA_WA1/2020 cultured in Vero cells (University of Texas Medical Branch, World Reference Center for Emerging Viruses and Arboviruses).",included,included,included,ND,https://www.fda.gov/media/137423/download,https://www.fda.gov/media/137424/download,5/4/2020 13:44,5/11/2020 23:31,,
,"Bio-Rad Laboratories, Inc",Platelia SARS-CoV-2 Total Ab assay,,https://www.bio-rad.com/en-us/product/platelia-aspergillus-ag?ID=M4T15K2B7,Kit,USA,"EUA granted Apr 29, 2020",Laboratory,H,Serology,IgA/IgM/IgG,ELISA,Serum and plasma,NA,NA,N (full length),Manual,Microplate reader (manufacturer not specified),ND,NA,,No cross-reactivity detected in wet lab testing,92.20%,51,Clinical,99.60%,687,99.59%,91.70%,,"Sensitivity determined by comparison to PCR positive specimens <9d post-symptom onset (5/8), 9-20d pso (36/37), and >20d pso (3/3).",not included,included,included,ND,https://www.fda.gov/media/137493/download,https://www.fda.gov/media/137494/download,5/4/2020 13:39,5/5/2020 0:26,,
,"LabGenomics Co., Ltd.",LabGun COVID-19 RT-PCR Kit,,http://www.labgenomics.co.kr/eng/invest/news.php?act=view&encData=aWR4PTI3MA==,Kit,South Korea,"EUA granted Apr 29, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, or oropharyngeal, anterior nasal and mid-turbinate nasal swabs, as well as nasopharyngeal wash/aspirate or nasal aspirate specimens and sputum",VTM,ORF1ab (RdRP region) E,NA,Qiagen QIAamp Viral RNA Mini kit,"ABI 7500 Real-time PCR Instrument system with software version 2.3
 or BioRad CFX96™ Real-time PCR detection system with Bio-Rad CFX Manager 3.1",~ 2.5 hrs (detection),20 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,50,Contrived,100.00%,100,100.00%,100.00%,,PPA determined with contrived NP/OP (n=50) and sputum (n=50) specimens spiked with SARS-CoV-2 viral genomic RNA obtained from National Culture Collection for Pathogens of Korea (NCCP No.43326).,not included,included,included,ND,https://www.fda.gov/media/137483/download,https://www.fda.gov/media/137484/download,5/4/2020 13:39,5/11/2020 23:31,,
,"Rheonix, Inc.",Rheonix COVID-19 MDx Assay,,https://rheonix.com/covid-19/,Kit,USA,"EUA granted Apr 29, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swabs, oropharyngeal (throat) swabs, anterior
 nasal swabs, mid-turbinate nasal swabs, nasal washes, nasal aspirates and bronchoalveolar
 lavage (BAL) fluid samples","UVT, VTM",N (N1 region),NA,Rheonix Encompass MDx® Workstation,Rheonix Encompass MDx® Workstation,<5 hours,625 copies/mL,,No cross-reactivity predicted in silico,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with contrived NP specimens spiked with SARS-CoV-2 RNA,not included,included,included,ND,https://www.fda.gov/media/137489/download,https://www.fda.gov/media/137490/download,5/4/2020 13:39,5/11/2020 23:31,,
,SEASUN BIOMATERIALS,U-TOP COVID-19 Detection Kit,,http://www.seasunbio.com/english/etc.html#tab01,Kit,South Korea,"EUA granted Apr 27, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Oropharyngeal and nasopharyngeal
 swab specimens, anterior nasal and mid-turbinate nasal swabs, nasopharyngeal wash/aspirate
 or nasal aspirate specimens and sputum",VTM,ORF1ab N,NA,Qiagen QIAamp DSP Viral RNA Mini Kit,"Bio-Rad CFX 96 real-time PCR detection system with software CFX manager V3.1, ABI real-time PCR system 7500 with Software 2.0.6",ND,"1,000 copies/mL",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with contrived NP specimens spiked with SARS-CoV-2 RNA from National Culture Collection for Pathogens No. 43326.,not included,included,included,ND,https://www.fda.gov/media/137425/download,https://www.fda.gov/media/137420/download,5/4/2020 13:39,5/25/2020 8:49,,
,"Wadsworth Center, New York State Department of Health",New York SARS-CoV Microsphere Immunoassay for Antibody Detection,,https://www.wadsworth.org/,Lab,USA,"EUA granted Apr 30, 2020",Laboratory,H,Serology,IgA/IgM/IgG,Homogeneous Immunoassay,Serum,None,NA,N (full length),Manual,Luminex FlexMap dual laser cytometer,ND,NA,,"1/5 positive for West Nile Virus antibody-positive specimens, 2/5 indeterminates for Chikungunya Virus antibody-positive specimens and 1/5 indeterminates from HIV antibody-positive specimens",88.00%,108,Clinical,98.80%,433,99.40%,79.40%,,"Sensitivity determined by comparison to >20 days post-symptom onset PCR positive specimens; Sensitivity for earlier windows: 17.9% (<7 dps, n=179), 31.3% (7-10 dps, n=67), 48.9% (11-15 dps, n=47), 49.2% (16-20 dps, n=126).",included,included,included,ND,https://www.fda.gov/media/137541/download,https://www.fda.gov/media/137540/download,5/4/2020 13:39,5/11/2020 23:37,,
,Biocerna,SARS-CoV-2 Test,,http://www.biocerna.com/,Lab,USA,"EUA granted Apr 28,2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, mid-turbinate, nasopharyngeal, and oropharyngeal swab and bronchoalveolar
 lavage (BAL)","OraCollect-RNA, VTM",ORF1ab N S,NA,"ABI/ThermoFisher MagMAX Viral/Pathogen Nucleic acid isolation
 kit automated on the KingFisher Flex Purification system",ABI QuantStudio 5 real-time PCR system with ABI Design and Analysis Software version 2.3.3,ND,"250 copies/mL for Genotek OR-100
 collection device and 375 copies/mL for the Copan eSwab",,No cross-reactivity predicted in silico,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with contrived NS specimens spiked with genomic RNA (BEI).,included,included,included,ND,https://www.fda.gov/media/137450/download,https://www.fda.gov/media/137451/download,5/4/2020 11:29,6/19/2020 18:44,,
,"Altru Diagnostics, Inc.",Altru Dx SARS-CoV-2 RT-PCR assay,,https://www.altru.org/coronavirus/,Lab,USA,"EUA granted Apr 30, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper respiratory specimens such as nasal, midturbinate, nasopharyngeal, and oropharyngeal swab specimens",ND,ORF1ab N S,NA,"ThermoFisher KingFisher Flex Purification System with
 Applied Biosystems MagMax Viral/Pathogen Nucleic Acid Isolation Kit","ABI QuantStudio 12K Flex Real-Time PCR System (384-well, Block) with
 Software version: QuantStudio 12K Flex Software V.1.2.2",ND,625 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,35,Clinical and Contrived,100.00%,30,100.00%,100.00%,,"PPA determined with contrived NS specimens (n=30) spiked with genomic RNA from NR52285 v2019-nCoV/USA-WA1/2020, and clinical nasal swab specimens (n=5) confirmed positive by Houston Department of Health and Human Services (HDHHS) using the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel.",included,included,included,ND,https://www.fda.gov/media/137546/download,https://www.fda.gov/media/137545/download,5/4/2020 10:52,5/25/2020 8:43,,
,"BioFire Diagnostics, LLC",BioFire Respiratory Panel 2.1,,https://www.biofiredx.com/covid-19/,Kit,USA,"EUA granted May 1,2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal swab,VTM,"S M Adenovirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A, including subtypes H1, H3 and H1-2009, Influenza B, Parainfluenza Virus 1, Parainfluenza Virus 2, Parainfluenza Virus 3, Parainfluenza Virus 4, Respiratory Syncytial Virus, Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumonia.",NA,BioFire FilmArray® 2.0 or FilmArray® Torch systems,BioFire FilmArray® 2.0 or FilmArray® Torch systems,~45 min,300 copies/mL (SARS-CoV-2),,No cross-reactivity predicted in silico nor detected in wet lab testing (for CoV-2),99.00%,99,Clinical and Contrived,100.00%,59,99.95%,100.00%,,"PPA determined with clinical NP specimens (n=49) compared to Hologic Panther Fusion® SARS-CoV-2 (14/15), LDT-based on CDC EUA assay (15/15), Roche cobas® SARS-CoV-2 (20/20), and contrived NP specimens (n=50) spiked with inactivated SARS-CoV-2 isolate USA-WA1/2020.",not included,included,included,ND,https://www.fda.gov/media/137583/download,https://www.fda.gov/media/137580/download,5/4/2020 1:49,5/25/2020 8:43,,
,"Bio-Rad Laboratories, Inc",Bio-Rad SARS CoV-2-ddPCR Test,,https://www.bio-rad.com/featured/en/coronavirus-covid-19-assay-development-vaccine-research.html,Kit,USA,"EUA granted May 1, 2020",Laboratory,H,Molecular,RNA,rRT-digital PCR,"Nasopharyngeal, anterior nasal and mid-turbinate nasal swabs,nasopharyngeal wash/aspirate and nasal aspirate","VTM, UTM",N (N1 and N2 regions),NA,ABI/ThermoFisher MagMAXViral/Pathogen NucleicAcid Isolation Kit or QIAamp Viral Mini Kit,"Bio-Rad AutoDG QXDx, QX200,7 C1000 Touch Thermal Cycler with 96–Deep Well Reaction Module andS1000 Thermal Cycler with 96-Deep Well Reaction Module",~ 5.5 hrs (detection),625 copies/mL,,No cross-reactivity predicted in silico,94.90%,39,Clinical,95.00%,40,99.72%,49.97%,,PPA and NPA were determined by comparing to the Seegene Allplex 2019-nCoV Assay,not included,included,included,ND,https://www.fda.gov/media/137579/download,https://www.fda.gov/media/137576/download,5/4/2020 0:16,5/25/2020 8:43,,
,Roche Diagnostics,Elecsys Anti-Sars-CoV-2,,https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html,Kit,USA,"EUA granted May 2, 2020",Laboratory,"H,M",Serology,IgM/IgG,Homogeneous Immunoassay,Serum and plasma,NA,NA,ND,None,"cobas e 411, e 601, e 602 or e 801 immunodiagnostic analyzers",18 min,NA,,No cross-reactivity detected in wet lab testing,100.00%,29,Clinical,99.80%,5272,100.00%,96.50%,,"Sensitivity determined by comparison to >13d post PCR positive specimens.
 Sensitivity for earlier windows: 65.5% (<7d ppp n=116), 88.1% (7-13d ppp, n=59)",not included,not included,included,ND,https://www.fda.gov/media/137605/download,https://www.fda.gov/media/137602/download,5/3/2020 19:03,5/25/2020 9:20,,
,Abbott Laboratories Inc.,SARS-CoV-2 IgG assay,,https://www.corelaboratory.abbott/us/en/offerings/segments/infectious-disease/sars-cov-2,Kit,USA,"EUA granted Apr 26, 2020; amended May 9, 2020",Laboratory,H,Serology,IgG,Homogeneous Immunoassay,"Serum, serum separator tube and plasma",NA,NA,ND,ARCHITECT i and Alinity i Systems,ARCHITECT i and Alinity i Systems,ND,NA,,2/205 positives for Cytomegalovirus (CMV) antibody-positive specimens,100.00%,88,Clinical,99.60%,1070,100.00%,92.94%,,"Sensitivity determined by comparison to >13d post-symptom onset PCR positive specimens; Sensitivity for earlier windows: 0% (<3d pso, n=4), 25% (3-7d pso, n=8), 86.4% (8-13d pso, n=22). NPA determined using pre-COVID outbreak samples.",not included,included,included,ND,Architect: https://www.fda.gov/media/137383/download; Alinity: https://www.fda.gov/media/137910/download,https://www.fda.gov/media/137384/download,5/2/2020 9:46,6/1/2020 0:11,,
,Ultimate Dx Laboratory,UDX SARS-CoV-2 Molecular Assay,,https://ultimatedx.com/,Lab,USA,EUA granted Apr 24 2020,Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal and oropharyngeal swabs",ND,ORF1ab,NA,ABI/ThermoFisher KingFisher Flex Purification RNA extraction,ABI QuantStudio 12K platform with QuantSutdio 12K Flex Software v 1.4,ND,100 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,PPA determined with 30 contrived NP UTM and 30 contrived NP ThinPrep specimens spiked with Synthetic SARS-CoV-2 RNA pseudovirus. NPA determined with 30 contrived NP UTM and NP 30 contrived ThinPrep samples.,not included,included,included,ND,https://www.fda.gov/media/137372/download,https://www.fda.gov/media/137371/download,4/26/2020 17:42,5/25/2020 8:51,,
,Autobio Diagnostics Co.Ltd.,Anti-SARS-CoV-2 Rapid Test,,http://www.autobio.com.cn/en/,Kit,USA,"EUA granted Apr 24,2020",Laboratory,"H,M",Serology,IgM/IgG,Lateral Flow,Serum or Plasma,NA,NA,ND,None,Gold with visual read,15 - 20 min,NA,,No cross-reactivity in wet lab testing,99.00%,302,Clinical,99.00%,312,99.90%,84.40%,,PPA determined with 405 clinical serum and plasma specimens positive by PCR; there were 48 false negatives. NPA was determined with clinical serum and plasma specimens negative by PCR. There were 3 false positives.,not included,included,not included,ND,https://www.fda.gov/media/137367/download,https://www.fda.gov/media/137364/download,4/26/2020 17:12,6/20/2020 7:47,,
,"Ortho Clinical Diagnostics, Inc.",VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack,,https://www.orthoclinicaldiagnostics.com/en-us/home/covid-19-antibody-test-released-by-ortho-clinical-diagnostics,Kit,USA,"EUA granted Apr 24, 2020; amended May 20, 2020",Laboratory,"H,M",Serology,IgG,Homogeneous Immunoassay,Serum,NA,NA,IgG,Ortho VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600 Integrated Systems,Ortho VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600 Integrated Systems,48 min to first result (37 min inucbation),NA,,No cross-reactivity detected in wet lab testing,90.00%,40,Clinical,100.00%,407,99.48%,100.00%,,"Sensitivity was determined with 40 PCR positive specimens collected >15 days post symptom onset; Sensitivity for earlier windows: 83.3% (12-15d pso n=15).
 Specificity was determined with presumed SARS-CoV-2 negative samples from healthy blood donors.",not included,not included,not included,ND,https://www.fda.gov/media/137363/download,https://www.fda.gov/media/137360/download,4/26/2020 16:13,6/1/2020 0:32,,
,DiaSorin Inc.,LIASON SARS-CoV-2 S1/S2 IgG,,https://www.diasorin.com/home/,Kit,USA,"EUA granted Apr 24,2020",Laboratory,"H,M",Serology,IgG,Homogeneous Immunoassay,Serum or plasma,"sodium heparin, lithium heparin, and potassium EDTA",NA,S (recombinant S1 and S2 regions),Manual,LIASON XL analzyer,35 min,NA,,No cross-reactivity in wet lab testing,97.60%,41,Clinical,99.30%,1090,99.90%,88.00%,,PPA determined with clinical serum and plasma specimens compared to SARS-CoV-2 RT-PCR positive patients admitted in three hospitals. NPA determined with presumed negative samples from a European laboratory (n=90) and European blood donors (n=1000) that were collected prior to the COVID-19 outbreak.,not included,not included,not included,ND,https://www.fda.gov/media/137359/download,https://www.fda.gov/media/137356/download,4/26/2020 14:15,6/11/2020 12:12,,
,Diatherix Eurofins Laboratory,SARS-CoV-2 PCR Test,,http://eurofins-diatherix.com/covid-19/,Lab,USA,"EUA granted Apr 22, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swabs, nasopharyngeal swabs/wash, oropharyngeal swabs/throat swabs, bronchial aspirates, or sputum",ND,ND,NA,Qiagen ClearMag or Omega Bio-tek MagBind Viral DNA/RNA on Thermo Fisher Scientific KingFisher Flex System,"Amplification: ABI GeneAmp 9700, Thermo Fisher Scientific Veriti 96-well Thermal Cycler; Detection: Sensovation AG SensoSpot Fluorescence Low Density Microarray Analyzer",ND,1 copy/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,98.90%,88,Contrived,100.00%,183,99.94%,100.00%,,"PPA determined (87/88) with 27 contrived sputum, 25 NP swabs, 11 nasal swabs, 14 throat swabs, and 11 BAL specimens spiked with either genomic SARS-CoV-2 RNA (32 samples) or in vitro transcribed RNA (56 samples); 100% (5/5) with clinical specimens (sample type not disclosed) confirmed by Alabama Public Laboratory (test method not disclosed). NPA determined with nasal swabs, NP swabs, throat swabs, bronchial washes, and sputum specimens; 100% (5/5) with clinical specimens (sample type not disclosed) confirmed by Alabama Public Laboratory (test method not disclosed).",included,included,included,ND,https://www.fda.gov/media/137255/download,https://www.fda.gov/media/137256/download,4/23/2020 23:39,5/11/2020 23:30,,
,Altona Diagnostics GmbH,RealStar SARS-CoV02 RT-PCR Kits,,https://altona-diagnostics.com/en/products/reagents-140/reagents/realstar-real-time-pcr-reagents/realstar-sars-cov-2-rt-pcr-kit-ruo.html,Kit,USA,"EUA granted Apr 22, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swabs, oropharyngeal (throat) swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal washes and nasal aspirates",UTM,E S,NA,Altona AltoStar Purification Kit 1.5 with the AltoStar Automation System AM16,"Bio-Rad CFX96™ Touch Real-Time PCR Detection System, Bio-Rad CFX96™ Touch Deep Well Real-Time PCR Detection System",,1.0 x 10^-01 plaque forming units/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,97.00%,34,Contrived,100.00%,34,99.84%,100.00%,,PPA determined with contrived NP specimens spiked with heat inactivated SARS-CoV-2 cell culture supernatant (source not disclosed). NPA determined with with NP specimens(source not disclosed).,not included,included,included,ND,https://www.fda.gov/media/137252/download,https://www.fda.gov/media/137257/download,4/23/2020 22:56,6/11/2020 12:12,,
,"SD Biosensor, Inc.",STANDARD M nCoV Real-Time Detection Kit,,http://sdbiosensor.com/xe/product/7653,Kit,South Korea,"EUA granted Apr 23, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, nasal, and midturbinate nasal swab, and sputum",UTM,ORF1ab (RdRP region) E,NA,Qiagen QIAamp® Viral RNA Mini Kit,Roche LightCycler® 480 (S/W version 1.5.1.62); Bio-Rad CFX96™ Dx System (S/W version 3.1); ABI 7500 Real-Time PCR Instrument System (S/W version 2.0.6),ND,0.5 copies/µL for upper and lower respiratory specimens (ABI 7500); 0.25 copies/µL for upper respiratory specimens and 0.125 copy/µL for lower respiratory specimens (CFX95); 0.5 copies/µL for upper respiratory specimens and 0.25 copy/µL for lower respiratory specimens (LC480),,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,PPA determined with 30 contrived NP and 30 contrived sputum specimens spiked with SARS-CoV-2 viral genomic RNA (source not disclosed). NPA determined with 30 NP specimens and 30 sputum specimens (source not disclosed).,not included,included,included,ND,https://www.fda.gov/media/137302/download,https://www.fda.gov/media/137303/download,4/23/2020 22:38,5/11/2020 23:31,,
,"Abbott Diagnostics Scarborough, Inc.",ID Now COVID-19,,https://www.alere.com/en/home/product-details/id-now-covid-19.html,Kit,USA,"EUA granted Mar 25, 2020; amended Apr 21, 2020","Laboratory, POC","H,M,W",Molecular,RNA,RT-NEAR,"Nasal swab, nasopharyngeal swab, throat swab",Not allowed,ORF1ab (RdRp region),NA,Abbott ID Now,Abbott ID Now,≤ 13 minutes,125 GE/mL,,No cross-reactivity predicted in silico,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with contrived NP swab specimens spiked with purified viral RNA containing target sequences from the SARS-CoV-2 genome (source not disclosed). NPA determined with NP swab specimens (source not disclosed).,not included,included,included,ND,https://www.fda.gov/media/136525/download,https://www.fda.gov/media/136522/download,4/23/2020 15:22,6/11/2020 11:59,,
,Abbott Molecular,Abbott RealTime SARS-CoV-2 EUA test,,https://www.molecular.abbott/us/en/products/infectious-disease/RealTime-SARS-CoV-2-Assay,Kit,USA,"EUA granted Mar 18, 2020; amended Apr 1, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal,nasopharyngealandoropharyngeal swabs",ND,"ORF1ab (RdRp region)
 N",NA,Abbott m2000,Abbott m2000,ND,100 GE/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,31,100.00%,100.00%,,PPA determined with contrived NP specimens spiked with recombinant virus containing SARS-CoV-2 RNA sequences (source not disclosed). NPA determined with NP specimens (Source not disclosed).,not included,included,included,ND,https://www.molecular.abbott/sal/9N77-095_SARS-CoV-2_US_EUA_Amp_PI.pdf,https://www.fda.gov/media/136617/download,4/23/2020 15:22,5/11/2020 23:30,,
,"Atila BioSystems, Inc.",IAMP COVID-19 DETECTION KIT,,https://atilabiosystems.com/covid-19/,Kit,USA,"EUA granted Apr 10, 2020",Laboratory,H,Molecular,RNA,RT-OMEGA,"Nasal Swabs, nasopharyngeal swabs and/or oropharyngeal swabs",ND,ORF1ab N,NA,Atila iAMP Sample Buffer,"Atila Power-Gene 9600 Plus, Bio-Rad CFX96, ABI7500, and other commonly used RT-qPCR instruments with FAM and HEX fluorescent channels",60 min incl sample prep,4 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,35,Contrived,100.00%,40,100.00%,100.00%,,PPA determined with with contrived OP swab specimens spiked with AccuPlex SARS-CoV-2 Verification Panel from SeraCare (0505-0129). NPA determined with OP swab samples (source not disclosed).,not included,included,included,ND,https://www.fda.gov/media/136870/download,https://www.fda.gov/media/136872/download,4/23/2020 15:22,6/11/2020 11:58,,
,"Avellino Lab USA, Inc.",Avellino SARS-CoV-2/COVID-19 (AvellinoCoV2),,https://www.avellinocoronatest.com/product/,Lab,USA,"EUA granted Mar 25, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal and oropharyngeal swab,ND,N,NA,Qiagen QIAamp DSP Viral RNA Mini Kit,Applied Biosystems 7500 Fast Real-Time PCR System with software version 2.3,ND,55 copies/µL,,No cross-reactivity predicted in silico,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with contrived NP and OP swab specimens spiked with whole viral SARS-CoV-2 RNA (USA-WA1/2020). NPA determined with individual clinical oropharyngeal swabs and nasopharyngeal swab (source not disclosed).,included,included,included,ND,https://www.fda.gov/media/136453/download,https://www.fda.gov/media/136450/download,4/23/2020 15:22,5/25/2020 8:43,,
,"Becton, Dickinson & Company",BD SARS-CoV-2Reagents for BD MAX System,,https://www.bd.com/en-us/support/covid-19-response-manual-inventory-allocation,Kit,USA,"EUA granted Apr 8, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal swabs","UVT, Copan UTM",N (N1 and N2 regions),NA,BD MAX,BD MAX,ND,40 GE/mL,,No cross-reactivity predicted in silico,95.00%,40,Contrived,100.00%,10,99.74%,100.00%,,PPA determined with with contrived NP specimens spiked with SARS-CoV-2 USA-WA1/2020 strain. There were 2 false negatives. NPA determined with clinical NP specimen (source not disclosed).,not included,included,included,ND,https://www.fda.gov/media/136816/download,https://www.fda.gov/media/136813/download,4/23/2020 15:22,5/11/2020 23:30,,
,"Becton, Dickinson & Company (BD), BioGx",BioGX SARS-CoV-2 Reagents for BD MAX System,,https://www.bd.com/en-us/offerings/capabilities/molecular-diagnostics/molecular-tests/biogx-sars-cov-2-reagents,Kit,USA,"EUA granted Apr 2, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal swabs","UVT, Copan UTM",N (N1 and N2 regions),NA,BD MAX,BD MAX,ND,40 GE/mL,,No cross-reactivity predicted in silico,100.00%,29,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with contrived retrospective collected nasopharyngeal swab clinical specimens spiked with SARS-CoV-2 USA-WA1/2020 strain. NPA determined with clinical NP specimens (source not disclosed).,not included,included,included,ND,https://www.fda.gov/media/136653/download,https://www.fda.gov/media/136650/download,4/23/2020 15:22,5/11/2020 23:30,,
,BGI Genomics Co. Ltd,Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2,,https://www.bgi.com/global/company/news/bgi-responds-to-novel-coronavirus-with-real-time-detection-kits-deploys-emergency-team-to-wuhan/,Kit,China,"EUA granted Mar 26, 2020; amended Apr 24, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Throat swabs, nasopharyngeal swabs, anterior nasal swabs, midturbinate nasal swabs, nasal washes, nasal aspirates and bronchoalveolar lavage fluid (BALF)",ND,ORF1ab,NA,"Qiagen QIAamp Viral RNA Mini Kit, MGI Easy Nucleic Acid Extraction Kit - manual and with MGI SP-960RS High-throughput Automated Sample Preparation System","Applied Biosystems™ Real time PCR system 7500 with software v2.0.5, ABI 7500 Fast Real-Time PCR System, ABI QuantStudio 5 RealTime PCR System, Roche LightCycler 480 System",ND,150 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,88.10%,126,Clinical,100.00%,258,99.38%,100.00%,,"PPA determined with 126 samples: 58 retrospective BALF, 34 Throat swab samples, and 34 extracted BALF RNA specimens from patients who had 1) recently travelled to Wuhan, 2) had COVID symptoms, and tested positive by RT-PCR (test not specified); there were 15 false negatives. NPA was determine d with 258 samples: 165 clinical BALF, 67 Throat swab, and 26 extracted BALF RNA specimens from diagnosed negative patients (test not disclosed).",not included,included,included,ND,https://www.fda.gov/media/136472/download,https://www.fda.gov/media/136473/download,4/23/2020 15:22,5/5/2020 1:47,,
,"BioFire Defense, LLC",BioFire COVID-19 test,,https://www.biofiredefense.com/covid-19test/,Kit,USA,"EUA granted Mar 23, 2020; amended Apr 30, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,Nasopharyngeal swabs,"Remel M4, Remel M4-RT, Remel M5, Remel M6, BD UVT, Sigma Virocult, Copan Aimes Medium","ORF1ab
 ORF8",NA,BioFire FilmArray® 2.0 or FilmArray® Torch systems,BioFire FilmArray® 2.0 or FilmArray® Torch systems,~45 min,330 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,97.50%,40,Clinical and Contrived,100.00%,71,99.87%,100.00%,,"PPA determined with clinical NP specimens (9/10) tested positive by the Roche cobas SARS-CoV-2 EUA Test, and contrived specimens spiked with live SARS-CoV-2 virus cultured from the USA_WA1/2020 strain (30/30). NPA determined with negative specimens (source not disclosed).",included,included,included,ND,https://www.fda.gov/media/136353/download,https://www.fda.gov/media/136356/download,4/23/2020 15:22,5/25/2020 8:43,,
,Cellex Inc.,qSARS-CoV-2 IgM/IgG Rapid Test,,https://cellexcovid.com/,Kit,USA,"EUA granted Apr 1, 2020",Laboratory,"H,M",Serology,IgM/IgG,Lateral Flow,"WB Plasma, Serum",NA,NA,ND,None,Gold with visual read,20 min,ND,,No cross-reactivity detected in wet lab testing,93.80%,128,Clinical,96.00%,250,99.66%,55.24%,,"Sensitivity determined with clinical serum or plasma specimens positive by PCR (91/98) or clinically confirmed (29/30). Specificity determined with plasma or serum specimens collected pre-September, 2019.",not included,included,not included,ND,https://www.fda.gov/media/136625/download,https://www.fda.gov/media/136622/download,4/23/2020 15:22,6/20/2020 7:47,,
,Centers for Disease Control and Prevention's (CDC),CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel (CDC),,https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html,Kit,USA,"EUA granted Feb 4, 2020; amended Mar 15, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate)",ND,N,NA,"Qiagen 2 QIAmp Viral RNA Mini Kit (manual and with QIAcube), Qiagen EZ1 Virus Mini Kit, Roche MagNA Pure, bioMérieux NucliSENS® easyMAG® and EMAG®",ABI 7500 Fast Dx Real-Time PCR Systems with SDS 1.4 software,ND,1 x 10^0.5 (EZ1); 1 x 10^0 (Viral RNA Mini),,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,104,100.00%,100.00%,,PPA determined with various respiratory clinical specimens confirmed by sequencing and/or culture (17/17) or composite comparator PCR assays and sequencing (13/13). NPA determined with various respiratory clinical specimens against composite comparator PCR assays.,included,included,included,ND,https://www.fda.gov/media/134922/download,https://www.fda.gov/media/134919/download,4/23/2020 15:22,5/25/2020 8:44,,
,Cepheid,Xpert Xpress SARS-CoV-2 test,,https://www.cepheid.com/coronavirus,Kit,USA,"EUA granted March 20, 2020; amended Apr 10 and Apr 28, 2020","Laboratory, POC","H,M,W",Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, nasal, mid-turbinate swabs, nasal wash/aspirate, nasal swab and lower respiratory tract","VTM, saline","E
 N (N2 region)",NA,"Cepheid GeneXpert Dx, GeneXpert Infinity 48 & 80, software 6.4b or higher","Cepheid GeneXpert Dx, GeneXpert Infinity 48 & 80, software 6.4b or higher",30 min,250 copies/mL using Accuplex 35/35 & 0.0100 PFU/mL using live SARS-CoV-2 virus samples (USA_WA1/2020) 22/22,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,20,Contrived,100.00%,30,100.00%,100.00%,,"PPA determined with contrived NP specimens spiked with SeraCare AccuPlex SARS-CoV-2 Reference Material Kit, Cat # 0505-0126. NPA determined with negative NP specimens (source not disclosed).",not included,included,included,ND,"Labs: https://www.fda.gov/media/136314/download
 POC: https://www.fda.gov/media/136315/download",https://www.fda.gov/media/136856/download,4/23/2020 15:22,5/25/2020 8:44,,
,CirrusDx Laboratories,CirrusDx SARS-CoV-2 Assay,,http://cirrusdx.com/wp-content/uploads/2020/04/COVID-19-Lab-Test-Statement.pdf,Lab,USA,"EUA granted Apr 15, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal swabs, nasopharyngeal swabs,
 oropharyngeal swabs, and BAL",UTM,"ORF1ab (RdRP region)
 E
 N",NA,ABI/ThermoFisher KingFisher Flex automated extraction or Qiagen QIAamp Viral RNA Mini Kit,"ABI QuantStudioTM 7 (software version 1.3), QuantStudioTM 5 (software version 1.4.1)",ND,78 copies/rxn,,No cross-reactivity predicted in silico nor detected in wet lab testing,96.70%,30,Contrived,100.00%,30,99.83%,100.00%,,"PPA determined with contrived NP specimens spiked with SARS-Related Coronavirus 2 RNA, Isolate USA-WA1/2020; Additional (18/18) study with clinical specimens compared to Simplexa COVID-19 Direct assay results (source not disclosed). NPA determined with NP specimens and additional 6 negative clinical specimens (source not disclosed).",included,included,included,ND,https://www.fda.gov/media/137034/download,https://www.fda.gov/media/137035/download,4/23/2020 15:22,5/25/2020 8:45,,
,"Co-Diagnostics, Inc.",Logix Smart Coronavirus COVID-19,,http://codiagnostics.com/products/diagnostic-solutions/logix-smart-covid19/,Kit,USA,"EUA granted Apr 3, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Lower respiratory tract fluids (e.g. bronchoalveolar lavage, sputum, tracheal aspirate), and upper respiratory tract fluids (e.g. nasopharyngeal and oropharyngeal swabs)",VTM,ND,NA,Qiagen QIAamp® Viral RNA Mini Kit,"CoDx Box BMS, Bio Molecular Systems",63-90 min,"4,290 copies/mL",,No cross-reactivity predicted in silico,100.00%,90,Contrived,100.00%,90,100.00%,100.00%,,"PPA determined with contrived specimens (type not reported) spiked with Genomic RNA of SARS-CoV-2, isolate USA-WA1/2020. No information provided on the type or source of the specimens used for NPA determination.",included,included,included,ND,https://www.fda.gov/media/136687/download,https://www.fda.gov/media/136684/download,4/23/2020 15:22,5/25/2020 8:45,,
,"DiaCarta, Inc",QuantiVirus SARS-CoV-2 test,,https://diacarta.com/products/coronavirus-test,Kit,USA,"EUA granted Apr 8, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal Swabs, Oropharyngeal Swabs and Sputum",UTM,"ORF1ab
 E
 N",NA,ThermoFisher PureLink™ viral RNA/DNA mini kit,"ABI QuantStudio 5, ABI 7500 Fast Dx, and Bio-Rad CFX 384",ND,"100 copies/mL ABI 7500;
 200 copies/mL ABI QuantStudio",,No cross-reactivity predicted in silico,97.00%,111,Contrived,100.00%,74,99.84%,100.00%,,PPA determined with contrived sputum specimens spiked with SeraCare AccuPlex SARS-CoV-2 Reference Material on ABI QuantStudio (57/60) and ABI 7500 (40/40). NPA determined with negative sputum specimens determined by both ABI platforms.,not included,included,included,ND,https://www.fda.gov/media/136809/download,https://www.fda.gov/media/136806/download,4/23/2020 15:22,5/25/2020 8:45,,
,Diagnostic Molecular Laboratory – Northwestern Medicine,SARS-Cov-2 Assay,,https://www.nm.org/conditions-and-care-areas/infectious-disease/covid-19,Lab,USA,"EUA granted Apr 2, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, throat (oropharyngeal) swab, nasal swab, mid-turbinate nasal swab and bronchoalveloar lavage (BAL)",ND,N (N1 region),NA,Qiagen QIAamp MinElute Virus Spin Kit,"ABI Quant Studio 6 Flex, equipped with Quant Studio Real-time PCR software v1.1",ND,100 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,36,Clinical and Contrived,100.00%,31,100.00%,100.00%,,PPA determined with 4 NP clinical specimens tested positive by Illinois Department of Public Health (test not disclosed) and 32 contrived NP specimens spiked with RNA from 4 clinical positive specimens (test not disclosed). NPA determined with 31 presumed negative NP (n=29) and BAL (n=2) clinical specimens.,included,included,included,ND,https://www.fda.gov/media/136669/download,https://www.fda.gov/media/136658/download,4/23/2020 15:22,5/25/2020 8:45,,
,DiaSorin Molecular LLC,Simplexa COVID-19 Direct,,https://molecular.diasorin.com/us/kit/simplexa-covid-19-direct-kit/,Kit,USA,"EUA granted Mar 19, 2020; amended Mar 26 and Apr 13, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,"Nasopharyngeal swabs (NPS), nasal swabs (NS), or bronchoalveolar lavage (BAL)","UTM, VTM, Remel M5, Remel M6, Copan ESwab™ (Liquid Amies), Puritan® UniTranz-RT®,
 or saline (0.9% sodium chloride in water)","ORF1ab
 S",NA,DiaSorin LIAISON® MDX,DiaSorin LIAISON® MDX,~1 hour,500 copies/mL (NP); 242 copies/mL (NS); 1208 copies/mL (BAL),,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,93,Contrived,100.00%,93,100.00%,100.00%,,PPA determined with contrived NP and BAL specimens spiked with heat-inactivated 2019-nCoV/USAWA1/2020 strain and tested at multiple sites. NPA determined with NP and BAL specimens tested at multiple sites (methods for determining negative patient status not disclosed).,not included,included,included,ND,https://www.fda.gov/media/136286/download,https://www.fda.gov/media/136288/download,4/23/2020 15:22,5/11/2020 23:30,,
,Exact Sciences Laboratories,SARS-CoV-2 Test,,https://www.exactlabs.com/lab-client-services/covid-19-fact-sheets,Lab,USA,"EUA granted Apr 14, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal, and oropharyngeal swab",VTM,"ORF1ab (RdRP region)
 E
 N",NA,Promega Maxwell RSC Viral Total Nucleic Acid Purification Kit with Promega Maxwell RSC 48 Instrument,ABI QuantStudio 5 (QS5) realtime PCR system with Design and Analysis Software version 1.5.1,ND,0.6 copies/µl (E and RdRP); 1.25 cp/µl (N),,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,55,Clinical,100.00%,33,100.00%,100.00%,,"PPA determined with 15 clinical NP and OP confirmed positive samples by the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel by Wisconsin State Laboratory of Hygiene; An additional 40 contrived NP or OP specimens spiked with AccuPlex SARS-nCOV-2019 Reference Material were tested. NPA was determined with 25 clinical NP and OP confirmed negative samples by the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel by Wisconsin State Laboratory of Hygiene; In addition, 8 contrived NP or OP negative specimens were tested.",included,included,included,ND,https://www.fda.gov/media/137095/download,https://www.fda.gov/media/137094/download,4/23/2020 15:22,5/25/2020 8:45,,
,Fosun Pharma USA Inc.,Fosun COVID-19 RT-PCR Detection Kit,,https://fosunpharmausa.com/,Kit,China,"EUA granted Apr 17, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper and lower respiratory specimens such as anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate",ND,"ORF1ab
 E
 N",NA,Qiagen QIAamp® Viral RNA Mini Kit,ABI 7500 instrument (software version #v1.4 or v1.5),ND,300 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,99.70%,50,Clinical,100.00%,493,99.98%,100.00%,,"PPA was determined with 50 clinical sputum and 25 throat swab specimens compared to FDA EUA CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel;
 In addition, 204 sputum and 79 throat swab were compared to another RT-PCR method (details not disclosed); there was 1 false-negative. NPA was determined with 50 sputum and 50 throat swab specimens vs. FDA EUA CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel; An additional 
 96.4% 180 sputum and 213 throat swab compared to another RT-PCR method (details not disclosed). There were 14 false-positives.",not included,included,included,ND,https://www.fda.gov/media/137120/download,https://www.fda.gov/media/137117/download,4/23/2020 15:22,5/4/2020 21:47,,
,"GenMark Diagnostics, Inc.",ePlex SARS-CoV-2 Test,,https://genmarkdx.com/solutions/panels/eplex-panels/eplex-sars-cov-2-test/,Kit,USA,"EUA granted Mar 19, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,Nasopharyngeal swabs,VTM,ND,NA,GenMark ePlex,GenMark ePlex,ND,1 x 10^5 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,94.40%,18,Clinical,100.00%,47,99.71%,100.00%,,PPA was determined with 18 prospective clinical NP specimens compared to a SARS-CoV-2 RealTime RT-PCR Diagnostic Panel authorized for EUA (test not disclosed). There was 1 false-negative. NPA was determined with prospective clinical 47 NP specimens as compared to a SARS-CoV-2 RealTime RT-PCR Diagnostic Panel authorized for EUA (test not disclosed).,not included,included,not included,ND,https://www.fda.gov/media/136282/download,https://www.fda.gov/media/136283/download,4/23/2020 15:22,5/4/2020 21:47,,
,"GenoSensor, LLC",GS COVID-19 RT-PCR Kit,,http://www.genosensorcorp.com/COVID19%20Kit.html,Kit,USA,"EUA granted Apr 16, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal/oropharyngeal swabs, nasal swabs and mid-turbinate swabs",VTM,"ORF1ab
 E
 N",NA,Qiagen QIAamp DSP Viral RNA Mini Kit,Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument,ND,1 copy/µL,,No cross-reactivity predicted in silico,100.00%,32,Contrived,100.00%,32,100.00%,100.00%,,PPA determined with 32 contrived NP/OP specimens spiked with SARS-CoV-2 whole viral genomic RNA. NPA determined with 32 NP/OP specimens (source and method not disclosed),not included,included,included,ND,https://www.fda.gov/media/137093/download,https://www.fda.gov/media/137090/download,4/23/2020 15:22,5/25/2020 8:46,,
,Gnomegen LLC,Gnomegen COVID-19 RT-Digital PCR Detection Kit,,https://gnomegendx.com/#a7e369e2-9ee2-4d49-904d-8f76962ed064,Kit,USA,"EUA granted Apr 6, 2020; amended Apr 28, 2020",Laboratory,H,Molecular,RNA,rRT-digital PCR,"Nasal, nasopharyngeal, and oropharyngeal swab",UTM,N,NA,Qiagen QIAamp DSP Viral RNA Mini Kit,QuantStudio™ 3D Digital PCR System and Gnomegen Real-Time Digital PCR Instrument,ND,8 copies/rxn,,No cross-reactivity predicted in silico,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with 30 contrived NP swab specimens spiked with whole viral RNA (COV20851-2). NPA determined with 30 NP specimens (source and method not disclosed).,not included,included,included,ND,https://www.fda.gov/media/136738/download,https://www.fda.gov/media/136735/download,4/23/2020 15:22,5/25/2020 8:46,,
,Hackensack University Medical Center (HUMC) Molecular Pathology Laboratory,CDI Enhanced COVID-19 Test,,https://www.hackensackumc.org/wellness/health-information/diseases-and-conditions/pathology/,Lab,USA,"EUA granted Apr 15, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper respiratory specimens including nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swab",BD UVT,"E
 N (N2 region)",NA,Roche MagNA Pure 24 System,Bio Molecular System Mic PCR cycler with micPCR software v2.8.0or v2.8.13,ND,4 copies/µL,,No cross-reactivity predicted in silico,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,PPA determine with contrived 60 NP swab specimens spiked with genomic RNA from BEI Resources tested with either 30TaKaRa or 30 Bioline master mixes. NPA determined with 60 NP swab specimens tested with either 30 TaKaRa or 30 Bioline master mixes.,included,included,included,ND,https://www.fda.gov/media/137036/download,https://www.fda.gov/media/137037/download,4/23/2020 15:22,5/11/2020 23:30,,
,"Hologic, Inc.",Panther Fusion SARS-CoV-2 assay,,https://www.hologic.com/package-inserts/diagnostic-products/panther-fusionr-sars-cov-2-assay,Kit,USA,"EUA granted Mar 18, 2020; amended Apr 1 and Apr 24, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal swabs","Remel MicroTest M4, M4RT, M5 or M6; Copan Universal Transport Medium; BD Universal Viral Transport Medium ; Saline, Liquid Amies, and Hologic specimen transport media",ORF1ab (1 and 2 regions),NA,Hologic Panther Fusion System,Hologic Panther Fusion System,ND,0.01 TCID50/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,69,Contrived,100.00%,109,100.00%,100.00%,,PPA determined with 69 contrived NP specimens spiked with inactivated cultured SARS-CoV-2 virus (USA-WA1/2020). NPA determined with 109 NP specimens (method not disclosed).,not included,included,included,ND,https://www.fda.gov/media/136156/download,https://www.fda.gov/media/136153/download,4/23/2020 15:22,5/25/2020 8:42,,
,"InBios International, Inc",Smart Detect SARS-CoV-2 rRT-PCR Kit,,https://inbios.com/smart-detecttm-sars-cov-2-rrt-pcr-kit/,Kit,USA,"EUA granted Apr 7, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, anterior nasal swab and mid-turbinate nasal swab",ND,"ORF1b (RdRP region)
 E
 N",NA,Qiagen QIAamp DSP Viral RNA Mini Kit,"ABI 7500 Fast Dx Real-Time PCR instrument with SDS Software, version 1.4 or Bio-Rad CFX96 Touch Real-Time PCR Detection System with the CFX Maestro Software (Bio-Rad)",~4 hours,"1100 copies/mL for Fast Dx
 Real-Time PCR Instrument;
 820 copies/mL for CFX96 Touch Real-Time PCR Detection System",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Contrived,97.00%,30,100.00%,63.69%,,"PPA determined with 30 contrived NP specimens spiked with genomic RNA (BEI catalog no. NR-52285, lot 70033320). NPA determined with 30 NP specimens (method not disclosed). There was 1 false positive.",not included,included,included,ND,https://www.fda.gov/media/136786/download,https://www.fda.gov/media/136787/download,4/23/2020 15:22,5/25/2020 8:46,,
,Infectious Disease Diagnostics Laboratory - Children's Hospital of Philadelphia,SARS-CoV-2 RT-PCR test,,https://www.chop.edu/coronavirus-updates,Lab,USA,"EUA granted Apr 2, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal aspirates, nasopharyngeal swabs, nasal swabs, mid-turbinate nasal swabs, tracheal aspirates, and bronchoalveolar lavage",ND,N (N2 region),NA,Roche MagNA Pure LC Total Nucleic Acid automated extraction platform,ABI Quant Studio DX automated PCR platform with software version 1.0.1,ND,"20,747 copies/mL",,No cross-reactivity predicted in silico,100.00%,30,Clinical and Contrived,100.00%,30,100.00%,100.00%,,PPA was determined with 4 clinical NP specimens confirmed at another laboratory (method not disclosed); an additional 26 contrived NP specimens spiked with genomic SARS-CoV-2 RNA were tested. There was 1 false negative. NPA was determined with 30 NP specimens (method not disclosed).,included,included,included,ND,https://www.fda.gov/media/136656/download,https://www.fda.gov/media/136657/download,4/23/2020 15:22,5/11/2020 23:32,,
,"Infectious Diseases Diagnostics Laboratory (IDDL), Boston Children’s Hospital",Childrens-Altona-SARS-CoV-2 Assay,,http://www.childrenshospital.org/conditions-and-treatments/conditions/c/coronavirus,Lab,USA,"EUA granted Apr 14, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, NP/OP, anterior
 nasal, and mid-turbinate nasal swab",ND,E S,NA,Qiagen Virus MinElute Spin kit performed on the QiaCube,Rotor-Gene Q 5Plex RT-PCR System,ND,2.3 copies/µL,,"Cross-reactivity >80% was predicted in silico for one primer of a pair against some targets. ""This renders amplification
 impossible and excludes unspecific cross-reactivity with the tested organisms""",100.00%,30,Clinical,100.00%,30,100.00%,100.00%,,PPA was determined with 30 clinical NP and NP/OP specimens that were PCR positive with CDC EUA SARS-CoV-2 assay at Massachusetts State Public Health Laboratory. NPA was determined with 30 clinical NP and NP/OP specimens that were PCR negative with CDC EUA SARS-CoV-2 assay at Massachusetts State Public Health Laboratory.,included,included,included,ND,https://www.fda.gov/media/136971/download,fda.gov/media/136972/download,4/23/2020 15:22,5/5/2020 2:12,,
,Integrity Laboratories,SARS-CoV-2 Assay,,https://integritylaboratories.com/index.php/about-us/,Lab,USA,"EUA granted Apr 13, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal and oropharyngeal swab","VTM, Aimes",N (N1 and N2 regions),NA,ABI MagMAX Viral/Pathogen Ultra Nucleic Acid Isolation Kit with MagMax Express 96,ABI QuantStudio 12K Flex RealTime PCR System,ND,10 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,43,Clinical and Contrived,100.00%,95,100.00%,100.00%,,"PPA was determined with 13 clinical specimens confirmed positive at other laboratories (type of specimen and test methods not disclosed); in addition, another 30 contrived NP specimens spiked with TWIST Synthetic SARS-CoV-2 RNA were tested. NPA was determined with 65 clinical specimens confirmed negative at other laboratories (type of specimen and test methods not disclosed); another 30 negative NP specimens were tested (method not disclosed).",included,included,included,ND,https://www.fda.gov/media/136942/download,https://www.fda.gov/media/136941/download,4/23/2020 15:22,5/11/2020 23:32,,
,Ipsum Diagnostics,COV-19 IDx assay,,https://www.ipsumdiagnostics.com/covid-19-resources/,Lab,USA,"EUA granted Apr 1, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal or oropharyngeal swabs,UTM,N,NA,ABI/ThermoFisher KingFisher Flex nucleic acid extraction systems using the Omega Bio-Tek Mag-Bind Viral DNA/RNA 96 Kit,ABI QuantStudio 12 Flex (QS12),ND,8.5 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,36,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with 36 contrived NP specimens spiked with BEI ATCC Genomic RNA from SARS Related Coronavirus 2. NPA determined with 30 NP specimens (method not disclosed).,included,included,included,ND,https://www.fda.gov/media/136621/download,https://www.fda.gov/media/136618/download,4/23/2020 15:22,5/25/2020 9:18,,
,KorvaLabs Inc.,Curative-Korva SARS-Cov-2 Assay,,https://www.korvalabs.com/,Lab,USA,"EUA granted Apr 16, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Oral fluid and nasopharyngeal swabs,"VTM, DNA/RNA Shield (Zymo Research)",N (N1 and N2 regions),NA,Tecan Resolvex A200,"BioRad CFX 96 Touch, BioRad CFX Connect Real-Time PCR systems BioRad CFX Maestro V1.1 and Roche LightCycler 480 II Real-Time PCR with Roche LightCycler Software V1.5",ND,200 copies/mL,,No cross-reactivity predicted in silico,100.00%,80,Clinical,100.00%,36,100.00%,100.00%,,"PPA determined with 48 clinical NP, 16 OF and 16 NS specimens compared to the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel run by CMB Laboratories; 34 NP (34/34), OF (34/34) and NS (32/33) specimens were compared to each other. This assumes 2 concordant results are the truth - samples were not verified by another method; 5 clinical OF specimens were compared to the Thermo Fisher Scientific, Inc. TaqPath COVID-19 Combo Kit run by UCLA Clinical Microbiology Laboratory. NPA was determined with 36 clinical NP, 12 OF and 12 NS specimens compared to the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel run by CMB Laboratories; also 18 clinical NP, 18 OF and 18 NS specimens were compared to each other. 5 clinical OF specimens compared to the Thermo Fisher Scientific, Inc. TaqPath COVID-19 Combo Kit run by UCLA Clinical Microbiology Laboratory",not included,included,included,ND,https://www.fda.gov/media/137089/download,https://www.fda.gov/media/137088/download,4/23/2020 15:22,5/4/2020 21:47,,
,Laboratory Corporation of America (LabCorp),COVID-19 RT-PCR test,,https://www.labcorp.com/coronavirus-disease-covid-19,Lab,USA,"EUA granted Mar 16, 2020; amended Apr 14, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper and lower respiratory specimens (such as nasal, nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate)",ND,N (N1 and N2 regions),NA,"Roche MagNA Pure-96 (MP96) using MagNA Pure 96 DNA and Viral NA Small Volume Kit (single-plex and multiplex), and Thermo Fisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit on the Thermo Fisher KingFisher Flex instrument (multiplex only)",Applied Biosystems QuantStudio7 Flex (QS7) instrument with software version 1.3,ND,6.25 cp/µL for NP swabs and 12.5 cp/µL for BAL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,66,Contrived,100.00%,132,100.00%,100.00%,,PPA was determined with 40 contrived NP and BAL specimens spiked with live SARS-CoV-2; also 5 clinical specimens were compared to the CDC assay and 16 clinical NP specimens were compared to multiplex. NPA was determined with with 50 NP and BAL specimens; an additional 5 clinical specimens compared to the CDC assay and 77 clinical NP specimens were compared to multiplex.,included,included,included,ND,https://www.fda.gov/media/136151/download,fda.gov/media/136148/download,4/23/2020 15:22,5/11/2020 23:31,,
,Luminex Corporation,Aries SARS-CoV-2 Assay,,http://info.luminexcorp.com/covid19,Kit,Canada,"EUA granted Apr 3, 2020; amended May 11, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,Nasopharyngeal swab,UTM,ORF1ab N,NA,Luminex Aries,Luminex Aries,ND,3.3 x 10^2 copies/mL; 5.48 x 10^-2 TCID50/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,30,100.00%,100.00%,,PPA was determined with 60 contrived NP specimens spiked with viral genomic RNA (USA_WA1/2020 strain - n =30) or Gamma-irradiated SARS-CoV-2 viral fluid (USA_WA1/2020 (NRC-52281 - n = 30). NPA was determined with 30 clinical NP specimens compared to a commercially available nucleic acid test or an in-house PCR followed by bi-directional sequencing (method not disclosed).,not included,included,not included,ND,https://www.fda.gov/media/136693/download,https://www.fda.gov/media/136694/download,4/23/2020 15:22,6/1/2020 0:48,,
,"Luminex Molecular Diagnostics, Inc.",NxTAGCoV Extended Panel Assay,,http://info.luminexcorp.com/covid19,Kit,Canada,"EUA granted Mar 27, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal swab,UTM,"ORF1ab
 E
 N",NA,"bioMérieux®NucliSENS®easyMAG®System, bioMérieuxEMAG®System",Luminex® MAGPIX® including xPONENT® Software,ND,5.0 x 10^3 GCE/mL,,No cross-reactivity predicted in silico,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with 30 contrived NP specimen spiked with viral genomic RNA (USA_WA1/2020 strain). NPA determined with 30 clinical NP specimens compared to a commercially available nucleic acid test or an in-house PCR followed by bi-directional sequencing (method not disclosed).,not included,included,not included,ND,https://www.fda.gov/media/136500/download,https://www.fda.gov/media/136497/download,4/23/2020 15:22,5/11/2020 23:31,,
,Maccura Biotechnology (USA) LLC,SARS-CoV-2 Fluorescent PCR Kit,,https://www.maccura.com/en/product/vAMA7UmFXAE-.html,Kit,USA,"EUA granted April 15, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Oropharyngeal swabs, nasopharyngeal swabs, nasal swabs, and mid-turbinate swabs",VTM,"ORF1ab
 E
 N",NA,Maccura Nucleic Acid Extraction Kit {Manual or Fast),ABI 7500 Real-Time PCR systems with v2.3 software,ND,"1,000 copies/mL",,No cross-reactivity predicted in silico,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with 30 contrived OP/NP specimens spiked with SARS-CoV-2 whole genomic RNA. NPA determined with 30 clinical OP/NP specimens (method not disclosed).,not included,included,included,ND,https://www.fda.gov/media/137026/download,https://www.fda.gov/media/137023/download,4/23/2020 15:22,5/11/2020 23:31,,
,Massachusetts General Hospital,MGH COVID-19 qPCR assay,,https://www.massgeneral.org/news/coronavirus/,Lab,USA,"EUA granted Apr 3, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal and oropharyngeal swab and bronchoalveolar lavage (BAL)",ND,N (N1 and N2 regions),NA,Qiagen QIAamp Viral RNA Mini Kit,"Roche Cobas Z 480 real-time PCR analyzer and analysis software, ABI QuantStudio 7 Flex Real-Time PCR System and analysis software, ThermoFisher ViiA 7 Real-Time PCR System and analysis software",ND,5 copies/µL,,No cross-reactivity predicted in silico,100.00%,30,Clinical,100.00%,30,100.00%,100.00%,,PPA was determined with 30 clinical NP specimens on Cobas confirmed at State Public Health Laboratories; 15 different subsets of the Cobas 30 tested on 2 x Quantstudios and 1 x Viia platforms (different subset for each platform). These subsets were not included in PPA. NPA was determined with 30 clinical NP specimens on Cobas confirmed at State Public Health Laboratories (n=2) or collected prior to outbreak (n=28).,included,included,included,ND,https://www.fda.gov/media/136699/download,https://www.fda.gov/media/136700/download,4/23/2020 15:22,5/4/2020 21:47,,
,"Mayo Clinic Laboratories, Rochester, MN",SARS-CoV-2 Molecular Detection Assay,,https://newsnetwork.mayoclinic.org/category/covid-19/,Lab,USA,"EUA granted Apr 20, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper and lower respiratory specimens (such as nasopharyngeal swabs, throat swabs,
 nasal swabs, sputum, tracheal secretions, BAL fluid, and bronchial washings)",ND,ORF1ab N,NA,bioMérieux easyMAG and EMAG,Roche LightCycler 480 amplificationsystem.,ND,0.156 copies/µL in NP swabs and 12.5 copies/µL in sputum samples,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,115,Clinical and Contrived,100.00%,90,100.00%,100.00%,,"PPA was determined with 15 clinical NP specimens compared to CDC EUA method at other labs (n=8) and Roche cobas SARS-CoV-2 EUA method at Mayo (n=7); another 100 contrived NP (n=50) and sputum (n=50) specimens spiked with a quantified, positive clinical specimen and compared to the CDC EUA method. NPA was determined with 30 clinical NP specimens compared to CDC EUA method at other labs or Roche cobas SARS-CoV-2 EUA method at Mayo; another 30 clinical NP and 30 sputum compared to the CDC EUA method.",included,included,included,ND,https://www.fda.gov/media/137163/download,https://www.fda.gov/media/137163/download,4/23/2020 15:22,5/11/2020 23:32,,
,Mesa Biotech Inc.,Accula SARS-CoV-2 test,,https://www.mesabiotech.com/coronavirus,Kit,USA,"EUA granted Mar 23, 2020; amended Apr 30, 2020",Laboratory,"H,M,W",Molecular,RNA,rRT-PCR,"Throat swab and nasal swab combined (Accula and Silaris), nasal swab only (Accula)",Not allowed,N,NA,Mesa Biotech Accula™ or Silaris™ Dock,Mesa Biotech Accula™ or Silaris™ Dock,30 min,100 copies/rxn,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA was determined with 30 contrived combined throat and nasal clinical swabs spiked with SARS-CoV-2 RNA (SARS-CoV-2 RNA/strain USA_WA1/2020). NPA was determined with 30 negative clinical combined throat and nasal swabs.,available,included,included,ND,https://www.fda.gov/media/136355/download,https://www.fda.gov/media/136345/download,4/23/2020 15:22,5/11/2020 23:31,,
,Mount Sinai Laboratory,COVID-19 ELISA IgG Antibody Test,,https://www.mountsinai.org/health-library/tests/covid-19-test,Lab,USA,"EUA granted Apr 15, 2020",Laboratory,H,Serology,IgG,ELISA,Serum and plasma,NA,NA,S (recombinant RBD region and full length),Manual,Microplate reader (manufacturer not specified),ND,NA,,No cross-reactivity predicted in silico,92.50%,40,Clinical,100.00%,74,99.58%,100.00%,,PPA determined with PCR positive clinical serum specimens (PCR test not disclosed); NPA determined with 74 with clinical serum specimens collected before pandemic.,included,included,included,ND,https://www.fda.gov/media/137029/download,https://www.fda.gov/media/137032/download,4/23/2020 15:22,5/21/2020 7:57,,
,"NeuMoDx Molecular, Inc.",NeuMoDx SARS-CoV-2 Assay,,https://www.neumodx.com/neumodx-announces-us-fda-emergency-use-authorization-eua-for-sars-cov2-test/,Kit,USA,"EUA granted Mar 30, 2020; amended Apr 23, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, bronchoalveolar lavage (BAL) or nasal swab","UTM, UVT","ORF1ab (Nsp2 region)
 N",NA,NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System,NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System,80 min,150 copies/mL,,Cross-reactivity >80% homology in one primer to 2 organisms in silico - confirmed no impact in wet lab test,100.00%,84,Clinical and Contrived,100.00%,59,100.00%,100.00%,,"PPA was determined with 40 clinical NP specimens positive with another EUA test, and 44 contrived NP specimens spiked with SARS-CoV-2 genomic RNA. NPA was determined with 59 negative NP specimens.",not included,included,included,ND,https://www.fda.gov/media/136565/download,https://www.fda.gov/media/136566/download,4/23/2020 15:22,5/11/2020 23:31,,
,"Orig3n, Inc.",Orig3n 2019 Novel Coronavirus (COVID-19) Test,,https://orig3n.com/covid19/,Lab,USA,"EUA granted Apr 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Oropharyngeal, nasopharyngeal, anterior nasal, and mid-turbinate nasal swab",ND,"N (N1, N2 and N3 regions)",NA,Omega Bio-Tek Mag-Bind Viral DNA/RNA 96 kit,ABI QuantStudio7 Flex (QS7) instrument with QuantStudio Real-Time PCR software version 1.3,ND,5 copies/µL,,No cross-reactivity predicted in silico,100.00%,95,Contrived,100.00%,35,100.00%,100.00%,,PPA determine with 90 contrived clinical NP specimens spiked withSARS-CoV-2 genomic RNA (source not disclosed); another 5 clinical specimens confirmed at a separate lab (method not disclosed). NPA determined with 30 clinical NP specimens another 5 negative clinical NP specimens were confirmed at a separate lab.,included,included,included,ND,https://www.fda.gov/media/136873/download,https://www.fda.gov/media/136874/download,4/23/2020 15:22,5/11/2020 23:31,,
,"Ortho Clinical Diagnostics, Inc.",VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack,,https://www.orthoclinicaldiagnostics.com/en-us/home/ortho-covid-19-answer,Kit,USA,"EUA granted Apr 8, 2020; amended May 9, 2020",Laboratory,"H,M",Serology,IgM/IgG,Homogeneous Immunoassay,Serum and plasma,K2 EDTA,NA,ND,Ortho VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600 Integrated Systems,Ortho VITROS ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS 5600/XT 7600 Integrated Systems,48 min to first result (37 min incubation time),NA,,No cross-reactivity detected in wet lab testing,100.00%,49,Clinical,100.00%,400,100.00%,100.00%,,Sensitivity was determined with 49 PCR positive clinical specimens collected >8 days post symptom onset; Sensitivity for earlier windows: 80.0% (>7d pso n=20). Specificity was determined with 400 presumed negative specimens.,not included,not included,not included,ND,https://www.fda.gov/media/136967/download,https://www.fda.gov/media/136966/download,4/23/2020 15:22,6/1/2020 0:36,,
,OSANG Healthcare,GeneFinder COVID-19 Plus RealAmp Kit,,http://www.osanghc.com/en/customer_en/archive/?pageid=1&mod=document&keyword=COVID&uid=50,Kit,South Korea,"EUA granted Apr 18, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, nasal, and mid-turbinate nasal swab specimens, bronchoalveolar lavage fluid (BAL), and sputum",ND,"ORF1ab
 E
 N",NA,"Qiagen QIAamp viral RNA Mini Kit, Roche MagNA Pure 96 DNA and Viral NA Small Volume Kit","ABI 7500 Real-Time PCR System (software version 2.3), Bio-Rad CFX Real-Time PCR Detection System (software version 1.6)",ND,0.5 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,PPA determined with 30 contrived upper respiratory and 30 sputum specimens spiked with whole genome RNA. NPA determined with 30 upper respiratory and 30 sputum un-spiked specimens.,not included,included,included,ND,https://www.fda.gov/media/137116/download,https://www.fda.gov/media/137113/download,4/23/2020 15:22,5/25/2020 8:48,,
,Pathology/Laboratory Medicine Lab of Baptist Hospital Miami,COVID-19 RT-PCR Test,,https://newsroom.baptisthealth.net/press-release/fda-approves-miami-cancer-institute-a-part-of-baptist-health-south-florida-to-perform-new-in-house-test-for-covid-19-in-its-molecular-diagnostic-lab/,Lab,USA,"EUA granted Apr 13, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Upper respiratory specimens including nasopharyngeal and oropharyngeal swabs,VTM,N (N1 and N2 regions),NA,ABI/ThermoFisher MagMAX Viral/Pathogen Ultra Nucleic Acid Isolation Kit with MagMax Express 96,ABI QuantStudio 7 Flex using QuantStudio Real-Time PCR software,ND,2 copies/µL,,No cross-reactivity predicted in silico,94.30%,35,Clinical,97.00%,35,99.69%,62.33%,,PPA determined with 30 clinical specimens that were PCR positive with Abbott RealTime SARS-CoV2 assay on the M2000 platform (specimen type not disclosed); there were 2 false negatives; another 5 clinical specimens were tested that were PCR positive with another EUA assay (specimen type and method not disclosed). NPA was determined with 30 clinical specimens that were PCR negative with Abbott RealTime SARS-CoV2 assay on the M2000 platform (specimen type not disclosed); another 5 clinical specimens that were PCR negative with another EUA assay (specimen type and method not disclosed).,included,included,included,ND,https://www.fda.gov/media/136944/download,https://www.fda.gov/media/136943/download,4/23/2020 15:22,5/25/2020 8:48,,
,"PerkinElmer, Inc.",PerkinElmer New Coronavirus Nucleic Acid Detection Kit,,https://perkinelmer-appliedgenomics.com/home/products/new-coronavirus-2019-ncov-nucleic-acid-detection-kit/,Kit,USA,"EUA granted Mar 24, 2020; amended Apr 1, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Oropharyngeal swab and nasopharyngeal swab,VTM,ORF1ab N,NA,PerkinElmer Nucleic Acid Extraction Kits and PreNAT II (software version 1.00.06) and Chemagic Viral DNA/RNA 300 Kit special H96 and Chemagic 360 with chemagic Rod Head Set 96 (chemagic MSM I software version 6.1.0.5),ABI TM 7500 Real-Time PCR System (software version 2.3),ND,"pre-NAT II: 9.307 copies/mL (ORF1ab) 30.467 copies/mL (N gene);
 Chemagic(TM) 360 platform: 7.142 copies/mL (ORF1ab) 23.380
 copies/mL (N gene)",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,44,Contrived,100.00%,94,100.00%,100.00%,,PPA was determine with 44 contrived NP and OP swabs spiked with inactivated cultured virus (Isolate 2/231/human/2020/CHN). NPA was determined with 94 negative NP and OP swabs.,not included,included,included,ND,https://www.fda.gov/media/136410/download,https://www.fda.gov/media/136407/download,4/23/2020 15:22,5/25/2020 8:49,,
,Primerdesign Ltd.,Genesig real-time PCR COVID-2019 assay,,https://www.genesig.com/products/10037-novel-coronavirus-strain-2019-ncov,Kit,UK,"EUA granted Mar 20, 2020; amended Apr 8, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swabs, & oropharyngeal swabs, bronchoalveolar lavage",VTM,ND,NA,"Qiagen QIAmp Viral RNA Mini Kit, GenoXtract GXT DNA/RNA Extraction kit","ABI 7500 Real-Tiime PCR System, Bio-Rad CFX Connect Real-Time PCR Detection System, Roche LightCycler 480 II w software v 1.5",ND,0.33 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,96.00%,50,Contrived,100.00%,50,99.79%,100.00%,,PPA was determined with 50 contrived OP specimens spiked with with SARS-CoV-2 whole viral genomic RNA (European Virus Archive - GLOBAL); there were 2 false negatives. NPA was determined with 50 contrived negative OP specimens.,not included,included,included,ND,https://www.fda.gov/media/136823/download,https://www.fda.gov/media/136306/download,4/23/2020 15:22,5/11/2020 23:31,,
,QIAGEN GmbH,QiaStat-Dx Respiratory SARS-CoV-2 Panel,,https://qiastat-dx.com/na/,Kit,Germany,"EUA granted Mar 30, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,Nasopharyngeal swabs,UTM,"ORF1ab (RdRP region)
 E
 Adenovirus, Coronavirus 229E, Coronavirus HKU1, Coronavirus NL63, Coronavirus OC43, SARS-CoV-2, Human Metapneumovirus A+B, Influenza A, Influenza A H1, Influenza A H3, Influenza A H1N1/pdm09, Influenza B, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Rhinovirus/Enterovirus, Respiratory Syncytial Virus A+B, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.",NA,Qiagen QIAstat-Dx Analyzer 1.0,Qiagen QIAstat-Dx Analyzer 1.0,ND,500 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA was determined with 30 contrived NP specimens spiked with a quantified clinical specimen obtained from a Hospital in Barcelona (Spain). NPA was determined with 30 negative NP specimens.,not included,included,included,ND,https://www.fda.gov/media/136571/download,https://www.fda.gov/media/136569/download,4/23/2020 15:22,5/11/2020 23:31,,
,"Quest Diagnostics Infectious Disease, Inc.",Quest SARS-CoV-2 rRT-PCR,,https://testdirectory.questdiagnostics.com/test/test-detail/39433/sars-cov-2-rna-qualitative-real-time-rt-pcr?q=39433&cc=MASTER,Lab,USA,"EUA granted Mar 17, 2020; amended Mar 26, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs, sputum, tracheal aspirates, and bronchoalveolar lavage)",Quest V-C-M transport medium or other comparable transport medium that will be validated,N (N1 and N3 regions),NA,Roche MagNA Pure 96 DNA and Viral NA,ABI 7500 Real Time PCR System,ND,136 copies/mL,,No cross-reactivity predicted in silico,100.00%,30,Clinical,100.00%,30,100.00%,100.00%,,PPA was determined with 30 clinical RNA samples from 15 NP/OP and 15 sputum specimens extracted and confirmed positive by a well-established clinical laboratory using an RT-PCR kit commercially available in the Republic of Korea (method not disclosed). NPA was determined with 30 clinical RNA samples from 15 NP/OP and 15 sputum specimens extracted and confirmed negative by a well-established clinical laboratory using an RT-PCR kit commercially available in the Republic of Korea (method not disclosed).,included,included,included,ND,https://www.fda.gov/media/136231/download,https://www.fda.gov/media/136228/download,4/23/2020 15:22,5/4/2020 21:47,,
,Quidel Corporation,Lyra SARS-CoV-2 Assay,,quidel.com/molecular-diagnostics/lyra-sars-cov-2-assay,Kit,USA,"EUA granted Mar 17, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal, or oropharyngeal swabs","M4, M4-RT, M5, M6, MTM and UTM) (1 mL and 3 mL), CDC Viral Transport Media",ORF1ab,NA,bioMerieux NucliSENS® easyMAG® system or EMAG® system,"ABI 7500 Fast Dx, Applied Biosystems 7500 Standard, Roche100 LightCycler 480, Qiagen Rotor-Gene Q, Bio-Rad CFX96 Touch, ABI QuantStudio 7 Pro.",ND,8.0 x 10^1 genomic RNA copies/µL,,No cross-reactivity predicted in silico,100.00%,92,Contrived,100.00%,265,100.00%,100.00%,,"PPA determined with contrived NP specimens spiked with genomic RNA from SARS-related coronavirus 2 (SARS-CoV-2), 389 isolate USA-WA1/2020. NPA determined with 265 clinical NP specimens.",included,included,included,ND,https://www.fda.gov/media/136820/download,https://www.fda.gov/media/136224/download,4/23/2020 15:22,5/21/2020 1:03,,
,"Roche Molecular Systems, Inc. (RMS)",cobas SARS-CoV-2,,https://diagnostics.roche.com/us/en/products/params/cobas-sars-cov-2-test.html,Kit,USA,"EUA granted Mar 25, 2020; amended May 18, 2020",Laboratory,"H,M",Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal and oropharyngeal swabs and BAL","Copan UTM-RT, BD UVT, Cobas® PCR Media or 0.9% physiological saline","ORF1ab
 E",NA,Roche cobas 6800 and 8800,Roche cobas 6800 and 8800,ND,46 copies per mL for both targets with AccuPlex SARS-CoV-2; 0.009 TCID50/mL (ORF1ab) and 0.003 TCID50/mL (E gene) with live virus,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,50,Contrived,100.00%,100,100.00%,100.00%,,PPA determined with 50 contrived clinical NP specimens spiked with cultured virus (USA-WA1/2020 strain). NPA determined with 100 clinical NP specimens.,not included,included,included,ND,https://www.fda.gov/media/136049/download,https://www.fda.gov/media/136049/download,4/23/2020 15:22,6/1/2020 0:57,,
,Rutgers Clinical Genomics Laboratory-Rutgers University,ThermoFisher - Applied Biosystems TaqPath COVID-19 Combo Kit,,https://www.rutgers.edu/news/rutgers-launches-genetic-testing-service-new-coronavirus,Lab,USA,"EUA granted Apr 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Oropharyngeal swab, nasopharyngeal swab, anterior nasal swab, mid-turbinate nasal swab and saliva","VTM; Spectrum Solutions LLC SDNA-1000
 Saliva Collection Device (saliva only)","ORF1ab
 N
 S",NA,Qiagen QIAamp® DSP Viral RNA Mini Kit,ABI 7500 Fast Dx Real-Time PCR Instrument,under 3 hours,200 copies/mL,,No cross-reactivity predicted in silico,100.00%,60,Clinical and Contrived,100.00%,60,100.00%,100.00%,,PPA determined with 30 contrived clinical NP specimens spiked with SARS-CoV-2 in vitro transcripts (Exact Diagnostics); another 30 prospective clinical saliva specimens were compared to NP (n=26) and OP (n=4) samples. NPA determined with 30 contrived NP specimens spiked with human gDNA (Exact Diagnostics) and 30 prospective clinical saliva specimens compared to NP (n=27) and OP (n=3).,included,included,included,ND,https://www.fda.gov/media/136875/download,https://www.fda.gov/media/136876/download,4/23/2020 15:22,5/14/2020 18:38,,
,ScienCell Research Laboratories,ScienCell SARS-CoV-2 Coronavirus Real-time RT-PCR (RT-qPCR) Detection Kit,,https://www.sciencellonline.com/PS/7038.pdf,Kit,USA,"EUA granted Apr 3, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal, oropharyngeal swab specimens, and
 bronchoalveolar lavage",ND,N,NA,Qiagen QIAamp® DSP Viral RNA Mini kit,Roche LightCycler® 96 Real-Time PCR System with LightCycler® Software 1.01.01.0050,ND,3 copies/µL,,No cross-reactivity predicted in silico,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with 30 contrived NP spiked with genomic RNA obtained from University of Texas Medical Branch. NPA determined with 30 NP swab specimens.,not included,included,included,ND,https://www.fda.gov/media/136691/download,https://www.fda.gov/media/136688/download,4/23/2020 15:22,5/11/2020 23:31,,
,Seegene,Allplex 2019-nCoV Assay,,http://www.seegene.com/assays/allplex_2019_ncov_assay,Kit,South Korea,"EUA granted Apr 21, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, oropharyngeal swab, anterior nasal swab, midturbinate and sputum",UTM,"ORF1ab
 E
 N",NA,Seegene STARMag 96 X 4 Universal Cartridge Kit on Microlab STARlet IVD or Seegene STARlet with Seegene Launcher V6,Bio-Rad CFX96™ Real-time PCR Detection System-IVD or CFX96 Touch™ Real-Time PCR Detection System with CFX Manager™ Software V3.1 or CFX Maestro™ Software V1 and Seegene Viewer Software V3.20 for analysis and interpretation of result,ND,"1,250 copies/mL (CFX96TM)
 4,167 Copies/mL (CFX96 Touch)",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,98,Clinical,96.00%,194,100.00%,56.82%,,"PPA determined 49 clinical NP/OP (n=49) and 49 clinical sputum specimens compared to a validated assay identical to the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, but using alternate extraction and PCR instrumentation. NPA was determined with 100 clinical NP/OP and 94 sputum specimens compared to a validated assay identical to the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, but using alternate extraction and PCR instrumentation. There were 8 false positives.",not included,included,included,ND,https://www.fda.gov/media/137178/download,https://www.fda.gov/media/137179/download,4/23/2020 15:22,5/4/2020 21:47,,
,Specialty Diagnostic (SDI) Laboratories,SDI SARS-CoV-2 Assay,,https://sdilabsinc.com/covid-19-testing/,Lab,USA,"EUA granted Apr 10, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal and oropharyngeal swab,"UTM, SDI swab media",ORF1ab,NA,AusDx MT-Prep Extraction System,ABI Real time PCR system 7500 with software v2.0.5,ND,0.5 copies/µL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Contrived,100.00%,30,100.00%,100.00%,,PPA determined with 30 contrived NP/OP specimens spiked with pseudovirus (source not disclosed). NPA determined with 30 NP/OP specimens (source not disclosed).,included,included,included,ND,https://www.fda.gov/media/136877/download,https://www.fda.gov/media/136878/download,4/23/2020 15:22,5/11/2020 23:31,,
,Stanford Health Care Clinical Virology Laboratory,Stanford SARS-CoV-2 assay,,https://med.stanford.edu/covid19.html,Lab,USA,"EUA granted Apr 8, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal, oropharyngeal, nasal, and mid-turbinate nasal swabs, bronchoalveolar lavage",VTM,E,NA,"Qiagen EZ1 Virus Mini Kit v2.0, Qiagen QIAsymphony DSP Virus/Pathogen Midi Kit with Qiagen EZ1 XL and QIAsymphonySP/AS",Qiagen Rotor-Gene Q real-time PCR thermal cycler,ND,"1,000 copies/mL",,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,30,Clinical,100.00%,30,100.00%,100.00%,,PPA determine with 30 clinical NP specimens compared to PCR positive specimens detecting the RdRP region. NPA determine with 30 clinical NP specimens.,Included,Included,Included,ND,https://www.fda.gov/media/136818/download,https://www.fda.gov/media/136817/download,4/23/2020 15:22,6/11/2020 11:55,,
,"Thermo Fisher Scientific, Inc.",TaqPath COVID-19 Combo Kit,,https://www.thermofisher.com/us/en/home/clinical/clinical-genomics/pathogen-detection-solutions/coronavirus-2019-ncov/genetic-analysis/taqpath-rt-pcr-covid-19-kit.html,Kit,USA,"EUA granted Mar 13, 2020; amended Mar 24 and Apr 20, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Bronchoalveolar lavage, nasopharyngeal swab and aspirate, oropharyngeal, nasal, and midturbinate swab",ND,"ORF1ab
 N
 S",NA,"ABI/ThermoFisher MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit with ABI/ThermoFisher KingFisher Flex Magnetic Particle Processor, ABI/ThermoFisher MagMAX Viral/Pathogen Nucleic Acid Isolation Kit, ABI/ThermoFisher MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit, ABI MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit","ABI 7500 Fast Dx Real-Time PCR Instrument, ABI 7500 Real-Time instrument, ABI QuantStudio 5 with 0.1ml Block, and QuantStudio 5 with 0.2 ml Block; ABI QuantStudio 7 Flex Real-Time PCR system, 384-well (RUO) and ABI QuantStudio 5 Real-Time PCR system 384-well (ROU) instruments, with Applied Biosystems COVID‑19 Interpretive Software v2.2, (",~40 min (detection),10 GCE/reaction,,No cross-reactivity predicted in silico,100.00%,60,Contrived,100.00%,60,100.00%,100.00%,,PPA determined with 30 contrived BL and 30 contrived NP specimens spiked with SARS-CoV-2 viral genomic RNA. NPA determined with 30 contrived BAL and 30 contrived NP specimens.,not included,included,included,ND,https://www.fda.gov/media/136112/download,https://www.fda.gov/media/136113/download,4/23/2020 15:22,6/1/2020 0:52,,
,Trax Management Services Inc. (mfd by Procomcure Biotech GmbH),PhoenixDx 2019-CoV,,https://shop.procomcure.com/produkt/phoenixdx-2019-ncov-rna-detection-kit/,Kit,Austria,"EUA granted Apr 20, 2020; amended May 11, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasal, nasopharyngeal and oropharyngeal swabs and BAL",UTM,ORF1ab (RdRP region) E,NA,RTA Viral RNA Extraction Kit; Qiagen QIAamp MiniElute Virus Spin kit and Roche High Pure Viral RNA Kit,Bio-Rad CFX96™ Real-time PCR Detection System-IVD with BioRad CFX Manager Software version 3.0; Qiagen Rotor-Gene Q and Applied Biosystems ABI 7500 Fast Real time PCR Dx,ND,100 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,100.00%,60,Contrived,100.00%,120,100.00%,100.00%,,"PPA determined with contrived 30 NP and 30 contrived BAL specimens spiked with a quantified clinical specimen positive for SARS-CoV-2 (source not disclosed). NPA determined with clinical OP (30), nasal (30), NP (30) and BAL (30) specimens compared to an FDA authorized SARS-CoV-2 test at another laboratory (method not disclosed).",not included,included,included,ND,https://www.fda.gov/media/137153/download,https://www.fda.gov/media/137150/download,4/23/2020 15:22,6/1/2020 0:28,,
,University of North Carolina Medical Center,UNC Health SARS-CoV-2 real-time RT-PCR test,,https://www.unchealthcare.org/coronavirus/,Lab,USA,"EUA granted Apr 10,2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal and oropharyngeal specimens, tracheal aspirates, bronchoalveolar lavages/bronchial washings, and nasopharyngeal aspirates/nasal washings",UTM,E,NA,"Roche MagNAPure 24 system, bioMerieux EasyMag system",ABI PRISM 7500 Sequence Detection System,ND,17.6 copies/rxn (NP and OP); 64.2 copies/rxn (Tracheal aspirates and BAL/BW); 17.6 copies/rxn (Nasal aspirates and Nasal washes),,No cross reactivity detected in wet-lab testing; cross-reactivity >80% was predicted in silico to 5 Coronavirus genomes - not tested,100.00%,35,Contrived,100.00%,78,100.00%,100.00%,,PPA determined 30 contrived NP and OP specimens spiked with extracted nucleic acid of a positive COVID-19 specimen from Mayo Medical Laboratories; another 5 clinical specimens confirmed at another laboratory (method not disclosed). NPA determined with 30 negative NP and OP specimens and 48 clinical negative specimens confirmed at another laboratory (method not disclosed).,included,included,included,ND,https://www.fda.gov/media/136880/download,https://www.fda.gov/media/136879/download,4/23/2020 15:22,5/11/2020 23:31,,
,Viracor Eurofins Clinical Diagnostics,Coronavirus SARS-CoV-2 RT-PCR assay,,https://www.viracor-eurofins.com/test-menu/8300-coronavirus-covid-19-sars-cov-2-rt-pcr/,Lab,USA,"EUA granted Apr 6, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swab, nasal swab, nasopharyngeal wash, nasal wash,
 oropharyngeal swab and bronchoalveolar lavage","VTM, sterile PBS",N,NA,bioMerieux NucliSENS easyMAG or eMAG instrument,ABI 7500 Real-Time PCR Systems (SDS v1.5.1),ND,73 copies/mL,,No cross-reactivity predicted in silico nor detected in wet lab testing,99.50%,191,Contrived,100.00%,30,99.97%,100.00%,,"PPA determined (185/186) with 62 contrived BAL (62/62), 62 Nasal wash (62/62) and 62 NP (61/62) specimens spiked with 1.5 kb in vitro transcribed (IVT) RNA of the SARS-CoV-2 N gene (positions 28061 – 29533 of GenBank accession NC_045512.2); there was 1 false negative. Another 5 patient specimens (specimen type not disclosed) were confirmed by Missouri DOH (method not disclosed). NPA was determined with 30 NP specimens and 5 patient specimens (specimen type not disclosed) confirmed by Missouri DOH (method not disclosed).",included,included,Included,ND,https://www.fda.gov/media/136740/download,https://www.fda.gov/media/136739/download,4/23/2020 15:22,5/11/2020 23:31,,
,"Wadsworth Center, New York State Department of Public Health's (CDC)",New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel,,https://www.wadsworth.org/news/fda-coronavirus-fact-sheets,Lab,USA,"EUA granted Feb 29, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,Nasopharyngeal/oropharyngeal swabs and sputum,ND,N,NA,"Qiagen EZ1 Advanced XL EZ1 DSP Virus Kit, bioMerieux easyMAG NucliSENS, bioMerieux EMAG NucliSENS, Scientific Device Laboratory Snap n digest (sputum)",ABI 7500 Fast Dx Real-Time PCR Instrument with SDS version 1.4 software,ND,"25 copies/rxn (bioMerieux NucliSENS easyMAG and EMAG);
 125-250 copies/rxn ( Qiagen EZ1)",,No cross-reactivity detected in wet lab testing,88.10%,126,Contrived,100.00%,87,99.38%,100.00%,,"PPA was determined with 126 contrived sputum specimens spiked with extracted whole virus genomic RNA (source not disclosed) with easyMAG (42/43), eMAG (38/40) and EZ1 (31/43). There were 15 false negatives. NPA was determined with 87 sputum specimens (all extraction kits combined).",included,included,included,ND,https://www.fda.gov/media/135847/download,https://www.fda.gov/media/135661/download,4/23/2020 15:22,5/11/2020 23:31,,
,"Yale New Haven Hospital, Clinical Virology Laboratory",SARS-CoV-2 PCR test,,https://www.ynhhs.org/patient-care/covid-19/covid-19-testing.aspx,Lab,USA,"EUA granted Mar 31, 2020; EUA amended June 4, 2020",Laboratory,H,Molecular,RNA,rRT-PCR,"Nasopharyngeal swabs, oropharyngeal swabs, nasal swabs, mid-turbinate nasal swabs, BALs, and sputum, NP swab, OP swab, Ns swabs, MTNs swab, BAL, Spu, Sal",ND,N (N1 and N2 regions),NA,biomerieux NUCLISENS EASYMAG,ABI QuantStudio Flex 6 Real-Time PCR System with software version 1.3,ND,"2 copies/uL in OP/NP matrix
100 copies/uL in pooled saliva",,No cross-reactivity predicted in silico,95.05%,101,Clinical and Contrived,98.54%,137,100.00%,100.00%,,"PPA determined with 1) 12 positive clinical OP/NP specimens from either the State Department Public Health laboratory (DPH, n = 7) or the Yale New Haven Hospital (YNHH, n = 5) confirmed by the DPH with an undisclosed EUA authorized test, 2) 6 contrived OP/NP specimens from DPH spiked with nCoV PC (positive control provided by CDC), 3) contrived OP/NP (n = 30), sputum (n = 10), and BAL (n = 10) specimens (sample provenance not disclosed) spiked with in vitro RNA transcripts purchased from Biosynthesis, and 4) 33 positive clinical saliva specimens collected concurrently with paired NP specimens from symptomatic outpatients suspected of having COVID-19 (positive determination conducted on the paired NP specimens using the EUA authorized CDC assay). 
NPA determined with 1) 8 clinical specimens from DPH (specimen type not disclosed; method of negative determination not disclosed), 2) 5 clinical specimens from YNHH (specimen type not disclosed; negative determination with an undisclosed EUA authorized test), 3) 3 frozen extracted eluates spiked with RNase-free water (specimen provenance not disclosed), 4) 30 individual negative NP/OP specimens (sample provenance not disclosed; method of negative determination not disclosed), and 5) 91 negative clinical saliva specimens collected concurrently with paired NP specimens from symptomatic outpatients suspected of having COVID-19 (negative determination conducted on the paired NP specimens using the EUA authorized CDC assay)",included,included,included,ND,https://www.fda.gov/media/136602/download,https://www.fda.gov/media/136601/download,4/23/2020 15:22,6/9/2020 10:00,,ALG (8/24)